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ABSTRACT 
Histamine receptors H3 and H4 are classic G-protein coupled receptors (GPCRs) and are 
potential therapeutic targets for a number of CNS pathologies and inflammatory diseases, 
respectively. They are highly related both in terms of protein sequence and gene structure, 
and are likely to share key molecular pharmacological features. Pharmacological 
heterogeneity between and within species has hindered efforts to bring H3R directed drugs 
to the clinic. Possible mechanisms underlying this variability are the subject of these 
investigations. Current opinion on GPCRs suggests that many function as obligate dimers 
or higher oligomers. In addition alternative splicing of H3 and H4R cDNA generates splice 
variants which result in the potential expression of different receptor isoforms. Two 
common human H3R isoforms expressed in the basal ganglia are the focus of this thesis: 
the full length H3 (445) isoform and the shorter H3 (329) isoform. For the human H4 receptor 
only two isoforms have been identified to date. These are drastically truncated versions of 
the full length receptor. Many of the H3 isoforms and both the H4 isoforms appear to be 
non-functional with respect to ligand binding and signalling. To determine whether these 
attributes could be a source of receptor heterogeneity, five major hypotheses have been 
addressed: 1. Human H3 and H4 receptors are able to homo-oligomerise; 2. Human H3 and 
H4 receptors are able to hetero-oligomerise with their respective splice variants; 3. Splice 
variants can act as dominant negative regulatory subunits; 4. N-glycosylation is a 
prerequisite for receptor dimerisation; 5. H3 and H4 histamine receptors are both expressed 
in brain and subserve distinct functions. 
A new panel of anti- H3R and H4R specific antibodies have been generated, and used as 
immunological probes to test the thesis hypotheses using a combination of biochemical, 
i 
biophysical and pharmacological techniques. Cross-linking experiments suggested the 
presence of human and rodent H3R and human H4R homo-oligomers, further corroborated 
by FRET analysis for the hH3R, and by both nickel column purification and BRET in the 
case of the hH4R. FRET experiments also provided evidence for the existence of hetero- 
oligomers, consisting of the full length receptor with a respective shorter isoform. Neither 
of the truncated hH4 isoforms can bind or transduce a signal. The effect of the two 
isoforms on surface expression of the full length receptor was investigated using the 
surface biotinylation technique. Results confirmed that the shorter isoforms decreased the 
surface expression of the full length hH4 (390) isoform in line with the effects of the two 
isoforms on the number of [3H] histamine binding sites. Both the human H3 and H4 
receptors are modestly N-glycosylated, however N-glycosylation is not a prerequisite for 
receptor dimerisation. In the case of the H3 receptor preventing glycosylation has only a 
modest effect on ligand binding to the receptor. 
in conclusion, variability in the level of homo- and hetero-oligomerisation and propensity 
for N-glycosylation may contribute to H3 and H4 receptor heterogeneity. Furthermore 
shorter isoforms are able to act as dominant negative subunits which would have 
profound functional consequences on both H3 and H4 receptors in vivo. This study also 
provides the first evidence that both the H3 and H4 receptors are expressed in the human 
and rodent brain. 
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CHAPTER 1 
INTRODUCTION 
1. Histamine and the histaminergic system 
Histamine is a basic amine formed from the amino acid L-histidine by histidine 
decarboxylase, a reaction which can be blocked for experimental purposes by the 
enzyme inhibitor a-fluoromethylhistidine (a-FMH). 
NH2 
r" 11C}1fi1NP 
x NOýH Decazboxylase HN,,. 
Hisüdine Histurdne 
NHz 
It is metabolized to N-methylhistamine by an N-methyl-transferase or to imidazole 
acetic acid by diamine oxidase. The N-methylhistamine can be further metabolized to 
N-methyl-imidazole acetic acid by monoamine oxidase. 
r: 7ý 
HN,,., ý 
Imidaxole acetic acid 
HSCINNlz: ý/ N 
N-Methylhistamine 
It is found in most tissues of the body but is present in high concentrations in the 
lungs and the skin and in particularly high concentrations in the gastrointestinal tract. 
It is found mainly in mast cells and basophils, associated with heparin, but non-mast- 
cell histamine occurs in `histaminocytes' in the stomach and in histaminergic neurons 
1 
in the brain (Parsons & Ganellin, 2006). Most of the early studies describing the 
biological action of histamine in the periphery were carried out by Sir Henry Dale and 
colleagues in the early 1930s. Anti-histamines were developed as successful therapies 
for allergic and inflammatory conditions. It was soon recognized that classical anti- 
histamines had a sedative action and were therefore affecting the CNS. Evidence for a 
role for histamine in brain aminergic systems began to accumulate (Green, J. P. in 
Handbook of Neurochemistry, 1970) and lesion studies (Garbarg et al, 1974) 
identified the approximate source of brain histamine. Knowing where histamine is 
found in the brain and the effects it has on different brain areas is crucial to gaining an 
understanding of its function. There are many similarities between the histaminergic 
system and the other three aminergic systems i. e. the serotonergic, dopaminergic and 
noradrenergic systems. All four of these systems consist of small groups of neurons 
with widespread projection networks to most brain areas and the spinal cord. This is 
compatible with their having a broad modulatory effect on neuronal function. 
Specificity of action is achieved by the different brain regions from which they 
receive input and by the distinct distribution of receptor subtypes in target regions. 
The central histamine system is involved in many CNS functions: arousal, activation 
of the sympathetic nervous system, stress-related release of hormones from the 
pituitary and of central aminergic neurotransmitters, anti-nociception, water retention 
and suppression of eating. Histamine is synthesized and transported in the brains of 
almost all animal species and the histaminergic system is phylogenetically highly 
conserved (Haas & Panula, 2003). In vertebrates the tuberomamillary nucleus (TMN), 
which is part of the posterior hypothalamus, is the soul source of histaminergic 
neurons and their projections (Fig. 1.1). In all mammals the cerebral cortex, 
amygdala, substantia nigra and striatum receive moderate or dense histaminergic 
2 
innervation (Watanabe et al, 1984; Inagaki el al, 1988; Panula et al, 1989). The 
density of projections into the hippocampus (Panula et al, 1989; Greene et al, 1990; 
Brown et al, 2001) and thalamus (McCormick & Williamson, 1989; McCormick, 
1992; Pape & McCormick, 1995) varies, and the retina and spinal cord also receive 
histaminergic input. Afferent projections to the TMN come from many different areas. 
Major sources are the infralimbic cortex, lateral septum and preoptic nucleus (Ericson 
et al, 1991). The brainstem innervation derives mainly from adrenergic cell groups 
C1-C3, noradrenergic groups Al-A3 and from serotonergic groups B5-B9. By 
contrast the locus coeruleus and the dopaminergic groups of the substantia nigra and 
ventral tegmental area send only a few fibres to the TMN (Ericson et al, 1989). 
CA"orcl `f ftýlý 
f .` 
1 
To stna!, 1 
To hippo yr x1 
and ar "dala 
To MK** 
MtOdOmC lM9aa 
Haas & Panula, 2003 
Fig 1.1 The Histaminergic System 
3 
The TMN neurons contain several other neurotransmitters and modulators besides 
histamine. Glutamic acid decarboxylase the y-aminobutyric acid (GABA) 
synthesizing enzyme and GAGA itself are found in many TMN neurons. This may 
have functional significance because TMN neurons extend widely throughout the 
CNS so that they could mediate general inhibition. The neuropeptides galanin, 
thyrotropin releasing hormone, proenkephalin-derived peptides and substance P are 
also found in subsets of histamine producing TMN neurons, although their function 
here is not known (Staines et al, 1986; Airaksinen & Panula, 1988). Most TMN 
neurons also express adenosine deaminase (ADA), the enzyme that converts 
adenosine to inosine (Staines et al, 1986; Senba et al, 1991). 
Histaminergic neurons are pacemakers that fire at a slow regular rate (below 3Hz), 
although this rate can vary depending on the behavioural state (Brown et al, 2001). 
This is likely to be relevant to their presumed modulatory role possibly contributing to 
the maintenance of homeostasis. In many species a proportion of brain histamine 
derives from mast cells. Histamine from mast cells is likely to affect neuronal 
receptors, for instance during inflammation. 
2. Histamine receptors 
The wide ranging effects of histamine are mediated via four histamine receptors: Hi, 
H2, H3 and H4. They are all G-protein coupled receptors of the Rhodopsin-like class A 
type. H1, H2 and H3 are all prominently expressed in the brain. The most recently 
described receptor H4 has so far been detected predominantly in the periphery. The H1 
and H2 receptors mostly excite neurons or potentiate excitatory inputs whereas H3 is 
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an inhibitory receptor. Histamine can also modulate currents gated by the glutamate 
N-methyl-D-aspartate (NMDA) receptor (Haas, 1984). Since the H3 and H4 receptors 
are the subject of this thesis the H1 and H2 receptors are covered in less detail here. 
However they are both important receptors in the brain, in addition some of the effects 
of H3R stimulation result from a reduction in histamine activation at H1 and H2 
receptors. 
2.1 The first histamine receptors: H1 and H2 
The first classical anti-histamines antagonized the effects of histamine on a range of 
smooth muscles. From these compounds drugs were developed to treat various 
allergic disorders such as hay fever, allergic rhinitis and urticaria. However these anti- 
histamines failed to inhibit some of the actions of histamine, suggesting that there 
were at least two types of receptors sensitive to histamine (Ashford et al, 1949). 
H1R distribution in different animal tissues has been mapped with the use of selective 
radioligands one of the first being [3H]-mepyramine. In addition to the brain it is 
found in a wide variety of tissues including: smooth muscle from airways, 
gastrointestinal tract, genitourinary system, and the cardiovascular system; adrenal 
medulla; endothelial cells and lymphocytes (Hill et al, 1990). In human brain, higher 
densities of H1R are found in neocortex, hippocampus, nucleus accumbens, thalamus 
and posterior hypothalamus, whereas cerebellum and basal ganglia show lower 
densities (Martinez-Mir et al, 1990; Villemagne et al, 1991; Yanai et al, 1992). The 
H1R influences eating, drinking and thermoregulation (Brown et al; 2001). It may also 
be involved in learning and memory (Knoche et al, 2003; Dai et al, 2007). 
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H2R was first described in the periphery where it modulates smooth muscle and 
gastric acid secretion (Black et al, 1972). H2R antagonists are widely prescribed to 
control excessive gastric acid secretion. It is also found in cardiac tissue and on 
immune cells, where it has been shown to negatively regulate histamine release and a 
number of cell functions such as antibody synthesis in B cells, and T cell proliferation 
(reviewed by Hill et al, 1990; Chand & Eyre, 1994). [12SI]iodoaminopotentidine has 
been used for autoradiographic mapping of H2R in mammalian brain where it is 
widely distributed. Highest densities are found in the basal ganglia, hippocampus, 
amygdala and cerebral cortex. Lowest densities are detected in cerebellum and 
hypothalamus (Traiffort et al, 1992; Vizuete et al, 1997; Honrubia et al, 2000). 
Overall the effect of H2R activation on neurons is most often excitatory (Chen et al, 
2003; Chen et al, 2005; Tang et al, 2007). As with the H1R, there is evidence for H2R 
playing a part in learning and memory (Dai et al, 2007). 
The H1 and H2 receptors were both cloned in 1991 (Yamishita et al, 1991 and Gantz et 
al, 1991 respectively). The gene for the human H1 is located on chromosome 3 
(Leconiat et al, 1994). The receptor signals through G proteins of the Gg/11 subtype 
which stimulate the phopholipase C, diacyl glycerol (DAG), inositol triphosphate 
(IP3) pathway (Leurs et al, 1994). DAG activates protein kinase C (PKC), whilst IP3 
releases calcium from intracellular stores. H1R activation can also lead to the 
formation of arachidonic acid (AA), probably through the action of phospholipase A2 
(Leurs et al, 1994) and to the formation of cGMP (Richelson, 1978). The cGMP 
formation may arise from an increase in intracellular calcium [Ca]; leading to 
activation of nitric oxide synthase, production of nitric oxide (NO) and subsequent 
stimulation of guanylate cyclase. Therefore H1R activation may be able to modulate 
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presynaptic transmitter release as both AA and NO have been proposed to act as 
retrograde messengers, however such modulation has yet to be shown. H1R 
stimulation can indirectly generate cAMP by substances acting at receptors coupled to 
G$ G proteins (Baudry et al, 1975; Daum et al, 1982; Leurs et al, 1994) e. g. histamine 
acting at H2R or adenosine acting at the A2R. 
The H2R shares 28% homology with the H1R. The gene for H2R is located on human 
chromosome 5 (Traiffort et al, 1995). It is a GPCR which mostly couples through Gs 
G proteins, activation of which leads to stimulation of adenylyl cyclase and 
production of the second messenger cAMP (Baudry et al, 1975; Hegstrand et al, 
1976). The major pathway is activation of cAMP dependent protein kinase A (PKA). 
PKA can phosphorylate a range of target regulatory proteins in the cytosol or in the 
cell membrane, alternatively it can translocate to the cell membrane and activate the 
transcription factor cAMP response element binding (CREB) protein. 
2.2 Histamine H3 receptor 
The H3R was first identified by Arrang et al, 1983, describing auto-inhibition of brain 
histamine release via a novel histamine receptor. It is pharmacologically distinct from 
the Hl and H2 receptors. 
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2.2.1 Anatomical distribution 
Autoradiographic studies with the H3R selective ligand [3H]R-(a)-methylhistamine 
have shown the presence of specific binding in several rat brain regions (Arrang et al, 
1987), particularly cerebral cortex, striatum, hippocampus, olfactory nucleus, and the 
bed nuclei of the stria terminalis, which receive ascending histaminergic projections 
from the magnocellular nuclei of the posterior hypothalamus. H3R have also been 
visualised in human brain and the brain of nonhuman primates (Martinez-Mir et al, 
1990). 
More recently a detailed mapping of the H3R and its gene transcripts has been carried 
out in the rat brain (Pillot et al, 2002) The distribution of H3R mRNA in rat brain was 
compared in the same animals with (125I]iodoproxyfan binding, a selective 
radioligand. The signal was quantified or rated and compared for each probe to 
identify the neuronal populations expressing the receptor. This study (Pillot et al, 
2002) is unique in its' meticulous comparison of mRNA with the distribution of H3R 
protein in the same animals, thus providing evidence for the presence of receptors on 
many neuronal perikarya, dendrites and projections. Strong mRNA signal was 
detected in intermediate and deep layers of the cerebral cortex, while binding (i. e. 
corresponding to H3R protein) was high in all layers except layer V. High binding in 
layer IV, combined with high levels of message in thalamic nuclei, suggest the 
presence of H3R as hetero-receptors on thalamocortical projections. Strong mRNA 
signal but low binding was detected in distinct regions of the hippocampal structure, 
therefore the H3R appears to be present on projections pf pyramidal cells of the CAI 
and CA3 regions. In the basal ganglia high binding was found in the striatal complex 
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and the olfactory tubercles. H3R mRNA in cortical layer V may code for H3R hetero- 
receptors on cotricostriatal neurons. In addition message in the substantia nigra pars 
compacta was compatible with the presence of H3R on nigrostriatal afferents. 
Message in the caudate putamen and nucleus accumbens suggests striatal H3 receptors 
on both the direct and indirect movement pathways. In the amygdala levels of binding 
and mRNA were uniformly high. In the thalamus binding detected in some 
association nuclei may be on neurons emanating from deep cortical layers. However, 
low binding in most nuclei combined with a strong mRNA signal suggests that the 
majority of the H3 receptors are on thalamic projections. The pattern of binding and 
mRNA signal reported in the lower brain stem i. e. high mRNA signal but negligible 
binding, is compatible with the presence of presynaptic H3 receptors regulating 
noradrenaline (Schlicker et al, 1989) and serotonin release (Schlicker et al, 1988). In 
the cerebellum there was negligible binding but high levels of message, suggesting the 
presence of receptors on efferent projections. The distribution of the H3R both at the 
structural and cellular level is critical to understanding of its' physiological role. 
Immunological identification of the H3R protein in mouse brain (Chazot et al, 2001) 
was generally in concordance with the ligand-autoradiographical data from both the 
above study and that described in mouse forebrain (Cumming et al, 1994). 
H3R mRNA and protein is also found in some non-brain tissues including skin, dorsal 
root ganglia (Cannon et al, 2007), stomach, intestines (Chazot et al, 2007) and brown 
adipose tissue (Karlstedt et al, 2003). H3R mRNA was detected in a wide range of 
tissues from developing rats (Heron et al, 2001) with highest expression in the central 
and peripheral nervous system, adipose tissue, skin, thymus, respiratory and tongue 
epithelia. Expression in some areas was found to be developmentally regulated. 
9 
2.2.2 Auto- and hetero-receptors: matching anatomy and functional data 
The new H3 receptor was shown initially to inhibit histamine release and synthesis 
(Arrang et al, 1983). Subsequently H3R have been found to function as both auto- and 
hetero-receptors inhibiting the release of many other transmitters including glutamate 
(Brown & Reymann, 1996), GABA (Garcia et al, 1997), noradrenaline (Schlicker et 
al, 1989), dopamine (Schlicker et al, 1993), acetylcholine (Arrang et al, 1995), 
serotonin (Schlicker et al, 1988) and various peptides (Hill et al, 1997). It is this 
property together with its' widespread CNS distribution which has generated such 
great interest in the H3R as a potential therapeutic target. 
Differential responses to GABAA or H3 receptor antagonists suggest the existence of 
distinct subpopulations among histaminergic neurons (Giannoni et al, 2006). Using 
dual probe microdialysis, with one electrode in the TMN and a second electrode in 
different histaminergic projection sites, the effects of administration of either an H3 or 
GABAA antagonist (thioperamide or bicuculline respectively) on the target region 
were compared. Results confirmed that both GABA and HA tonically modulate HA 
neuronal activity. The different responses evoked by intra-TMN administration of 
either thioperamide or bicuculline on HA release in distinct projection areas suggested 
the presence of functionally distinct HA neuronal populations. Our group in 
collaboration with. teams at Oxford and Florence Universities have new data showing 
neurons in the rat TMN double stained for GABA (anti-GAD67 antibody) and H3R 
(anti-H3R antibody). Although modest in numbers, there was clear evidence of GAD- 
positive neurons expressing H3R. There were a large number of neurons which were 
H3R positive but GAD negative, and GAD positive and H3R negative, confirming 
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significant heterogeneity of TMN neurons (Appendix). Using a combination of 
pharmacological and physiological approaches other examples of heterogeneity have 
been described including differences in histaminergic and orexinergic neurons in 
relation to GABAA receptors subunit composition (Haas et al, 2006), and evidence for 
distinct control by H3R of dopamine release in the substantia nigra (SNr) and 
prefrontal cortex (PFC) - brain regions which differ in the origin of their 
dopaminergic innervation (Garduno-Torres et al, 2006). In superfused rat SNr slices 
depolarisation-evoked [3H]-dopamine release was diminished by the H3R agonist 
immepip. In contrast, immepip failed to affect [3H]-dopamine release from PFC 
synaptosomes. This same group showed the presence of H3R coupled to Ga, iJo proteins 
on thalamic nerve terminals, activation of these H3 receptors modulated 
glutamatergic, but not GABAergic transmission. 
2.2.3 H3 receptor structure and signalling 
In 1983 the first evidence for an additional histamine receptor, the H3R, was obtained 
(Arrang et al, 1983). However, it was not cloned until 1999 (Lovenberg et al, 1999). 
This was largely because it shares only 22 and 20% homology with H1R and H2R 
respectively so genomic searches based on sequence homology proved unsuccessful. 
Indeed it was finally cloned from a human thalamus cDNA library using a potential 
GPCR-related sequence tag (EST) sequence with homology to a2 adrenergic 
receptors. The gene is located on human chromosome 20 (Tardivel-Lacombe et al, 
2001; Coge et al, 2001), it encodes a gene of 445 amino acids. 
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The H3R belongs to superfamily 1 of the seven transmembrane (TM) domain 
containing receptors that couple to G-proteins. This family includes those receptors 
activated by small ligands, such as biogenic amines; larger peptide ligands and 
glycoprotein hormones. In common with other family members, H3 receptors are 
characterised by unique sequence motifs (Leurs et al, 2000) as follows: 
DRY (DRF for the H3R) or ERW motif at the interface of TM3 and intracellular loop 
2; the NPXXY motif in TM7 (NPVLY in all H3R so far); conserved aspartates at 
positions 80 in TM2 and 114 in TM3; conserved tryptophan residues W174 and 
W371 in TM4 and TM6 respectively; conserved prolines P210 and P373 in TM5 and 
TM6 respectively; and a conserved asparagine N404 in TM7. Other features of the 
H3R common to many GPCRs include putative disulphide bridge sites between the 
first and second cysteine residues (C107 and C188 on extracellular loops 1 and 2 
respectively, Leurs et al, 2000); and potential sites for palmitoylation (C428 near the 
carboxy terminus) and N-linked glycosylation (N11). Sites for phosphorylation by 
protein kinases have been identified in all three intracellular loops: at serines S63 or 
S64 (first intracellular loop), serine S141 and threonine T149 (second intracellular 
loop), and at serines S310, S319, S341, S343 or threonines T314 and T345 (third 
intracellular loop) (Leurs et al, 2000). 
Publication of the human H3R gene sequence lead quickly to the cloning of the rat 
(Lovenberg et al, 2000) and guinea-pig (Tardivel-Lacombe et al, 2000) H3 receptor 
orthologues. The sequence of the mouse receptor has also been published (Genbank 
Accession nos. NP598610; AY044153; NM133849, Koyama et al, 2002; AY142145, 
Chen et al, 2002) and further characterised (Chen et al, 2003). Abbott Laboratories 
have cloned the monkey H3 receptor (Accession no. AY231164, Yao et al, 2003a) and 
12 
obtained partial peptide sequences for the canine receptor (Accession nos. AY231165 
and AY231166, Witte et al, 2003). Comparison of all these sequences shows a high 
degree of homology. Approximately 92% of the amino acids are conserved across the 
five species whose complete sequences are available. By contrast, other than modest 
homology to the H4 receptors (Hough, 2001), the H3R does not show a high degree of 
homology to any other known or orphan GPCR. 
a) Splice variants generate receptor isoforms 
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Fig. 1.2 Reported human histamine H3 receptor isoforms (Dave Weiner, Acadia 
Pharmaceuticals, San Diego, CA, USA). Isoform 1 is similar to that previously 
reported by Lovenberg et al, 1999, whereas isoform 2 has an 80-amino-acid deletion 
in the third intracellular loop. This deletion is combined with an 8-amino-acid longer 
C-tail (isoform 4). Isoform 3 contains a deletion of 144 amino acids, which includes 
the 80-amino-acid deletion of isoform 2 but also eliminates transmembrane domain 
(TM) 6 and TM7. This deletion is also found in combination with the eight additional 
amino acids in the C-terminal tail (isoform 6). Finally, isoform 5 is generated as a 
result of a 409-nucleotide deletion and a frameshift. This results in a protein with a 
deleted TM4 and TM5, and a new 30-amino acid C-terminus. The figure was kindly 
provided by Kim Retra (Leiden/Amsterdam Center for Drug Research, Vrije 
Universiteit, The Netherlands). 
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The genes coding for many GPCRs lack introns, however several introns have been 
found in the H3R gene. Two different studies of the human gene (Tardivel-Lacombe 
et al, 2001; Wiedemann et al, 2002) suggest a gene with three exons and two introns. 
However Coge (Coge et al, 2001) reported a gene with a minimum of four exons and 
three introns (Fig 3.1, Chapter 3). In addition their analysis suggests the possibility of 
a fourth intron which would split exon 4 in two. A further exon may result in an 
additional 8 amino acids in the carboxy terminus of the human H3R (Itadani et al, 
2001 European Patent Application, # EP 1,142,909, Al) thus generating a protein 
453 aa's long. The consequence of these diverse exon/intron junctions, is the 
occurrence of alternative splice sites with the potential to generate multiple, distinct 
splice variants or receptor isoforms which may account for receptor heterogeneity 
found both between and within species. Two studies were unable to detect human 
isoforms (Liu et al, 2000; Wiedemann et al, 2002), but these contradict other work 
where human isoforms have been identified (Coge et al, 2001; Wellendorph et al, 
2002). H3R isoforms have also been reported in guinea-pig (Tardivel-Lacombe et al, 
2000), rat (Drutel et al, 2001; Morisset et al, 2001) and mouse (Rouleau et al, 2004). 
The majority of the splice variants would result in isoforms with deletions within the 
third intracellular loop. The deletions often start at a common nucleotide position 
(corresponding to aa's 274 or 275). Interestingly, the sequence of the monkey receptor 
at this putative splice site differs from the other species and expression of splice 
isoforms of the monkey receptor has not been detected (Yao et al, 2003). The 
mechanisms regulating alternative splicing of the H3R gene remain to be investigated. 
It is unlikely that all the possible splice variants are actually expressed as protein. 
Furthermore, receptors with deletions in regions thought to be important in ligand 
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binding and/or signal transduction may not be functional in respect of those two 
particular properties. However these truncated versions might still be physiologically 
relevant if they alter the expression levels or functioning of the native receptor, either 
directly or indirectly by their interactions with other cellular proteins. There is indeed 
evidence that this occurs (Bakker et al, 2006), although the underlying mechanism is 
still a matter for speculation. Oligomerisation of GPCR's is a topic on which there is 
presently a great deal of debate. Most GPCR's studied to date appear to be able to 
oligomerise but whether this happens in native tissue and what its' functional 
significance might be remains unknown (see section 3). The potential for receptor 
cross-talk and a role in regulatory mechanisms such as receptor trafficking is currently 
an active area of research for these important receptors. This topic will be a focus of a 
large part of this thesis. 
b) Genetic polymorphism 
Independent publications and GenBank submissions of human H3R sequences have 
either glutamic acid (Accession nos. XM009561, ABO19000 and AB045369) or 
aspartic acid (AF363791) at position 19 (Hancock et al, 2003). Wiedemann et al, 
2002 have identified a polymorphism at position 280 (A to V) in a patient with Shy- 
Drager syndrome, a disease characterised by neuronal degeneration and autonomic 
failure. Abbott Laboratories have confirmed this finding and identified another 
polymorphism at amino acid 197 (cysteine for phenylalanine, Yao et al, unpublished). 
Similarly genetic polymorphism has been reported in the rat H3 receptor, with several 
single amino acid substitutions in intracellular loop 3 (Coge et al, 2001). Polymorphic 
sites may also be present in the mouse where complete sequences (Coge et al, 2001b; 
Chen et al, 2003) differ from the partial mouse sequence (Goodearl et al, 1999 
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International Patent Application # WO 99/28470. ). Other polymorphic sites may 
remain to be discovered in both these and other species. 
c) Signalling pathways 
Even before the H3R was cloned there was evidence for it coupling to G; /o, that is to 
the inhibitory class of G proteins shown by the pertussis-toxin (PTX) sensitivity of 
H3R agonist-dependent [35S]GTPyS binding in the rat brain (Clark & Hill, 1996; 
Laitinen & Jokinen, 1998). This was confirmed by Lovenberg et al when they cloned 
the receptor in 1999. Our laboratory provided the first evidence for a direct interaction 
of native H3 receptors in rat striatum with the Gai3 protein (Victoria Hann PhD Thesis, 
2003). A number of studies have consistently linked both human and rat recombinant 
H3R to the adenylyl cyclase system (Lovenberg et al, 1999,2000; Wieland et al, 
2001; Morisset et al, 2000; Uveges et al, 2002; Coge et al; 2001; Gomez-Ramirez et 
al, 2002). Effects on adenylyl cyclase have also been shown for various H3R isoforms 
using cAMP-dependent reporter systems (Drutel et al, 2001). Drutel and colleagues 
identified eDNA's of three functional rH3 isoforms which they termed H3A, H3B and 
H3C and one non-functional truncated receptor H3T. H3A was the full length clone of 
445 as whereas H3B and H3C both had deletions within the 3`d intracellular loop. This 
study was the first to demonstrate coupling of all three isoforms to the P44/P42 
mitogen activated protein kinase (MAPK) cascade, again in a PTX-sensitive manner. 
None of the isoforms coupled to phospholipase C. The MAPK pathway is believed to 
be important in neuronal plasticity and is activated in hippocampal LTP (English & 
Sweatt, 1996). The H3 receptor has been shown to play a role in learning and memory, 
therefore these results suggest a possible mechanism. New signalling pathways, also 
with significance for neuronal survival and memory consolidation, have recently been 
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reported. In transfected SK-N-MC cells the hH3R 445 isoform modulates the activity 
of the Akt/Glycogen synthase kinase 30 (GSK-30) axis both in a constitutive and an 
agonist-dependent manner (Bongers et al, ERRS 2006; Bongers et al, 2007). The H3R 
mediated activation of the protein kinase Akt can be inhibited by the H3R inverse 
agonist thioperamide as well as by wortmannin and pertussis toxin (PTX), suggesting 
that Akt activation occurs via a Gj, a-mediated activation of phosphoinositide-3-kinase 
(PI-3-K). H3R activation also leads to phosphorylation of GSK-3ß, which acts 
downstream of Akt and plays an important role in brain neuronal development and 
function. In rat embryonic day (ED) 17 cortical neurons H3R activation 
phosphorylates Ser473 Akt in a time-dependent manner (Mariottini et al, EHRS 2006). 
Akt activation, besides promoting neuronal survival, regulates synaptic strength and is 
critical for memory consolidation and retrieval. 
d) Effector mechanisms: H3R and calcium channels 
H3R have been shown to be coupled to Gj, o and high voltage activated calcium 
ion 
(Ca2) channels. An important physiological role of H3R activation may be a reduction 
in Ca2+ ion influx. Mobilisation of Ca2+ ions is important in neurotransmitter release. 
Therefore a direct G-protein mediated inhibition of presynaptic calcium channels 
appears to be the most likely mechanism underlying inhibition of neurotransmitter 
release by H3R activation. In dissociated TM neurons H3R activation suppressed N- 
and P-type calcium channels via a pertussis toxin-sensitive G-protein (Takeshita et al, 
1998). The increase in noradrenaline release in myocardial ischaemia can be 
ameliorated by addition of an H3 agonist (Levi & Smith, 2000) and is a direct effect of 
reduced intracellular Ca 2+ (Silver et al, 2001). 
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e) Constitutive activity 
An important property of the H3R is that it demonstrates a high level of constitutive 
activity, this means that at least a proportion of the receptor population is active even 
in the absence of histamine. Constitutive activation of GPCR's was first reported by 
Lefkowitz et al, 1993 when they produced a mutant alB-adrenoceptor which was able 
to generate an inositol phosphate accumulation in the absence of agonist. The H3R 
naturally contains within the C-terminal region of its' third intracellular loop the 
residues that are normally mutated into a GPCR to make it constitutively active. 
Noting this Morisset et al, 2000 carried out a series of experiments to demonstrate that 
the H3R is indeed constitutively active and importantly produced the first evidence 
that this is also the case in native tissue. This has significant implications for the way 
in which the H3R may be regulated in vivo. It also means that many so-called 
antagonists are more properly thought of as inverse-agonists. Neutral antagonists 
simply inactivate a receptor, whereas an inverse-agonist has highest affinity for the 
receptor in its inactive conformation. Thus an inverse-agonist stabilises the receptor in 
a form that is not coupled to its respective G-protein. 
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2.2.4 Histamine H3 receptor pharmacology 
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Figure 1.3 Imidazole-containing histamine H3 receptor agonists. 
This compound is not an agonist, but a neutral antagonist. 
So far all H3R agonists are very similar to histamine (compound 1, Fig 1.3) and 
contain a 4(5)-substituted imidazole ring. Replacements of this moiety and/or 
attachments to the imidazole ring eliminate H3R activity (Leurs et al, 1995; de Esch & 
Belzar, 2004). However, small structural changes to the imidazole side chain of 
histamine have resulted in very potent and selective H3R agonists. Methylation of the 
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basic amine group of histamine generates N-a- methylhistamine (compound 2), an 
H3R agonist that is about three times more active than histamine itself (Lipp et al, 
1995). The tritiated analogue of this compound is frequently used in H3R binding 
studies. The related compound (R)-a-methylhistamine (RAMH, compound 3), pK; 8.4 
for the hH3R (Arrang et al, 1987), is considered as the standard H3R agonist. RAMH 
has been used in many pharmacological investigations however its' in vivo use is 
limited because it is both highly basic and hydrophilic, extensively metabolised and of 
low bioavailability (Krause et al, 1995). These problems have been overcome with the 
use of prodrugs, bioavailable precursor drugs which undergo a chemical conversion to 
the active agent by metabolic processes. Novel azomethane prodrugs of (R)-a- 
methylhistamine were developed (Krause et al, 1995) such as BP 2-94 (compound 4). 
The use of RAMH and imetit (compound 5, pK; 9.2 for the hH3R) for in vivo 
experiments is limited by their lack of selectivity. For example both agonists have 
cardiovascular effects: RAMH via a2 adrenergic receptors and imetit through 5-HT3 
serotonin receptors (Coruzzi et al, 1995). In addition RAMH can cause 
bronchconstriction due to H1R activation (Hey et al, 1992). The recently discovered 
H4R can be activated by H3R agonists such as immepip (compound 7a, pK; 9.6 for the 
hH3R), RAMH and imetit (see section 2.3.4). The selectivity of these agonists for H3 
over the related H4R is only 27-55 fold (Hough, 2001). An immepip analogue 
(compound 8, immethridine) has recently been produced (Leurs et al, 2005). 
Immethridine is slightly less active than immepip at the H3R but shows a 300-fold 
selectivity for this receptor compared with H4R (Kitbunnadaj et al, 2004). 
Methimepip (compound 9) has both high affinity for the H3R (pK19 hH3R) and 2000- 
fold selectivity over the hH4R (Kitbunnadaj et al, 2004; Leurs et al, 2005). 
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Compound No 
See Fig 1.3 
Name pKi at native 
hH3R 
Selectivity over 
hH4R 
1 Histamine 8.59a 1.5 
2 NAMH 9.4l a 46 
3 RAMH 8.41 a 200 
5 Imetit 9.67' 9 
7 Imme i 9.58a 23 
8 Immethridine 9.07b 300 
9 Methime i 9.00 2000° 
Table 1.1 Affinities to hH3R and selectivity over 11114R of imidazole-containing 
histamine H3 receptor agonists 
NAMH = N-a-methylhistamine; RAMH = R-a-methylhistamine 
a Ireland-Denny et al, 2001 b Kitbunnadaj et al, 2004 
° Kitbunnadaj et al, 2005 
d Liu et al, 2001 
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b) Antagonists 
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Figure 1.4 Imidazole-containing histamine H3 receptor antagonists. 
Thioperamide (compound 13, Fig 1.4) was for many years the reference H3 antagonist 
since it was the first potent antagonist to lack activity at H1 and H2 receptors (Arrang 
et al, 1987). It is now more accurately described as an inverse agonist. It shows high 
affinity for the rat H3R (pK; 8.4) but is less active at the hH3R (pK; 7.2) (Lovenberg et 
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al, 2000) In addition it has high activity at the hH4R (pKi 7.3), the rat 5-HT3 serotonin 
receptor (pK; 5.6) and a2A adrenergic receptor (pK; 6.9) and the human a2c adrenergic 
receptor (pK; 6.5) (Esbenshade et al, 2003). Another early imidazole-containing H3R 
antagonist that has been widely used to characterise the H3R is clobenpropit 
(compound 14, pK; 9.4 hH3R). This compound is related to the agonist imetit. In 
general increasing the distance between the basic moieties of agonists such as 
histamine or imetit and/or attaching larger lipophilic moieties in the side chain creates 
potent H3R antagonists. The basic moieties in the imidazole side chain can 
alternatively be omitted as in the proxyfan class. Proxyfan (compound 15) has 
recently been identified as a neutral H3R antagonist (pK; 8.0, rH3R) (Morisset et al, 
2000). However proxyfan is an example of what has been called a protean agonist in 
that it shows agonistic, neutral antagonistic and inverse agonistic properties depending 
on the signalling assays being used (Gbahou et al, 2003). Protean comes from Proteus 
the Greek god who could change shape and appearance at will. A possible explanation 
for the phenomenon of protean agonism is that the degree of constitutive activity in 
any particular system may determine the effect of a given protean compound. 
Therefore (obtusely) it is not really a property of the compound itself rather of the 
receptor and its environment. Proxyfan's mode of action can be altered by relatively 
minor alterations to its' structure. For example ciproxifan (compound 16) is a potent 
inverse agonist (pK; 9.2, rH3R) (Ligneau et al, 1998; Hancock et al, 2004). 
Ciproxyfan has been used in various in vivo studies but has only moderate affinity for 
the human H3R (pK; 6.99), in addition it shows moderate activity at a number of other 
important receptors (Ebenshade et al, 2003). An important characteristic of the H3R 
antagonists is that there is evidence for considerable inter-species variability (Ireland- 
Denny et al, 2001). 
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Compound No 
See Fig 1.4 
Name pKi at native 
human H3Ra 
pKi at 
native rat 
H3Ra 
Selectivity over 
hH4Rb 
13 Thioperamide 7.13 8.1 0 
14 Cloben ro it 9.08 9.38 21 
16 Ci rox fan 6.99 9.15 0 
Table 1.2 Affinities to hH3R and selectivity over hH4R of imidazole-containing 
histamine H3 receptor antagonists 
a Ireland-Denny et al, 2001 
b Liu et al,. 2001 
ii) Non-imidazole H3R antagonists 
Most of the imidazole-containing antagonists (thioperamide, clobenpropit and 
ciproxifan) have the disadvantage of interacting with cytochrome P450. Therefore 
much effort has been put into developing non-imidazole H3R antagonists (Leurs et al, 
2005) and it is these latest compounds which hold most promise as future drugs, e. g. 
potential anti-obesity drugs A-423579 and NNC 0038-000-1202 from Abbott 
Laboratories and Novo Nordisk respectively (Hancock et al, 2004; Malmlof et al, 
2007 respectively) and ABT-239 from Abbott Laboratories as a possible treatment for 
Alzheimer's Disease (Fox et al, 2004; Esbenshade et al, 2004). 
2.2.5 Pharmacological heterogeneity 
Pharmacological heterogeneity of H3 receptors both within and between species has 
long been a conundrum. Cloning of the H3R has lead to far more detailed 
understanding of its structure. Receptor polymorphisms and the possibility of multiple 
receptor isoforms are likely to underlie at least some of this diversity (Hancock et al, 
2003). There is accumulating evidence for differential distribution of splice variants in 
different brain regions in human (Coge et al, 2001; Wellendorph et al, 2002), rat 
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(Drutel et al, 2001; Morisset et al, 2001) and mouse (Rouleau et al, 2004). 
Interestingly expression of the different isoforms within the CNS varied in key areas 
involved in regulation of sensory, endocrine, cognitive and motor functions. It should 
be emphasised that studies mapping native distribution of splice variants rely solely 
on detecting expression of mRNA. So far it has not been possible to directly probe 
protein expression, an issue addressed for the first time in this thesis. 
a) Cross-species heterogeneity 
Radioligand binding (RLB) studies and functional assays have been used to compare 
the pharmacology of native H3 receptors across species. Several histamine 
homologues have different effects on noradrenaline release in mouse cortex compared 
with their effect on neurogenic contractions in guinea pig jejunum (Leurs et al, 1996). 
This could also be accounted for by H3R heterogeneity between tissues. In the same 
study different potencies for several compounds were found when comparing guinea 
pig functional assays with rat brain radioligand binding. Comparing antagonist 
potencies (thioperamide or ciproxifan) to modulate [3H]-histamine release from 
human and rat cortex or in other functional or radioligand binding studies, lower 
potencies at human receptors were described for these antagonists but not for agonists 
(review by Schwartz et al, 2001). Cross-species studies of radioligand binding to rat 
cortex, [3H]-noradrenaline release in mouse cortex, or reversal of H3R agonist induced 
inhibition of electrically produced contractions of guinea pig intestine were performed 
with a series of imidazole-based ligands related to iodoproxyfan (Schlicker et al, 
1996) as well as compounds related to immepip and imetit (Alves-Rodrigues et al, 
2001). In the latter study an immepip analogue VUF4929 showed a nearly 20fold 
increase in affinity to block guinea pig jejunal contraction than to antagonise 
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noradrenaline release in rat cortices, while a reversed agonist potency order (10fold) 
was observed for immepip. Somewhat surprisingly a better correlation was found 
when comparing antagonist potencies between guinea pig and rat radioligand binding 
affinities than when comparing rat binding affinities to apparent blocking potencies in 
the mouse (Schlicker et al, 1996). It is now known from studies on the pharmacology 
of cloned receptors that the protein sequences in the mouse and the rat are identical at 
key sites shown to be important in determining binding affinity. 
Inter-species potency differences for antagonist compounds were also suggested by 
radioligand binding competition assays carried out in rat, monkey and human cortices. 
The affinity of thioperamide was significantly lower in primates compared to the 
rodent (West et al, 1999). 
By contrast, comparing human saphenous vein to guinea pig ileum showed no big 
differences in the antagonist potencies of either thioperamde or clobenpropit 
(Valentine et al, 1999). 
b) Evidence for amino acids at key sites being responsible for inter-species 
differences 
Extensive comparison of native receptors in radioligand binding and functional assays 
also confirmed distinct cross-species pharmacology which could be explained by 
amino acid differences between human, canine, rat and guinea-pig receptors (Ireland- 
Denny et al, 2001). Most agonists were nearly equipotent at cloned human, cloned rat 
or native rat cortical receptors. However the antagonist thioperamide had a 10-fold 
lower affinity at the cloned human receptor compared to the cloned rat receptor. 
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Clobenpropit on the other hand was nearly equipotent at human and rat receptors in 
both radioligand binding and cAMP based functional assays (Ireland-Denny et al, 
2001; Lovenberg et al, 2000). Ligneau et al, 2000 obtained similar results for both 
thioperamide and ciproxifan reporting 9-fold and 12-fold lower affinities respectively 
at cloned human H3R compared with the cloned rat receptor. As in the previous study 
clobenpropit was found to be approximately equipotent at the two receptors. By 
contrast the situation was reversed for the antagonist potency of FUB(349) with 
affinity at the human receptor 6-fold greater than at the rat receptor. 
Similar evidence of interspecies heterogeneity has been reported in radioligand 
binding assays with the antagonist A-304121 (Hancock et al, 2003). Comparing 
affinities at rat and human cortices with guinea pig ileum the order was as follows: rat 
30-fold > guinea pig 300-fold > human. Ligneau et al, 2000 demonstrated that key 
amino acids are responsible for these species differences. They mutated rat receptors 
either at a single site V 122A or doubly V 122A together with A 119T, effectively 
turning the rat receptor into the human equivalent. The single mutation produced a 5- 
fold decrease in the affinity of ciproxifan binding while the double mutation resulted 
in an 18-fold decrease making the mutated rat receptor pharmacologically identical to 
the human receptor. In analogous studies (Yao et al, 2003) used recombinant 
technology to ligate the N terminus through TM3 of the human receptor to TM4 
through to the carboxy terminus of the rat receptor. Subsequent pharmacological 
analysis confirmed TM3 as being critical for the affinity of several species-selective 
ligands. The importance of the amino acids at positions 119 and 122 in affinity of the 
binding domain of ciproxifan, thioperamide and several non-imidazole antagonists 
was also established. 
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Previously cited studies (Schlicker et al, 1996) showed a higher correlation between 
antagonist potencies for 16 iodoproxifan analogues in the guinea pig ileum assay and 
rat radioligand binding affinities than between rat binding affinities and antagonist 
potencies in mouse perfusion studies measuring radiolabeled noradrenaline release 
from cortical slices. This is surprising because it is now known that rat and mouse 
receptors are identical at positions 119 and 122 in TM3, whereas guinea pig has 
threonine and valine at these positions. However these differences could reflect 
differential tissue distribution of H3R isoforms since receptors in guinea pig ileum are 
being compared with receptors found in mouse cortical slices. In general the findings 
relating key sites in TM3 to particular pharmacological profiles has been confirmed in 
several other species (review by Hancock et al, 2003). 
c) Heterogeneity within species 
Pharmacological data has since the 1990's pointed to H3R heterogeneity and the 
possibility of receptor subtypes. Different classes of binding site were defined in rat 
cortical membranes (West et al, 1990a) having either slow or fast off rates for [3H]- 
R-a-methyl histamine (RAMH). These same workers described high (rat H3A) and 
low (rat H3B) affinity sites in rat brain slices using the inverse agonists thioperamide 
and burimamide (West et al, 1990b). Other studies in rat are broadly in agreement 
with these initial findings (Arrang et al, 1990; Jansen et al, 1994). 
The rank order of potency for thioperamide, impromidine and burimamide, in 
experiments to block H3R-agonist inhibition of sympathetic-elicited hypertension in 
the guinea-pig, were found to reflect that described at the rat H3B site (Hey et al, 
1992). These findings were used to make a case for the physiological relevance of the 
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low affinity site. However these results should be interpreted with care since the rat 
and guinea pig receptors are pharmacologically different. Conversely Schlicker et al, 
1992 proposed that control of CNS noradrenaline in the mouse cortex was mediated 
via the high affinity H3A site. Potency orders for several H3R ligands to regulate 
potassium-stimulated [H3]-acetylcholine release from preloaded slices of rat 
entorhinal cortex also suggested subtype heterogeneity (Clapham & Kilpatrick, 1992). 
Nevertheless other workers (Schlicker et al, 1996; Brown et al, 1996) were unable to 
obtain radioligand binding data in support of high and low affinity states in either rat 
or guinea pig tissues. 
Thus far it has not proved possible to conclusively distinguish between distinct high 
and low affinity sites on the same receptor, different states arising from modulation of 
agonist affinity due to the receptor being coupled/uncoupled to G protein (or possibly 
in a constitutively active conformation), or the expression of different receptor 
subtypes in different tissues within the same species for which there is some evidence 
(Harper et al, 1999; Coge et al, 2001; Ebenshade et al, 2005). Conceivably all these 
mechanisms may contribute in some manner to the observed heterogeneity within 
species. 
d) Evidence for different splice variants exhibiting distinct pharmacologies 
With recognition of the existence of splice variants it was obvious to ask whether 
different affinity states might reflect potency differences between receptor isoforms. 
A 5-fold difference in affinity of thioperamide (39 and 199nM) for human isoform 1 
(445) compared with isoform 2 (365) was reported by Wellendorph et al, 2002. 
However other studies failed to show affinity differences for ciproxifan, thioperamide 
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or clobenpropit at these two isoforms (Coge et al, 2001), although this was not 
surprising for clobenpropit where no differences are observed in native rat tissue 
either. Abbott Laboratories also found no differences for thioperamide at these 
isoforms. Large potency differences were not found for a series of antagonists in 
either radioligand binding or functional assays (review by Hancock et al, 2003). By 
contrast other workers (Morisset et al, 2001) found thioperamide more potent at the 
shorter isoforms of the rat receptor (445< 413< 397). Likewise clobenpropit and 
ciproxifan were 5-fold more potent at the shorter isoforms, although FUB465 and 
proxifan were more potent at 445, as were the agonists histamine and imetit. These 
findings are in agreement with those of Drutel et al, 2001. In conclusion several 
studies, although not all, support lower potencies and affinities for full length 
compared with shorter isoforms - both for antagonists and agonists. However these 
differences appear modest compared with first reports of possible receptor subtypes 
referred to as H3A and H3B (West et al, 1990 a and b). 
A further source of pharmacological heterogeneity may be the co-expression of 
different receptor isoforms. The pharmacology of the full length rat H3R is altered by 
the presence of shorter isoforms (Bakker et al, 2006). Heterogeneous co-expression 
of the rH(3A) with the rH(3D) isoform resulted in the intracellular retention of the rH(3A) 
and reduced rH(3A) functionality. This study investigates whether human H3 and H4 
isoforms could play a similar regulatory role. 
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2.2.6 In vivo role of histamine H3 receptors 
As alluded to earlier histamine and the histaminergic system appear to be important in 
nervous system regulation and behaviour. Roles in arousal, attention and homeostatic 
mechanisms are well documented (review by Brown et al, 2001). In the following 
section the main focus will be on current evidence for the involvement of the H3 
receptor in these areas. 
a) Arousal 
Lesions in the TMN and the adjacent posterior hypothalamus lead to hypersomnia 
(Lin et al, 1989). Firing of histaminergic neurons mirrors the sleep/wake cycle and 
histamine release in the prefrontal cortex is correlated to waking (Sakai et al, 1990). 
Mice lacking brain histamine are unable to stay awake when high vigilance is needed 
(Parmentier et al, 2002). As H3 receptors can function as auto-receptors controlling 
histaminergic transmission it is not surprising that there is both pharmacological and 
behavioural data which provides evidence for their involvement in the sleep/wake 
cycle. H3R antagonists lead to increased levels of brain histamine which in turn 
increase wakefulness. H3R -/- mice are insensitive to the wake-promoting effects of 
the H3R antagonist thioperamide (Toyota et al, 2002), confirming the role of the H3R 
as a mediator of wakefulness. Interestingly there was no evidence for an increase in 
arousal in H3R -/- mice. Several possible explanations could account for this (Chazot 
& Shenton, 2004) reflecting the complexity of the interactions both within the 
histaminergic system itself and between this system and other transmitter circuits. As 
discussed later H3R blockade might also improve vigilance and cognitive responses. 
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b) Homeostasis 
Pharmacological studies support a role for histamine in homeostatic mechanisms 
involving the hypothalamus. These include fluid balance, eating, thermoregulation 
and cardiovascular regulation. 
i) Fluid intake 
Histamine injected into the cerebral ventricles of hypothalamic sites leads to an 
increase in drinking. At the same time this results in an increase in vasopressin levels 
and a decrease in urine output mediated via both Hl and H2R (Brown et al, 2001). 
Dehydration-induced vasopressin release is also strongly depressed by blockade of 
histamine synthesis by a-FMH (an inhibitor of histamine synthesis), activation of 
presynaptic H3R or antagonism of postsynaptic histamine receptors (Kjaer et al, 
1994). 
ii) Food intake 
There is consistent evidence for histamine involvement in eating. Increased brain 
histamine following i. c. v. injection or loading with the precursor L-histidine, or 
application of thioperamide, leads to decreased feeding (Brown et al, 2001). 
Conversely a-FMH or antagonists of H1R lead to increased feeding (Brown et al, 
2001). H3 -/- mice manifest a mild obese phenotype (Takahashi et al, 2002) 
characterised by increased body weight, food intake and adiposity and decreased 
energy expenditure. The anorexigenic effect of thioperamide is not seen in these mice. 
Studies in the Siberian hamster have shown an involvement of the H3R in regulation 
of food intake related to hibernation. Catabolism of intra-abdominal fat reserves is one 
of the most striking physiological adaptations to winter hibernation. A screen of gene 
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expression revealed that H3R mRNA in the dorsomedial posterior hypothalamic 
nucleus is photoperiodically regulated, with significantly lower expression associated 
with weight loss when the hamsters were switched from a long to short photoperiod 
(Barrett et al, 2005). 
iii) Cardiovascular control 0 
H3R have been identified as inhibitory hetero-receptors in cardiac adrenergic nerve 
endings and H3R activation decreases carrier-mediated noradrenaline release in 
guinea-pig and human heart (Silver et al, 2001). Silver et al, 2001 demonstrated that 
stimulation of H3R on H3R transfected SKNMC neuroblastoma cells inhibited the 
Na+/H+ exchanger which is pivotal to the transport of noradrenaline across the cell 
membrane. This study focussed on the possibility of H3R activation limiting the 
excessive release of noradrenaline during protracted myocardial ischaemia and thus 
having a cardioprotective effect. The role of the H3R on adrenergic neurons under 
normal physiological conditions was not explored. 
c) Cognition, learning and memory 
Cognition is a complex of multiple integrated neurological and behavioural activities 
in which arousal and attention are very important. The central histaminergic system is 
known to play a role in cognition, learning and memory. Histaminergic neurons 
innervate structures which are important in cognition including the basal forebrain, 
cerebral cortex, cingulate cortices, amygdala, and thalamus through cholinergic 
projections to the hippocampus. The excitatory action of histamine on some of these 
projection sites is well documented (Brown et al, 2001). Direct or indirect activation 
of brain histamine has been shown to have procognitive effects (reviewed by Passani 
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et al, 2000). For example increases in brain histamine improve social memory in rats 
whereas decreases have a detrimental effect (Prast et al, 1996). Interactions of 
histamine with the N-methyl-D-aspartate (NMDA) receptor polyamine site (Witkin & 
Nelson review, 2004) and evidence of histamine-induced facilitation of long-term 
potentiation in rat hippocampal slices (Selbach et al, 1997) also support a role for 
histamine in cognition. 
Decrease in levels and/or function of acetylcholine in the brain are thought to be a 
major factor in age related cognitive decline. Increased levels of histaminergic activity 
in aging human brain (Prell et al, 1991) and increased levels of histamine in rat brain 
with age (Onodera et al, 1992) may play a part in decreased acetylcholine uptake and 
function. H3R antagonists may be able to prevent the reductions in acetylcholine 
release and cognition brought about by histamine (Blandina et al, 1996; Orsette et al, 
2002; Bacciottini et al, 2002). 
H3R antagonists have been shown to have procognitive effects in animal models 
(Passani et al, 2000) and to prevent impairments in cognitive performance caused by 
scopolamine (cholinergic antagonist), MK-801 (NMDA antagonist) or age (Miyazaki 
et al, 1995; Blandina et al, 1996; Onodera et al, 1998; Giovannini et al, 1999; 
Molinengo et al, 1999). This suggests that H3R antagonists may be more effective in 
enhancing cognition in impaired systems or systems under stress. 
H3 -/- mice showed insensitivity to the amnesic effects of scopolamine in passive 
avoidance conditioning (Toyota et al, 2002). Interestingly the H3 -/- mice were not 
insensitive to scopolamine in a second model, the open field habituation test. The fact 
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that the H3 -/- mice were sensitive to the effect of scopolamine only in an aversion 
model may indicate a specific role for the H3R in memory formation associated with 
painful or unpleasant stimuli. H3 -/- mice showed enhanced spatial learning and 
memory in the Barnes maze (Rizk et al, 2004). In this same study H3 -/- mice showed 
reduced measures of fear avoidance in limited models involving exploratory 
behaviour and avoidable fear-provoking stimuli. However, the effects of acute H3R 
blockade on fear avoidance and cognition (Bongers et al, 2004) were found to differ 
markedly from the effects of constitutive H3R deficiency seen in H3 -/- mice. Whereas 
measures of fear in tests involving exploratory behaviour and avoidable fear- 
provoking stimuli were increased after acute H3R blockade, they were unchanged in 
constitutive H3R deficiency. Therefore the use of H3 antagonists to treat cognitive 
impairments should be very carefully evaluated. 
Conversely H3R agonists generally impair cognitive performance. Pre-training 
(Blandina et al, 1996) but not post-training (Giovannini et al, 1999) administration of 
RAMH or imetit impaired the performance of rats in object recognition and passive 
avoidance. In the pre-training study impairment of performance was produced at 
agonist doses which decreased the release of acetylcholine in vivo. These data suggest 
that the H3R might preferentially influence learning rather than already acquired 
behaviours, although other findings show that H3R antagonists can also facilitate 
learned behaviours. The H3 agonist immepip produced cognitive deficits in tests of 
olfactory and social memory, whereas thioperamide had the opposite effect (Prast et 
al, 1996). 
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However the above observations are by no means universal. H3 agonists have been 
reported to improve cognition. RAMH improved spatial learning in a water maze 
(Smith et al, 1994). Possibly specific neuronal circuits underlie spatial learning which 
relies on hippocampal function in contrast to attentional functions or episodic memory 
functions, and these may involve different regulatory mechanisms. Similarly H3 
antagonists do not show efficacy in all animal models of cognition (Miyazaki et al, 
1995; Miyazaki et al, 1997; Kirkby et al, 1996). Under conditions where neither 
thioperamide nor VU9153 showed improvement in object recognition and passive 
avoidance tests when administered before training to normal animals, both 
compounds attenuated scopolamine deficits (Giovannini et al, 1999). However, in 
similar experiments (Molinengo et al, 1999) it was found that H3 antagonists could 
improve the performance of both normal and scopolamine treated mice. It should be 
noted that the Giovannini experiments were carried out in rats, not mice. Also 
thioperamide can reverse cognitive impairment produced by means other than just 
cholinergic blockade (ie resulting from scopolamine treatment). A cognitive deficit 
produced by the NMDA receptor ion channel antagonist MK-801 could be improved 
by administration of thioperamide (Chen et al, 1999; Huang et al, 2004). 
With regard to these apparent anomalies in the experimental evidence linking the H3R 
with cognition it should be remembered that there are many factors which may 
impinge on the final outcome: 
- the time of administration of the drug may be important, that is before, during 
or after training or different combinations of all three 
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the behavioural state both before and during testing, for example fearful or 
aroused, may be important. As histamine levels and histaminergic activity is 
tightly linked to the sleep/wake cycle this should also be taken into account 
as mentioned earlier H3R antagonists may be more effective at improving 
impaired cognition or learning under stress 
the effects on cognition are dose-dependent and the dose-effect curves are 
typically NOT monophasic. The lack of linearity could be due to the multiple 
central activities of H3R ligands. 
the effects are mediated via several different systems and receptors including: 
cholinergic system, NMDA receptors, H1R and H2R. 
different brain regions may be differentially affected 
effects may be different in different species. 
the ligands used vary in their H3 selectivity, some of them do not exclusively 
target the H3R 
d) Pain and Stress 
A large number of studies have examined the role of the central histamine system in 
modulating the perception of pain. Whilst peripheral histamine is involved in the 
stimulation of nociceptive fibres it appears that central histamine is important in anti- 
nociception (Hough, 1988; Chazot & Shenton, 2004). Histamine when administered 
icv can elicit either anti-nociceptive or hypernociceptive effects depending on the site 
of injection and the dose in a number of rodent models (Chung et al, 1984; Glick & 
Crane, 1978; Malmberg-Aiello et al, 1994). Other strategies of increasing brain 
histamine, including application of L-histidine, the H3R antagonist thioperamide, and 
the catabolism inhibitor metoprine, have all resulted in anti-nociception (Malmberg- 
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Aiello et al, 1994). Both Hi and H2R antagonists when applied icv or into the 
periaquaductal gray have been shown to block histamine induced anti-nociception 
(Bhattacharya & Parmar, 1985; Thoburn et al, 1994; Lamberti et al, 1996). Recent 
work with KO mice has further implicated the postsynaptic H1 and H2 receptors in 
pain transmission. H1 -I- mice showed significantly fewer nociceptive responses in a 
wide range of pain models, including the hot plate tail flick, tail pressure, formalin, 
capsaicin and abdominal constriction tests (Mobarakeh et al, 2000). Nociceptive 
responses in H2 -/- mice are similarly reduced, it appears that H1 and H2 receptors 
function cooperatively to modulate pain perception in the CNS (Mobarakeh et al, 
2006). The H3R also plays a role in nociception. Neither RAMH nor thioperamide 
alone elicited any anti-nociceptive effect upon thermal or chemical tests. However 
thioperamide reduced the effects of morphine in the tail-emersion model, while 
RAMH enhanced its effects in the hot-plate test (Owen et al, 1994). This illustrates 
the integration of the opioid and histaminergic systems in certain pain states. H3R -/- 
mice are refractory to the nociceptive effects of thioperamide (Cannon & Hough, 
2005). Initial studies indicated that the anti-nociceptive action of H3R agonists might 
result from inhibition of transmission by sensory C fibres at peripheral loci. However 
recent immunohistochemical studies (Cannon et al, 2006 in press) is at odds with 
these findings. A case can be made for H3R-containing, ASIC3-expressing, deep 
dermal fibres being involved in mechanical nociceptive transmission. In addition 
H3R- containing, deep dermal, peptidergic AS fibres have been identified. These 
fibres lie close to the adventitial layers of arterioles suggesting that they may be 
involved in regulating blood flow ((Fundin et al, 1997). During injury H3R containing 
deep dermal , perivascular fibres could contribute to the pain and inflammation 
(Chazot & Shenton, 2004). 
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A note of caution should be added here in that the most recently discovered H4R is 
also an important mediator of inflammatory responses (see later). Since some of the 
drugs hitherto considered selective for the H3R are now known to have at least some 
activity against this latest histamine receptor, findings of past studies may need to be 
re-evaluated. 
As outlined in section 1.1, histamine acting on the hypothalamus affects the release of 
many hormones from the pituitary gland. The hypothalamic-pituitary-adrenal axis 
(HPA axis) constitutes a major part of the neuroendocrine system that controls 
reactions to stress and regulates various body processes including digestion, the 
immune system, mood and sexuality, and energy usage. Species from humans to the 
most ancient organisms share components of the HPA axis. It is the mechanism for a 
set of interactions among glands, hormones and parts of the mid-brain that mediate a 
general adaptation response. Since histamine has a key role in learning and memory 
as well as homeostasis during times of stress or threat, a persuasive case has been 
made for the physiological role of histamine and the histaminergic system as a danger 
response system (Brown et al, 2001). 
2.2.7 Potential H3R targeted therapies 
Taken together with the physiological role of histamine and the histaminergic system, 
the anatomical distribution of the H3R and its modulation of key transmitter systems, 
as discussed above; strongly suggests that this receptor may be a potential therapeutic 
target in a broad range of diseases and disorders. Current areas of interest are in the 
treatment of cognitive deficits (Leurs et al, 2005; Hancock, 2006), dementias 
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(Medhurst et al, 2007) and psychoses (Akhtar et al, 2006); movement disorders 
(Gomez-Ramirez et al; 2006); sleep disorders (Leurs et al; 2005); obesity (Hancock, 
2006); migraine (Millan-Guerrero et al; 2003) and gastric inflammatory pain (Coruzzi 
et al, 2007; Coruzzi et al, EHRS 2007); epilepsy (Yokoyama et al, 1993; Vohora et al, 
2000; Kakinoki et al, 1998; Yoshida et al, 2000; Chazot & Hann, 2001); cerebral 
ischaemia (Lozada et al; 2005) and cardiac arrhythmias (Levi & Smith, 2000). 
2.3 Histamine H4 Receptor 
2.3.1 Cloning 
After the cloning of the human H3 receptor in 1999 (Lovenberg et al, 1999) two 
separate groups used homology studies to identify and clone the latest human 
histamine H4 receptor within the following year (Oda et al, 2000; Nakamura et al, 
2000). The gene encoding the H4 receptor is on human chromosome 18, spans >20.6 
kb and has a similar intron-exon arrangement to the H3R gene (Coge et al, 2001). The 
H4 receptor is expressed predominantly in bone marrow, eosinophils and mast cells. 
There is mounting evidence for its presence in some brain areas although there may 
be important species differences (see section 2.3.2 below). The H4R shows 
considerable homology with the H3R (58% for the transmembrane regions, but 34- 
35% overall) (Nguyen et al, 2001). There is substantial variation between species, 
with only 65-70% homology across human, mouse, rat and guinea-pig H4 receptors 
(Liu et al, 2001) (see also section 2.3.4). This is in contrast to the H3R which is 
approximately 92% conserved across species (Liu et al, 2001). Reflecting their 
dissimilarity H4 receptors have different pharmacological profiles. H4R from humans 
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and guinea pigs have high affinity for histamine (5nM), whereas the affinity of the rat 
114R is 136nM. The rat H4R is also less sensitive to other H4R ligands (Liu et al, 
2001). 
This 390-residue GPCR is encoded by three exons. The similarity between the H4 and 
H3 gene structure and organisation suggests that multiple H4R isoforms might exist 
and indeed two isoforms have recently been reported (van Rijn et al, 2007 submitted). 
The first, H4R(302), lacks exon 2 which results in a deletion of 88 amino acids between 
TM2 and TM4. The second, H4R(67), is a truncated receptor containing only the first 
67 amino acids of the full length receptor. 
2.3.2 Anatomical distribution 
Mapping of anatomical distribution of H4 receptors is hampered by the fact that the 
receptor appears to be expressed at low levels in most tissues. In addition expression 
levels may be altered by the activation state of the cell. It is expressed predominantly 
in bone marrow, eosinophils and mast cells. The tissue distribution of this receptor has 
been profiled in a range of human (using RT-PCR) and mouse (using in situ 
hybridisation) tissues (Zhu et al, 2001). In human tissues H4R expression was most 
abundant in bone marrow and lung. It was expressed at a high level in human 
neutrophils. Interestingly receptor expression was higher in resting mononuclear cells, 
CD4+ T cells, and CD8+ T cells than in the activated cells. Very low levels of 
expression were found in resting and activated CD 19+ B cells and resting CD 14+ 
monocytes. In mouse tissue H4R was detected in the hippocampal formation, 
particularly in the granular cell layer of the dentate gyrus and the pyramidal cell layer, 
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but not in the rest of the brain or other tissues such as skeletal muscle, fat, heart, liver, 
spleen, thymus, lymph node, adrenal gland, spinal cord or kidney. Another study 
using in situ hybridisation reported expression of the H4R in both adult and embryonic 
rat brain where it was speculated to contribute to the migration of developing neurons 
(Lozada et al, EHRS 2004). Immunohistochemistry has shown that H4 receptors are 
present in nerves from the human nasal mucosa (Nakaya et al, 2004). This thesis 
addresses the hypothesis that the H4 receptor is expressed in the rat and human brain 
and may play a distinct role to the H3R within the CNS. 
2.3.3 Signal transduction 
The H4R is coupled mainly to Gi/0 proteins. Heterologous expression of H4R leads to a 
pertussis-toxin-sensitive decrease in the forskolin-induced production of cAMP and 
the inhibition of downstream events such as cAMP responsive element-binding 
protein (CREB)-dependent gene transcription (Oda et al, 2000; Nakamura et al, 2000; 
Zhu et al, 2001; Liu et al, 2001). In addition in stably transfected HEK293 cells, H4R 
stimulation leads to the pertussis-toxin-sensitive activation of downstream mitogen- 
activated protein (MAP) kinase pathways (Morse et al, 2001). As with most Gi/o- 
coupled GPCRs, H4R activation increases [35S]GTPyS binding (Morse et al, 2001). 
Furthermore increased basal levels of [35S]GTPyS binding seen in H4R transfected 
cells compared with non-transfected cells indicates that the H4R is constitutively 
active, as already observed in the other histamine receptor subtypes. Histamine 
mediated activation of either endogenous H4R in mast cells (Hofstra et al, 2003) or 
H4R stably expressed in L1.2 cells (Nakayama et al, 2004) results in a Ca2+ response. 
Histamine-induced Ca2+ signalling is also described in eosinophils (Buckland et al, 
42 
2003). Both Gu0 proteins and phospholipase C (PLC) are involved in histamine- 
induced calcium mobilization and chemotaxis in mast cells, because these responses 
were completely inhibited by pertussis toxin and the PLC inhibitor U73122. These 
observations suggest that phospholipase C is activated via Gßy subunits dissociating 
from Gj1o proteins following H4R activation. The Ca2+ response in mast cells is 
probably linked to cellular chemotaxis because histamine-induced mast-cell 
chemotaxis shows similar sensitivity to pertussis toxin and U73122. In addition there 
is evidence for H4R down-regulation of both STAT1 (Hon et al, 2006) and STAT6 
(Michel et al, 2007) in sensitised human lymphocytes. The Jak/Stat pathway is 
involved in responses to many cytokines. Dimerisation of cytokine receptors occurs 
when the cytokine binds, this attracts a cytosolic tyrosine kinase unit (Jak) which 
associates with the dimer. Among the targets for phosphorylation by the receptor-Jak 
complex are a family of transcription factors (Stats). Phosphorylation leads to 
activation of the Stat which then migrates to the nucleus and activates gene 
expression. H4R activation may down regulate the transcription activity of STAT6 by 
influencing cleavage of the transcription activation domain (TAD) (Michel et al, 
EHRS 2007). 
2.3.4 Pharmacology 
In view of the high homology between the H3 and H4 receptors in the transmembrane 
regions it is not surprising that several H3 ligands also activate the H4R. Amongst this 
group are the agonists immepip (H4R K; 9nM) (Liu et al, 2001), imetit (H4R K; 5nM) 
(Nguyen et al, 2001) and RAMH (H4R K; 146nM) (Jablonowski et al, 2003). In 
addition the H4R is activated by the H2IH3R antagonist burimamide (H4R K118OnM) 
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(Jablonowski et al, 2003) and the H3R antagonist clobenpropit (H4R K; 13nM) (Liu et 
al, 2001). Thioperamide the prototypical inverse agonist at H3R is also an inverse 
agonist at H4R (H4R K; 27nM) (Jablonowski et al, 2003). Consequently these 
compounds can no longer be considered to be H3R selective. However newer H3R 
ligands such as the agonists immethridine and methimmepip (Kitbunnadaj et al, 2004 
and 2005 respectively), and the non-imidazole H3R antagonists JNJ6379490 and 
A349821 (Shah et al, 2002 and Faghih et al, 2003 respectively) have wide margins of 
selectivity making them useful research tools for the future. In addition other 
compounds with better H4R selectivity, both agonists (Hashimoto et al, 2003; Lim et 
al, 2006) and antagonists (Jablonowski et al, 2003; Thurmond et al, 2004; Terzioglu 
et al, 2004), are showing promise. Interestingly the neuroleptic clozapine has also 
been shown to activate the H4R (Oda et al, 2000). It is possible that H4R activation 
may underlie the serious drug-induced agranulocytosis which clozapine can 
sometimes cause (Krupp & Barnes, 1992; Alphs & Anand, 1999). In addition, given 
preliminary evidence for some H4R expression in the brain, it is possible that it may 
play a part in the therapeutic action of clozapine. 
Full details of the H4R ligand-binding site are yet to be described. The binding pocket 
for histamine is formed by transmembrane domains TM3, TM5 and TM6 (Shin et al, 
2002). Not surprisingly it has characteristics common to the binding sites of other 
aminergic GPCR's (Shi & Javitch, 2002). A cluster of highly conserved aromatic 
residues in TM6, which faces the binding site, is thought to be involved in receptor 
binding and activation. Amino acid differences at key sites within the binding pocket 
are likely to account for differences in the affinity of histamine for the different 
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histamine receptors. Histamine shows increased affinity for H3R and H4R compared 
with H1 and H2 receptors. 
As alluded to earlier (section 2.3.1) there are considerable species differences in 
pharmacology of the H4R (Liu et al, 2001). In a recent study chimeric receptors of the 
human and mouse H4R were constructed to address the molecular basis for the 
different affinity of histamine at these two receptors (Lim, EHRS 2007). The second 
extracellular loop of the H4R was found to be responsible. An important additional 
finding of this study was the possibility that the widely used human H4R antagonist 
JNJ7777120 (Jablonowski et al, 2003) may not afterall be an antagonist at the rat 
H4R, this requires further investigation. 
2.3.5 In vivo role of histamine H4 receptor 
Several studies support a role for H4 receptors in chemotaxis of immune cells, 
including human monocyte-derived dendritic cells and eosinophils (Gutzmer et al, 
2005; Buckland et al, 2003; Ling et al, 2004; O'Reilly et al, 2002), and most recently 
in human monocytes (Dijkstra et al, in press). H4 receptor stimulation leads to actin 
polymerisation which is a key step in the polarisation and subsequent shape change of 
the cell which drives chemotaxis (Buckland et al, 2003). Most leukocyte attractants 
also affect the function and expression of adhesion molecules which are important for 
interactions with the microvascular epithelium. In line with its chemoattractant 
effects, histamine upregulates CD1 lb and CD54 in eosinophils (Buckland et al, 2003; 
Ling et al, 2004). Histamine also induces migration of mast cells in vivo. Histamine 
inhalation leads to an increase in the total number of mast cells in the trachea of mice 
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(Thurmond et al, 2004). These increases are mediated via H4 receptors as 
demonstrated by the ability of H4R antagonists to inhibit the migration. The H4R also 
has a role in the secretion of IL-16 from CD8+ T cells (Gantner et al, 2002). IL-16 is 
produced by several cell types and is a chemoattractant for CD4+ T cells. Stimulation 
of both H4 and H2R appears to be necessary for this effect because inhibitors of either 
block the response. Furthermore H4R modulation of CD4+ T cell activation and Th2 
responses has been described in a murine asthma model (Danford et al, 2006). In this 
study blockade of the H4R on dendritic cells lead to decreases in cytokine and 
chemokine production and limited their ability to induce Th2 responses. The 
monocyte fraction of peripheral blood mononuclear cells, where H4R have most 
recently been demonstrated (Dijkstra et al, 2007 in press), contain direct precursors of 
dendritic cells and skin associated macrophages. Stimulation of H4R on monocytes 
(Dijkstra et al, 2007 in press) lead to an inhibition of the production of the chemokine 
CCL2 which resulted in a decrease in monocyte recruitment. 
The widespread expression of H4 receptors on immune cells including mast cells, 
eosinophils and monocytes, together with their ability to mediate chemotaxis and 
influence the secretion of some chemokines; suggests a role for the H4R in 
inflammation and immune responses. The increase in vascular permeability caused by 
histamine is mediated through its action at H1R. However H4 receptors appear to be 
responsible for other well documented inflammatory events. H4R antagonists block 
neutrophilia in pleurisy models and peritonitis induced by zymosan (Thurmond et al, 
2004; Takeshita et al, 2003). It should be noted that the maximum inhibition achieved 
in these two models is only about 50%, implying that H4 activation is not the sole 
mechanism underlying the response. In vivo inhibition of neutrophilia is unlikely to 
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result from a direct effect on neutrophils (Takeshita et al, 2004; Thurmond et al, 
2004), it could be that H4R antagonists reduce the level of other neutrophil 
chemoattractants. 
Histamine has an important role in the development of several cell types mediated via 
the different histamine receptors. Recent investigations demonstrate that the H4R 
plays a critical role in dendritic cell (DC) differentiation and also regulates cytokine 
production by these cells (Jelinek et al, EHRS 2005). Thymic selection and T cell 
development also appear to be influenced by the H4R (Pällinger et al, EHRS 2005). In 
addition there is evidence for H4R involvement in placental development (Szewczyk 
et al, 2007). 
2.3.6 Potential H4R targeted therapies 
Considering the putative in vivo role of H4R in mediating certain aspects of 
inflammatory responses, H4R selective drugs might prove beneficial in the treatment 
of some allergic (Daugherty, 2004) and inflammatory conditions (de Esch et al, 2005; 
Lim et al, 2006). Selective H4R antagonists significantly inhibited both paw oedema 
and thermal hyperalgesia induced by subplantar injection of carrageenan in the rat 
(Coruzzi et al, 2007). Importantly these activities were not associated with gastric 
damage, which is an unwanted side effect of many commonly used non-steroidal anti- 
inflammatories (NSAIDs). 
In addition H4R mediated influences on cell differentiation suggest cancer therapies 
could be an area of interest. Preliminary evidence for H4R involvement has been 
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reported for colon cancer (Cianchi et al, 2005; Darvas et al, ERRS 2007), pancreatic 
carcinoma (Martin et al, EHRS 2007) and mammary carcinogenesis (Medina et al, 
2006). 
3. GPCR Oligomerisation 
The subject of GPCR oligomerisation is currently attracting great interest. Since the 
early 1990s, evidence has been growing not only for the existence of GPCR oligomers 
but also for their functional significance (George et al, 2002; Hill, 2006). The terms 
oligomer and dimer have been used interchangeably here, although strictly speaking a 
dimer consists of only two units, while an oligomer may be two or more. Experiments 
making use of GPCR chimeras whereby co-expression of two individually 
nonfunctional receptors could restore functionality (a2/M3 and M3/a2 chimeras Maggio 
et al, 1993) were among the first to demonstrate the potential for dimerisation. More 
recently biophysical techniques such as Fluorescent Resonance Energy Transfer 
(FRET) and Bioluminescent Resonance Energy Transfer (BRET) have provided 
evidence that oligomers exist in living cells (Bulenger et al, 2005). In these assays 
close proximity between donor and acceptor fluorophore tagged receptors allows 
excitation of the acceptor which results in a fluorescent emission. 
One of the most well known demonstrations of a receptor hetero-dimer being essential 
for function is provided by studies of GABABR1 and GABABR2 (Marshall et al, 
1999). GABABR2 is necessary for the successful trafficking and expression of 
receptors at the cell surface, GABABRI is essential for ligand binding (Jones et al, 
1998). A further compelling example is provided by sweet and unami (savoury) taste 
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receptors. These receptors are coded for by three genes T1R1, T1R2 and T1R3. Two 
of the three genes need to be expressed in order to give a functional receptor (Zhao et 
al, 2003). The T1R1/T1R3 combination codes for the unami receptor while 
T1R2/T1R3 results in the expression of sweet taste receptors (Nelson et al, 2001). 
Therefore the receptor binding site is clearly altered by the presence of either the T1R1 
or the T1R2 subunit. 
Both the GABAB and the taste receptors belong to the GPCR class C family of 
GPCRs, however there is also support for dimerisation in the rhodopsin-like class A 
GPCRs, to which the histamine receptors all belong. Impressive atomic force 
microscopy images have been published of rhodopsin homo-dimers in native retinal 
discs (Fotiadis et al, 2003). Furthermore the 3D structure of rhodopsin (Palczewski et 
al, 2000) and heterotrimeric G proteins (Sondek et al, 1996; Lambright et al, 1996) 
suggests that a 2: 1 (GPCR: G protein) stoichiometry is necessary for receptor/G protein 
coupling. Direct proof of this has come from neutron-scattering experiments on the 
sölubilised receptor for leukotriene B4 (BLT1R) (Baneres & Parello, 2003). A 
pentameric assembly was demonstrated in the presence of agonist, consisting of a 
BLTR1 dimer coupled to a trimeric G protein. 
Here emphasis will be given to functional evidence for class A GPCR dimers, 
suggestive of a potential in vivo role. 
a) Homo-dimerisation 
Functional roles for homo-dimers have been implicated in a number of investigations 
(Brady & Limbird, 2002). The level of dimerisation of mouse 8 opioid receptors 
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expressed in CHO cells was found to be agonist dependent (Cvejic & Devi, 1997). 
Increasing the agonist concentration brought about an increase in the level of dimers 
and a concomitant decrease in receptor monomers. Morphine, however, did not affect 
the levels of either form. Since morphine, unlike other opioid agonists, does not induce 
receptor internalization, this may suggest a relationship between the ability of agonists 
to reduce the levels of dimer and to induce receptor internalization. At odds with these 
findings levels of human 6 opioid receptor homo-dimers constitutively expressed in 
HEK293 cells were not affected by either agonist or inverse-agonist (McVey et al, 
2001). A peptide derived from TM6 of the p2- adrenoceptor (AR) was able to inhibit 
the formation of homo-dimers (Hebert et al, 1996). Importantly this same peptide was 
able to inhibit agonist-promoted stimulation of adenylyl cyclase activity. Agonist 
binding was found to stabilise dimers, whereas inverse agonist favoured formation of 
the monomer. Therefore interconversion between monomeric and dimeric states could 
be important for biological activity. In agreement with these observations, agonist was 
shown to increase the BRET signal generated by the formation of p2-AR homo-dimers 
in whole cells (Angers et al, 2000). Using photoincorporation of radiolabelled ligands 
selective for dopamine D2 receptors, spiperone was shown to target monomers 
whereas nemonapride was incorporated into both monomers and dimers (Ng et al, 
1996). 
b) Hetero-dimerisation 
Hetero-dimerisation between x and 8 opioid receptors results in pharmacology quite 
distinct from that of the individual component receptors (Jordan & Devi, 1999). 
Recently an opioid agonist, 6'-guanidinonaltrindole (6'-GNTI), which is selective for 
x/S opioid hetero-dimers has been described (Waldhoer et al, 2005). Importantly this 
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study demonstrated the potential for tissue selective drug-targeting based on GPCR 
dimerisation. 6'-GNTI induces analgesia only when it is administered in the spinal 
cord but not in the brain, suggesting tissue specific expression of K/6 opioid hetero- 
dimers. Many class A GPCRs do not reach the cell surface in heterologous expression 
systems (Minneman, 2006). This "technical inconvenience" has been turned to 
advantage in experiments to investigate the combinations of receptor subunits which 
facilitate receptor expression at the cell surface. Within the al-AR subfamily, a1D-ARs 
are almost entirely intracellular (Chalothorn et al, 2002). However co-expression of 
a1D-ARs with a1B-ARs leads to quantitative surface expression of the a1D-AR subtype 
(Hague et al, 2004). Consistent with this, a1D-ARs are expressed on the cell surface 
when they are transfected into DDT1 smooth muscle cells which endogenously 
express alB-ARs (Han et al, 1992); while in rat aortic smooth muscle cells, which do 
not endogenously express a1B-ARs, they remain intracellular (Hague et al, 2004). 
Olfactory receptors (ORs) make up about half of the entire human GPCR family, in 
common with other class A GPCRs many of them are not trafficked to the cell surface 
in heterologous expression systems. However co-expression of the mouse M71-OR 
with the ß2-AR subtype in HEK293 cells leads to a substantial translocation of 
functional M71-ORs to the cell membrane (Hague et al, 2004). Importantly, in this 
same study, in situ hybridisation showed extensive co-localisation of M71-OR with P2' 
AR mRNA in mouse olfactory epithelium. Interestingly all Drosophila olfactory 
neurons express two ORs: one specific to a particular olfactory neuron while the other 
(OR83b) is ubiquitously expressed in most olfactory neurons (Larsson et al, 2004). 
Without OR83b specific ORs do not localise to appropriate dendritic compartments 
and the neurons are not stimulated by odour in electrophysiological assays. 
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Furthermore flies lacking OR83b do not respond to odour in behavioural experiments 
(Larsson et al, 2004). 
c) Mechanism of dimerisation 
The manner in which GPCRs dimerise has not been resolved and given the diversity of 
GPCR structures even within any one class it is unlikely that there is a universal 
mechanism. Initial studies for family A GPCRs implicated involvement of both N 
(Abdalla et al, 1999) and C (Cvejic & Devi, 1997) termini in receptor dimerisation. 
However more recently the focus has been on the TM helices. Several studies have 
used peptides with sequences corresponding to the predicted site of interaction to 
disrupt dimers. For example a peptide matching a sequence in TM6 of 02-ARs 
abolished immunoreactive species of a size compatible with homo-dimers (Hebert et 
al, 1996). Similarly putative dopamine D2 receptor homo-dimer immunoreactivity was 
removed by peptides directed at sequences in TM6 and TM7 (Ng et al, 1996). 
Characterisation of the yeast alpha factor receptor (a receptor for the alpha-mating 
pheromone in the yeast Saccharomyces cerevisiae) has identified a GXXXG 
dimerisation motif in TM1 (Overton et al, 2003). This same sequence is present in the 
TM regions of many GPCRs. It is also found within the H3R sequence (GALAG) 
although here it is in the extra-cellular N-terminus. Mutation and truncation studies 
with al-AR subtypes (Hague et al, 2004) suggest the hydrophobic core and/or 
intra/extracellular loops are the sites of interaction between dimer components. 
However data on the importance of different regions and motifs has sometimes been 
conflicting (Milligan et al, 2004) and this may indicate that there are multiple sites 
and no common mechanism involved in these interactions. 
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Two types of inter-molecular association have been proposed for GPCR homo- 
oligomers: disulphide bonds and TM-domain interactions. Homo-oligomers of several 
class A GPCRs can be dissociated using reducing agents (George et al, 2002), 
suggesting that a disulphide linkage is important for oligomer formation. Interestingly, 
this is not detected in all receptors (including the histamine H3 and HLRs, from our 
own observations), and the complete dissociation by a reducing agent of all receptor 
dimers to receptor monomers is not always seen, even in receptors that are sensitive to 
this treatment. Therefore other interactions besides disulphide bonds appear to be 
involved. As described above there is increasing evidence for TM-domain interactions. 
Computer models of adrenoceptors have indicated that GPCRs might undergo a 
process known as "domain swapping" (Gouldson et al, 2000). Domain swapping has 
been shown to occur in the oligomerisation of several other proteins (Bennett et al, 
1994) and it could explain the rescue of binding seen in experiments where ligand 
binding is restored by the co-expression of two nonbinding GPCR mutants, with 
mutations in different TM domains both involved in the binding site (Maggio et al, 
1993,1996; Monnot et al, 1996). There is however some evidence against domain 
swapping, not least that in class A GPCRs the TM domains appear to be arranged in a 
tightly packed hydrophobic bundle, rendering folding rearrangements unlikely. 
Photoaffinity labelling of the cholesystokinin receptor failed to demonstrate domain 
swapping in cholesystokinin oligomerisation (Hadac et al, 1999); and functional 
rescue was not seen on co-expression of full length vasopressin V2 receptors 
containing the R181 C (TM4) and the Y280C (TM6) missense mutations (Schulz et al, 
2000). Therefore "contact" oligomers have been proposed, as an alternative 
arrangement (Fig 1.5) 
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Potential GPCR dimer interfaces 
Contact dimers Domain swapped dimers 
Fig 1.5 Comparison of contact dimers and domain-swapped dimers 
In practice it may often not be possible to distinguish between these two different 
configurations (Gouldson et al, 2000), and it is quite likely that they are not mutually 
exclusive. 
Bioinformatics techniques are increasingly being used to predict dimer and oligomer 
interfaces. These techniques begin with multiple sequence alignments and share the 
assumption that proteins that are evolutionarily related probably share common 
structural and functional features corresponding to detectable patterns in their 
sequences (Reggio, 2006). 
The occurrence of lipid-exposed residues in predictions from bioinformatics methods 
has been analysed and used to search for dimerization/oligomerization interfaces of 
GPCRs (Filizola & Weinstein, 2005). Residues most frequently identified cluster in 
TM helices 4-6. Among the residues identified within each of these 3 helices, 4.58, 
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5.48, and 6.42 have the greatest number of occurrences. In TM6, residue 6.30 (at the 
boundary between TM6 and the third intracellular loop) had nearly the same 
frequency of occurrence as 6.42. 
Applying a computer modelling approach to aminergic GPCR sequences revealed 
different evolutionarily conserved and accessible patches on TM helices 4-6 in most 
aminergic families and helices 4 and 5 in the muscarinic and opsin family (Soyer et al, 
2003), thus lending support to the premise that the dimerisation mechanism may not be 
the same for all GPCRs, even within one family. 
d) Possible role of GPCR dimers 
The physiological role of receptor dimerisation is still largely unknown. GPCR's are 
important because they usually play a regulatory role, modulating all known 
physiological processes in mammals. The nature of ligand-GPCR-effector interactions 
is such that it is uniquely amenable to adjustments and fine tuning. This is because the 
responses are relatively slow and involve multiple steps and interactions, providing 
many opportunities for continual adjustment. Dimerisation provides another means of 
moderating a response and tailoring it to meet continually changing external demands. 
Several possible mechanisms can be envisaged (e. g. facilitating cell surface 
expression) and there is growing evidence for some of them as alluded to above. 
Dimerisation may serve the same or different purposes depending on the receptors in 
question. 
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3.1 GPCR interactions with other proteins 
It is now understood that GPCR function is regulated by interacactions with other 
membrane and intracellular proteins. Receptor inactivation is brought about by GPCR 
kinases (GRKs) (Lefkowitz, 1993) which phosphorylate serine/threonine residues in 
the C-terminus, followed by arrestin binding (Zuckerman et al, 1985). Arrestins block 
the GPCR/G protein interaction. GRKs are receptor specific and mainly phosphorylate 
activated i. e. agonist bound, receptors. This is called homologous desensitisation. 
Arrestins and GRKs are also involved in endocytosis of receptors and cell signalling. 
They can act as "adaptors" linking receptors both to endocytic machinery and 
signalling proteins (Ferguson, 2001). 
Receptor Activity Modifying Proteins (RAMPS) are a family of membrane proteins 
that bind GPCRs and alter their function. It was found that the receptor for a 
neuropeptide (calcitonin gene-related peptide: CGRP) lacked activity without the 
presence of another membrane bound protein, since designated RAMP 1 (McLatchie et 
al, 1998). Surprisingly this same receptor when complexed with a different RAMP 
(RAMP2) shows specificity for a completely different peptide, therefore specificity is 
conferred by the RAMP rather than the GPCR. It is not known how widespread this 
form of regulation is. 
Many more multidomain scaffolding proteins and accessory/chaperone proteins have 
now been identified. These provide a broad range of mechanisms for ligand 
recognition, signalling, receptor regulation and trafficking (reviewed by Brady & 
Limbird, 2002), an exhaustive account will not be provided here. 
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3.2 Post-translational changes and GPCR function 
Post-translational modifications of proteins involved in cell signalling are important to 
their function. Two of the most common are palmitoylation and glycosylation. 
Palmitoylation is a covalent attachment of palmitic acid to one or more cysteine 
residues via a hydroxylamine-labile thioester bond. Glycosylation is the addition of 
saccharides either via the amide nitrogen of asparagines (N-linked glycosylation) or 
the hydroxyl oxygen of serine and threonine residues (0-linked glycosylation). The 
effects of both have been investigated for several GPCRs (Palmitoylation review: 
Qanbar & Bouvier, 2003; Glycosylation review: Duvernay et al, 2005). 
Studies of the palmitoylation sites of rhodopsin (Moench et al, 1994) revealed that 
anchoring of the palmitates in the membrane results in the formation of a fourth 
cytoplasmic loop. However palmitoylation has been reported to regulate a range of 
other functions in different family members. In the vasopressin Via receptor 
palmitoylation status controls both phosphorylation and sequestration of the receptor, 
furthermore palmitoylation, phosphorylation and sequestration are all regulated by 
agonist (Hawtin et al, 2001). Palmitoylation of the human endothelinB receptor is 
critical for G-protein coupling (Okamoto et al, 1997), while in the vasopressin V2R 
palmitoylation enhances cell surface expression (Sadeghi et al, 1997). 
Since 0-glycosylation lacks a consensus site it has proved more difficult to study, 
therefore most of the literature relates to N-glycosylation which occurs exclusively at 
the consensus site NXS/T. The involvement of glycosylation in modulating GPCR 
targeting to the cell surface varies among different GPCRs. N-linked glycosylation of 
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the angiotensin II type 1 receptor (AT1R) is an absolute requirement for cell surface 
expression (Deslauriers et al, 1999). By contrast, although mutation of the two 
glycosylation sites on p2-AR leads to a significant decrease in plasma membrane 
expression, receptor function is not greatly affected (Rands et al, 1990). In the case of 
the histamine H2R removal of glycosylation sites does not prevent their cell surface 
expression (Fukushima et al, 1995). The molecular mechanism by which glycosylation 
is able to regulate GPCR maturation and export trafficking is unclear and is unlikely to 
be the same for all receptors. There is evidence to suggest that the glycosylation state 
might determine which Rab GTPase is activated and thereby direct the pathway by 
which the receptor is trafficked from one compartment to another (Wu et al, 2003; 
Filipeanu et al, 2004). The Rab family is part of the Ras superfamily of small 
GTPases. The different Rab GTPases are located on the cytosolic face of specific 
intracellular membranes, where they function as regulators of distinct steps in 
membrane traffic pathways. In the GTP-bound form, the Rab GTPases recruit specific 
sets of effector proteins onto membranes. Through their effectors, Rab GTPases 
regulate vesicle formation, actin- and tubulin-dependent vesicle movement, and 
membrane fusion. Finally a recent study has shown that receptor sialylation and N- 
glycosylation participate with disulphide bonding in the stabilisation of human 
bradykinin B2 receptor dimers at the cell surface (Michineau et al, 2005). 
4. Conclusions and Aims 
The biology of histamine and its receptors is complex. Histamine is available in many 
parts of the body and receptor distribution is widespread. In the periphery histamine is 
a mediator in inflammatory and immune reactions, it also controls vascular 
permeability, gastric acid secretion and smooth muscle contraction. In the CNS 
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histamine appears to play a key role in important homeostatic mechanisms regulating 
arousal, the sleep/wake cycle, feeding behaviour, learning and memory, and responses 
to stressful or painful stimuli. It interacts with a myriad of other receptors and 
chemical messengers so that the final outcome is an integrated response to multiple 
influences. The age of molecular biology has seen an extraordinarily rapid increase in 
our knowledge of all the components involved in cell signalling. Despite this our 
ability to predict the effect of manipulating a particular receptor in a whole animal is 
still extremely limited in many cases and this is exemplified in responses to H3 
receptor ligands. Cloning of the H3 receptor has provided insights into possible 
mechanisms underlying experimental observations. The possibility of multiple splice 
site variants with differential tissue distribution, pharmacology and signalling is one 
confounding factor. Another is the multifaceted nature of GPCR signalling and 
regulation. GPCR's appear to operate by interacting with a range of other proteins, 
thus enabling them to act as modulators responding flexibly over time to changing 
stimuli. There is a growing consensus that GPCR function as dimers or higher 
oligomers and this is likely to be important both in signalling and receptor regulation. 
Furthermore the significance of post-translational changes such as glycosylation to 
receptor function is gaining recognition. 
While cloning of the H3 receptor has lead to a rapid increase in our understanding of 
its structure and function, tools to exclusively demonstrate expression of H3 receptor 
protein are limited. Our laboratory was the first to develop a specific anti-H3R 
antibody (Chazot & Hann, 2001). This antibody has been used to map H3R 
distribution in rodent brain and further characterise the receptor. In the light of current 
thinking on GPCR biology the aim of this PhD project was as follows: First, to 
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develop further anti-H3 receptor isoform specific antibodies with which to map the 
expression of H3R isoforms in native tissue; and second to use these antibodies as 
probes to investigate potential sources of receptor heterogeneity, in particular 
oligomerisation and glycosylation. An additional aim was to generate the first anti-H4 
receptor antibody following our previously successful anti-H3R strategy, and to use 
this antibody in studies to characterise the histamine H4 receptor. 
Hypotheses to address relating to the human H3 and H4 histamine receptors: 
1) H3 and H4 receptors are able to homo-oligomerise 
2) H3 and H4 receptors are able to hetero-oligomerise with their respective splice 
variants 
3) Splice variants can act as dominant negative regulatory subunits 
4) N-glycosylation is a prerequisite for receptor dimerisation 
5) H3 and H4 histamine receptors are both expressed in brain and subserve distinct 
functions 
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CHAPTER 2 
MATERIALS AND GENERAL METHODS 
2.1 Source of materials 
2.1.1 Sigma-Aldridge chemical company (Poole, Dorset, UK) 
N-2-hydroxyethylpiperazine-N'-2-ethane sulphonic acid (HEPES). 
Thyroglobulin. 
Folin-ciolcalteau phenol reagent. 
Pre-stained molecular weight markers (molecular weight range 30 - 220 kDa). 
Tween - 20. 
p-coumaric acid. 
Luminol. 
Hydrogen peroxide (30% v/v). 
Kodak D-19 developer. 
Kodak fixer. 
Ampicillin. 
Agarose. 
Teriffic broth. 
Agar. 
Dulbecco's modified eagle medium/F12 containing L-glutamine. 
Dulbecco's modified eagle medium/F12. 
7.5% (w/v) Sodium bicarbonate. 
Penicillin (5001 U/ml) / streptomycin (500µg/ml) solution. 
Sodium hydroxide. 
Trypsin 0.5g, EDTA 0.2g per litre of Hanks. 
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Ethylenediaminetetracetic acid (EDTA). 
Ethylenebis(oxyethylenenitrilo)tetracetic acid (EGTA). 
Metyrapone. 
Glutaraldehyde. 
Sodium phosphate 
3-maleimimdobenzoic acid N-hydroxysuccinimide ester (MBS). 
Freund's adjuvant complete. 
Freund's adjuvant incomplete. 
CH-sepharose beads. 
Tris (hydroxymethyl) methylamine. 
Sodium azide. 
Sodium phosphate. 
Diaminobenzidine tablets. 
Triton X-100. 
Anti-ß-actin 
Anti-FLAG M2 monoclonal antibody (Product code F3165) 
Dithiothreitol (DTT). 
Poly(ethyleneimine) solution. 
Dialysis tubing (visking size 11/4"). 
Bis (sulfosuccinimidyl) suberate. 
Sodium dodecyl sulphate (SDS). 
ß-mercaptoethanol. 
Albumin bovine fraction V powder 
Acrylamide/bis-acrylamide 30% 
Bromophenol blue 
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Streptavidin beads 
2.1.2 BDH laboratory supplies (Leicestershire, UK) 
N, N, N', N'-teramethylethylenediamine (TEMED). 
Amonium persulphate. 
Methanol. 
Chloroform. 
Glycerol. 
Isopropanol. 
Ethanol. 
Dimethyl sulphoxide (DMSO). 
Sodium hydrogen carbonate. 
Potassium phosphate. 
Hydrochloric acid. 
Citric acid. 
Sodium chloride. 
Acetic acid. 
DPX mountant. 
Potassium chloride. 
Diethylamine. 
2.1.3 Cambrex Bio Science (Verviers, Belgium) 
Foetal calf serum. 
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2.1.4 Promega Ltd (Southampton, UK) 
VECTASTAIN® ABC kit. 
HB101 Competent E. coli cells. 
2.1.5 Amersham International (Aylesbury, Bucks, UK) 
Blotting paper. 
Nitrocellulose. 
HyperfilmTM. 
HRP linked secondary antibody- rabbit. 
HRP linked secondary antibody-mouse. 
Binding filters. 
2.1.6 Tocris (Bristol, UK) 
Thioperamide. 
Iodophenpropit. 
(R )-(-)-a-Methylhistamine dihydrobromide. 
2.1.7 Boehringer mannheim GMBH (Lewes, Sussex, UK) 
N-glycosidase F', recombinant. 
2.1.8 Immune systems (Bristol, UK) 
Histamine H3R peptides 
Rat histamine H3 c (268 - 277) EAMPLHRGSK-Cys 
a sequence specific to the i3 region in the rat H3C isoform 
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2.1.9 Sigma-Genosys (Cambridge, UK) 
Histamine H3R peptides 
PI: human H3 365 (270 - 279) i3 just before TM6 CMPLHRKVAKS 
P2: human H3 415 (229 - 238) i3 CTRLRLKGHGE 
P3: human H3 329, &13 (222 - 231) TM5 i3 CYLNIQSFTQR 
Sequences specific to the i3 region of the respective isoforms 
human H3220(211-220) Isoform 5 CRRPRPRWRSA 
Histamine H4R peptides 
Chazot 3 human H4 (374-390) C-terminal CIKKQPLPSQHSRSVSS 
Chazot 4 human 114(251-266) C-terminal CERRRRKSSLMFSSRTK 
2.1.10 QIAGEN Ltd (Dorking, Surrey, UK) 
QIAGEN® plasmid maxi kit. 
2.1.11 Calbiochem (Nottingham, UK) 
Protease inhibitor cocktail, Set III 
2.1.12 Pierce (Rockford, UK) 
Sulpho-NHS-S S-Biotin 
2.1.13 Miscellaneous 
[3H]-clobenpropit, 43Ci/mmol, 99% purity James Black Foundation. 
H3R -/- mouse material (US Patent 7151200) a gift from Prof Tim Lovenberg 
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Human putamen prepared for SDS-PAGE gift from Dr Margaret Piggott, Newcastle 
University 
pCI neo H3 (445) construct was a gift from Prof Tim Lovenberg. 
Human H3R cDNA C-terminally labelled with FLAG a gift from Prof Francis Coge: 
hH3 (445/Pc DNA 3.1 (-) 
hH3 (365/pc DNA 3.1(-) 
hH3 (329/pc DNA 3.1 D-V5-His-TOPO 
Human H4R cDNA a gift from Prof Rob Leurs 
Anti-haemaggluttinin antibody a gift from Prof Rob Leurs 
Human embryonic kidney (HEK) 293 cells from the European collection of cell 
cultures, Salisbury, Wilts. 
2.2 Instruments and Equipment 
Spectrophotometry: Jenway Genova spectrophotometer 
Centrifuges: A sorval RC5C centrifuge was used with a GS-3 fixed angle rotor (for 
large volumes >400m1). A Biofuge fresco Heraeus (Kendro Laboratory Products) 
was used for all volumes less than 1.5ml. 
Incubators: shaking incubator, cell incubator Shel Lab (Sheldon Manufacturing 
Inc. ). 
Orbital shaker: Stuart scientific 505. 
Water bath: Niive bath. 
Heating block: QBT2 heating block (Grant). 
Hot plate: FALC 
Stirrer: Bibby Sterilin 
Rocker: Grant-Bio PMR-30 
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Balances: Milligram amounts were weighed using a Mettler Toledo classic. All 
other amounts were weighed using a Scouts Pro balance (Ohous). 
Electrophoresis equipment: Polyacrylamide gels were cast in a Hoefer SE 245 dual 
gel caster using gel plates of IOx8cm, electrophoresis was performed using a Hoefer 
mini-vertical gel electrophoresis unit SE260 and transferred using a Hoefer TE 22 
tank transfer unit, power was from an Electrophoresis Power Supply EPS 301, all 
supplied by Amersham Biosciences. 
Radioligand binding equipment: Bound radioactivity was collected using a Brandel 
cell harvester. Radioactivity was counted using a TriCarb 1600TR Liquid 
Scintillation Analyser (Packard). 
Microscopes: Nikon Eclipse E400 used for Immunohistochemistry and cells. 
Photography: Nikon digital camera Coolpix E950 used for Immunohistochemistry. 
Kodak camera for agarose gels. 
Other equipment: Immunoblotting cassette, pH meter was a Mettler Toledo 
MP220, automatic pipetteman 
Glassware, plastics and disposables: Hamilton syringe. Dounce glass/glass 
homogeniser. Cell scrapers, 250m1 sterile cell culture flasks, petri dishes and sterile 
pipettes from Greiner. Sterile filters: 0.24m Sartorius Sartolab- V150 filter unit. 
Microtitre plates. Cryogenic vials. Sterile pipettes and 250m1 sterile filter lid cell 
culture flasks from Bibby sterilin. Falcon tubes. Columns. Filters for radioligand 
binding, Whatman GF/B filters, radioligand binding tubes, Eppendorf tubes, pipette 
tips, syringes from SLS, UK. 
67 
2.3 Preparation of standard solutions 
2.3.1 Lowry reagent A: 
2% (w/v) sodium carbonate, O. 1M sodium hydroxide and 5% (w/v) SDS. 
2.3.2 Lowry reagent B: 
2% (w/v) sodium potassium tartrate. 
2.3.3 Lowry reagent C: 
1% (w/v) copper sulphate. 
2.3.4 Stacking gel buffer: 
0.5M Tris-glycine, pH 6.8, containing 8mM EDTA and 0.4% (w/v) SDS. 
2.3.5 Resolving gel buffer: 
50mM Tris, 384mM glycine, 1.8mM EDTA and 0.1% (w/v) SDS pH 8.8. 
2.3.6 Stock acrylamide: 
30% (v/v) acrylamide and N, N'-methylenebisacrlyamide 
2.3.7 Electrode buffer: 
50mM Tris, 384mM glycine, 1.8mM EDTA and 0.1% (w/v) SDS pH 8.8. 
2.3.8 Sample buffer: 
30mM sodium hydrogen phosphate, pH 7.0,30% (v/v) glycerol, 0.05% (v/v) 
bromophenol blue and 7.5% (w/v) SDS. 
. 2.3.9 Pre-stained molecular weight markers: 
Pre-stained standards (protein molecular weight range 6.5-200 KDa, Sigma), stored 
in sample buffer, section 2.3.8. 
2.3.10 Transfer buffer: 
25mM Tris, pH 8.4,192mM glycine and 20% (v/v) methanol. 
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2.3.11 TEE buffer: 
50mM Tris-citrate pH 7.1, containing 5mM EDTA and 5mM EGTA. 
2.3.12 Phosphate buffered saline (PBS): 
0.01M sodium hydrogen phosphate, 1.7mM potassium hydrogen phosphate, pH 7.4, 
137mM sodium chloride, 107mM potassium chloride. 
2.3.13 Tris buffered saline (TBS): 
50mM Tris-HC1, pH 7.4. 
2.3.14 HEPES buffered saline (HBS): 
280mM sodium chloride and 1M sodium hydrogen phosphate pH7.12. 
2.3.15 Tris/EDTA (TE) buffer: 
10mM Tris, 1mM EDTA, pH8.0 
2.3.16 TBE buffer: 
0.9M Tris, 0.9M boric acid and 40mM EDTA. 
2.3.17 Homogenisation buffer: 
50mM Tris-HC1 pH 7.4, containing 5mM EDTA and 5mM EGTA. 
2.4 General methods 
2.4.1 Membrane Preparation for Immunoblotting 
Either adult Wistar rats or adult mice strain C57B6 were stunned and decapitated. 
The required brain tissue was dissected and kept cool on ice. The tissue was then 
homogenised in ice-cold homogenisation buffer (section 2.3.17) supplemented with 
320mM sucrose using a dounce glass/glass homogeniser. Membrane debris was 
pelleted by spinning the homogenate at 1,200 x g, 4°C for 10 minutes. The 
supernatant was transferred to a clean JA20 centrifuge tube, the volume was made up 
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to 10 ml with homogenisation buffer + sucrose and it was spun at 20,000 x g, 4°C for 
30 minutes. The supernatant was discarded and the pellet briefly drained before 
resuspension in homogenisation buffer (without sucrose), 5m1 of buffer for every 
gram of starting material. The homogenate was stored in 100µ1 aliquots at -20°C. 
2.4.2 Determination of Protein Concentration 
The protein concentration was determined using the method of Lowry et al., (1951) 
employing bovine serum albumin (BSA) as the standard protein. A stock solution of 
BSA (10 mg/ml) was serially diluted in water, to give a range of standard BSA 
concentrations from 0 to 100 gg/ml. Lowry reagent A (section 2.3.1), Lowry reagent 
B (section 2.3.2 ) and Lowry reagent C (section 2.3.3) were mixed in a volume ratio 
of A (50): B (1): C (1). To both the BSA standards and the unknown protein samples 
(50 µl) 0.5 ml of the mixture of reagent A, B and C was added, each sample was 
vortexed and incubated at room temperature for 10 minutes. All samples were 
assayed in triplicate. On the addition of 50 µl of Folin-Ciocalteau phenol reagent (1 
M, 1: 1 mix of Folin reagent and water) each sample was mixed and incubated at 
room temperature for 30 minutes. The reaction was terminated by the addition of 
5O0µ1 of water. The O. D. at X= 750 nm was determined for each sample using a 
Jenway Genova spectrophotometer. 
A calibration curve was plotted of O. D. at X= 750 nm for the BSA samples. This was 
then used to determine the unknown protein concentration. 
2.4.3 SDS-Polyacrylamide Gel Electrophoresis 
Immunoblotting was carried out essentially as described by Duggan et al., (1991), 
using SDSJPAGE in 7.5% polyacrylamide mini-slab gels under reducing conditions. 
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2.4.3.1 Preparation of Resolving Gel 
The resolving gel (7.5 %) was prepared by mixing water (6 ml) with resolving gel 
buffer (section 2.3.5), TEMED (6 µl), stock acrylamide (section 2.3.6) (3 ml), and 10 
% (w/v) ammonium persulphate (APS) (6Oµ1). The polyacrylamide solution was 
immediately poured into a Hoefer SE 245 dual gel caster, using 2 gel plates of 10 x8 
cm and spacers of 1 mm width. Saturated water/butanol solution (100 µl) was added 
over the top of each gel. The gels were covered with parafilm and were allowed to 
polymerise for 60 minutes at room temperature. Gels were individually wrapped in 
tissue and stored in electrode buffer (section 2.3.7) at 4°C until use. 
2.4.3.2 Chloroform/methanol Method for Protein Precipitation and Preparation 
of Protein Samples for SDS-PAGE 
Protein samples for SDS-PAGE were precipitated using chloroform/methanol 
precipitation described as follows. To the protein samples (25-50 µg), methanol (4 
vol) was added and the samples were vortexed and centrifuged at room temperature at 
18,000xg for 1 minute. Chloroform (1 vol) was added to the samples, which were 
vortexed and centrifuged at 18,000xg at room temperature for lminute. To each of 
the samples water (3 vol) was added which were again vortexed and centrifuged at 
room temperature at 13000 rpm for 1 minute. The upper layer was carefully discarded 
and methanol (1 vol) was added to each of the samples. The samples were centrifuged 
at 18,000xg at room temperature for 4 minutes. The supernatant was removed and the 
samples were air-dried. The dried protein pellet was resuspended by vortexing in 
sample buffer (section 2.3.8), 200mM DTT (2 µl) and water to a final volume of 15 
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µl. The samples were boiled in a water bath for 5 minutes and then centrifuged at 
18,000xg for 30 seconds at room temperature before analysis by SDS- PAGE. 
2.4.3.3 SDS-Polyacrylamide Gel Electrophoresis 
The resolving mini-slab gel was clamped into a Hoefer mini-vertical gel 
electrophoresis unit SE260. The stacking gel was prepared by mixing water (2.3 ml) 
with stacking gel buffer (section 2.3.4) (1 ml), stock acrylamide (section 2.3.6) (650 
µl) and TEMED (5 µl) and 10% (w/v) ammonium persulphate (80 µl) was added to 
the stacking gel solution and this was immediately poured into the mini-slab gel 
above the resolving gel. A welled comb was inserted into the stacking gel. After the 
polymerisation of the gel, the comb was carefully removed and the wells were 
washed with water. Electrode buffer (section 2.3.7) (- 300 ml) was poured into the 
wells and into the base of the electrophoresis unit. Protein samples (15 µl) and pre- 
stained standards (protein molecular weight range of 200-6.5 kDa, ) (15 µl) were 
loaded into the wells of the stacking gel using a Hamilton syringe. Electrophoresis 
was carried out at a constant current of 15 mA for -2 h until the appropriate pre- 
stained molecular weight marker (25 kDa) was at the bottom of the gel. 
2.4.4 Immunoblotting 
After SDS-PAGE (section 2.4.3.3), the proteins from the gels were transferred to 
nitrocellulose membranes. A transfer cassette sandwich was constructed with the 
following order of components each of which had been pre-equilibrated in transfer 
buffer (section 2.3.10) sponge, two sheets of blotting paper and nitrocellulose 
membrane. The SDS-PAGE gel, two sheets of blotting paper and a final piece of 
sponge were added to the transfer cassette sandwich. On the addition of each 
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component to the transfer cassette air bubbles were carefully removed by pressing 
each layer with a test tube. Proteins were transferred at a constant voltage of 50 V for 
2.5 hours using a Hoefer TE 22 tank transfer unit containing transfer buffer kept cool 
with ice and ice packs. 
Following the transfer of the proteins, the nitrocellulose membrane was briefly rinsed 
with TBS (section 2.3.13) and incubated with blocking buffer which was TBS, 
containing 5% (w/v) dried milk and 0.02 % (v/v) Tween-20 (15 ml) for 1 hour at 
room temperature with gentle shaking. After blocking of the non-specific antibody 
sites the nitrocellulose membranes were washed with -10 ml of TBS. The appropriate 
affinity-purified primary antibodies were diluted in incubation buffer, which was 
TBS, pH 7.4 containing 2.5 % (w/v) dried milk to working concentrations (0.25-5 
pg/ml). The nitrocellulose membranes were incubated with the diluted primary 
antibody solution (10 ml) for 1 hour at room temperature, or overnight at 4°C with 
gentle shaking. 
After incubation with the primary antibody the nitrocellulose membranes were 
washed four times in wash buffer containing, TBS, containing, 2.5 % (w/v) dried 
milk and 0.2 % (v/v) Tween-20 (10 ml) at 10 minute intervals with gentle shaking at 
room temperature. Nitrocellulose membranes were then incubated with horseradish 
peroxidase (HRP) labelled secondary antibody, either anti-rabbit or anti-mouse 
depending on what the primary antibody was raised in, at a dilution of 1/2000 in 
incubation buffer (10 ml). The membrane was incubated for 1 hour at room 
temperature with gentle shaking. The unbound secondary antibody was removed by 
washing the membrane as described above. The nitrocellulose membrane was drained 
of excess wash buffer and briefly rinsed in TBS. Immunoreactive bands on the 
nitrocellulose membranes were developed by processing in a solution containing, 68 
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mM p-coumaric acid (100 µl), 1.25 mM luminol (10 ml) and 30 % H202 (6 µl) for 1 
minute at room temperature. After removal of the reagents the immunoblot was 
wrapped in cling film, and placed in a film cassette. The immunoblot was exposed to 
HyperfilmTM for various times (1-5 minutes). The film was then developed in Kodak 
D-19 Developer until the immunoreactive bands were visible and fixed in Kodak 
Unifix for 5 minutes at room temperature. 
2.4.5 Transformation of competent E. Coli Cells 
This method was performed essentially as described by Dagert and Ehrlich (1979). 
For the transformation of competent E. coli cells, a frozen aliquot (100µl) of 1113101 
competent cells were removed from -80°C and thawed on ice for 5 minutes. The 
appropriate plasmid DNA (20 ng/µl) was added to the competent cells (100 µl) and 
mixed gently. The cell mixture was then incubated on ice for 30 minutes and heat- 
shocked by placing in a water bath at 42°C for 60 seconds. After 2 minutes incubation 
on ice, Terrific broth (section 2.1.1) (900 µl) was added to the transformed cells. 
Following a1 hr incubation in an orbital shaker at 250xg, 37°C the cell suspension 
(100 µl) was plated onto culture plates prepared with 1.5 % (w/v) agar in terrific 
broth containing ampicillin (50 µg/ml). The culture plates were incubated at 37°C for 
18-20 h in an inverted position. 
2.4.6 Glycerol Stocks of transformed Competent E. Coli Cells 
Transformed competent E. Coll cell stocks were prepared by mixing 5O0µ1 of Terrific 
broth supplemented with 50% (v/v) sterile glycerol and 50pg/ml ampicillin with 
500gl of the small overnight culture (section 2.4.7.1). The cell culture mixture was 
immediately added to a cryogenic vial and stored at -80°C until use. 
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2.4.7 Amplification and preparation of Plasmid DNA 
2.4.7.1 Preparation of Small-Scale Culture of Plasmid DNA 
Terrific broth (10 ml) containing ampicillin (50 gg/ml) was added to a sterile 50 ml 
Falcon tube and inoculated with one isolated colony from the culture plate (section 
2.4.5) using a sterile loop. The small culture was incubated for 18-20 hours in an 
orbital shaker at 250xg, 37°C. 
2.4.7.2 Preparation of Large - Scale Culture of Plasmid DNA 
Terrific broth (500 ml) containing ampicillin (50 gg/ml) was inoculated with 3ml of 
the small overnight culture (section 2.4.7.1) in a sterile 500 ml flask. The large 
culture was incubated for 18-20 hours in an orbital shaker at 250xg, 37°C. 
2.4.7.3 Harvesting the Large Scale Culture and Purification of Plasmid DNA 
Using QIAGENTM Plasmid Maxi-Kit 
E. Coli cells were harvested by transferring the large overnight culture (section 
2.4.7.2) into two ice- cold centrifuge tubes, and centrifuged at 6500xg for 10 minutes 
at 4°C. The supernatant was discarded and the remaining pellet was resuspended in 
ice-cold P1 buffer (10ml). Bacteria containing the plasmid were then lysed by the 
addition of P2 Buffer (10ml) mixed by gentle inversion and incubated at room 
temperature for 5 minutes. The mixture was then neutralised with chilled P3 buffer 
(10m1) mixed by gentle inversion and incubated on ice for 20 minutes. The solution 
was then centrifuged at 14000xg for 30 minutes at 4°C and the clear lysate was 
removed into fresh tube. 
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A QIAGENTM 500 tip was equilibrated with QBT buffer (10ml). The lysate was 
gently poured onto the column and allowed to pass through the column under gravity 
flow. The column was washed twice with QC buffer (30m1), then QF buffer (15ml) 
was added to the column to elute the plasmid DNA. Ice-cold isopropanol (0.7vol) 
(10.5ml) was added to the eluted DNA and the solution was centrifuged at 14000xg 
for 30 minutes at 4°C. The remaining pellet was carefully washed with ice-cold 
ethanol (lml) and air-dried for approximately 30 minutes. The purified DNA was 
dissolved in TE buffer (section 2.3.15) (500µl) and stored at 4°C until the purity and 
yield of the DNA was calculated. 
2.4.7.4 Quantification and determination of Purity of the DNA Yield : 
The purity of plasmid DNA was determined by measuring the OD at %= 260 nm and 
X= 280 nm (Sambrook et al., 1989). The ratio of the optical densities at ?= 260 nm 
and, % = 280 nm (ODD, = 260 nm / ODD, = 280 nm) should be within the range 1.8 - 2.0 
for pure plasmid DNA. The plasmid DNA concentration was determined by 
measuring the O. D. at ?= 260 nm. An O. D. =1 corresponds to -50 pg/µl for double 
standard DNA (dsDNA). 
The DNA was then diluted to a final concentration of 1 µg/ml in TE buffer and stored 
in 100µ1 aliquots at-20°C until use. Once thawed DNA was stored at 4°C. 
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. CHAPTER 3 
DEVELOPMENT AND CHARACTERIZATION OF NOVEL 
ANTI-H3 RECEPTOR ISOFORM SPECIFIC ANTIBODIES 
3.1 OBJECTIVES 
Develop and characterise novel anti-H3 receptor isoform specific antibodies, and map 
the distribution of H3 receptor isoforms in the brain. 
3.2 INTRODUCTION 
Due to lower than expected homology with histamine receptors H1 and H2, the H3 
receptor was not cloned until 1999 (Lovenberg et al, 1999) more than a decade after it 
was first described (Arrang et al, 1983). It was discovered as part of an effort to 
identify orphan GPCR's. Lovenberg and colleagues identified a partial clone 
(GPCR97) that had significant homology to biogenic amine receptors. The GPCR97 
clone was used to probe a human thalamus library, which resulted in the isolation of a 
full-length clone encoding a putative G protein- coupled receptor. Homology analysis 
showed the highest similarity to M2 muscarinic acetylcholine receptors and overall 
low homology to all other biogenic amine receptors. Transfection of GPCR97 into a 
variety of cell lines conferred an ability to inhibit forskolin-stimulated cAMP 
formation in response to histamine, but not to acetylcholine or any other biogenic 
amine. Subsequent analysis revealed a pharmacological profile practically 
indistinguishable from that for the histamine H3 receptor. 
In two analyses of the human gene (Tardivel-Lacombe et al, 2001; Wiedemann et al, 
2002) a 1063 base pair (bp) intron beginning 250 nucleotides downstream of the start 
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codon (corresponding to as 84) and another 1564 bp intron at position 417 
(corresponding to as 139) suggests a gene with three exons and two introns. By 
contrast Coge (Coge et al, 2001; see Fig 3.1) has put forward a gene having a 
minimum of four exons and three introns. In their analysis the coding region is 
interrupted by introns of 1062,1565 and 240 bp. A further exon may result in an 
additional 8 amino acids at the C-terminus, leading to a protein of 453 as (Nakamura 
et al, 2000). The result of these diverse exon/intron junctions is the occurrence of 
alternative splicing to generate multiple splice variants which may potentially lead to 
several receptor isoforms. 
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Fig 3.1 Schematic organisation of the human H3 histamine receptor gene and 
cDNA 
(A) Restriction map of the genomic DNA fragment from human chromosome 20 
(accession number AL078633). B, BamHI; P, PstI; S, Sacl. (B) Schematic structure of 
the H3 gene with the location of exons (E1-4) shown by boxes and the location of 
introns (I1_3) shown by horizontal lines. The exons are numbered from the 5' end of 
the gene with exon E1 containing the first ATG codon. The initiation (ATG) and 
termination (TGA) codons are indicated. Exon Eo and intron io were deduced from the 
H3 receptor cDNA described by Lovenberg et al. (Lovenberg et al, 1999), but are not 
confirmed. (C) Structure of the human H3-receptor cDNA. The coding region is shown 
by boxes and the 5'- and 3'-UTRs are shown by horizontal lines. The putative TMs 
(1-7) are mentioned in the coding region. The translation initiation site (ATG), the 
termination site (TGA) and the polyadenylation signal sequence (AATAAA) are 
indicated. The forward (F) and reverse (B) primers used for RT-PCR analysis are 
shown under the cDNA structure. 
The cloning of the H3 receptor has initiated a new era in histamine research. In 
particular the recognition of the existence of multiple H3 receptor isoforms has opened 
up possibilities to account for the pharmacological heterogeneity in H3 receptors, 
within and across species, which has long been recognised. The reasons for this 
heterogeneity are complex and not fully understood. In all species tested so far the full 
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length H3 receptor encodes a polypeptide of 445 amino acids (predicted polypeptide 
Mr 47,000). Shorter isoforms with deletions predominantly in the third intracellular 
loop domain have also been identified (predicted polypeptide Mr range 35,000- 
45,000). While the full length clone is found in most abundance in the CNS in all 
species studied so far, there is regional variation in the distribution of the different 
isoforms (Harper et al, 1999; Coge et al, 2001; Sogawa et al, 2004; Ebenshade et al, 
EHRS abstract, 2005). This has given rise to speculation that H3 heterogeneity could 
underlie different activities and functions of H3 receptors in specific brain areas. 
The evidence for heterogeneity in anatomical distribution is based mostly on the 
distribution pattern of mRNA coding for the various isoforms. Note that these splicing 
events yield potentially different protein sequences in rodents and man. In order to 
define the importance of H3 receptor heterogeneity, specific immunological probes are 
required. Our laboratory has developed the first anti-H3 receptor antibodies (Chazot et 
al, 2001; Cannon et al, 2007; Victoria Hann PhD thesis, 2004). The first two 
antibodies were raised against human H3 receptor sequences common to most human 
and rodent isoforms: anti-H3 (346-358) and anti-H3 (175-187) (see Fig 3.2 rat and 
human isoform sequences). They both detected two specific immunoreactive protein 
species (Mr 68,000 and 93,000) which were suppressed by prior incubation with their 
respective peptide antigens, in many adult rat and mouse brain regions. These species 
are most likely derived from dimeric and/or glycosylated versions of the receptor. In 
an attempt to generate an antibody specific to the rat H3C (397) isoform a peptide 
sequence was chosen which spanned the deletion within the third is loop (see Fig 3.2 
A) and B) rat isoform sequences) and would therefore be unique to this isoform. When 
tested against three of the major human and rat isoforms heterologously expressed in 
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HEK 293 cells namely hH3 (445), 3 (365) and IIH3 (329); rH3A (445), rH313 (413) and rH3c 
(397), the antibody was found to be selective for both the full length human and rat 
isoforms hH3 (445) and rH3A (445), as well as the expected rH3c (397) isoform. Furthermore 
it detected protein species in both human and rodent (mouse and rat) native tissue. 
Therefore this antibody was used to map the distribution of the H3R in mouse brain 
slices and to compare the immunoreactivity obtained with this 445 specific antibody to 
that previously described with the pan-specific H3R antibody. In addition it was used 
to further characterize both the human and the rat H3R as described in subsequent 
chapters. Antibodies specific for three of the other major human H3R isoforms were 
also sought with peptide sequences unique to the 415,365, and 329 DI3 human H3R 
isoforms (see Fig 3.2 human isoform sequences). Finally a peptide sequence unique to 
human H3 220 was chosen (Wellendorph et al, 2002, Isofomm 5). Human H3 (220) has a 
170-306 deletion plus a frame shift and a novel stop codon, so that the C terminus is 
exclusive to that isoform. Therefore the last 10 amino acids were selected. 
Herein are described the methods for preparing the peptides for immunization, the 
immunization procedure, antibody purification and the experiments performed to 
check the individual antibody specificity. Results of immunohistochemical analysis 
using the human/rodent antibody in mouse brain slices from both wildtype (WT) and 
H3R -/- (H3R KO) mice (kind gift of Prof Tim Lovenberg, Johnson & Johnson) are 
also presented. 
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A) Full length Rat H3A sequence 
1 merappdglm nasgtlagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61 adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcas 
121 svfnivlisy drflsvtrav syraqqgdtr ravrkmalvw vlafllygpa ilsweylsgg 
181 ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldggreag 
241 pepppdaqps pppappscwg cwpkghgeam plhrygvgea gpgveageaa lgggsgggaa 
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sqsitqrfrl srdkkvaksl 
361 aiivsifglc wapytllmii raachgrcip dywyetsfwl lwansavnpv lyplchysfr 
421 raftkllcpq klkvqphgsl eqcwk 
B) Rat sequence showing rH3c deletion (deletion red and in bold) 
Peptide sequence used to immunise rabbit blue and underlined 
1 merappdglm nasgtlagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61 adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcas 
121 svfnivlisy drflsvtrav syraqqgdtr ravrkmalvw vlafllygpa ilsweylsgg 
181 ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldggreag 
241 pepppdaqps pppappscwg cwpkghgeam plhrygvgea gpgveageaa lgggsgggaa 
301 asptsssgss srgterprsl kr skpsass aslekrmkmv sqsitqrfrl srdkkvaksl 
361 aiivsifglc wapytllmii raachgrcip dywyetsfwl lwansavnpv lyplchysfr 
421 raftkllcpq klkvqphgsl eqcwk 
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C) Full length Human H3 (445) 
Peptide sequences used to generate first pan anti-H3R antibodies blue and underlined 
1 merappdgpl nasgalagda aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61 adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts 
121 safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg 
181 ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa 
241 gpepppeaqp spppppgcwg cwqkghgeam plhrygvgea avgaeageat lgggggggsv 
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sgsftgrfrl srdrkvaksl 
361 avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421 raftkllcpq klkiqphssl ehcwk 
D) Human sequence showing H3 (365) deletion (deletion red and in bold) 
Peptide sequence used to immunise rabbit blue and underlined (P 1) 
1 merappdgpl nasgalagda aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61 adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts 
121 safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg 
181 ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa 
241 gpepppeaqp spppppgcwg cwgkghgeam plhrygvgea avgaeageat lgggggggsv 
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sgsftgrfrl srdrkvaksl 
361 avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421 raftkllcpq klkiqphssl ehcwk 
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E) Human sequence showing H3 (415) deletion (deletion red and in bold) 
Peptide sequence used to immunise rabbit blue and underlined (P2) 
1 merappdgpl nasgalagda aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61 adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts 
121 safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg 
181 ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa 
241 gpepppeaqp spppppgcwg cwgkghgeam plhrygvgea avgaeageat lgggggggsv 
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrl srdrkvaksl 
361 avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421 raftkllcpq klkiqphssl ehcwk 
F) Human sequence showing H3 (329 Di3) deletion (deletion red and in bold) 
Peptide sequence used to immunise rabbit blue and underlined (P3) 
1 merappdgpl nasgalagda aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61 adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts 
121 safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg 
181 ssipeghcya effynwyfli tastlefftp flsvtffnls iylnigrrtr lrldgareaa 
241 gpepppeagp spppppgcwg cwgkghgeam plhrygvgea avgaeageat lgggggggsv 
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sgsftgrfrl srdrkvaksl 
361 avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421 raftkllcpq klkiqphssl ehcwk 
Fig 3.2 The amino acid sequences of the full length rat and human H3 receptor 
isoforms are shown, with the deletions giving rise to the shorter isoforms and the 
peptide sequences used to generate specific antibodies to those isoforms 
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3.3 METHODS 
3.3.1 Choice of peptide sequences 
The following peptide sequences were chosen for the short peptides used to immunize 
the rabbits. The choice was made based on their specificity: that is being unique to 
that particular receptor isoform, and likely immunogenicity. See Fig 3.2 showing the 
full length as sequences of each isoform with the sequences of the immunizing 
peptide underlined. A cysteine residue was added to one end of each sequence so that 
the peptide could be coupled to the carrier protein thyroglobulin (see below). 
First antibody 
rH3C (268 - 277) EAMPLHRGSK-Cys 
a sequence specific to the i3 region in the rat H3C isoform 
Subsequent three antibodies: P 1, P2, P3 
PI: hH3 (365) (270 - 279) i3 just before TM6 CMPLHRKVAKS 
P2: hH3 (415) (229 - 238) i3 CTRLRLKGHGE 
P3: hH3 (329 AI3) (222 - 231) TM5 i3 CYLNIQSFTQR 
Sequences specific to the i3 region of the respective isoforms 
Also hH3 -5 (Wellendorph et al, 2002; Isoform 5) (aa 211 - 220) CRRPRPRWRSA 
(but this antibody has yet to be purified and characterised) 
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3.3.2 Antibody production 
As the peptide on its own is too small to stimulate an immune response it is coupled to 
a large immunogenic carrier protein, in this case thyroglobulin, before injection into 
the rabbit. Serum was collected and purified using peptide-affinity chromatography. 
3.3.3 The 3-Maleimimdobenzoic Acid N-hydroxysuccinimide Ester (MBS) 
Method of Coupling peptides to Carrier Proteins 
This method was performed essentially as described previously (Duggan et al, 1991) 
and was used to conjugate the peptide to the carrier protein thyroglobulin through its 
carboxyl-terminal cysteine residue. 
Thyroglobulin was dissolved in lOmM KH2PO4, IOmM Na2HPO4 buffer pH 7.2 to a 
final concentration of 20mg/ml. This preparation was then dialysed against 500m1 of 
the same buffer overnight at 4°C. 50µ1 of the buffer was added to 4mg (200µ1) of 
dialysed carrier protein. The carrier protein was then activated by dropwise addition of 
85µ1 stock MBS (3mg/ml MBS in N, N-dimethylformamide) and incubated at room 
temperature for 30 minutes with shaking. The activated carrier was separated from free 
MBS by dialysis against 50mM KH2PO4,50mM Na2HPO4 buffer pH 6.0, for 2 hours 
at room temperature, 2X1 litre changes. lml of 4mg/ml peptide dissolved in 10mM 
KH2PO4, IOmM Na2HPO4 buffer pH 7.2 was added to the dialysed activated carrier 
protein and incubated overnight at room temperature with gentle mixing. The peptide 
conjugate was then separated from the uncoupled peptide by dialysis against PBS for a 
total of 4 hours at 4°C, 4X 500ml changes. The dialysed peptide protein conjugate 
was diluted with PBS to a final concentration of lmg/ml and stored in l00µ1 aliquots 
at -20 °C. 
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3.3.4 Inoculation procedure 
Routinely, 200µ1 of sterile PBS was mixed with 100µg (100µl) of freshly thawed 
peptide-carrier protein conjugate, and emulsified with an equal volume of Freund's 
Adjuvant. This preparation was then injected intramuscularly into both hind legs of a 
Dutch rabbit. The primary immunisation was performed with complete Freund's 
Adjuvant, for subsequent immunisations, at 1 month intervals, incomplete Freund's 
Adjuvant was used. Rabbits were bled from the marginal ear vein 7-10 days following 
the booster injections, 10-15m1 of blood was collected. Blood was allowed to stand at 
room temperature for 2 hours, then clot contraction was allowed to occur over 16 
hours at 4°C. Cellular material was removed by centrifugation at 12000g for 10 
minutes at 4°C, and the serum was stored in 1 ml aliquots at -20 °C. All procedures 
were performed in accordance with the Animals (Scientific Procedures) Act 1986 
(PPL 602/657). 
3.3.5 Affinity purification 
3.3.5.1 Coupling of peptides to sepharose beads via sulphydryl groups 
This method was carried out as described formerly (Duggan et al, 1991) and was used 
to couple the peptide to activated thiol-sepharose beads via its C-terminal cysteine 
residue. 
0.35g of activated thiol-sepharose was allowed to swell in 100ml water for 15 minutes 
at room temperature. The swollen sepharose was placed in a 25m1 column and washed 
with 100ml of O. 1M Tris-HCl pH8.0, containing 0.3M NaCl, lmM EDTA. It was then 
drained until just 2/3m1 of the buffer remained. lml of 5mg/ml peptide dissolved in the 
same buffer was added to the sepharose and incubated with gentle shaking for 2 hours 
at room temperature. The reaction was terminated by draining the column and washing 
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the sepharose with lOml of O. 1M citric acid pH 4.5. Next all remaining unreacted thiol 
groups on the sepharose were blocked by incubation with 3ml of 1mM ß- 
mercaptoethanol in O. 1M citric acid pH 4.5 for 1 hour at room temperature. The 
blocking reaction was terminated by washing with 25m1 O. 1M citric acid pH 4.5. 
Finally the sepharose column was equilibrated with 25m1 PBS and stored in lOml PBS 
containing 0.02% (w/v) sodium azide, at 4°C until use. 
3.3.5.2 Peptide affinity purification of antibodies 
For the purification of anti-peptide polyclonal antibodies a sepharose column (lml) 
linked to the appropriate peptide was equilibrated with 100mis of TBS. 4m1 of immune 
serum was applied to the column followed by incubation either for 2 hours at room 
temperature or overnight at 4°C, with gentle mixing. Unbound immune serum was 
drained from the column, the column was then washed with 100mis TBS. The bound 
antibody was eluted from the column with 10mis of 50mM glycine/HC1 pH 2.3. The 
eluate was collected in 10 X lml fractions. Each lml fraction was collected into a 
microtube containing 1M Tris (15µi) to neutralise the contents to a final pH of 7.4. For 
each fraction the O. D. at ?= 280nm was determined and the protein concentration 
calculated using the Beer Lambert law, 
C=A/EL 
Where, 
C, is the protein concentration of the antibody 
A, is the absorbance at %= 280nm 
E, is the molar extinction coefficient 
L, is the path length 
88 
The fractions containing the highest protein concentrations were pooled and dialysed 
against 500mls TBS overnight at 4°C. The affinity column was regenerated with 
100mis of TBS and stored in 10mis TBS containing 0.02% (w/v) sodium azide at 4°C 
until later use. 
3.3.6 Culture and transfection of HEK (Human Embryonic Kidney) 293 cells 
3.3.6.1 Preparation of DMEM/F12 media + L-glutamine 
All procedures were performed under sterile conditions. Powdered Dulbecco's 
Modified Eagle Medium/F12 (DMEM/F12 1: 1 mixture) (15g/1) containing L- 
glutamine (0.0365g/1) and 15mM N-2-hydroxyethylpoiperazine-N'-2-ethane sulphonic 
acid (HEPES) was mixed with sterile water (800m1). The mixture was supplemented 
with 10% (v/v) foetal calf serum (FCS), 40m1 of 7.5% (w/v) NaHCO3 (final conc. 
3.0g/1) and penicillin (500 IU/ml)/ streptomycin (500µg/ml) solution (20ml). The pH 
of the media was adjusted to pH 7.6 using 1OM NaOH and the final volume made up 
to 1 litre with sterile water. The media was filter sterilised using a 0.2µm Sartorius 
Sartolab-V 150 filter unit and stored at 4°C until use. 
3.3.6.2 Subculturing of HEK 293 cells 
HEK 293 cells were grown in in DMEM/F12 media containing L-glutamine in 250 ml 
Greiner culture flasks at 37°C in 5% CO2 in a Sanyo incubator. Every 7 days the cells 
were subcultured. Sterile PBS for washing, fresh media and trypsin-EDTA were all 
prewarmed to 37°C. The old media was removed and the cells washed with 10ml of 
prewarmed, sterile PBS. 2ml of trypsin-EDTA was added to the cells, following a1 
minute incubation at 37°C, the cells were resuspended in 10 ml of fresh media by 
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gentle pipetting up and down. 2ml of the cell suspension was added to a new flask 
along with a further 10 ml of fresh media. The flask was then returned to the incubator. 
3.3.6.3 Preparation of new stocks of HEK 293 cells 
The old media was removed from a flask of HEK 293 cells and the cells washed with 
10 ml sterile PBS. Following a1 minute trypsinisation with 4 ml trypsin-EDTA 
covering the cells for 1 minute at 37°C, the cells were resupended in 20 ml fresh 
media. The cells were pelleted by centrifugation at 200g for 5 minutes at 4°C. The 
pellet was resuspended in 4.8 ml of media supplemented with 0.6m1 of FCS and 0.6m1 
dimethylsuphoxide (DMSO). The cell suspension was immediately divided into three 
cryogenic vials and stored at -80°C for 24 hours before transfer to liquid nitrogen. 
For the preparation of a new culture a single cryogenic vial of frozen HEK 293 cells 
was thawed at 37°C. The cells were pelleted by centrifugation at 200g for 5 minutes at 
4°C and resuspended in 15 ml fresh media. The cells were added to a tissue culture 
flask for culture at 37°C in 5%C02- 
3.3.6.4 LipofectaminePLUS transfection method 
cDNA for transfection: hH3 (445) FLAG, hH3 (365) FLAG, hH3 (329) FLAG 
rH3A (445) rH3B (413), rH3C (397) 
cDNA vector: pcDNA 3.1 
The LipofectaminePlus method (Tucker et al, 2003) was utilised. Briefly for each 
cDNA clone mixtures were produced in two microtubes: tube 1 contained 2µg cDNA, 
6p1 of lipofectaminePLUS reagent and 150µl of Optimem-I media (Gibco); tube 2 
contained 5µl lipofectamine reagent and 15011 of Optimem-I media. The mixtures 
were incubated at room temperature for 15 minutes after which the contents of tube 2 
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were added to tube 1 followed by a further 5 minute incubation. In the meantime the 
HEK 293 cells at 50-80% confluence in 2m1 petri dishes were washed three times with 
Optimem-I media. At the end of the second incubation period the contents of tube 1 
were made up to 1.5m1 with Optimem-I media and added to the washed HEK 293 
cells. The cells were incubated at 37°C for 6 hours. The transfection mixture was then 
removed and replaced with ordinary growth media. The cells were harvested after a 
further 48 hours growth. They were homogenised and aliquots stored frozen at -20°C 
prior to immunoblotting. 
3.3.6.5 Harvesting and membrane preparation of HEK 293 cells 
Transfected HEK cells were harvested 48 hours post transfection. The culture media 
were removed and replaced with lml of ice-cold homogenisation buffer (50mM Tris- 
HCI pH 7.4,5 mM EDTA, 5 mM EGTA). Cells were scraped off the bottom of the 
petri dish using Greiner cell scrapers. The resuspended cells were transferred to a 
dounce glass/glass homogeniser on ice glass and homogenised with at least 30 strokes 
of the plunger. The homogenate was placed in a microtube and spun down for 5 
minutes at 18000g in a benchtop microfuge at 4°C. The supernatant was removed and 
replaced with another 1 ml of ice cold homogenisation buffer. The cells were 
resuspended and rehomogenised as before in the dounce glass/glass homogeniser. 
After the second homogenisation the homogenate was divided into l00µ1 aliquots and 
stored in microtubes at -20°C. 
3.3.7 Immunoblots 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out using either 6% or 7.5 % polyacrylamide slab gels under reducing conditions. 
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Immunoblots were probed either with anti-FLAG antibody in the case of the human 
H3R clones epitope tagged with FLAG, or with the appropriate rabbit anti-H3R 
antibody. 
3.3.7.1 Preparation of resolving gel 
The resolving gel (6% or 7.5%) was prepared by mixing water (6.6 or 6m1) with 
resolving gel buffer (3ml), stock acrylamide (2.4 or 3m1), TEMED (6µl) and 10% 
(w/v) ammonium persulphate (APS) (60µl). The polyacrylamide mixture was poured 
immediately into a HoeferTM SE 245 dual gel caster, for 8X9 cm gels of 1 mm 
thickness. The top of each gel was covered with saturated water/butanol solution 
(l00µ1). The gels were covered with parafilm and allowed to polymerise for 60 
minutes at room temperature. The tops of the gels were rinsed with water, then they 
were individually wrapped in tissue soaked in electrode buffer and stored in sealed 
plastic bags at 4°C until use. 
3.3.7.2 Preparation of protein samples for SDS-PAGE 
100µl aliquots ' of homogenised cells were thawed and pelleted by spinning for 1 
minute at 18000g in a benchtop microfuge. The supernatant was removed and the cells 
resupended in 151i1 sample buffer containing 100mM Dithiothreitol (DTT). The 
samples were boiled in a water bath for 5 minutes and then centrifuged at 18000g for 
30 seconds. The samples were then vortexed briefly and applied to the gel. Rodent 
brain material was prepared as described in section 2.4.1. Human putamen was 
supplied in Laemmli buffer ready prepared for SDS-PAGE (gift from Dr Margaret 
Piggott, Newcastle University). 
I 
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3.3.7.3 SDS-PAGE 
The resolving mini-slab gel was clamped into a HoeferTM SE 260 mini-vertical gel 
electrophoresis unit. The stacking gel was prepared by mixing water (2.3m1) with 
stacking gel buffer (lml), stock acrylamide (650µ1), TEMED (5µl) and 10% (w/v) 
ammonium persulphate (APS) (80µl). This mixture was poured immediately onto the 
resolving gel. A welled comb was inserted into the stacking gel. Following 
polymerisation of the gel (after about 15 minutes) the comb was carefully removed 
and the wells washed with water. Electrode buffer (approximately 300m1) was poured 
into the wells, the space behind the gel and into the base of the electrophoresis tank. 
Protein samples (15µl) and pre-stained molecular weight markers (15µ1) were loaded 
into the wells of the stacking gel using a Hamilton syringe. Initially electrophoresis 
was carried out at a constant current of 10mA, increasing to 15mA after the first 30 
minutes. The gel was run for approximately 2 hours in total until the lowest pre- 
stained molecular weight marker was at the bottom of the gel. 
3.3.7.4 Immunoblotting 
After SDS-PAGE the proteins from the gels were transferred to nitrocellulose 
membranes. A transfer cassette sandwich was constructed with the following order of 
components each of which had been pre-equilibrated in transfer buffer: layer of 
sponge, two sheets of blotting paper, nitrocellulose membrane, gel, another two sheets 
of blotting paper and a final piece of sponge. As each layer of the sandwich was added 
care was taken to roll out any air bubbles with a clean test tube. Proteins were 
transferred at a constant voltage of 50V for 2.5 hours using a HoeferTu TE 22 tank 
transfer unit containing transfer buffer. The buffer was kept cool by strapping two ice 
packs to the front and back of the tank and constant, steady stirring throughout the run. 
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Following the transfer of the proteins the nitrocellulose membrane was rinsed briefly 
with TBS and incubated with blocking buffer consisting of TBS containing 5% (w/v) 
dried milk and 0.2% (v/v) Tween-20 (15m1), for 1 hour at room temperature with 
gentle mixing. After blocking of membrane sites capable of nonspecific protein 
binding, blocking buffer was removed and replaced with the primary antibody diluted 
appropriately in incubation buffer which was TBS containing 2.5% (w/v) dried milk 
(10ml). Peptide specific antibodies were usually used at a final protein concentration 
of 0.5 - 2µg/ml (occasionally up to 5gg/ml was used), while the anti-FLAG antibody 
was used at a 1: 5000 dilution. The incubation was carried out overnight at 4°C with 
gentle mixing. Following incubation in primary antibody nitrocellulose membranes 
were given 4X 10 minute washes in 10m1 wash buffer made up of TBS containing 
2.5% (w/v) dried milk and 0.2% (v/v) Tween-20. The washes were carried out at room 
temperature with gentle mixing. The membranes were then incubated with horseradish 
peroxidase (HRP) labelled secondary antibody, either anti-rabbit (for the peptide 
specific antibodies) or anti-mouse (for the monoclonal anti-FLAG antibodies), at a 
dilution of 1: 2000 in incubation buffer (10m1). The membrane was incubated with the 
secondary antibody for 1 hour at room temperature with gentle mixing. Unbound 
secondary antibody was removed by washing the membrane as before. The 
nitrocellulose membrane was drained of wash buffer and rinsed briefly in TBS. 
Immunoreactive bands on the membrane were developed by processing in 1.25 mM 
luminol (10ml) containing 68mM p-coumaric acid (100µl) and 30% H202 (6µ1). The 
reaction was allowed to take place over 1 minute at room temperature. The membrane 
was then removed from the reaction mixture, gently blotted, wrapped in cling film and 
placed in a film cassette. In the dark the sealed membrane was covered with a piece of 
HyperfilmTM, the film cassette was shut and the film exposed to the immunoblot for a 
94 
period of between 1 to 5 minutes. The film was then developed in Kodak D-19 
Developer. When the immunoreactive bands were visible the film was rinsed briefly in 
tap water before fixing in Kodak Unifix for 5 minutes. 
3.3.8 Immunohistochemical analysis 
Immunohistochemical analysis was carried out by conventional procedures as 
described previously (Thompson et al, 1992). Briefly adult mouse brains (wild-type 
and H3 (-/-) animals kindly provided by Professor LB Hough, NY, USA) (Toyota et al, 
2002 and US Patent 7151200) were perfusion-fixed with 4% (w/v) paraformaldehyde, 
0.05% (v/v) glutaraldehyde in O. lM phosphate buffer, pH 7.4. Brains were removed, 
post-fixed overnight and then cryoprotectd by incubation in 30% (w/v) sucrose in 
0.01M phosphate buffer, pH 7.4, at 4°C for 48h. The tissue was then frozen in 
isopentane (-80°C), and coronal sections (20µm thick) were cut on a cryostat. Free- 
floating sections were initially treated with 10% (v/v) methanolic and 3% (v/v) 
hydrogen peroxide in 50mM TBS, pH 7.4, for 10 min to quench endogenous 
peroxidase activity. Sections were incubated in TBS, 0.2% (w/v) glycine and 0.2% 
(v/v) Tween-20, for 15 min to mop up residual unreacted aldehyde groups from the 
fixative. Non-specific, antibody binding sites on the tissue were blocked by incubating 
with either goat or foetal calf serum (2%, v/v) in TBS/Tween-20 (0.2%, v/v) for 60 
minutes. Sections were then incubated overnight at 4°C in anti-H3 445 antibody at a 
final concentration of 0.1 gg/ml in goat or foetal calf serum/TBS (1% serum, v/v). 
After washing three times in 1% serum/TBS antibody binding was detected by means 
of the Vectastain ABC Elite kit. The biotin linked, anti-rabbit, secondary antibody was 
followed by a streptavidin-horse radish peroxidase (HRP) complex. The immune 
reaction was visualised using 3,3'-diaminobenzidine tetrahydrochloride as the HRP 
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substrate. Antibody specifity was confirmed by means of a peptide block test (see 
below). In addition a control was carried out where the primary anti-H3 445 antibody 
was left out. This was to rule out nonspecific binding of the secondary antibody to the 
slice. 
3.3.8.1 Peptide block to confirm antibody specificity 
In order to confirm that immunoreactivity detected either in blots or in 
immunohistochemical analysis was specific to the amino acid sequence of the 
immunizing peptide, a peptide block was carried out in which the antibody was 
incubated overnight at 4°C with an equal volume of the relevant peptide. The peptide 
concentration during this incubation was 500µg/ml well in excess of that needed to 
completely block the antibody and therefore prevent it from binding to equivalent sites 
in an immunoblot or on a tissue slice in IHC analysis. For the test the antibody dilution 
was adjusted to take account of the initial 1: 2 dilution with peptide. Bands or 
immunstaining persisting after the antibody block were considered to be due to 
nonspecific antibody binding. 
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3.4 RESULTS 
3.4.1 Determination of antibody concentration following peptide affinity 
purification 
Immunization with a peptide coupled to a carrier protein will elicit antibodies to both 
the peptide sequence and the carrier protein. Affinity purification of the serum is 
undertaken to separate the antibodies specific to the peptide from those that react with 
the carrier protein. The pure peptide is coupled to sepharose beads which are then 
placed in a column. The rabbit serum is incubated with the peptide coupled beads 
under conditions which allow specific peptide antibodies to bind to the peptide on the 
sepharose column. Following washing to remove all the serum proteins which may 
have adhered nonspecifically to the beads the anti-peptide antibodies are eluted off in 1 
millilitre fractions. The optical density (OD) at X=280nm was measured for each 
fraction and those two or three fractions giving the highest OD value, and thus having 
the greatest protein concentration were pooled and dialysed overnight against PBS. 
After dialysis the final protein concentration in the pooled fractions was calculated 
according to the following formula: 
OD280 pooled fractions / 1.35 = protein concentration mg/ml 
Finally, approx. 0.05% (w/v) sodium azide was added and the purified antibody stored 
at 4°C for future use. 
Concentrations in the range of 83 - 354 µg of purified antibody/ml of immune serum 
were obtained. The following graph (Fig. 3.3) shows a representative series of OD's 
from eluted column fractions. 
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Fig 3.3 A representative elution profile 
Column fractions 2-4 were chosen on this occasion. 
Table 3.1 shows the concentrations of antibodies purified from different bleeds of 
immunized rabbits 
rH3C (268 - 277) EAMPLHRGSK-Cys 
Rabbit Bleed 1 Bleed 2 Bleed 4 
12MY - - 163 gg/ml 
13MY 137 µg/ml 150 gg/ml - 
15MY 244 µg/ml - 148 µg/ml 
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Subsequent three antibodies: P 1, P2, P3 
P1: hH3 (365) (270 - 279) i3 just before TM6 CMPLHRKVAKS 
P2: hH3 (415) (229 - 238) i3 CTRLRLKGHGE 
P3: hH3 (329) A13 (222 - 231) TM5 i3 CYLNIQSFTQR 
Sequences specific to the i3 region of the respective isoforms 
Bleed 1 Bleed 2 
Pi 83 gg/ml 195 µg/ml 
P2 failed - 
P3 354 gg/ml 215 µg/ml 
For unknown reasons the affinity column used to purify P2 serum failed in that all the 
elution fractions were of a similar low absorbance: around 0.020. For subsequent 
immunoblots the whole serum was used in the hope that specific antibody might 
nonetheless be present. However no specific immunoreactivity could be detected with 
this serum. 
3.4.2 Immunoblotting analysis of anti-H3 receptor antibodies against recombinant 
rat and human H3 receptor isoforms expressed in HEK 293 cells 
3.4.2.1 Isoform specificity of the rH3C (268 - 277) antibody 
rH3C (268 - 277) EAMPLHRGSK-Cys 
Sequence specific to the i3 region in the rat H3C isoform. This antibody was shown to 
be selective for the rat H3A and rat H3C isoforms (Fig 3.4) and the human H3 (445) 
isoform (Fig 3.5). Antibodies purified from different rabbits and different bleeds 
consistently showed the same H3 (445) selectivity (Fig 3.6). 
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Rat H3 isoforms A BC 
Fig. 3.4 Immunoblot showing rH3C (268-277) antibody reactivity against rat H3 
receptor isoforms expressed in HEK 293 cells 
HEK 293 cells transfected with three of the major rat H3R isoforms rH3A/rH3 (445), 
rH3B/rH3 (413) and rH3c/rH3 (397) were homogenized and run out on an SDS-PAGE gel 
as described previously. Anti-hH3 (445) (268 - 277) antibody (purified from first bleed 
of rabbit 15MY) was used at a final concentration of I µg/ml. The antibody was 
selective for the rat A and C isoforms, no reactivity being evident for isoform B. 
Notably, higher molecular weight species were detected in the rH3A lane but were not 
evident for the rH3C isoform. Representative blot from at least 10 experiments. 
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Fig. 3.5 Immunoblot of three different FLAG tagged human H3 receptor 
isoforms probed with anti-FLAG antibody (Lanes 1-3) and antibodies raised to 
peptide sequence rH3 (268 - 277) (Lanes 4-6) 
Homogenates of HEK 293 cells transfected with three different human H3 receptor 
isoforms (329,365 and 445) all epitope tagged with FLAG were prepared. Cell 
homogenates were loaded (approximately 50 µg of protein/well) onto a 7.5% PAGE 
gel. Identical samples were run on the left and right hand sides of the gel. Following 
separation the proteins were transferred to a nitrocellulose membrane which was then 
divided vertically between the two sets of samples. The left hand side was probed 
with a monoclonal mouse anti-FLAG antibody (dilution 1: 5000) and the right hand 
side with affinity purified anti-H3 receptor antibody (first bleed from rabbit 15MY) at 
a final concentration of 1 p. g/ml. The FLAG antibody clearly reacts with all three 
isoforms with monomeric species running at Mr 33,000; 36,500 and 44,500 as 
expected. By contrast the anti-H3 receptor antibody is selective for the full length 445 
isoform with negligible reactivity against the two shorter isoforms. In both blots, there 
is clear evidence of higher molecular weight species, most prominently with the 329 
isoform. Representative blot from at least 10 similar experiments. 
Recombinant cells expressing FLAG tagged human H3 receptors 
Lanes 1 and 4, HEK 293 cells expressing hH3 (329) receptor; Lanes 2 and 5, HEK 293 
cells expressing hH3 (365) receptor; Lanes 3 and 6, HEK 293 cells expressing hH3 (445) 
receptor 
Lanes 1-3 were probed with anti-FLAG 1: 5000; Lanes 4-6 were probed with anti rH3 
(268-277) at 1 p. g/ml. 
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Fig 3.6 Anti-rH3C (268 - 277) from different rabbits and different bleeds used 
against human isoforms 
Fig 3.6 shows a similar blot to the one described above to test the purified antibodies 
from different rabbits, and different bleeds from the same rabbit all immunized with 
the rH3C (268 - 277) peptide sequence. All three antibodies show selectivity for the 
full length hH3 (445) isoform. The monomer is detected as a strong band running at Mr 
44,500, in addition higher molecular weight species are clearly evident as before. 
Recombinant cells expressing FLAG tagged human H3 receptors 
Lanes 1,4 and 7, HEK 293 cells expressing hH3 (329) receptor; Lanes 2,5 and 8, HEK 
293 cells expressing hH3 (365) receptor; Lanes 3,6 and 9, HEK 293 cells expressing 
hH3 (445) receptor 
Antibodies from different rabbits and bleeds immunized with rH3 (268- 
277)(11ag/ml) 
Lanes 1-3, rabbit 15MY, Bleed 4; Lanes 4-6, rabbit 12MY, Bleed 4; Lanes 7-9, rabbit 
15MY, Bleed 1 
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3.4.3 Purified antibodies from rabbits immunised with peptide sequences unique 
to human H3 365,415 and 329 isoforms failed to detect their particular isoforms 
when tested in immunoblots 
As shown in Fig 3.7 antibodies generated against human H3 365,415 (immune serum 
as affinity purification was unsuccessful with this antibody) and 329 isoform specific 
sequences did not react with their respective isoforms expressed in HEK 293 cells. 
Interestingly, modest, yet isoform specific, reactivity was discernable against the 329 
isoform using the P1 derived antibody. 
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Fig 3.7 Immunoblot of human H3 receptor isoforms expressed in HEK 293 cells 
probed with antibodies or immune sera from rabbits immunized with three 
different H3 receptor peptide sequences. 
Homogenates of HEK 293 cells transfected with three different human H3 receptor 
isoforms (329,365 and 329 + 445 co-transfected) all epitope tagged with FLAG were 
prepared and run on an SDS-PAGE gel as previously described. Three replicates from 
three independent transfections were run in parallel on the same gel. Following 
separation, the proteins were transferred to a nitrocellulose membrane which was then 
divided vertically between the three sets of samples. Each strip of nitrocellulose was 
probed with either purified antibody or serum from the second bleed of immunized 
rabbits. 
Lanes 10-12 are a reprobe of lanes 4-6 using a monoclonal mouse anti-FLAG antibody 
at a 1: 5000 dilution to detect each of the FLAG tagged isoforms and thereby confirm 
their position on the blot. The FLAG antibody clearly reacts with all three isoforms 
with monomeric species running at Mr 33,000; 36,500 and 44,500 as expected. Modest 
immunoreactivity corresponding to the 329 isoform is seen in Lanes 1 and 3. No 
specific immunoreactivity was detected by either the purified antibody or the immune 
serum from the other two rabbits. 
Recombinant cells expressing FLAG tagged human H3 receptors 
Lanes 1,4,7 and 10 HEK 293 cells expressing hH3 (329) receptor; Lanes 2,5,8 and 11 
HEK 293 cells expressing hH3 (365) receptor; Lanes 3,6,9 and 12 HEK 293 cells co- 
expressing hH3 (329) and hH3 (445) receptors 
Antibodies or immune sera 
Lanes 1-3, Antibodies from rabbit immunized with H3 (365) sequence 5µg/ml; Lanes 4- 
6, Antibodies from rabbit immunized with H3 (329 X13) sequence 5µg/ml; Lanes 7-9, 
Immune serum from rabbit immunized with H3 (415) sequence 20µ1/8m1; Lanes 10-12, 
Anti-FLAG antibody 1: 15000 
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3.4.4 The anti-rat H3 (268 - 277)/anti-hH3 (445) was able to detect native 113R in 
both rodent and human brain 
Further immunoblot analysis of the anti-rH3A (268 - 277)/ anti-hH3 (445) antibody was 
carried out using it to probe both rodent (Fig 3.8) and human (Fig 3.9) native tissue. In 
rat forebrain the original pan anti-H3 (346-358) antibody consistently detected higher 
molecular weight species running at Mr 93,000 + 5000 and 68,000 + 5000 as described 
previously (Victoria Hann thesis, 2004). These band sizes are compatible with the 
presence of glycosylated receptors, receptor dimers and/or receptors associated with 
other proteins. Using the new anti-rat H3 (268 - 277)/anti-hH3 (445) antibody (from 
rabbit 15MY Bleed 1) bands of a size suggestive of receptor monomers were most 
frequent as summarised in Table 3.2 below. However using antibody purified from a 
different rabbit (13MY) a higher molecular weight species at Mr 83,000 + 3000 was 
noted on a couple of occasions (2/4 repeats). The anti-rat H3 (268 - 277)/anti-hH3 (445) 
antibody used for all the following experiments in this thesis was that purified from 
rabbit 15MY Bleed 1. The putative monomeric species were frequently diffuse and/or 
gave the appearance of doublets or triplets, again consistent with glycosylated forms of 
the receptor (see chapter 6). 
anti-rat H3 (268 - 
277)/anti-hH3 (ags) 
60,000 + 2000 (3/6 repeats) 
49,000 + 2000 (6/6 repeats) 
38,000 + 2000 (6/6 repeats) 
Table 3.2 Summary of immunoreactive species detected in rat forebrain using 
anti-rat H3 (268 - 277)/anti-hH3 (445) (Rabbit 15MY Bleed 1) 
Sizes are Mr values with the range for 6 replicate blots from n>4 rat brain 
preparations. 
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Similarly in human putamen, a doublet at Mr 90,000 + 3000 and a higher molecular 
weight species Mr 99,000 + 3000 were detected (5 individuals, 4 replicate blots). In 
the same samples the original pan anti-H3R antibody identified multiple bands at Mr 
103,000 + 4000; 76,000 + 6000; 64,000 + 3000 and 51,000 + 1000) (5 individuals, 4 
replicate blots, Fig 3.9). A summary is set out in Table 3.3 below. 
Pan anti-H3 anti-rat H3 (268 - 
277)/anti-hH3 (445) 
103,000 + 4000 99,000 ± 3000 
Doublet 
90,000 + 3000 
76,000 ± 6000 
64,000 ± 3000 
51,000 ± 1000 
Table 3.3 Summary of immunoreactive species detected in human putamen using 
pan anti-H3 (346-358) and anti-rat H3 (268 - 277)/anti-hH3 (445) 
Sizes are Mr values with the range for 4 replicate blots from n=5 individuals. 
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Fig 3.8 Rat forebrain probed with pan anti-H3 and anti-rH3 (268-277)/ antihH3 
(445) 
Each lane was loaded with approximately 40 µg of rat forebrain (20 µg/µl). Panel A 
shows representative blots from numerous (n > 10) experiments using the pan anti-113 
antibody (1-2 µg/ml). Two major bands were consistently detected at Mr 93,000 
5000 and 68,000 ± 5000. 
In panel B the anti-rH3 (268-277)/ anti-hH3 (445) antibody from rabbit 15MY Bleed 1 
was used at 1 µg/m1. Two representative blots are shown from a total of six replicates. 
Major immunoreactive species ran at Mr 60,000 ± 2000 (3/6 repeats); 49,000 ± 2000 
(6/6 repeats) and 38,000 ± 2000 (6/6 repeats). On most of the blots bands were either 
diffuse or appeared as doublets or triplets compatible with the occurrence of 
glycosylated receptors (see chapter 6). 
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Fig 3.9 Human putamen probed with pan anti-H3 and anti-rH3 (268-277)/ 
antihH3 (445) 
The anti-rH3, vc/anti-hH3 (445) antibody was used to probe human putamen. 
Immunoreactivity of this new antibody (Lane 2) was compared with that of our 
previously described pan anti-H3 antibody (Lane 1). The blot shown is typical of 
results from 5 individuals, repeated on 4 occasions. The pan anti-H3 antibody detected 
species running at Mr 103,000 ± 4000; 76,000 ± 6000; 64,000 ± 3000 and 51,000 ± 
1000); whereas the anti-hH3 445 antibody identified a doublet at 90,000 ± 3000 and a 
higher molecular weight species Mr 99,000 ± 3000 (5 individuals, 4 replicates). 
Human putamen 50 p. g both lanes, probed with: Lane 1 pan anti-H3 R 5µg/ml, 
incubated for 72 hours at 4°C; Lane 2 anti-rH3Aic/ anti-hH3 (445) 2µg/m1, incubated for 
72 hours at 4°C. 
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3.4.5 The anti-rH3A/c/ anti-hH3 (445) identified bands in immunoblots of (113R +/+) 
wild type mouse brain which were not evident in brain from (H3R -/-) knockout 
mice 
The specificity of the anti-hH3 445 antibody was confirmed by using it to probe 
immunoblots of (H3R +/+) wild type (WT) and (H3R -/-) knockout (KO) mouse brain. 
Two bands at Mr 50,000 ( 2000) and Mr 44,000 (+ 2000) were consistently detected 
in WT mouse brain but not in the KO material (3/3 repeats). A further species at Mr 
40,000 (± 2000) was also always present in the WT, however it also appeared twice in 
the KO (2/3 repeats). A species running at 59,000 was visible once in the KO but 
never in the WT; in addition a band at approximately 88,000 was evident once in both 
the KO and the WT (1/3 repeats. ) The findings are summarised in Table 3.4. Possible 
explanations for these results are explored in the discussion. 
Protein species Mr WT KO 
50,000 (± 2000) ++ (3/3 repeats)* 
44,000 (+ 2000) + (3/3 repeats) _ 
40,000 (+ 2000) ++ (3/3 repeats)* +/± (2/3); - (1/3) 
* Possibly equivalent to bands detected in rat forebrain at Mr 49,000 (± 2000) and 
38,000 (++ 2000). 
Table 3.4 Summary of results comparing immunoreactive species present in KO 
and WT mouse brain using anti-rat H3 (268 - 277)/anti-hH3 (445) 
Sizes are Mr values with the range for 3 replicate blots. 
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Fig 3.10 Immunoblot using anti-rH3, Jc/ anti-hH3 (445) to compare H3 receptor 
immunoreactivity in H3R -/- knockout (KO) mice with H3R +/+ wild type (WT) 
mice 
KO and WT mouse forebrain (10 . tg protein) was probed in parallel with anti-rH3fvc/ 
hH3 (445) R used at 1 µg/ml. Two bands at Mr 50,000 + 2000 and 44,000 ± 2000 were 
consistently detected in WT but not in KO material (3/3 repeats). A band at 40,000 ± 
2 000 was also detected in WT on 3/3 occasions however it also appeared once in the 
KO material. A species running at 59,000 was detected once in the KO lane but never 
in the WT, while a high molecular weight band at approximately 88,000 was seen 
once in both KO and WT. After each immunoblot the nitrocellulose sheet was stained 
with Ponceau S to confirm that the total protein loading was the same for both the KO 
and WT lanes. 
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3.4.6 Immunohistochemical studies using anti-rH3, tJc/ anti-h113 (445) antibody to 
compare immunoreactivity in H3R -/- (KO) mice with wild type (WT) mice 
clearly demonstrated the specificity of this antibody 
The IIH3 (445) isoform specific antibody was used to carry out a detailed 
mapping of the anatomical distribution of the H3R in mouse brain. IHC was carried out 
in wild type (H3R +/+) mouse brain slices alongside identical slices obtained from 
(H3R -/-) animals. Additional controls included the prior incubation of the anti-hH3 (445) 
antibody with its respective peptide such that specific immunoreactivity would be 
blocked. To achieve this, the primary antibody was incubated with the peptide at a 
final concentration of 500µg/ml overnight at 4°C. For use the antibody/peptide mixture 
was diluted such that the final antibody concentration was the same as for the 
unblocked antibody. As a second control IHC was carried out with the secondary 
antibody alone. 
Immunohistochemical (IHC) studies in the mouse 
A descriptive summary of the immunoreactivity in selected brain regions is shown in 
Tables 3.5 a) and b) for both wild type and H3R -/- mice. Table a) and b) show results 
using the pan anti-H3R (346-358) antibody and the isoform specific anti-rH3ac/ anti- 
hH3 (445) antibody, respectively. The data are from three different mice and the findings 
are in agreement with those from an independent laboratory using our antibodies to 
screen at least four further WT and KO animals (Dr Keri Cannon, Johnson & 
Johnson). Intensity of staining has been graded 0-4, with 0 being equivalent to 
background and 4 representing intense labelling. The strongest specific staining (that is 
not present in knockout animals) was seen in cortical laminae II, somatosensory 
cortex, piriform cortex, and the amygdaloid complex (Fig 3.11). Moderate reactivity 
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was also noted in the str terminalis, str: caudate putamen, fimbria of the hippocampus 
and the cingulum. Weak non-specific reactivity was observed in some of the brain 
structures of knockout animals using the anti-rH3AJC/ anti-hH3 (445) antibody (Fig 3.11). 
This non-specific staining was not seen with an immunofluorescence detection system 
using rhodamine linked anti-rabbit secondary antibodies (Fig 3.12). 
The background strain of the H3R -/- mice is C5731/6J (US Patent no. 7151200). In 
contrast to results using the pan anti-H3 (346 - 358) in B6C3Fe mice (Chazot et al, 
2001), there was negligible immunostaining in the deeper cortical layers and little 
detectable signal above background in the CAI, CA2 and CA3 regions of the 
hippocampus. In B6C3Fe mouse brain slices pan anti-H3 (346 - 358) 
immunoreactivity was detected in cortical layers II and V, and in the CA3 region of 
the hippocampus (Chazot et al, 2001). 
Table 3.5 a) Summary of some key brain structures using pan-H3 receptor 
antibody 
Tissue H3R +/+ H3R -/- 
Striatum +3-4 0 
Sunstantia nigra +3 0 
S1/S2 cortex +3-4 +1 
Cingulate cortex +3 0 
Entorhinal cortex +3 0 
Thalamus +3 0 
Amygdaloid complex +3-4 0 
Hippocampus CAI 0-1 0-1 
Medial septal cortex 0 0 
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Table 3.5 b) Summary of some key brain structures using anti- rII3A/3C / hII3 (445) 
antibody 
Tissue H3R +/+ H3R -/- 
Substantia nigra +4 +1 
Striatum +3 +1 
Cingulum +3 +2 
Somatosensory cortex +3 0 
Fimbria of the hippocampus +3 +2 
Hippo: CA1/CA2/CA3 0 0 
Cortex layer II +4 0 
Piriform cortex +4 0 
Str terminalis +4 +1 
Amygdaloid complex: ACo, 
PLCo 
+4 0 
Data are from n=3 mice of each type 
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H3R +/+ H3R-/- 
Somatosensory cortex 
x 200 
Cortex II 
x 200 
Fig 3.11 Comparing anti-rH3 A/C" anti-hH3 (445) immunoreactivity in H3 +/+ 
(wildtype) mice with H3 -/-(knockout) mice in selected key brain structures 
Immunostaining of mouse 20µm coronal brain slice (x 200) using anti-hH3 (445) at 0.1 
µg/ml. 
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H3 +1+ H3 -/- 
Piriform Cortex 
x 200 
Amygdaloid 
Complex 
x 200 
Fig 3.11 Comparing anti-rHsni3c /anti-hH3 (445) immunoreactivity in H3 +/+ 
(wildtype) mice with H3 -/- (knockout) mice in selected key brain structures 
Immunostaining of mouse 20µm coronal brain slice (x 200) using anti-hH3 (445) at 0.1 
µg/ml. 
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Fig 3.11 Comparing anti-rH3AJ3C /anti-hH3 (445) immunoreactivity in H3 +/+ 
(wildtype) mice with H3 -/- (knockout) mice in selected key brain structures 
Immunostaining in the hippocampal formation of a mouse 20 µm coronal brain slice (x 
20 and x 200), using anti-hH3 (445) at 0.1 µg/ml. 
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A 
Pan anti-H3R (346-358) antibody 
H3 +/+ H3 -/- 
Striatum 
Substantia nigra 
pars reticulata 
B 
Anti-rH3 (A/c) /hH3R (445) antibody 
H3 +/+ H3 -/- 
Striatum 
Substantia nigra 
pars reticulata 
Fig 3.12 Immunofluorescent detection of H3 immunoreactivity in striatum and 
substantia nigra pars reticulata comparing H3 +/+ (wild type) mice with H3 -/- 
(knockout) mice 
A Pan anti-H3R (346-358) antibody, B Anti-rH3Ai3C /anti-hH3R (445) antibody in coronal 
mouse brain slices (x 100). 
Reproduced with kind permission of Dr Keri Cannon 
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3.5 DISCUSSION 
This chapter describes the development and characterization of novel anti-H3 receptor 
isoform specific antibodies, and their preliminary use in mapping the anatomical 
distribution of the H3R in mammalian brain. A peptide sequence unique to the rat H3C /H3 
(397) isoform was chosen and used to immunise rabbits for the generation of sequence 
specific antibodies. The antibody was affinity purified and screened against rat and 
human H3R isoforms expressed in HEK 293 cells, (Note: mouse clones would have been 
used but were not available at this time). Immunoblotting of cell homogenates revealed 
that in addition to detecting the rH3C /397 isoform it also labelled the full length 445 
isoforms of both the human and the rat H3R. The peptide sequence EAMPLHRGSK is 
found within the third intracellular loop of the rat rH3C /397 isoform, as 268 - 277. The 
sequence is present in both the human and rat full length forms but in the rH3C /397 
isoform it is split: EAMPLHR appearing on the 5' side of the deletion site and GSK on 
the 3' side. Presumably the tertiary structure of the receptor is such that the two halves are 
brought together in a form which the antibody can recognize. One might have expected 
the antibody to react with hH3 (365) (deletion 275-354) and rH313 /413 (deletion 275 - 306) 
since only the last two amino acids are missing from the EAMPLHRGSK sequence in 
these two isoforms. In addition in the full length mouse H3R the sequence is 
EAMPLHRYGV, with the last three amino acids being different from the immunising 
peptide, nevertheless specific anti-H3R immunostaining was detected with both the pan 
anti-H3 and the anti-rH3a3c /anti-hH3R (445) in mouse brain slices. However, the tertiary 
structure of the hH3 (365) and rH3B /413 may have been unfavourable, with the peptide 
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sequence not accessible to the antibody within these isoforms. The hH3 (329 etc) (deletion 
227 -342) does not possess any of this particular peptide sequence and, as expected, no 
reactivity was seen with this clone. 
The presence of higher molecular weight species even under the strong reducing and 
detergent conditions under which the gels were run indicates the possible presence of 
robust dimers or higher oligomers in addition to the monomer. However, the molecular 
weights of the higher bands were not all compatible with multiples of the H3 receptor 
monomer. At least two explanations might account for this: firstly, anomalous running of 
the oligomers possibly due to post-translational changes, eg. glycosylation, and secondly 
other cellular proteins could be robustly interacting with the H3 receptor. Results obtained 
with recombinant proteins should be interpreted with caution. The receptor is not being 
expressed in its natural environment and receptor levels are generally higher than in 
native tissue. However, higher molecular weight species were also observed in 
immunoblots of native tissue, especially in the human material; suggesting that this is 
indeed a real phenomenon. Immunoreactivity in human putamen was investigated 
because high levels of H3R mRNA have been reported in this brain structure for human 
(Cogd et al, 2001), rat (Pillot et al, 2002) and mouse (Rouleau et al, 2004). Furthermore 
it is of interest as a key region in voluntary movement. In the Pillot study the mRNA 
signal was matched with strong ligand binding, indicative of H3R protein expression. 
Evidence for message coding for several different isoforms in addition to the full length 
isoform was found in both human and mouse cortex (Cogd et al, 2001 and Rouleau et al, 
2004, respectively), a brain area which sends projections to the striatum which includes 
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the putamen. Message for several isoforms was also found in the striatum itself in the 
Rouleau study. In agreement with these reports both the pan anti-H3R and the anti-rat H3 
(268 - 277)/anti-hH3 (445) antibody identified multiple bands in human putamen, both 
putative monomers (with the pan anti-H3R) and higher molecular weight species (with 
both antibodies). Interestingly, in immunoblots of rodent brain higher molecular weight 
species were seldom seen, suggesting there may be species differences in oligomer 
stability. However the data from these experiments are limited because the material was 
from only a small number of animals (n = 3). There was some indication that the different 
isoforms may differ in their potential to oligomerise and/or interact with other proteins. 
With rat isoform H3C/397 expressed in HEK 293 cells, higher molecular weight species 
were less apparent than with the full length rH3A/445 isoform. The evidence for H3R 
oligomers is further investigated in Chapter 4. 
Attempts were made to generate antibodies against three more human H3R isoforms 
using an identical strategy, however these met with only limited success. However, one 
of these antibodies appears to selectively recognise the 329 isoform with moderate 
affinity. This requires further investigation. 
The rH3C (268 - 277)/hH3 (445) antibody was used to map the anatomical distribution of the 
H3R in mouse brain slices. Immunohistochemical (IHC) studies using wild-type and H3R- 
/- mice (Lovenberg, Johnson and Johnson, US Patent no. 7151200) showed a marked 
reduction in immunoreactivity in the knockout animals compared to the wild type, 
demonstrating the specificity of the new antibody. In this investigation only material from 
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three animals was available to us, however the findings are in agreement with an 
extensive IHC study using our antibodies and the same H3R -/- animals, an 
immunofluorescent detection system was used on this occasion (see Fig 3.12, Cannon et 
al, 2007). The immunoreactivity in wild type animals was similar for both the original pan 
anti-H3 (346-358) antibody and the new isoform selective antibody. The findings also 
confirmed those of a previous study using the pan anti-H3 (346-358) antibody (Chazot et 
al, 2001) to map the anatomical distribution of the H3R in mouse brain slices; with the 
exception of cortex layer V which showed moderate/strong staining in the first study but 
only light staining in the present investigation, and the hippocampus (regions CAI-CA3 
and dentate gyrus) where there was some moderate reactivity, not found here. It is 
possible that these minor differences might be accounted for by the fact that different 
mouse strains were used (B6C3Fe, Chazot et al, 2001; C5731/6J in this study), however 
further work is necessary to validate these observations and confirm their reproducibility. 
IHC using the anti-rH3c/hH3 (aas) antibody demonstrated clear specific immunoreactivity 
in substantia nigra, cortical laminae II, somatosensory cortex, piriform cortex, and the 
amygdaloid complex. Moderate reactivity was also noted in the striatum, str terminalis, 
fimbria of the hippocampus and the cingulum. Background labelling was evident in some 
brain areas in knockout animals, notably the fimbria of the hippocampus and cingulum, 
and to a lesser degree in the striatum; nevertheless it was at a lower level than in 
equivalent areas from wild type mice. This background labelling was not apparent using 
an immunofluorescent detection system e. g. basal ganglia (Fig 3.12). However in 
immunoblots comparing mouse brain homogenates from WT and KO the animals there 
was an indication of some immunoreactivity in the KO material (Fig 3.10). In the H3R -/- 
121 
mice the H3R gene is disrupted by homologous recombination (US Patent no. 7151200). 
A 0.7 kb region covering part of the first intron and the 5' end of the second exon is 
replaced. Although the gene is rendered non-functional by this disruption with no 
detectable [3H]-RAMH binding in KO animals (Toyota et al, 2002; US Patent no. 
7151200) there could possibly be some low level expression of non-functional H3R 
protein remaining. The staining might be entirely non-specific but this is unlikely because 
the peptide block experiment wherein the antibody was pre-incubated with its respective 
peptide completely removed the reactivity, therefore demonstrating that the antibody is 
binding to that particular peptide sequence. Alternatively the sequence might occur in 
other proteins in this region which are not H3R. However a standard BLAST screen 
performed as described previously (Chazot et al, 2001) yielded no mammalian brain 
protein hits. Such proteins could conceivably be other histamine receptor subtypes not yet 
identified. Although there is evidence for the most recently discovered histamine H4 
receptor subtype in both human brain (Coge et al, 2001) and mouse brain (Zhu et al, 
2001) cross-reactivity with this particular receptor is unlikely. The EAMPLHRGSK 
sequence is not found within the H4R as sequence and the anti-rH3c/hH3 (44s) antibody 
does not detect recombinant H4R expressed in HEK 293 cells. 
Specific immunoreactivity in the amygdaloid complex could be of significance in that this 
area of the brain is known to be involved in fear and memory. The H3 receptor appears to 
play a role in memory in some experimental models. It was found using the passive 
avoidance model, that H3R -/- mice learned as normal, but were insensitive to the 
amnesia-inducing effects of the muscarinic antagonist scopolamine (Toyota et al, 2002). 
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This is in agreement with studies where H3 receptor antagonists have been shown to have 
the same effect on scopolamine-induced memory deficits (Giovannini et al, 1999). 
Interestingly, the H3R -/- mice were not insensitive to scopolamine in the open field 
habituation test, which measures memory as the habituation of exploratory activity in a 
new environment. The fact that H3 -/- mice were only insensitive to the effects of 
scopolamine in an aversion model may point to a specific role for the H3 receptor in 
memory formation associated with painful stimuli. 
The high expression in the basal ganglia, particularly in the substantia nigra, is consistent 
with recent double labelling confocal studies using these H3 receptor antibodies 
(Appendix). These have shown that the H3 receptor is expressed on minor subpopulations 
of GABA-ergic neurons in the sustantia nigra and frontal cortex, and furthermore on 
subpopulations of histaminergic neurons in the tubermammilary nucleus, which suggests 
distinct control of output neurons to other brain regions by the H3 receptor (unpublished 
findings, see Appendix). 
In conclusion a novel anti-H3R antibody was generated which was selective for two rat 
isoforms: rH3A and rH3c and only for the human hH3 (445) isoform. This antibody was used 
to further characterise rodent and human H3R in both heterologous and native tissue. In 
addition it was used to map the distribution of these isoforms in mouse brain. Two 
potential sources of receptor heterogeneity are indicated by these results. Firstly there was 
clear evidence of higher molecular weight species on immunoblots. These could be 
accounted for by any or all of the following: receptor oligomers, the receptor associated 
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with other cellular proteins, and/or post-translational changes. Secondly different isoforms 
may vary in their propensity to form homo and hetero-oligomers (see Chapter 4); for 
example in contrast to the rH3A isoform, higher molecular weight species were not evident 
with the rH3c following heterologous expression in HEK 293 cells. There could also be 
interspecies differences in receptor oligomersisation in native tissue, higher molecular 
weight species were rarely detected in rodent brain using the rH3C (268 - 277)/hH3 (445) 
antibody in contrast to observations in human putamen. In the following chapter the 
presence of human and rat H3R oligomers will be investigated and its' relevance to 
receptor heterogeneity and function will be discussed. Note chapter 4 will also take 
advantage of the subtype selectivity of the new antibody for the full length human H3 
receptor. 
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CHAPTER 4 
EVIDENCE FOR HUMAN AND RODENT H3 RECEPTOR OLIGOMERS: 
BIOCHEMICAL AND BIOPHYSICAL APPROACHES 
4.1 OBJECTIVES 
Investigate oligomer formation, both homo-oligomers between the same isoforms and 
the possibility of hetero-oligomers consisting of splice variants of the receptor. 
4.2 INTRODUCTION 
Oligomerisation of histamine receptors has been demonstrated for the H1R (Carillo et 
al, 2003; Bakker et al, 2004), the H2R (Fukushima et al, 1997), rat H3R (Bakker et al, 
2006; Shenton et al, 2005) and the H4R (Chapter 5 and van Rijn et al, 2006). In H1 
receptors transiently expressed in COS-7 cells, Bakker and colleagues (Bakker et al, 
2004) demonstrated the presence of domain swapped H1 receptor dimers in which 
there was a reciprocal exchange of TM domains 6 and 7. 
Heterogeneity in the pharmacology of the H3 receptor both between and within species 
is well documented (see chapter 1) and the reasons for it are likely to be complex. The 
existence of several H3 receptor isoforms in all mammalian species studied so far and 
their differential distribution within brain regions could in theory provide potential 
mechanisms for generating this heterogeneity. Multiple receptor isoforms generated by 
differential splicing of receptor RNA have been reported for other GPCRs (reviewed 
by Bockaert & Pin, 1999). However the functional relevance of these splice variants is 
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largely unknown. A variant of the gonadotrophin-releasing hormone receptor 
(GNRHR) impairs receptor signalling possibly by preventing proper trafficking of the 
full length GNRHR (Grosse et al, 1997). A non-functional transmembrane truncated 
variant of the arginine vasopressin V2 receptor (AVPR2) co-expressed with the full 
length AVPR2 acted as a negative regulator of normal AVPR2 function (Zhu & Wess, 
1998). The truncated isoform reduced both the surface expression of the full length 
receptor and the maximum cAMP resonse induced by ligand stimulation. 
Thromboxane A (2) is a potent mediator of inflammation, vasoconstriction and 
oxidative stress. Its receptor (TP) is expressed as two alternatively spliced isoforms 
alpha and beta. TP alpha does not undergo constitutive or agonist-induced endocytosis 
when co-expressd with TP beta (Laroche et al, 2005). Co-transfection of vasoactive 
intestinal peptide (VIP) receptor (VPAC2) with a short deletion (SD) splice variant SD 
VPAC2, leads to a decreased VIP enhancement of IL-4 production by Th2 cells 
compared with the full length VPAC2 receptor alone (Huang et al, 2006). The 
evidence suggested a competitive interaction between the two isoforms in the same 
signalling pathway, with the SD VPAC2 isoform inhibiting the increase of nuclear 
levels of transcription factors. However hetero-oligomerisation was not investigated in 
this study. 
In the case of rat H3 receptors, our group and colleagues have provided evidence for 
truncated rH3 isoforms acting as dominant negative hetero-dimers which impede the 
expression of the full length rH3A isoform at the cell surface (Bakker et al, 2006). 
Therefore the evidence to date tends to suggest a potential negative regulatory role for 
GPCR splice variants. 
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As described in chapter 3 and previously in the laboratory (Chazot et al, 2001; 
Victoria Hann PhD thesis, 2004) immunoblots of both recombinant and native rat H3R 
provided evidence for robust oligomers (insensitive to 200mM DTT). The purpose of 
the experiments described in this chapter was to confirm the existence of human H3R 
homo- and hetero-dimers (ie dimerisation between different isoforms) when expressed 
in HEK 293 cells. The studies focussed on the full length 445 H3 isoform and another 
major isoform the 329 EiIC. mRNA coding for both these isoforms is abundant within 
human brain and they appear to exist together in some important brain regions (Coge 
et al, 2001). In order to address the question as to whether the H3R is capable of 
forming both homo- and hetero-oligomers (ie oligomers between different splice 
variants), different approaches were used: a) biochemical, using a chemical cross- 
linking technique to stabilise putative homo-dimers, and b) biophysical, using 
Fluorescent Resonance Energy Transfer (FRET) to confirm the presence of both 
homo- and hetero-dimers within the cell membrane. 
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4.3 METHODS 
Culture and transfection of HEK 293 cells 
Harvesting and membrane preparation of HEK 293 cells for blotting 
Lowry assay for protein estimation 
Immunoblotting 
Chloroform/ methanol protein extraction 
All as described in Chapters 2 and 3. 
In addition to the usual sample preparation described in Chapter 3, a method involving 
incubation of the sample with urea at 4°C was used (Gazi et al, 2003) which was found 
to enhance the visualisation of higher oligomers. For this method, the sample buffer 
was as follows: 100mM Tris-HCl pH 6.8,4% SDS, 0.2% bromophenol blue, 20% 
glycerol and 8% urea. The sample was dissolved in 13 gl of this sample buffer plus 
2µl of 1.5M DTT (giving a final DTT concentration of 200mM). Following a2-4 
hour incubation period at 4°C, the sample was subjected to standard gel 
electrophoresis. Where a particularly clean preparation was required the protein was 
occasionally extracted using a standard chloroform/ methanol method. 
4.3.1 Chemical cross-linking 
HEK 293 cells were transfected with either rat or human H3R cDNAs. The human 
isoforms were both epitope tagged with FLAG (Coge et al, 2001). Two days post- 
transfection, the cells were harvested and homogenised, homogenates were then 
incubated with increasing concentrations of the irreversible chemical cross-linker 
bis(sulphosuccinimidyl) suberate sodium salt (BS3). This involves the covalent 
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coupling of proteins via primary amine bonds. The cross-linking method was adapted 
from that of Haugeto et a1,1996. Aliquots of transfected HEK cells were pelleted, the 
suspension buffer was removed and replaced with 150µl cross-linking buffer (150mM 
NaCl, 100mM Na-HEPES, 5mM EDTA pH7.5,5mM DTT) to give a final protein 
concentration of approx. 5mg/ml. The BS3 was dissolved in 20mM HCl to give a 
100mM stock solution. The stock was added at doubling dilutions to nine tubes of 
resuspended cells to give final cross-linker concentrations ranging from 0 to 4mM. 
The tubes were incubated at room temperature with continual mixing for 12 minutes 
after which they were spun down at 10000rpm for 5mins, the cross-linking mixture 
was removed and the pellet prepared for immunoblotting either in the usual way or 
using the method outlined above, using sample buffer plus urea at 4°C. The blots were 
carried out on 6% PAGE gels following cross-linking to allow larger molecular weight 
species to be resolved on the gel. Either anti-FLAG antibody or the new anti-H3 (445) 
specific antibody described in Chapter 3 was used as the primary antibody. As 
reported in Chapter 3 the latter antibody was selective for the hH3 (445) isoform and the 
rat H3A and H3C isoforms, but not the hH3 (365), hH3 329 or rH3B. 
Immunoblots were quantified by densitometry using NIH ImageJ in the linear range of 
the film. Optical density values were normalised to respective background as 
described previously (Chazot et al, 2002). 
4.3.2 tr-FRET 
This method uses differential labelling of membrane receptors with a donor (europium 
3+) and an acceptor (allophycocyanin APC) fluorophore and the subsequent transfer of 
resonance energy from one to the other provided the two receptors are close enough 
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together. If the two receptors are within I00A of each other in the membrane, 
excitation of the Eu 3+ fluorophore will result in resonance energy transfer to the APC 
fluorophore which will emit fluorescence at 665nm (Fig 4.1 Schematic representation 
of FRET for homo-dimers). In order to demonstrate the presence of hetero-oligomers a 
slightly different strategy was necessary (Fig 4.2 Schematic representation of FRE"I' 
for hetero-dimers). 
R to "R"""' 
Antibody and APC anti-FLAG 
mmvýim 
fl 
n ý 
Fig 4.1 Schematic representation of tr-FRET to show H3R homo-dimers. 
HEK 293 cells were transfected with an H3R isoform epitope tagged with FLAG. The 
transfected cells were incubated with a mixture of Eu3+ labelled- and allophycocyanin 
(APC) labelled-anti-FLAG antibodies. Excitation of the Eu3+ fluorophore with a 
337nm wavelength generates an emission at 620nm. If an APC labelled antibody 
bound to an adjacent receptor is within 100A range, resonance energy transfer can 
occur. The ensuing 665nm emission thus indicates the formation of receptor homo- 
oligomers within the cell membrane. 
ýý 
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Fig 4.2 Schematic representation of tr-FRET to show H3R hetero-dimers. 
HEK 293 cells were co-transfected with H3 (329) and H3 (445)R isoforms The 329 isoform 
is epitope tagged with FLAG whereas the 445 isoform is untagged. The transfected 
cells were incubated with a rabbit anti-hH3 (445)R selective antibody (Chapter 3) 
initially. Following washing steps the cells are then incubated with a mixture of Eu 
3+ 
labelled anti-rabbit and allophycocyanin (APC) labelled-anti-FLAG antibodies. 
Excitation of the Eu 3+ fluorophore bound via the rabbit anti-hH3 (445)R to a 445 isoform, 
generates an emission at 620nm. If an APC labelled antibody bound to an adjacent 329 
receptor is within 100A range, resonance energy transfer can occur. The ensuing 
665nm emission thus indicates the formation of receptor hetero-oligomers within the 
cell membrane. 
For the homo-dimer experiment HEK-293 cells were individually transfected with 
either the 329 isoform or the 445 isoform both epitope tagged with FLAG. For the 
hetero-dimer experiment cells co-transfected with FLAG tagged 329 and unta ged 445 
isoforms were used. The tr-FRET assay was adapted from that described previously by 
Bakker et al, 2006. Bakker used whole cells, however as the antibodies used here were 
all directed to intracellular portions of the receptor, it was necessary to disrupt the cells 
in order to allow the antibodies access to the relevant epitopes. Two days post- 
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transfection, cells were harvested and suspended in PBS containing 50% FCS (v/v). 
Suspensions of 1.5 x 106 cells/ml were made for cells transfected with 329 alone, 445 
alone or 329 + 445 (untagged) together. Additional batches of cells individually 
transfected with 329 or 445 (untagged) were prepared at 0.75 x 106 cells/ml. These 
latter cells were mixed 1: 1 and used as a control for the hetero-dimerisation 
experiment. The cells were homogenised by sonication and the membranes purified by 
passage through a Sephadex G25 mini-column. Passage through the column results in 
the formation of cell membrane vesicles, it was assumed that 50% of the vesicles 
would have the receptors inside out, i. e. with the C-terminal tail on the extracellular 
side, and 50% in the correct orientation. This step was necessary because the FLAG 
tag was at the C-terminal end of the receptor and likewise the anti-H3 (445) antibody is 
directed towards the 3ic, which is also intracellar. Each column contained 0.5m1 
packed volume of Sephadex G25 pre-swelled in milliQ water. A total volume of 0.5m1 
of homogenised cells was added to the column, once this had run through a further 
0.5m1 of the PBS/FCS diluent was added to elute the disrupted membranes from the 
column as vesicles. Eluted vesicles were pelleted and the PBS/FCS removed. The 
vesicles were then resuspended in 300µl of fresh PBS/FCS containing the fluorophore 
labelled antibodies. For the homo-dimer experiment a combination of both europium 
3+ (Eu3)-labelled and allophycocyanin (APC)-labelled anti-FLAG antibodies was 
used, at 0.8nM and 8nM concentrations respectively. Control vesicles were incubated 
with Eu3+-labelled anti-FLAG (0.8nM) alone. Vesicles were incubated in the dark for 
two hours, at room temperature on a rotating wheel; after which they were washed 
twice with PBS. The final pellet was resuspended in 150 µl PBS and this was split into 
three 50pl samples on transfer to three wells of a 384-microtiter plate. Energy transfer 
was measured by exciting the Eu 3+ at 320nm and monitoring the allophycocyanin 
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emission for 500µs at 665nm using a Novostar (BMG Labtechnologies) configured for 
tr-fluorescence after a 100 µs delay. For the hetero-dimer experiment cells co- 
transfected with 329 + 445 (untagged) were used and the control was a 1: 1 mixture of 
cells (329 transfected cells mixed with 445(untagged) transfected cells). Following 
column separation these vesicles were pelleted and then resuspended in rabbit anti-hH3 
(445) specific antibody at 1µg/ml. After the initial 2 hour incubation the primary 
antibody was removed and replaced with either Eu3+-labelled anti-rabbit alone (only 
for the co-transfected cells) or a mixture of Eu3+-labelled anti-rabbit and APC-labelled 
anti-FLAG for both the co-transfected cells and the cell mixture. The fluorophore 
labelled antibodies were used at the same concentrations as in the homo-dimer 
experiment. Following an additional two hour incubation period, the energy transfer 
was measured as before. All tests and controls were performed in triplicate. These 
experiments were performed on 3-4 separate occasions with similar results. 
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4.4 RESULTS 
4.4.1 Chemical cross-linking studies show rat H3 (A) dimers and H3 (() dimers 
In the rat full length H3 (A) isoform increasing concentrations of the cross-linker (0 - 
0.25 mM) clearly showed increasing levels of higher molecular weight species 
compatible with the presence of receptor dimers and higher oligomers. In addition to 
the monomer, proteins running at Mr > 173,000; 133,000 and 89,000 ± 3000 were 
evident (summarised in Table 4.1). These increased in intensity in the presence of 
cross-linker while the bands corresponding to the monomers tended to decrease. By 
contrast the shorter H3 (C) isoform did not appear to form higher molecular weight 
species so readily (Fig 4.3). 
Rat H3 (A) isoform Rat H3 (C) isoform 
>173,000 
133,000 
89,000 + 3000 
47,000 doublet 39,000 doublet 
32,000 < 32,000 
Table 4.1 Summary of protein species detected following chemical cross-linking 
of rat H3 (A) and H3 (C) isoforms 
Mr values for protein species identified in replicate experiments from two independent 
transfections. Putative dimeric/ oligomeric species are shown in red. 
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Fig 4.3 Cross-linking of recombinant rat H3R expressed in HEK 293 cells 
HEK 293 cells were transfected with either the rat H3R (A) or H3R (c) isoforms. Two 
days post-transfection the cells were harvested and homogenized. Homogenates were 
pelleted and the suspension buffer replaced with 150µl cross-linking buffer (150mM 
NaCl, 100mM Na-HEPES, 5mM EDTA pH 7.5,5mM DTT) to give a final protein 
concentration of approx. 5mg/ml. Homogenates were incubated with increasing 
concentrations of the cross-linker BS3 (0,0.12 and 0.25 mM) for 12 minutes at room 
temperature, with continual mixing. Following this they were spun down at 10000 rpm 
for 5mins, the cross-linking mixture was removed and the pellet prepared for 
immunoblotting. The blots were carried out using 6% PAGE gels following cross- 
linking to allow larger molecular weight species to be resolved on the gel. Two blots 
are shown, which are replicate experiments from two independent transfections. 
4.4.2 Chemical cross-linking enhances both hH3R(445) and hH3R(329) homo-dimers 
Using the chemical cross-linking technique, higher oligomers were demonstrated for 
both the human full length H3R(445) isoform and the hH3R(329) isoform expressed in 
HEK 293 cells. With the hH3R(329) isoform higher oligomers were clearly evident even 
in the absence of cross-linker. For the 445 isoform the dimeric species running at Mr 
106,000 (3 replicates: twice probed with anti-hH3 (445) Fig 4.4a, once probed with anti- 
FLAG Fig 4.4b) increased in strength while the strength of the monomer was 
diminished as the cross-linker concentration increased from 0-0.25mM (Fig 4.4c). 
Above 1 mM cross-linker concentration the monomer and higher oligomers were 
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removed altogether, presumably because the receptors were all converted to oligomers 
too large to enter the resolving gel. For the 329 isoform, in addition to the putative 
dimer running at Mr 79,000; a band at 48,000 (4 replicates) was also enhanced by the 
presence of cross-linker (Fig 4.5a). Presumably this arises from an association between 
the H3 (329) isoform and another, as yet unidentified protein expressed in the HEK 293 
cells. A higher oligomeric species at Mr 117,000 + 6000 was also identified (4 
replicates). Up to 0.25 mM cross-linker concentration, the oligomeric species 
increased in strength while the strength of the monomer was diminished (Fig 4.5b). As 
with the full length isoform, above 1mM cross-linker concentration the monomer and 
higher oligomers were removed altogether. 
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Fig 4.4 a) Cross-linking of human H3R(445) expressed in HEK 293 cells 
HEK 293 cells were transfected with either the human H3Rc445) full length isoform. 
Two days post transfection the cells were harvested and homogenized. Homogenates 
were pelleted and the suspension buffer replaced with 150µl cross-linking buffer 
(150mM NaCl, 100mM Na-HEPES, 5mM EDTA pH7.5,5mM DTT) to give a final 
protein concentration of approx. 5mg/ml. Homogenates were incubated with the cross- 
linker BS3 at different concentrations at room temperature with continual mixing for 
12 minutes. The samples were spun down at 10000rpm for 5min, the cross-linking 
mixture was removed and the pellet prepared for immunoblotting. The blots were 
carried out on 6% PAGE gels following cross-linking to allow larger molecular weight 
species to be resolved on the gel. Lane 1 Control, no cross-linker; Lanes 2-7: 0.03, 
0.06,0.12,0.25,0.5,1 mM BS3. Probed with anti-hH3 (445) at 1µg/ml. One 
representative immunoblot from 3 replicate experiments. 
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Fig 4.4 b) Cross-linking of human FLAG-H3R(445) expressed in HEK 293 cells 
probed with anti-FLAG and anti-hH3 (445) 
Chemical cross-linking carried out as described above on cells transfected with human 
FLAG-H3R(445). Lanes 1 and 2 probed with anti-FLAG antibody (1: 5000) and anti- 
hH3 (445) at 1 µg/ml, respectively. 
AB 
ý ; 
ý S 
445 monomer 445 dimer 
Fig 4.4 c) Graph to show densitometric evaluation of hH3R(445) immunoreactivity 
in the presence of increasing cross-linker concentration 
The data are from one representative experiment as described in Fig 4.4 a). The 
graphs illustrate the gradual loss of the monomeric species (A) and concomitant 
increase in intensity of the putative dimer (B) with increasing cross-linker 
concentration up to 0.25 mM. At greater cross-linker concentrations the higher 
oligomeric species were also diminished. Graphs are from one representative 
immunoblot out of 3 replicate experiments. 
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Fig 4.5 a) Cross-linking of human H3R(329) expressed in HEK 293 cells 
Cross-linking experiment carried out as described for the human H3R(445) isoform. 
The H3Rc329) cDNA was C-terminally tagged with FLAG, therefore mouse anti-FLAG 
antibody was used as the primary antibody for the immunoblot. 
Lane 1 Control, no cross-linker; Lanes 2-8: 0.03,0.06,0.12,0.25,0.5,1,2 mM BS3. 
One representative immunoblot from 3 replicate experiments. 
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Fig 4.5 b) Graph to show densitometric evaluation of FLAG-hH3R(329) 
immunoreactivity in the presence of increasing cross-linker concentration 
The data are from one representative experiment as described in Fig 4.5 a). The 
graphs illustrate the gradual loss of the monomeric species (A) and concomitant 
increase in intensity of the putative dimer (B) and an additional species (329-X) 
presumed to be the hH3 (329) associated with an as yet unidentified cellular protein (C), 
with increasing cross-linker concentration up to 0.25 mM. At greater cross-linker 
concentrations the higher molecular weight species were also diminished. Graphs are 
from one representative immunoblot out of 3 replicate experiments. 
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4.4.3 FRET studies confirmed the presence of rat H3R(A) homo-dimers 
FRET studies on the full length rat H3R(A) isoform were performed by our 
collaborators. Their results (Fig 4.6) confirmed the presence of rat H3R(A) homo- 
dimers (Bakker et al, 2006). 
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Fig 4.6 FRET studies confirm the presence of full length rat H3R(A) dimers 
adapted from Bakker et al, 2006 
Cells co-transfected with FLAG tagged and Haemagluttinin (HA) tagged rH3(AAR 
were homogenised and then incubated either with fluorophore Europium 3+ (Eu 
+) 
labelled anti-FLAG or allophycocyanin (APC) XL665 labelled anti-HA separately, or 
with a mixture of both antibodies together. Excitation at 337nm stimulates an 
emission from the Eu 3+ fluorophore. Resonance energy can be transferred to the APC 
fluorophore providing it is wthin a distance of l 00A. The Eu 3+ anti-FLAG/ APC anti- 
HA mixture resulted in an approximately three fold increase in the APC665 emission, 
confirming the presence of rH3(A) homo-oligomers. Results are expressed as the cell 
fold increase in signal (that is the APC665 emission from co-transfected cells divided 
by the APC66s resulting from a 1: 1 mixture of cells transfected individually with 
FLAG- rH3(A) and HA- rH3(A))" 
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4.4.4 FRET assays confirmed the presence of human 113 receptor homo-dimers 
and provided evidence for the existence of 329/445 hetero-dimers. 
Herein, we assessed whether human H3 receptor isoforms homo- and hetero- 
oligomerise. Fig 4.7 shows the FRET signal expressed as the acceptor/donor ratio (that 
is APC665 emission/Eu 3+620 emission generated by excitation of the donor at 337nm) in 
a representative experiment to demonstrate the existence of homo-dimers. The 
acceptor/donor ratio was 0.265 (SD 0.049) for the 445 isoform and 0.355 (SD 0.054) 
for 329 transfected cells, more than double the signal obtained when the cell vesicles 
were incubated with the Eu3+ labelled antibody alone (3 independent replicates). There 
was some indication that 329 homo-dimers form more readily than 445 homo-dimers, 
although this did not reach statistical significance over the three repeats of the 
experiment. Figs 4.8 and 4.9 show FRET results from a representative hetero-dimer 
experiment. The acceptor/donor ratio (Fig 4.8) was 0.211 (SD 0.026) for the co- 
transfected cells compared with 0.152 (SD 0.026) for the cell mixture. The cell fold 
increase in signal (that is the co-transfected APC665 emission divided by the cell 
mixture APC665 emission) (Fig 4.9) was 1.594 (3 independent replicates). The fact that 
the acceptor/donor ratio was less than that seen for the homo-dimers may suggest that 
hetero-dimers form less frequently than homo-dimers, however it is not possible to 
make a direct comparison as the assay methods were not identical. 
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Fig 4.7 Homo-oligomerisation of the hH3 (329) and hH3 (445)R isoforms. 
Homogenates derived from HEK-293 cells transfected with either the hH3 (329) or hH3 
(445)R epitope tagged with FLAG were prepared. The homogenates were incubated for 
two hours with either Eu3+ labelled anti-FLAG antibody alone (filled bars, Eu3) or 
with a mixture of Eu3+ labelled anti-FLAG and Allophycocyanin (APC) XL665 
labelled anti-FLAG (open bars, Eu3+ + XL665). Data shown are from a representative 
experiment, replicated in n=3 independent experiments with similar results. 
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Fig 4.8 Hetero-oligomerisation of the hH3 (329) and hH3 (445)R isoforms. 
Homogenates from HEK-293 cells co-transfected with FLAG-tagged hH3 (329) and 
untagged hH3 (445)R (Co) were prepared. A mixture of cells transfected individually 
with the FLAG-329 and 445 isoforms (Mix) was used as a control. The homogenates 
were incubated for two hours with rabbit anti- hH3 (445)R antibody, they were then 
washed and incubated for a further two hours with a mixture of Eu 3+ labelled anti- 
FLAG and Allophycocyanin XL665 labelled anti-FLAG antibodies. As an additional 
control, half of the co-transfected homogenates were incubated with Eu3+ labelled 
anti-FLAG antibody alone (Eu 3) rather than the antibody mixture. The tr-FRET 
signal is expressed as the Acceptor/Donor ratio (that is APC665 emission/Eu 3+62o 
emission generated by excitation of the donor at 337nm). Data shown are from a 
representative experiment, replicated in n=3 independent experiments with similar 
results. 
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Fig 4.9 Demonstration of hetero-oligomerisation of the hH3 (329) and hH3 (445)R 
isoforms. 
Data from the same experiment as Fig 4.8 above, expressed as the cell fold-increase in 
signal (co-transfected APC665 emission divided by the cell mixture APC665 emission). 
I 
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4.5 DISCUSSION 
There is a growing consensus that many GPCRs, possibly all of them, function as 
dimers or higher molecular weight oligomers. Immunoblots of native rat and human 
brain tissue, probed with our anti-H3R specific antibodies showed multiple bands (see 
Figs 3.8 and 3.9 respectively, Chapter 3) suggesting that H3Rs are commonly present 
as oligomers. Similarly in blots of hH3R isoforms expressed in HEK 293 cells higher 
molecular weight species were apparent. 
Here two different approaches were used to study H3R oligomer formation: chemical 
cross-linking and tr-FRET, biochemical and biophysical techniques respectively. A 
criticism of chemical cross-linking studies is that the formation of protein aggregates 
can potentially give false positive results. The reducing agent dithiothreitol (DTT) is 
included in the cross-linking buffer (section 4.3.1) in order to prevent this, in addition 
both DTT and the detergent SDS are present in the sample buffer (section 2.3.8). The 
tr-FRET data was also in agreement with the cross-linking evidence. Time resolved 
(tr)-FRET is used to ensure that shorter-lived endogenous fluorescence is extinguished 
before the longer lasting FRET signal is measured. Homo-oligomerisation between the 
same isoforms, and hetero-oligomerisation between different isoforms were both 
investigated. The human H3 (445) and H3 (329) isoforms are both major isoforms with 
mRNA expressed in many important brain regions. Although they show differential 
expression there are some key brain areas such as the basal ganglia where they are 
found together, therefore the question of hetero-oligomersiation between these two 
isoforms may be of physiological relevance. 
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Using the chemical cross-linking method homo-dimers were clearly demonstrated for 
the rat H3 (A), and both the human H3 (445) and H3 (329) isoforms. By contrast rat H3 (C) 
dimers were not so obvious. Even in the absence of cross-linker hH3 (329) dimers were 
evident and these were enhanced by increasing concentrations of the cross-linker. 
Taken together these findings suggest that there could be differences in the potential 
for different isoforms to form robust homo-oligomers, ranging from the rH3 (C) where 
dimers may be either absent or only very weakly expressed through to the hH3 (329) 
where dimers appear to be constitutively expressed. However care should be taken not 
to over interpret results from recombinant systems, receptors are being expressed in a 
foreign environment at much higher levels than would normally be the case. 
With the H3 (329) isoform a species running at Mr 48,000 was also enhanced by the 
presence of the cross-linker, in addition to the Mr 79,000 species (compatible with the 
size of the putative dimer). Presumably the monomer is associating with a different, as 
yet unidentified cellular protein. In addition to this distinct Mr 48,000 species material 
of higher molecular weight is clearly visible with both the human isoforms, and to a 
lesser extent with the rat isoforms, even in the absence of cross-linker. While 
acknowledging the caveat that this is an artificial expression system, it is likely that 
GPCRs associate with a variety of cell proteins (Bermack & Zhou, 2001), the 
identities and functional significance of which remain to be unravelled. 
Tr-FRET assays confirmed the presence of H3R homo-dimers in cell membranes, since 
resonance energy transfer between fluorophore labelled H3R receptors was able to 
occur. Rat H3A dimers have been shown previously (Bakker et al, 2006), however the 
rH3C isoform was not included in this study. Tr-FRET on the human isoforms gave 
147 
clear evidence of H3 (aas) and H3 (329) homo-dimers, and hetero-dimerisation between 
the 329 and 445. Although statistical significance was not achieved, the trend 
suggested that 329 homo-dimers may form more readily than 445 dimers, in 
agreement with the cross-linking observations. Hetero-dimerisation appeared to be at a 
lower level than for homo-dimerisation, however further studies would be needed to 
confirm this as the FRET technique was modified slightly in order to be able to 
distinguish hetero- from homo-dimers, and therefore the results are not directly 
comparable. 
Preliminary pharmacological studies indicated that while the hH3 (329) isoform did not 
itself bind [3H]-clobenpropit, it reduced binding of the radioligand to the full length 
hH3 (445) isoform in co-transfected cells. These findings remain to be validated and are 
therefore not shown here. If verified this suggests that the shorter isoform may play a 
negative regulatory role similar to that described for truncated rat H3R isoforms 
(Bakker et al, 2006). 
In conclusion rat and human H3R isoforms can form both homo- and hetero-dimers, 
and this is likely to contribute to the observed H3 receptor heterogeneity. The potential 
to dimerise may be variable with some isoforms less likely to form robust dimers (rH3c) 
and others more commonly found as dimers (rH3A). In this study, the effect of 
histamine on oligomerisation was not investigated. Nevertheless in both recombinant 
systems and native tissue, oligomers were clearly evident (Figs 3.4 and 3.5 
recombinant; Figs 3.8,3.9 native, Chapter 3), even in the absence of histamine. 
Furthermore, van Rijn and colleagues (van Rijn et al, 2006) failed to show any effect 
of H4R agonists on oligomerisation. However, results from other studies looking at the 
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effects of ligand binding on GPCR oligomerisation have been inconsistent (Angers et 
al, 2002; George et al, 2002; Pfleger & Eidne, 2005). 
In Chapter 5, we investigate the highly related H4 histamine receptor to compare the 
structural properties to the H3 receptors. To this end, the first immunological probes 
were developed and characterised. The first evidence for the expression of the H4 
receptor in the rat and human brain is provided, and immunobiochemical and 
biophysical studies demonstrate that H4 homo- and hetero-oligomerisation can occur. 
The influence of H4 receptor isoforms upon the full length receptor is investigated to 
address the overall hypothesis "Expression of histamine receptor isoforms act as 
regulatory mechanisms to control central histaminergic function" 
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CHAPTER 5 
DEVELOPMENT OF THE FIRST ANTI-HUMAN 144 RECEPTOR 
ANTIBODIES: DEMONSTRATION OF THE EXISTANCE OF TIIE H4R IN 
THE HUMAN BRAIN AND H4R HOMO- AND HETERO-OLIGOMERS 
5.1 OBJECTIVES 
Develop new anti-HUMAN H4 receptor antibodies and investigate the possibility of 
brain H4 receptors, homo- and hetero-oligomerisation of H4 receptor isoforms and 
dominant negative effects of H4 (302) and H4 (67) isoforms. 
5.2 INTRODUCTION 
The discovery of the most recent histamine receptor, histamine H4R, followed shortly 
after the successful cloning of the human H3R in 1999 (Lovenberg et al, 1999). Using 
sequence information from the human H3R, several independent groups identified 
homologous GPCR sequences in the human-genome databases. In 2000, the hH4R was 
cloned from foetus and leukocyte cDNA (Oda et al, 2000; Nakamura et al, 2000 
respectively). Since then six other laboratories have reported the same finding 
(reviewed in de Esch et al, 2005). The H4R gene is on chromosome 18, it spans more 
than 20.6 kilobases and has a similar structure to the H3R (Fig 5.1 Cage et al, 2001) 
The H4R is 390 amino acids long and contains three exons coding for amino acids 1- 
64,65- 119 and 120-390. It is found at high levels in bone marrow, eosinophils and 
mast cells (Oda et al, 2000; Nakamura et al, 2000; Zhu et al, 2001; Nguyen et al, 2001; 
Morse et al, 2001; Liu et al, 2001; O'Reilly et al, 2002). However, although Zhu and 
co-workers found H4R mRNA expression to be highest in peripheral blood 
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mononuclear cell tissues such as bone marrow and lung, they also identified it 
expressed in mouse hippocampus. H4R mRNA has also been reported in both adult and 
embryonic rat brain (Lozada et al, abstract, EHRS 2004). Using RT-PCR, expression 
of 114R mRNA was found in several human brain regions (Coge et al, 2001). 
Expression was highest in cerebellum and hippocampus, no message was detected in 
either cerebral cortex or the raphe nuclei. Whether the H4R is expressed on immune 
cell infiltrates into the brain or on brain tissue itself is not yet known. 
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Fig 5.1 Schematic organisation of the H4R gene 
Restriction map of the genomic DNA fragment from the human chromosome 18 
(Accession number AP001327); B, BamHI; P, Pstl; S, SacI. (B) Schematic structure of 
the H4-receptor gene with the exons (E1.3) shown by boxes and the introns (I1.2) shown 
by horizontal lines. The exons are numbered from the gene 5'-end with exon E1 
containing the first ATG codon. (C) Structure of the human H4-receptor cDNA. The 
coding region is shown by boxes and the 5'- and 3'- untranslated regions by horizontal 
lines. The putative transmembrane domains (1-7) are mentioned in the coding region. 
The translation initiation site (ATG), the termination site (TAA) and the 
polyadenylation signal sequence (AATAAA) are indicated. 
The similarity between the H3R and H4R genes suggests that, as with the H3R, 
alternative splicing could result in different H4R isoforms. The first two hH4R 
isoforms: hH4 (302) lacking TM regions 3 and 4, and hH4 (67) consisting of only the first 
two TM regions, have recently been described by our collaborators (van Rijn et al, 
submitted). These isoforms are unable to bind either histamine or a selective H4R 
antagonist, JNJ7777120; neither do they transduce signal. Nevertheless, they may play 
a regulatory role since they reduce the level of histamine binding to H4 (390) by 55% 
(302 isoform) and 30% (67 isoform). Since mRNA message coding for these two 
4 m 6 7 
152 
splice variants is coexpressed in a number of white blood cell types along with 
message for the full length H4 (390) receptor, there is the potential for hetero- 
oligomerisation in native tissue. The published amino acid sequence of the human H4R 
shows it to be a class A rhodopsin-like GPCR, as are the other histamine receptors. 
The sequence from Oda's laboratory differs from the other reported sequences and the 
genomic sequence (Genbank Accession number AC007922) (Zhu et al, 2001). The 
three different amino acids V138A, R206H and R253Q could be polymorphic H4R 
variants but these discrepancies need to be validated. 
Based on the preliminary published report(s) of H4R mRNA expressed in mammalian 
brain and the similarity between the H3R and the H4R; our previously successful 
strategy for generating H3R selective antibodies (described in Chapter 3) was used to 
develop specific anti-hH4R antibodies. 
This chapter describes the development and characterisation of a novel anti-human 
H4R antibody. The specificity of the antibody was validated against both recombinant 
and native H4Rs using immunoblotting and immunohistochemistry as described for the 
anti-hH3R antibodies (Chapter 3). In addition. immunoprecipitation was used to 
confirm the identity of the immunoreactive species as the H4R. It was evident from 
immunoblots that higher molecular weight species were present both in recombinant 
and native tissue. Indeed, as with the H3R, the monomer was often not detected in 
native tissue. Homo-oligomerisation was further investigated using both biochemical 
(cross-linking and nickel column affinity purification) and biophysical techniques 
(Bioluminescence Resonance Energy Transfer). The potential for hetero-dimerisation 
of the full length receptor with the newly identified splice variants was explored using 
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immunoprecipitation. Finally, since co-transfection of clonal cells with hH4 (390) and 
either of the splice variants reduces the level of histamine binding it was relevant to 
ask whether the splice variants were affecting surface expression of the full length 
receptor. Surface expression of the different isoforms either individually or in 
combination, that is the full length with one of the shorter isoforms, was assessed. 
Following biotinylation of cell surface proteins, the surface fraction was separated 
from the intracellular fraction by streptavidin chromatography, and analysed by 
immunoblotting. 
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5.3 METHODS 
The following methods were performed as described in Chapter 3. 
Choice of peptide sequences 
Peptide conjugation 
The 3-maleimimdobenzoic acid N-hydroxysuccinimide ester (MBS) method for 
the coupling of peptides to carrier proteins 
Immunisation of rabbits 
Affinity purification 
Coupling of peptides to sepharose beads via sulphydryl groups 
Peptide affinity purification of antibodies 
Transfection 
Harvesting and membrane preparation 
5.3.1 Production of human phytohaemagglutinin (PHA) blasts 
Blast cells are immature, undifferentiated precursors of white blood cells. They are not 
found in normal peripheral blood, however they can be induced by stimulating 
mononuclear cells with the mitogen phytohaemagglutinin (PHA). PHA blasts were 
generated essentially as previously described (Bradford et al, 2005). Briefly, 
heparinized human whole blood was obtained from healthy volunteers (with Local 
ethical approval), and peripheral blood mononuclear cells (PBMCs) were separated 
using Lymphoprep (Axis-Shield Poc AS, Oslo, Norway) and centrifuged at 400 xg for 
25 min. The PBMCs were isolated from the interfacial layer, washed twice in Roswell 
Park Memorial Institute medium (RPMI) without L-glutamine (GibcoTM) and 
resuspended in RPMI complemented with 10% (v/v) Fetal Calf Serum, 1% (v/v) 
Penicillin, and Streptomycin, and 1% (v/v) L-Glutamine. Cell density was adjusted 
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accordingly to 1x 106 cells/ml with RPMI. 100µl PHA ('Lectin', Sigma, UK) was 
added to the cells to make PHA Blasts. These were grown in culture for 24h, harvested 
and a cell homogenate prepared in the presence of protease inhibitors (Protease 
Inhibitor Cocktail III, Calbiochem, UK). 
5.3.2 Immunoprecipitation to confirm H4R selectivity of the antibody 
HEK 293 cells were transfected with HA-H4 receptor, and solubilized with 1% Triton 
X100/0.15M NaCI for 30 min at 4°C. Immunoprecipitation was performed essentially 
as previously described (Chazot et al, 1994). Solubilized HEK 293 cell extracts were 
incubated with 5 µg of rat anti-HA antibody (Roche Diagnostics, Germany) or rat 
non-immune Ig (ADI, USA) at 4°C for 1 hour. 50 µl of pre-chilled washed Protein G 
agarose (Sigma, UK) slurry was added and incubated for 1 hour at 4°C on a rocking 
platform. Precipitation pellets were collected by centrifugation at 10,000xg for 30 
seconds at 4°C, washed with 3x PBS, resuspended in sample buffer, vortex-mixed 
and heated to 90-100°C for 3 minutes. The sample was then re-centrifuged, and the 
supernatant subjected to immunoblotting. Control experiments were performed using 
untransfected HEK 293 cells. 
5.3.3 Immunohistochemistry (IHC) 
The immunohistochemistry method was a modified version of that described in 
Chapter 3. This method has recently been adopted in the laboratory. Following the 15 
minute incubation in TBS, 0.2% (w/v) glycine and 0.2% (v/v) Tween-20 to mop up 
residual unreacted aldehyde groups from the fixative, four extra steps have been 
introduced to make the cell membranes more permeable and thus improve accessibility 
of cellular proteins (in this case the H4R) to the antibody. Tissue sections were next 
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incubated in Triton-X-100 in TBS (20pl/lOml) for 15 minutes, then in 50mM sodium 
citrate pH 8.4 for 30 minutes at room temperature followed by a further 30 minutes 
also in 50mM sodium citrate pH 8.4 but this time in a waterbath at 80°C. Finally 
sections were incubated in Triton-X-100 in TBS (20µ1/10ml) again for 15 minutes, 
before completing the procedure exactly as set out in Chapter 3. 
5.3.4 Receptor immobilisation on a nickel column 
This technique was used to provide evidence for H4R homo-dimers. Membranes of 
COS-7 cells transiently co-expressing haemagluttinin-H4R (HA-H4R) and c-myc-H4R- 
Histidine (His-1-14R) were homogenized, solubilized and subsequently immobilized on 
nickel columns: Ni-NTA (Invitrogen). Immobilized receptors were eluted using 250 
mM imidazole. Samples were chloroform/methanol extracted and analysed by 
immunoblotting using an anti-HA antibody (gift from Richard van Rijn) as the probe. 
The His-H4R can be immobilised via the Ni2+ ions on the column. HA-H4R can only be 
immobilised indirectly if it dimerises with a His labelled H4R (Fig 5.2). Therefore HA 
detected in the immobilised fraction eluted from the column confirms the presence of 
H4R homo-dimers. 
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Fig 5.2 Schematic representation of nickel column purification 
Haemagglutinin (HA) labelled receptors can only be immobilised on the nickel column 
via histidine (HIS) tagged receptors. Therefore HA detected in the eluted fraction 
confirms the existence of HIS-H4R/HA-H4R dimers. 
The method was carried out as recommended in the Invitrogen instruction manual 
using native conditions, with only minor modifications. Native conditions were chosen 
in order to minimise the disruption of putative receptor dimers. 
Native binding buffer 
50 mM NaH2PO4, pH 8.0,0.5 M Na Cl 
Solubilisation buffer 
Native binding buffer with 1% Triton-X- 100/ Calbiochem protease inhibitors 1: 100 
Wash buffer 
Native binding buffer with 20 mM imidazole, pH 8.0 
Elution buffer 
Native binding buffer with 250 mM imidazole, pH 8.0 
Homogenised membranes of H4R transfected COS-7 cells were pelleted and 
resuspended in approximately 1 ml solubilisation buffer. They were transferred to a 
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dounce glass-glass homogeniser and re-homogenised on ice with at least 30 strokes. 
The total volume was then made up to 8 ml with more of the solubilisation buffer. This 
was shaken for 30 minutes at 4°C, followed by another homogenisation, 30 strokes on 
ice. The solubilised protein was spun down for 5 minutes 3000 xg to pellet the cell 
debris. The insoluble pellet was resuspended in 1 ml solubilisation buffer and 
rehomogenised, 30 strokes on ice; 100 µl aliquots of both the insoluble and solubilised 
fractions were stored at -20°C for subsequent SDS PAGE analysis. The remainder of 
the supernatant was added to 1.5 ml Ni-NTA agarose prepared as described in the 
Invitrogen protocol. (Ni-NTA agarose preparation: 1.5 ml of the Ni-NTA agarose 
suspension was pipetted into a 10 ml purification column. The column was washed 
twice with 6 ml of sterile distilled water and twice with 6 ml of native binding buffer. ) 
Binding was carried out with gentle mixing for 1 hour at 4°C. After binding the 
column was drained and 100 gl aliquots of the unbound fraction were stored as before 
for future immunoblotting. The column was washed with 4x8 ml of wash buffer. The 
immobilised protein was then eluted from the column by gently mixing the resin in 2 
ml of the elution buffer for 10 minutes at 4°C, 100 µl aliquots of the eluate were 
retained as before. The column was washed several times with native binding buffer 
and then stored with 0.02% azide added to the same buffer as a preservative. 
As a control the Ni-NTA purification experiment was carried out with a physical 
mixture of COS-7 cells individually expressing HA-H4R and His-H4R. 
5.3.5 Bioluminescence Resonance Energy Transfer (BRET) 
Fusion proteins 
H4Rs were C-terminally fused to either Renilla luciferase (H4R-Rluc) or a yellow 
fluorescent protein (H4R-eYFP) (van Rijn et al, 2006). 
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The BRET assay is a biophysical technique used to demonstrate close association of 
two proteins within a cell membrane. The assay relies on the transfer of 
bioluminescence from a donor to an acceptor, excitation of the acceptor results in a 
detectable bioluminescent emission (see Fig 5.3). Transfer can only occur within a 
radius of 100, x. 
Fig 5.3 Schematic representation of the BRET assay 
Here BRET was performed on COS-7 cells expressing either the H4R-Rluc construct 
alone or co-expressing the H4R-Rluc with the H4R-eYFP. Renilla luciferase fused to 
the C-terminus of a receptor, catalyses the emission of light from the substrate 
coelenterazine at a wavelength of 470 nm. When in close proximity (< 100 A) this can 
excite the eYFP fused to another H4R to emit light at 530 nm. 
Transfected COS-7 cells were harvested and washed twice with PBS. The cells were 
resuspended and counted and their numbers adjusted to give 5x 105/ml either in PBS 
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or BRET buffer. BRET buffer was PBS supplemented with 1mM CaC12,1mM MgC12 
and 1% sucrose. The BRET buffer was a mini-trial since it had been recommended as 
an improvement over PBS in a recent paper (ref El-Asmar et al, 2005). 100 µl of cells 
(ie 50,000 cells) was transferred into a white 96 well plate, following this all work 
was carried out in the dark. 100µl of a 10µM coelenterazine solution in PBS was 
added to each well, thus exposing the cells to a final 5 µM concentration of the 
coelenterazine substrate. Light emission was measured in a Victor2 spectrophotometer 
at 470 and 530 nm. Results were expressed as the BRET ratio: 
5.3.5.1 BRET Ratio 
Emission at 530 - (Emission at 470 x Cf) 
Emission at 470 
Cf = Emission at 530/ Emission at 470 for the H4RRIuc expressed alone 
5.3.6 Immunoprecipitation (IP) to investigate hetero-dimerisation 
HEK 293 cells were transfected with untagged H4 (390) with or without FLAG H4 (302) 
or FLAG H4 (67). Cell samples were solubilised with 1% Triton X100 in Tris-HC1 pH 
7.4 (IP buffer) and incubated with 50 9150% (w/v) slurry of anti-FLAG sepharose 
beads (Sigma, UK) for 2hrs at 4°C. Following incubation, beads were centrifuged at 
9000rpm at 4°C for 5 min. The supernatant was retained (unbound fraction). The 
beads were washed in IP buffer and the bound fraction eluted from them by 
incubation in SDS PAGE Sample buffer/50mM DTT at 50°C for 30 min. The 
supernatant following centrifugation at 9000 rpm (bound fraction) was retained for 
analysis. 
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5.3.7 Surface Biotinylation - H4 isforms 
PBS/sucrose 
4% sucrose in PBS 
Quenching buffe 
50mM Tris-HC1 pH 8.0 containing 192 mM glycine and 4% sucrose 
Lysis buffer 
50mM Tris-HC1 pH 8.0 containing 2mM EDTA and protease inhibitor cocktail set III 
(1/100 dilution) 
HEK 293 cells were transfected with individual H4 isoforms or co-transfected with H4 
(390) with equal amounts of H4 (302) or (67) isoforms. 24-40 hours post transfection, the 
medium was carefully removed and the cells washed with ice-cold PBS/sucrose (3 xl 
ml per 35mm dish). The cells were then incubated for 30 min at 4°C with lmg/ml 
Sulfo-NHS-SS-Biotin in ice-cold PBS/sucrose (0.5 ml/dish) with gentle shaking. 
Following this cells were washed with ice- cold PBS/sucrose once ( lml/dish), and 
incubated for 10 min at 4°C with quenching buffer (0.5 mUdish). Cells were scraped 
into PBS/Sucrose and spun at 6000 rpm for 2 min. This wash procedure was repeated 
on a further occasion and the cells homogenised in lysis buffer/1% (w/v) SDS. The 
samples were diluted in lysis buffer /1% Triton-X100), and incubated with 40 µl 50% 
(w/v) slurry of streptavidin beads for 2 hrs at 4°C. Following incubation, the beads 
were centrifuged at 9000rpm at 4°C for 5 min. The supernatant (intracellular fraction) 
was retained and the beads washed in lysis buffer/1% Triton X100. The bound 
fraction was isolated by elution in SDS PAGE Sample buffer/5OmM DTT at 50°C for 
30 min. Supernatants following centrifugation at 9000 rpm (surface fraction) were 
retained for analysis. 
162 
5.4 RESULTS 
5.4.1 Choice of peptide sequences 
The following two sequences were chosen on the basis of their specificity to the hH4R 
as sequence and their potential immunogenicity: 
hH4R - CT (aa 374 - 390) Chazot 3 CIKKQPLI'SQHSRSVSS 
hH4R (aa 251 - 266) Chazot 4 CERRRRKSSLMFSSRTK 
The sequences are found at the C terminal end of the receptor (Chazot 3) and within 
the third intracellular loop (Chazot 4) (Fig 5.4). It should be noted that both sequences 
are also present in the hH4 (302) isoform but NOT in the severely truncated hH4 (67) 
isoform. Note: The sequences in RED are common between human, rat and mouse H4 
receptors. 
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Human sequence showing full length H4 R 
Third intracellular loop (i3) shown in red 
Peptide sequence used to immunise rabbit blue and underlined (Chazot 3) 
1 mpdtnstinl slstrvtlaf fmslvafaim ignalvilaf vvdknlrhrs syfflnlais 
61 dffvgvisip lyiphtlfew dfgkeicvfw lttdyllcta svynivlisy drylsvsnav 
121 syrtqhtgvl kivtlmvvvw vlaflvngpm ilvseswkde gsecepgffs ewyilaitsf 
181 lefvipvilv ayfmmniyws lwkrdrlsrc qshpgltavs snicghsfrg rlssrrslsa 
241 stevpasfhs errrrksslm fssrtkmnsn tiaskmgsfs qsdsvalhqr ehvellrarr 
301 lakslaillg vfavcwapys lftivlsfys satgpksvwy riafwlqwfn sfvnpllypl 
361 chkrfqkafl kifcikkqpl psghsrsvss 
Human sequence showing full length H4 R 
Third intracellular loop (i3) shown in red 
Peptide sequence used to immunise rabbit blue and underlined (Chazot 4) 
1 mpdtnstinl slstrvtlaf fmslvafaim lgnalvilaf vvdknlrhrs syfflnlais 
61 dffvgvisip lyiphtlfew dfgkeicvfw lttdyllcta svynivlisy drylsvsnav 
121 syrtqhtgvl kivtlmvvvw vlaflvngpm ilvseswkde gsecepgffs ewyilaitsf 
181 lefvipvilv ayfnmniyws lwkrdrisrc gshpgitavs snicg. hsfrg rlssrrslsa 
241 stevpasfhs errrrksslm fssrtkmnsn tiaskmgsfs qsdsvalhqr ehvellrarr 
301 lakslaillg vfavcwapys lftivlsfys satgpksvwy riafwlqwfn sfvnpllypl 
361 chkrfqkafl kifcikkqpl psqhsrsvss 
Fig 5.4 Full length amino acid sequence of the hH4R with the sequences of the 
immunising peptides highlighted 
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5.4.2 Antibody yields 
Immune serum has been collected from both of the immunised rabbits, however to 
date only the anti-H4(374-390) (H4-3) has been purified. Affinity purification and the 
calculation of antibody yield were performed exactly as described in Chapter 3. 
Antibody yields were 442 and 489 pg per ml immune serum for bleeds 2 and 3, 
respectively. 
5.4.3 The antibody was able to detect human H4R expressed in HEK 293 cells 
Evidence from immunoblots showed coincident bands where FLAG-hH4R transfected 
cells were probed with anti-H4 (374-390)R and anti-FLAG in parallel (n = 3). 
Immunoprecipitation experiments confirmed the H4R reactivity of the anti-H4 (374- 
390) antibody (Figs 5.5 and 5.6). 
165 
Fig 5.5 Anti-H4 (374-390) and anti-FLAG immunoreactivity are coincident 
Recombinant FLAG tagged human H4 and H3 receptors probed with anti-H4 (374-390) 
(Lane 1,2 µg/ml) and anti-FLAG (Lanes 2 -5 left hand blot, 1: 5,000). The right hand 
blot shows lanes 2-5 of the original blot following stripping of the first antibody by 
incubation of the nitrocellulose sheet in distilled water 15 mins, followed by 15 mins 
in 0.2M NaOH and a final 15 mins in water again. The sheet was then blocked in the 
usual way and reprobed with anti-H4 (374-390), 2µg/ml. The anti-H4 (374-390) is a 
rabbit antibody whereas the anti-FLAG is a monoclonal mouse antibody, therefore the 
secondary antibodies are anti-rabbit and anti-mouse, respectively. The H3R isoforms 
served as a negative control for the reprobe experiment. The immunoreactivity pattern 
was identical using the anti-FLAG and anti-H4 (374-390) antibodies in all cases. 
5.4.4 Immunoprecipitation of HA-H4Rs transiently expressed in HEK 293 cells 
To further characterize the selectivity of the H4R antibody an immunoprecipitation 
assay was performed. HA-H4Rs transiently expressed in HEK 293 cells (Fig 5.6, Lane 
2- 4) were immunoprecipitated using anti-HA antibodies (Fig 5.6, lane 3), or a non- 
immune Ig (Fig 5.6, lane 2). As negative control non transfected HEK 293 cells 
immunoprecipitated with anti-HA antibodies (Fig 5.6, lane 1) were used. As a positive 
control solubilized HEK 293 cells expressing HA-H4Rs (Fig 5.6, lane 5) were used. 
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All samples were subjected to immunoblotting using the anti-H4R antibodies. 
Immunoreactive species were only detected for the HEK 293 cells expressing the HA- 
H4R, which had been anti-HA immunoprecipitated (Fig 5.6, lane 3). The 
immunoreactive species represent the putative monomeric and dimeric H4R and are 
identical to the reactive species in the positive control (Fig 5.6, lane 4). In this 
experiment, the putative dimeric species appear more prominent that the monomeric 
species. The relative levels of these immunoreactive species varied between 
transfection experiments, presumably reflecting differences in transfection 
efficiencies often observed in transient heterologous expression systems. 
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Fig 5.6 The anti-H4R antibodies recognize anti-HA immunoprecipitated HA- 
H4Rs 
HEK 293 cells alone (lane 1-2) or transfected with cDNA encoding the HA-H4R (lane 
3-5) were subjected to immunoprecipitation with an anti-HA antibody (lane 2,4) or a 
non-immune Ig (lane 3). The precipitates (lane 2-4) or solubilized cells (lane 1,5) 
were immunoblotted using the anti-H4R antibody. Putative dimeric and monomeric 
species indicated using arrows. 
5.4.5 The antibody was specific for hH4R expressed in HEK 293 cells 
The selectivity of the anti-hH4R antibody was confirmed by blockade with the C- 
terminal Peptide of the H4R (Fig 5.7, lane 3) (n =3 replicates) and a lack of cross 
reactivity with the human H3R (n =3 replicates), the most related GPCR (de Esch et 
al, 2005) (Fig 5.7, lane 1). In transfected HEK 293 cells, the antibody detects two 
major reactive species at M, 35,000 + 1000 and 70,000 ± 5000 (Fig 5.7, lane 2). The 
lower bands appeared as a doublet (Mr 34,000 and 36,000) and most likely represent 
monomeric H4Rs. Occasionally an additional band (Mr approx. 45,000) was detected 
which is likely to be a proteolytic fragment. The Mr 34,000 is probably the 
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unglycosylated product of the species at M, 36,000 (see Chapter 6). The higher 
molecular weight species, could either represent a heavily glycosylated form of the 
H4R or dimeric H4Rs (see Chapter 6). In human PHA blasts a band at Mr 77,000 ± 
3000 (n =4 replicates) was similarly blocked by prior incubation of the antibody with 
the antigen peptide (n = 1) (Fig 5.7, lanes 4 and 5 respectively). Monomeric species 
were not detected. 
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Fig 5.7 Characterization of specific polyclonal H4R antibodies 
HEK 293 cells expressing hH3(445)Rs or hH4Rs, and human PHA blasts were probed by 
immunoblotting using the anti-H4 (374-390) antibody (0.5 µg /ml) either alone or pre- 
incubated for 16h at 4°C with 500 µg /ml (374-390) peptide. The major 
immunoreactive species labeled in the HEK 293 hH4R and the human PHA blasts 
were greatly suppressed by pre-incubation with the antigen peptide (lanes 3 and 5 
respectively), demonstrating the sequence selectivity of the antibody. Furthermore, no 
significant labeling of the hH3(445)R (lane 1) or in untransfected HEK293 cells (not 
shown) was detected. (HEK 293 + hH3(445), n=3; HEK 293 + hH4R, n> 10 separate 
replicates; PHA blasts, n=4 replicates; peptide block of H4R transfected cells and 
PHA blasts, performed on n=3 occasions with similar results. 
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5.4.6 The polyclonal H4R antibodies are able to detect specific immunorcactivity 
in native tissue, including human and rat brain. 
Although the H4R is found primarily on immune cells there are some reports of 
mRNA expression in mammalian brain (Zhu et al, 2001; Lozada et al, abstract, EHRS 
2004; Coge et al, 2001). The anti-H4 (374-390) antibody clearly identified 
immunoreactive species in homogenates of human putamen and rat forebrain (Fig 5.8) 
(n =3 replicates). The bands were of similar size running at Mr 77,000 ± 3000. 
Interestingly, as with the human PHA blasts, there was no evidence of H4R monomers. 
Pre-incubation of the antibody with the antigen peptide blocked immunoreactivity in 
both samples, demonstrating sequence specificity of the reactivity. A similar Mr 
77,000 species was detected in mouse forebrain (results not shown), again blocked by 
the respective antigen peptide (Chazot, unpublished findings). 
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Fig 5.8 Immunoblot using anti-H4 (374-390) receptor to probe human and rat 
brain. 
Lane 1 and 3: Human Putamen and Lane 2 and 4: Rat forebrain 
Lanes 1 and 2: anti-H4(374-390) receptor at 1 gg/ml; Lanes 3 and 4: anti-H4(374-390) 
preincubated with H4 peptide, at 1 µg/ml. n=3 replicates for both human putamen 
and rat forebrain; peptide block n=2 specificity replicates for both preparations (and 
mouse forebrain (not shown). 
5.4.7 The anti-H4 (374-390) identified H4R protein in human spleen lysates and 
tissue sections. 
The H4R is found predominantly on peripheral blood monocytes (PMBC) and in the 
tissues where these cells are found such as bone marrow and spleen. The anti-H4 (374- 
390) identified H4R protein in immunoblots of human spleen lysates (Fig 5.9 A) and in 
immunohistochemical staining of spleen tissue sections (Fig 5.9 B and Q. In the 
immunoblot bands were detected at Mr 31,000 compatible with the monomer; and Mr 
59 and 66,000; potentially glycosylated receptors and/or receptor dimers. Due to 
limited supply of human spleen material this experiment was only performed once. 
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Fig 5.9 anti-H4(374-390) reacts with human H4R in spleen lysate and tissue 
sections 
A: Immunoblot of human spleen lysate (10 µg). Anti-H4 (374-390)R antibodies were 
used at 2 µg/ml and incubated overnight at 4°C. In addition to the monomer at Mr 31 
kD, two higher molecular weight species were detected at 59 and 66 kD. B and C: 
Immunostaining of human spleen slice (x 200 and x 400 respectively), using anti- 
H4(374-390) at 1 pg/ml. A single experiment was performed for both the 
immunoblotting and the IHC of human spleen. 
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5.4.8 The anti-hH4(374-390) antibody also worked well as a probe to identify 
hH4R on human monocytes using fluorescence-activated cell-sorting (FACS) 
The anti-hH4(374-390) antibody was used to stain human monocytes for subsequent 
quantification using flow cytometry (Fig 5.10) (Dikkstra et al, 2007) 
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Reproduced with permission of Dorris Dijkstra (Hannover University, Germany) 
(Dijkstra et al, 2007) 
Fig 5.10 Staining of human monocytes with anti-H. 1(374-390) R 
Human monocytes labelled with anti-H4(374-390) (a-H4R); anti-H4(374-390) pre- 
incubated with antigenic peptide (a-H4R with H4R peptide); or non-immune rabbit 
immunoglobulin (Rabbit isotype (polyclonal)) followed by biotin conjugated goat 
anti-rabbit and fluorescein isothiocyanate (FITC) coupled streptavidin. Labelled cell 
populations were quantified by flow cytometry (FACS Calibur, Becton Dickinson). 
Scatter plot shows granularity (side scatter: SSC-height) against cell size (forward 
scatter: FSC-height). The population RI has characteristics typical of monocytes. The 
histogram shows cell numbers (counts) plotted against fluorescence intensity (FITC- 
H4R). 
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5.4.9 The existence of heterogeneously expressed H4R homo-dimers 
Characterisation of the novel anti-human H4R antibody provided evidence for higher 
molecular weight species in addition to the monomer. Dimeric versions of the receptor 
and/or post-translational modifications of the receptor, such as glycosylation, may 
account for these larger protein species. Dimerisation of the H3R, the GPCR most 
closely related to the H4R, has been established for both human (van Rijn et al, 2006; 
Chapter 4) and rodent (Bakker et al, 2006; Chapter 4) H3Rs. Three different 
approaches were used to confirm the presence of H4R homo-dimers. The chemical 
cross-linking technique was performed as described for the H3R in Chapter 4. In 
addition H4R dimers were isolated using nickel column purification, and a biophysical 
assay, Bioluminescence Resonance Energy Transfer (BRET) was used to demonstrate 
H4R dimers in the membranes of COS-7 cells. 
5.4.10 Cross-linking of H4Rs 
To further investigate the homo-oligomeric structure of the H4R, a crosslinking study 
was performed using N-terminally c-myc-tagged H4R expressed in COS-7 cells. Upon 
application of increasing concentrations of the cell impermeable crosslinker BS3, a 
progressive reduction in the monomeric doublet species (Mr 34,000 and 36,000) was 
observed (Fig 5.11, representative blot from n=3 replicates). The concomitant 
appearance of, initially, a diffuse species of Mr 77,000 (putative glycosylated and 
unglycosylated dimers) and, then, higher molecular weight species (Mr > 175,000) at 
0.25mM and 2mM BS3, respectively was noticed (Fig 5.11). These data are highly 
consistent with hH4Rs expressed in HEK 293 cells (data not shown). 
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Fig 5.11 Cross-linking evidence for hH4R dimers and higher oligomers 
COS-7 cells transfected with cDNA encoding the hH4R were subjected to cross- 
linking using increasing concentrations of BS3 (0.12-2 mM). The resultant pellets were 
subjected to immunoblotting and probed with the anti-hH4 (374-390) antibody (0.5 . tg 
/ml). Lane 1, COS-7 cells expressing hH4Rs as control; Lanes 2-5, COS-7 cells 
expressing hH4Rs treated with 0.12,0.25,0.5,1 and 2 mM BS3, respectively. The * 
species is likely to be a proteolytic fragment of the hH4R. Representative immunoblot 
from n=3 replicate crosslinking experiments. 
5.4.11 HA-H4Rs associate with c-myc-H4R-hislo 
To further investigate whether the H4Rs can associate with each other to form homo- 
oligomers, membranes of COS-7 cells co-expressing N-terminally c-myc and C- 
terminally hisio tagged hH4Rs (c-myc-H4R-his1o) and N-terminally HA-tagged hH4Rs 
(HA-H4R) were solubilized and loaded onto a Ni2+-resin column. The HA-H4Rs, 
when co-expressed with the c-myc-H4R-hislo, were retained on the Ni2+-column and 
could be eluted with 250 mM imidazole as detected with anti-HA antibodies (Figure 
5.12, lane 3; representative blot from n=3 replicates). When cells individually 
expressing c-myc-H4R-his1o and HA-H4Rs were mixed prior to solubilization, and 
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subsequently loaded on the column, no HA-H4Rs were found to interact with the Nit+- 
resin (data not shown). 
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Fig 5.12 Nickel column purification of H4R homo-oligomers 
Cells co-expressing H4Rs with an N-terminal c-myc- and C-terminal Hisio-tag (c- 
myc-H4R-hisio) and an N-terminal HA-tag H4Rs (HA-H4R) were solubilized and 
loaded onto a Nit+-NTA column. Samples were taken of the solubilized receptors 
before loading onto the column (lane 1), of the unbound fraction (lane 2) and of the 
bound fraction, that was eluted using 250 mM imidazole (lane 3). Samples were 
resolved by SDS-PAGE and then immunoblotted using anti-HA antibodies. 
Representative immunoblot from n=3 purification replicate experiments. 
5.4.12 BRET shows homo-oligomerization of hH4Rs 
The use of biophysical techniques has been of great value to the study of GPCR 
oligomerization. BRET was performed on COS-7 cells expressing either the H4R-Rluc 
or co-expressing the H4R-Rluc with the H4R-eYFP. After addition of coelenterazine a 
robust BRET signal could be observed in the cells co-expressing the two H4Rs (Table 
5.1 and Fig 5.13, see section 5.3.5.1 for definition of BRET ratio). As a negative 
control, coelenterazine was also added to cells expressing H4R-Rluc alone. In this 
experiment a comparison was made between PBS and BRET buffer as the cell diluent. 
BRET buffer is PBS supplemented with 1 mM CaC12,1 mM MgCl2 and 1% glucose, it 
has been recommended as an improvement over PBS in a recent paper (El -Asmar et 
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al, 2005). The BRET signal was stronger using the BRET buffer, although further 
experiments are required to confirm the reproducibility of this result as the experiment 
was only performed once as a pilot. 
Average BRET Ratio 
PBS BRET Buffer 
Rluc Rluc + eYFP Riuc Rluc + eYFP 
1x 10-5 4037 x 10-5 31 x 10-5 5752 x 10-5 
Table 5.1 Average BRET ratios confirming the formation of H4R homo-dimers 
in COS-7 cell membranes 
Evaluation of homo-oligomerization of the H4R by BRET using the co-expression of 
Renilla luciferase (Rluc) and eYFP C-terminal receptor-fusion proteins. Cells 
expressing the indicated receptor-fusion proteins were exposed to 5 µM 
coelenterazine after which energy transfer was measured. Cells individually 
expressing H4R-Rluc were used as a control, (A single experiment performed in two 
different buffer systems with triplicate samples for each measurement). 
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Fig 5.13 Average BRET ratios show the increase in signal from cells co- 
transfected with H4-Rluc and H4-eYFP compared to cells expressing H4-Rluc 
alone 
Data from Table 5.1 expressed as a bar chart. A robust BRET signal confirmed the 
formation of H4R homo-dimers bringing the Rluc C-terminal label close enough 
(within 100 A) to the eYFP label to allow energy transfer on the addition of the Rluc 
substrate coelenterazine, (A single experiment with two different buffer systems and 
triplicate samples for each measurement). Both systems showed a clear significant 
increase in BRET signal to similar ratio levels 
5.4.13 Immunoprecipitation confirms the presence of hII4R hetero-dimerisation 
Solubilised proteins derived from HEK 293 cells co-transfected with equal amounts of 
untagged h114 (390) together with a FLAG tagged isoform: hH4 (390) FLAG, hH4 (302) 
FLAG or hH4 (67) FLAG, were immunoprecipitated using anti-FLAG sepharose beads. 
The fractions isolated were analysed using immunoblotting with the novel anti-hH4R 
as probe. Bands of a size compatible with the presence of hH4R (390) were detected in 
all three of the precipitated fractions confirming association between the untagged 
hH4 (390) and the FLAG labelled isoform (Fig 5.14, representative blot from n=2 
replicates). Both monomeric and dimeric species were evident in fractions from cells 
co-transfected with untagged hH4 390 together with either hH4 (390) FLAG or hH4 (302) 
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FLAG. By contrast only higher molecular weight species were seen with hH4 (390) + 
hH4 (67) FLAG transfected cells. The anti-hH4R antibody would not be expected to 
react with the hH4 (67) isoform, therefore immunoreactivity in this cell fraction is due 
to the presence of dimers which include hH4 (390) as one of the partners. These results 
confirm FRET data (van Rijn et al, submitted) showing the presence of hH4R hetero- 
dimers. 
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Fig 5.14 Immunoprecipitation evidence for hH4 (390) receptor interaction with 
hH4 receptor isoforms, hH4 (302) and hH4 (67) 
HEK 293 cells co-transfected with equal amounts of hH4 (390) and a FLAG tagged 
isoform: hH4 (390) FLAG (lanes 1,2), hH4 (302) FLAG (lanes 3,4) or hH4 (67) FLAG 
(lanes 5,6), harvested 48h post transfection, solubilised with 1% Triton X100 and 
subjected to immunoprecipitation with anti-FLAG sepharose or sepahrose control 
beads for 2h at 4°C. Following washing, bound material was collected using SDS- 
PAGE sample buffer and analysed by immunoblotting. Immunoblots were probed 
with anti-H4 antibody, hH4 (67) is not detected by this antibody. Lanes 1,3 and 5 are 
control precipitations with sepahrose beads; lanes 2,4, and 6 are precipitations with 
anti-FLAG sepharose. hH4 (390) homo-dimers were detected (lane 2) as well as hetero- 
dimers between the hH4 (390) isoform and the two shorter versions (lanes 4 and 6). 
Protein species consistent with monomeric hH4(390) and hH4 (302) were seen in lanes 2 
and 4, however no hH4 (390) monomer was detected in lane 6. Representative blot from 
n=2 replicate immunoprecipitation experiments from independent transfections. 
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5.4.14 Surface labelling experiments confirm that the shorter hH4 isoforms are 
expressed at the cell surface 
Labelling of surface expressed receptors with biotin and their subsequent isolation by 
streptavidin chromatography, confirmed that both the hH4 (302) and hH4 (67) isoforms 
were expressed at the cell surface, albeit at low levels (Fig 5.15, representative from n 
=4 individual experiments with similar results). 
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Fig 5.15 Surface labelling of hH4 receptor isoforms 
302 monomer 
67 monomer 
HEK 293 cells were transfected with either hH4 (302) or hH4 (67) receptor isoforms. 
Intact cells were biotinylated for 30 min at 4°C with lmg/ml Sulfo-NHS-SS-Biotin, 
washed and homogenised. Biotinylated surface fraction was isolated by streptavidin 
chromatography, and analysed by immunoblotting. Lanes I and 3 UN: Unbound = 
Intracellular fraction; Lanes 2 and 4 B: Bound = Surface fractions, where Lanes I and 
2 are hH4 (302) FLAG samples, and Lanes 3 and 4 and hH4 (67) FLAG samples. Probed 
with anti-FLAG (1: 5000). The upper panel shows the same blot reprobed with anti-ß 
actin antibody (1: 800) as a control to confirm that intracellular proteins are not 
detected in the surface fraction (n =4 experiments). 
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5.4.15 The shorter hH4 isoforms reduce surface expression of the full length hli4 
(390) receptor 
Using the same surface labelling technique surface expression of the full length hH4 
(390) was investigated following co-transfection with equal amounts of hH4 (390), hH4 
(302) or h114 (67) cDNA. Co-transfection with a shorter isoform did not prevent surface 
expression of the full length receptor, however it was significantly reduced in each 
case (Fig 5.16 representative immunoblot from n=2 replicates; and Table 5.2 
densitometric quantification of H4R immunoreactivity in surface fractions following 
co-transfection of H4 (390) with the shorter variants, data from the same two 
immunoblots). Moreover co-transfection of the hH4 (390) with either the hH4 (302) or 
hH4 (67) isoform resulted in a dose dependent inhibition of hH4 (390) at the cell surface 
(Fig 5.17a and b, n=2 replicate individual transfections). 
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Fig 5.16 Surface Labelling of hH4 (390): effect of isoforms 
HEK 293 cells were transfected with hH4 (390) alone, or co-transfected with 111714 (390) 
together with either 111714 (302) or 111714 (67) receptor isoforms. Intact cells were 
biotinylated for 30 min at 4°C with lmg/ml Sulfo-NHS-SS-Biotin, washed and 
homogenised. Biotinylated surface fractions was isolated by streptavidin 
chromatography, and analysed by immunoblotting. Surface fractions: Lane 1: hH4 (390) 
alone; Lane 2: hH4 (390) + hH4 (302); Lane 3: hH4 (390) + hH4 (67). All Lanes were probed 
with anti-H4 receptor antibody. The hH4 (67) was not detected by this antibody. 
H4R Isoforms: 390 + 390 390 + 302 390 + 67 
Dimer OD*: 1897 406 + 29 388 + 24 
Monomer OD: 398 119+ 18 63 + 48 
* OD = optical density 
Table 5.2 Densitometric evaluation of surface expression of hH4R(390) in the 
presence of the three different isoforms: 390 itself and the shortened splice 
variants 302 and 67. 
Immunoblots were quantified by densitometry using NIH Image) in the linear range 
of the film. Optical density values were normalised to respective background as 
described previously (Chazot et al, 2002). Surface expression of the full length 390 
isoform is significantly reduced on co-expression with either the 302 or the 67 
isoform. Data are mean +/_ range values from the immunoblot shown in Fig 5.16 and 
another replicate blot. 
Further experiments were performed to confirm these results, on this occasion 
increasing amounts of H4 isoform cDNAs were utilised in order to assess the dose- 
dependency of the effect. 
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Fig 5.17 a) The two truncated H4R isoforms dose dependently reduce surface 
expression of the full length hH4 (390) isoform 
Surface expression of hH4 (390) was compared between cells transfected with hH4 
(390) cDna alone and cells co-transfected with hH4 (390) plus Green Fluorescent 
Protein (GFP) (A); hH4 (390) plus hH4 (302) (B); and hH4 (390) plus hH4(67) (C). 
GFP was used as a negative control and transfected in the ratio 1: 5 (hH4 (390): GFP 
cDNA). For the truncated hH4R isoforms co-transfections at 1: 1, and 1: 5 (hH4 (390): 
hH4 truncated isoform cDNA) were compared. Both the hH4 (302) and hH4 (67) 
isoforms dose dependently reduced the surface expression of the full length hH4 (390). 
Representative immunoblot from two independent sets of transfections. 
These data confirmed that both the H4 302 and H4 67 reduce the amounts of H4 390 
expressed at the cell surface. 
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Fig 5.17 b) Densitometric quantification of surface expression of hH4 (390) 
following co-expression with the shorter H4 isoforms 
Densitometric quantification of immunoblot shown in Fig 5.17 a. Representative 
experiment of two independent sets of transfections, replicated with similar results. 
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5.5 DISCUSSION 
A novel anti-human H4R has been developed using the same successful strategy as 
that employed to generate anti-H3R specific antibodies. Rabbits were immunized with 
two human H4R specific sequences: 
hH4R - CT (aa 374 - 390) Chazot 3 CIKKQPLISQHSRSVSS 
hH4R (aa 251 - 266) Chazot 4 CERRRRKSSLMFSSRTK 
Chazot 3 identifies the very last seventeen amino acids at the C-terminus, Chazot 4 is 
a sequence found within the third intracellular loop. Immune serum was generated 
from both these peptides, however only Chazot 3 (anti-hH4(374-390) R) has been 
validated in this thesis. Note: The sequences in RED are common between human, rat 
and mouse H4 receptors (see later for discussion of species cross-reactivities). 
Anti-hH4(374-390) identified FLAG-H4R expressed in HEK 293 cells. The monomer 
migrated at Mr 34,000 - 36,000 usually as a doublet; and a higher molecular weight 
species, likely to correspond to the receptor dimer, was visualised at Mr 70,000 ± 
5000. The anti-H4R immunoreactivity was coincident with anti-FLAG 
immunoreactive bands, thus confirming their identity as H4R. In addition, the 
antibody recognized the HA-H4R which had been immunoprecipitated using an anti- 
HA antibody and then subjected to immunoblotting. Anti-hH4(374-390) R 
immunoreactivity was greatly suppressed by prior incubation with the peptide antigen 
and no reactivity was seen against either HEK 293 negative cells or HEK 293 cells 
expressing the H3R, the GPCR with the greatest homology to the H4R (de Esch el al, 
2005). Therefore the antibody was both specific to the immunising antigen and 
selective for the H4R. 
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The new antibody also identified the H4R in native tissue. High levels of H4R mRNA 
expression have been shown in white blood cells, including T-lymphocytes (Hofstra 
et al, 2003; Morse et al, 2001; Nakamura et al, 2000; Oda et al, 2000; Zhu et al, 
2001), but H4R protein expression has so far not been shown. Western blot analysis of 
membranes of PHA blasts with our polyclonal anti-H4R antibody, indeed revealed the 
presence of H4R protein in PHA blasts. Interestingly, the endogenously expressed 
H4R was only detected as a high molecular weight species, migrating at Mr 77,000 ± 
3000. H4R is also expressed in tissues containing white blood cells such as bone 
marrow and spleen. Our novel antibody identified three major bands in human spleen 
lysate and strong immunoreactivity was observed in spleen tissue sections using 
immunohistochemistry. Interestingly a low molecular weight species was clearly 
visible in the spleen lysate at Mr 31,000, likely to be the receptor monomer. 
Monomeric species were not evident in either the PHA blasts or in brain tissue (see 
later). Furthermore the two higher molecular weight bands at Mr 59,000 and 66,000 
were smaller than the putative dimers/glycosylated versions of the receptors appearing 
in either in HEK 293-H4R transfected cells or in other native tissue preparations. 
Several possibilities could account for these observations. The level of glycosylation 
could be tissue specific, the receptors might associate with different cellular proteins 
in different tissues or there may be, as yet unidentified, tissue specific isoforms of the 
H4R. The possibility that the 59 and 66 kDa bands could be proteolytic fragments 
cannot be entirely dismissed since the spleen lysate was commercially supplied. 
However care was taken to avoid protein degradation during transit from the supplier 
and subsequent sample preparation. 
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The presence of H4R mRNA in several human brain regions has been reported using 
RT-PCR (Coge et al, 2001). (In the same study no signal was observed by Northern 
Blot in numerous brain regions or peripheral tissues. ) The H4R mRNA was 
predominantly expressed in the cerebellum and hippocampus, there was also 
expression in amygdala, caudate nucleus, substantia nigra, thalamus and 
hypothalamus; but none found in the cerebral cortex or raphe nucleus. Using in situ 
hybridisation analysis Zhu et al (2001) showed mouse H4R mRNA to be selectively 
expressed in the hippocampus, particularly in the granular cell layer of the dentate 
gyros and the pyramidal cell layer but not in the rest of the brain or other tissues such 
as skeletal muscle, fat, heart, liver, spleen, thymus, lymph node, adrenal gland, spinal 
cord or kidney. Given the findings of other studies it is surprising that no message was 
detected in spleen, thymus or lymph node. Liu et al, 2001 recorded high expression of 
H4R mRNA in mouse bone marrow and spleen using RT-PCR; and investigations of 
the distribution of human H4R message show it predominantly in immune cells. Using 
the novel anti-human H4R, we have provided the first evidence for the presence of 
H4R protein in human putamen and rat (and mouse) forebrain. The predominant band 
migrated with Mr 77,000 ± 3000 in all three species; lower molecular weight species 
were very weak or undetected. The size of this band was consistent with a 
glycosylated dimer of the species identified in the human spleen. Alternatively it is 
reasonable to speculate that it may represent an H4R variant. Pre-incubation of the 
antibody with the respective antigen peptide blocked immunoreactivity in both 
samples, demonstrating sequence specificity of the reactivity. Very recently, strong 
punctate decoration of putative neurons was observed by IHC using this antibody in 
both cortical and caudate nucleus regions of human brain; and thalamus, cortical layer 
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IV and CA3 hippocampus of mouse brain (Appendix, Chazot et al, EHRS, Florence, 
2007). 
Immunolocalisation of H4R in the rat gastrointestinal (GI) tract has been reported by 
our group using this anti-H4 antibody (Morini et al, Abstract for Digestive Disease 
Week Washington, 2006; EHRS, Florence, 2007). Immunoreactivity was detected in 
endocrine cells of the fundic mucosa and also in the myenteric plexus of all regions of 
the GI tract examined. This is the first report of the H4R in the mammalian 
parasympathetic nervous system. No H3R was detectable in the myenteric plexus. 
Furthermore, this study found evidence of H3R and H4R being present on mutually 
distinct subpopulations of GI endocrine cells. 
The rat and mouse H4Rs are significantly different from the human H4R sequence at 
69 and 68% homology, respectively (Liu et al, 2001). However, amino acids in the C- 
terminal sequence as 374 - 390, while not identical to the human receptor, do share 
some sequence similarity to their human counterpart (Liu et al, 2001). It appears that 
the tertiary conformation and sequence overlap of the rat (and mouse) H4R C- 
terminus is recognised by the anti-human H4 (374-390) antibody highlighted in 
Results section, based on the results in this chapter and other studies from 
collaborators (Morini et al., 2007; Chazot et al., 2007). 
In addition to its utility in immunoblotting and immunohistochemical techniques, the 
anti-H4 (374-390) antibody also worked well as a probe to identify hH4R on human 
monocytes using Fluorescence-Activated Cell-Sorting (FACS). 
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Higher molecular weight species were present on heterologous expression of H4R in 
HEK-293 cells and in native tissue. Indeed in native tissue, the monomeric species 
was often not detected, in agreement with our observations with endogenous H3 
receptors (Chazot et al, 2001; Victoria Hann PhD thesis, 2004). In view of the strong 
reducing conditions under which the gels are run, the H3 and H4 dimers appear robust. 
Three different techniques were used to verify the presence of H4R homo-dimers. 
Chemical cross-linking of H4Rs expressed in HEK 293 cells increased the intensity of 
putative dimeric species at Mr 77,000 and 175,000; with a simultaneous decrease in 
the strength of the monomer. The presence of homo-dimers was corroborated by 
immobilisation of His-H4R/HA-H4R dimers on a nickel column. The Ni2' resin 
isolated the His-tagged receptor and the HA-tagged receptor was subsequently 
identified on immunoblotting using an anti-HA antibody. Similarly the biophysical 
technique, Bioluminescent Resonance Energy Transfer (BRET) demonstrated H4R 
homo-dimers in COS-7 cell membranes. 
As with the H3R, H4R dimers appear to be constitutively expressed even in the 
absence of ligand. A number of studies have investigated the effect of agonists on 
receptor oligomerization. However, at present the effects of ligand stimulation on 
GPCR oligomerization are not consistent. It has been found that agonists can promote 
or reduce GPCR oligomerization, or are without effect on GPCR oligomerization. 
(Angers et al, 2002; George et al, 2002; Pfleger & Eidne, 2005). In the case of the 
H4R, our collaborators at the Vrije University, The Netherlands did not detect any 
significant difference in BRET signal when cells were treated with either the H4R 
agonist histamine, the neutral H4R antagonist iodophenpropit (Lim et al, 2005) or the 
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inverse H4R agonist thioperamide (Lim et al, 2005; Morse et al, 2001), suggesting 
that H4R ligands do not modulate H4R homo-oligomerization. These findings were 
confirmed at physiological expression levels of the H4R (van Rijn et al, 2006), since 
previously it has been reported that agonist induced oligomerization of somatostatin 
receptors was only detected at physiological expression levels, but not after over- 
expression (Patel et al, 2002). Similarly, no agonist or inverse agonist induced 
modulation of H4R oligomerization was detected in the tr-FRET assay (van Rijn et al, 
2006). Nevertheless, one should be aware that results concerning ligand effects on 
dimerization obtained with these biophysical assays can be difficult to interpret, since 
agonist induced changes in H4R conformation could potentially influence the energy 
" transfer between the energy acceptor and donor (Angers et al, 2000). 
The anti-H4R antibody was also used to investigate the expression and potential role 
of the newly described human H4R isoforms: hH4 (302) and hH4 (67)" 
Immunoprecipitation experiments in this chapter confirmed tr-FRET data (van Rijn et 
al, submitted) supporting the existence of hetero-oligomers between the full length 
receptor and the two shorter versions. Since mRNA coding for all three isoforms is 
found in several white blood cell types, hetero-oligomerisation may occur in native 
tissue. The two new isoforms are both non-functional as regards ligand binding and 
signalling. However they may play a regulatory role since they reduce histamine 
binding to the H4 (390) receptor by 55% (H4 (302)) and 30% (H4 (67)). Biotinylation of 
intact cells was used to assess surface expression of the three isoforms. All three were 
expressed at the cell surface, although this is a minor population, presumably due to 
the high levels of expression possible with the lipofectamine transfection method. 
Furthermore co-expression of the H4 (390 with either H4 (302) or H4 (67) resulted in 
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reduced surface expression of the full length receptor, as might be expected from their 
effect on ligand binding. These results provide further evidence to support the role of 
splice isoforms as dominant negative regulatory elements, which maybe a common 
theme in GPCR regulatory pathways. 
Our novel anti-H4R antibody clearly shows higher molecular weight species in 
immunoblots of both recombinant and native H4Rs. Since the other three histamine 
GPCRs are all known to form homo-dimers (previous chapter), it is highly probable 
that the H4R also dimerises. The presence of H4R homo-dimers is supported here by 
results obtained from three different strategies: chemical cross-linking, nickel column 
isolation and BRET. Nevertheless, the observed sizes are not always completely 
consistent with H4R dimers. There are several possible explanations for this, including 
novel H4R isoforms and post-translational changes such as glycosylation and 
palmitoylation. In the cross-linking experiment (Fig 5.11), the monomer was resolved 
into four distinct bands which could represent different levels of monomer 
glycosylation. Also in the cross-linking studies (Fig 5.11), the higher molecular 
weight species are diffuse which may again be due to heterogeneous receptor 
glycosylation. Both the H3R and the H4R have potential glycosylation sites. Therefore 
the question of receptor glycosylation has been investigated further in Chapter 6. 
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CHAPTER 6 
THE ROLE OF N-GLYCOSYLATION IN DIMERISATION AND 
PHARMACOLOGY OF H3 AND H4 RECEPTORS 
6.1 OBJECTIVES 
Demonstrate that H3 and H4 receptors are glycoproteins and to investigate the role of 
N-glycosylation in expression, dimerisation and pharmacology. 
6.2 INTRODUCTION 
As with many proteins expressed on the cell surface, GPCR's are glycosylated, and the 
N-terminal extra-cellular domain is the site of carbohydrate attachment. Both the H3 
and H4Rs have potential sites for N-linked glycosylation: H3R at N 11, H4R at N5 and 
N9 (Fig 6.1 putative glycosylation sites of H3 and H4 receptors). Relatively little is 
known about the effect of glycosylation on the function of GPCRs. N-glycosylation of 
the N-terminus of the human formyl peptide receptor (FPR) has been shown to be 
important for constitutive FPR activity (Seifert & Wenzel-Seifert, 2003). It does not 
appear to be essential for the production of a functional ligand binding pocket (Strader 
et al, 1994), but it has been shown to be important for appropriate processing and 
trafficking of many GPCRs to the membrane. Interestingly, glycosylation appears to 
have a differential role in H1 and H2 histamine receptor pharmacology (Mitsuhashi & 
Payan, 1989; Fukushima et al, 1995). 
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Fig 6.1 Putative sites of N-glycosylation 
In the N-terminus of the the hH3R Asn11 is a potential site for N-glycosylation ("), for 
the hH4R there are two potential sites (") at Asn5 and Asn9. 
In the previous chapters, immunoblots of both recombinant and native hH3 (Fig 3.5 
recombinant; Figs 3.8 and 3.9 native) and hH4 receptors (Fig 5.7) have clearly 
demonstrated the presence of higher molecular weight species. We have provided 
evidence for receptor dimers which can account for some of these immunoreactive 
species. However, receptor glycosylation is also likely to contribute to this 
heterogeniety. The larger protein bands often appear diffuse (Figs 3.5 and 5.7 for H3R 
and H4R respectively) which can be a characteristic of glycosylated receptors, and on 
some gels the monomers are resolved into multiple bands (Figs 4.4a and 4.5a for the 
H3R; Fig 5.11 for the H4R) which could correspond to different levels of monomer 
glycosylation. 
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We have investigated the question of receptor glycosylation making use of the 
specific anti-H3 and anti-H4 receptor antibodies described in chapters 3 and 5, and 
techniques which either inhibit the process of N-glycosylation during receptor 
assembly, or deglycosylate fully formed receptors. In order to study whether the 
higher molecular weight or multiple monomeric species were the N-glycosylated 
versions of the receptors, H3 and H4 receptors were expressed in the presence of the 
N-glycosylation inhibitor tunicamycin. Cells were harvested 48 hours post 
transfection and subjected to immunoblotting as described previously. In addition to 
inhibition of glycosylation using tunicamycin, both recombinant and native H4Rs 
were deglycosylated using the enzyme peptide-N-glycosidase F (PNGase F). The 
results were analysed by immunoblotting using standard methodologies. 
In order to determine whether N-glycosylation is important in ligand binding, cells 
expressing hH3 (445) and grown in increasing concentrations of tunicamycin were 
harvested and assayed using the selective H3R antagonist radioligand, [3H]- 
clobenpropit. 
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6.3 METHODS 
6.3.1 Tunicamycin experiments with recombinant H3 and H4 receptors 
Glycosylation was inhibited using the antibiotic tunicamycin as described previously 
(Chazot et al, 1995). HEK 293 cells expressing histamine receptors were incubated 
with increasing concentrations of tunicamycin ranging from 0-8 gg/ml (stock 
dissolved in DMSO at 2 mg/ml) immediately after transfection and harvested 48 h 
post-transfection, homogenized and subjected to immunoblotting. Cells grown in the 
absence of tunicamycin were incubated with the respective volume of DMSO. 
6.3.2 Deglycosylation of native H4 receptor 
Human PHA blast cell suspensions were resuspended in deglycosylation buffer (50µM 
sodium phosphate pH 6.0, containing 0.1% SDS, 0.1% ß-mercaptoethanol and 20mM 
EDTA) and incubated with either water (control) or PNGase F enzyme (Sigma, UK) at 
a final enzyme concentration of 400iu/ml (test) for 16 hours at 37°C. The samples 
were then subjected to immunoblotting and probed with anti-H4 374-390 antibody at a 
concentration of 2µg/ml. The NMDARI transfected into HEK 293 cells was used as a 
positive control essentially as described previously (Chazot et al, 1992). 
6.3.3 Specific binding of [3H]-clobenpropit to recombinant H3 receptors 
[3H]-clobenpropit binding was performed essentially as described previously (Harper 
et al, 1999). We have evidence that clobenpropit acts as a neutral antagonist in this 
system (Victoria Hann PhD thesis, 2004). Briefly, HEK 293 cell homogenates 
expressing H3 receptors (100-400 µg protein) were incubated, in triplicate for 3 hours 
at room temperature, with 501i1 of metyrapone (3mM) and 50µ1 of [3H] clobenpropit 
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(0.2nM) in 20mM HEPES buffer pH7.4, to a final volume of 500gl. Non-specific 
binding was defined using 50µ1 of R-alpha-methylhistamine (10"5M). The assay was 
terminated by rapid filtration through Whatman GFB filters pre-soaked in 0.3-1% 
polyethylenimine, which were washed (3x3m1) using ice cold 10mM sodium 
phosphate buffer pH 7.4, using a Brandell cell harvester. Filters were transferred into 
scintillation vials and lml of optiphase safe liquid scintillation cocktail was added. 
After 3 hours the bound radioactivity was determined by counting (3 minutes) in a 
Beckman liquid scintillation counter. 
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6.4 RESULTS 
6.4.1 Human H3 receptors are N-glycosylated and prevention of N-glycosylation 
does not have a major effect upon [3H]-clobenpropit binding to the hH3 445 
receptor 
The effect of increasing concentrations of tunicamycin was investigated using 
immunoblotting and radioligand binding assays with [3H] clobenpropit. Cells 
transfected with the hH3 445 receptor and grown in the absence of tunicamycin, 
yielded, upon immunoblotting, a closely spaced doublet immunoreactive species (Mr 
47,000 and Mr 45,000), consistent with the presence of a glycosylated and non- 
glycosylated hH3 receptor monomer, respectively. As previously reported, a range of 
higher molecular weight putative oligomers were also detected (Shenton et al, 2005), 
(Chapters 3 and 4). 
Incubation of HEK cells transfected with the hH3 445 with increasing concentrations 
of the N-glycosylation inhibitor, tunicamycin, dose-dependently reduced the 
molecular weight of the Mr 47,000 immunoreactive species to the Mt 45,000 
immunoreactive species (Fig 6.2 A). This suggests that the 11113 445 receptor is indeed 
modestly N-glycosylated, consistent with the predicted single putative glycosylation 
site. Inhibition of glycosylation did not appear to affect the size of the higher 
oligomers, however immunoreactivity was very strong in this region, therefore it is 
possible that modest reductions in size could have been masked on these particular 
immunoblots. As shown below, both inhibition of glycosylation using tunicamycin 
and deglycosylation with the enzyme PNGase do appear to affect the size of dimeric 
species in the case of the H4R. 
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In parallel, cell samples were subjected to [3H]-clobenpropit binding analysis, to 
assess whether N-glycosylation is absolutely required for ligand binding to the hH3 
445 receptor. Near complete prevention of N-glycosylation using 0.1 µg/ml 
tunicamycin resulted in no significant reduction in [3H]-clobenpropit binding, while 
complete prevention, yielded only a modest 33% reduction in specific binding (Figure 
6.2 B). 
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Fig 6.2 N-glycosylation inhibition of the human H3 445 receptor 
FLAG-tagged hH3 445 receptors expressed in HEK 293 cells were incubated with 
increasing concentrations of tunicamycin (TM), harvested 48h post-transfection and 
subjected, in parallel to immunoblotting (A) and [3H]-clobenpropit binding assays 
(B). 
(A) Lane 1 FLAG-tagged hH3 445 expressed in HEK 293 cells without tunicamycin; 
Lane 2-5 FLAG-tagged hH3 445 expressed in HEK 293 cells grown in the presence of 
0.02,0.1,0.5, and 2 µg/ml tunicamycin. The lower panel shows the same blot 
reprobed with anti-ß actin antibody (1: 800) as a control to confirm that total protein 
levels are very similar in each lane. Representative immunoblot, replicated twice more 
with similar results. 
(B) FLAG-tagged hH3 445 expressed in HEK 293 cells grown in the absence and 
presence of 0.02,0.1,0.5, and 2 µg/ml tunicamycin (mean ± SD for triplicate 
determinations from two independent transfections). 
" +ar r' 
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6.4.2 Biochemical evidence that the hH4R is an N-glycosylated homo-dimer 
In the N-terminus of the hH4R Asn5 and Asn9 are potential sites for N-glycosylation 
(Fig 6.3 A). To study whether the higher molecular weight species are the N- 
glycosylated forms of the hH4R, H4Rs were expressed in the presence of the N- 
glycosylation inhibitor tunicamycin. In the absence of tunicamycin, two major putative 
monomeric species, Mr 34,000 and Mr 36,000; and a diffuse Mr 65-75,000 species 
were detected (Fig 6.3 B, Lane 1). In the presence of 2 gg/ml tunicamycin, a complete 
loss of the Mr 36,000 species and concomitant increase in intensity of the Mr 34,000 
species and an additional species at Mr 32,000 was observed (Fig 6.3 B, lane 2). 
Furthermore, the diffuse Mr 65-75,000 species, detected in the absence of tunicamycin, 
was reduced to a single Mr 65,000 species. Notably, an increase in tunicamycin 
concentration had no further effect upon either the Mr 34,000 or Mr 65,000 species 
(Fig 6.3 B, lanes 3-5). The Mr 32,000 species observed upon tunicamycin treatment is 
likely to be a breakdown product of the glycosylated Mr 36,000 species in untreated 
cells. These data strongly suggest that the recombinant hH4R is N-glycosylated and 
forms dimers. This last process is independent of post-translational N-glycosylation. 
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Fig 6.3 The effect of inhibition of glycosylation on the expression of human H4R 
in HEK 293 cells. 
The hH4 receptor is an N-glycosylated dimer. A Snakeplot of the N-terminal tail and 
beginning of TM1 of the H4R, arrows are directed to possible N-glycosylation sites. 
B, HEK 293 cells transfected with the hH4R were grown in the absence and presence 
of 2,4,6 and 8 µg/ml tunicamycin for 48h. The cells were harvested, homogenates 
prepared and subjected to immunoblotting. Immunoblots were probed with the anti- 
hH4 (374-390) receptor antibody. Lane 1, hH4Rs in absence of tunicamycin; Lanes 2- 
5, hH4Rs in presence of 2,4,6 and 8 µg/ml tunicamycin, respectively. Representative 
immunoblot from two sets of independent transfection experiments. 
Enzymatic deglycosylation of human H4R expressed in HEK 293 cells (Fig 6.4) gave 
a similar result to inhibition of glycosylation with tunicamycin (Fig 6.3 B). The 
monomeric species decreased from Mr 36,000 to the deglycosylated Mr 34,000 
species, a putative breakdown product of the glycosylated monomer was again 
observed at Mr 32,000 (Fig 6.4, lane 2). Interestingly, the endogenously expressed 
H4R in human PHA blasts was only detected as high molecular weight species (Fig 
6.5, lane 1). Notably, upon enzymic N-deglycosylation of PHA blasts, the Mr 77,000 
species was greatly reduced in intensity, and a new Mr 34,000 species was detected, 
consistent with the monomeric hH4R (Fig 6.5, lane 2). These data do not directly 
exclude a heavily glycosylated (ca. 33 kDa) H4R protein. However the hH4Rs in 
human HEK 293 cells are only moderately glycosylated (ca. 2 kDa) and the high 
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molecular weight species coincide with the putative dimeric H4Rs when 
recombinantly expressed in COS-7 (77 kDa) and HEK 293 cells (72 kDa). These data 
can be explained by assuming that in human PHA blasts the hH4R functions 
predominantly as a dimer. Therefore, it appears that N-glycosylation is not a 
prerequisite for dimerization, but it may help to stabilize the H4R dimers once they are 
formed in vivo. A similar stabilizing effect of glycosylation on receptor dimers has 
recently been shown for the human bradykinin B2 receptors (Michineau et al, 2006). 
The putative H4R dimerization in native tissue clearly warrants further investigation. 
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Fig 6.4 Deglycosylation of human H4R expressed in HEK 293 cells. 
Cell homogenates were subjected to N-deglycosylation with PNGase F enzyme at a 
final enzyme concentration of 400 iu/ml for 16 hours at 37°C. Control cells were 
incubated in parallel with deglycosylation buffer alone. Samples were then subjected 
to immunoblotting, and immunoblots probed with the anti-hH4 (374-390) receptor 
antibody. Lane 1, control; Lane 2, in the presence of PNGase F. Enzymatic 
deglycosylation resulted in the reduction of monomeric species to Mr 34,000. The 
species apparent at approximately Mr 32,000 was presumed to be a breakdown 
product of the glycosylated monomer. There was also a decrease in the overall 
molecular size of the putative higher oligomers. This experiment was performed once 
but gave a result identical to inhibition of glycosylation with tunicamycin. 
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Fig 6.5 Deglycosylation of H4R in human blast cells. 
PHA blasts were subjected to N-deglycosylation with PNGase F enzyme at a final 
enzyme concentration of 400 iu/ml for 16 hours at 37°C. Control PHA blasts were 
incubated in parallel with deglycosylation buffer alone. Samples were then subjected 
to immunoblotting, and immunoblots probed with the anti-hH4 (374-390) receptor 
antibody Lane 1, control; Lane 2, in the presence of PNGase F. Enzymatic 
deglycosylation resulted in the reduction in intensity of the Mr 77,000 species and 
appearance of the Mr 34,000 putative monomer. Representative immunoblot from two 
independent experiments which gave similar results. 
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6.5 DISCUSSION 
N-linked glycosylation occurs exclusively at the consensus sequence NXS/T and is the 
most common post-translational modification of GPCRs. N-glycosylation is initiated 
in the endoplasmic reticulum (ER) and completed during transport through the Golgi. 
Strictly speaking N-glycosylation is a co-translational process and continues 
throughout protein folding and transport to the trans-Golgi. Differences in the 
glycosylation of potential glycosylation sites could be due to three-dimensional 
considerations, all sites might not be accessible for glycosylation. With increasing 
knowledge of GPCR structure and its relation to function there is now a great deal of 
interest in the role of co/post-translational changes, including N-glycosylation. The 
human histamine H3 and H4 receptors both have potential N-glycosylation sites within 
the extra-cellular N-terminus: H3 at Asntl; H4 at Asns and Asn9. 
In this chapter experiments have been undertaken to show whether the potential sites 
are indeed glycosylated, and to investigate the purpose of H3 and H4R glycosylation. 
Both receptors were expressed in HEK 293 cells in the presence of tunicamycin. The 
antibiotic tunicamycin blocks the transfer of G1cNAc-1-P from UDP-G1cNAc to 
dolichol phosphate, thereby blocking the synthesis of N-linked oligosaccharide chains 
on glycoproteins. Inhibition of glycosylation by tunicamycin clearly demonstrated 
that both histamine receptor subtypes are indeed glycosylated. 
In the case of the H3R tunicamycin dose-dependently reduced the molecular weight of 
the monomeric Mr 47,000 immunoreactive species to the Mr 45,000 immunoreactive 
species. There was no obvious effect on the amount or size of higher molecular weight 
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species. The fact that the amount of larger species was not altered suggests that 
glycosylation is not a prerequisite for H3R dimerisation. In a study of AT1 receptor N- 
glycosylation (Lanctot et al, 2005) it was found that mutant mono-glycosylated and 
aglycosylated receptors had a greater tendency to aggregate as dimers and trimers, 
however we found no evidence of this with the deglycosylated H3R. One might have 
expected the oligomeric species to be reduced in size at the same time as the monomer. 
Considering that the H3R has only one potential glycosylation site, and glycosylation 
of the monomer suggests that it undergoes only moderate glycosylation (+2 kDa), any 
decrease in the molecular weight of the oligomeric species would probably result in 
only a minimal reduction in mobility on the gel. 
With the H4R expressed in HEK 293 cells in the absence of tunicamycin, two major 
putative monomeric species, Mt 34,000 and Mr 36,000, were observed and a diffuse 
Mr 65-75,000 species (Fig 6.3 B, lane 1). In the presence of 2 µg/ml tunicamycin the 
Mr 36,000 species was lost with a concomitant increase in intensity of the Mr 34,000 
species together with the appearance of an additional species at Mr 32,000 (Fig 6.3 B, 
lane 2). Furthermore, the diffuse Mr 65-75,000 species, detected in the absence of 
tunicamycin, was reduced to a single Mr 65,000 species. Notably, an increase in 
tunicamycin concentration had no further effect upon either the Mr 34,000 or Mr 
65,000 species (Fig 6.3 B, lanes 3-5). The Mr 32,000 species observed upon 
tunicamycin treatment could be a breakdown product of the glycosylated Mr 36,000 
species in untreated cells. Alternatively the doublet could arise from some other post- 
translational change not affected by the presence of tunicamycin, both the 34,000 and 
32,000 bands could be the deglycosylated versions of the monomeric species. These 
data strongly suggest that the recombinant hH4R is N-glycosylated and forms dimers. 
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This last process is independent of post-translational N-glycosylation. It was not 
possible to determine whether both of the two potential glycosylation sites are actually 
glycosylated to any appreciable degree. In the canine histamine H2R only two of the 
three potential sites for N-glycosylation, Asn4 and Asn162 were primarily utilized 
(Fukushima et al 1995). 
The enzyme peptide-N-glycosidase F (PNGase F) removes N-linked carbohydrates 
from both immature and mature glycoproteins modified with complex, fully processed 
carbohydrates. Enzymatic deglycosylation of human H4R expressed in HEK 293 cells 
(Fig 6.4) gave a similar result to inhibition of glycosylation with tunicamycin (Fig 6.3 
B). Three monomeric species were detected in the untreated cell homogenate: one at 
Mr 36,000 likely to be the glycosylated monomer, a much fainter band at Mr 34,000 
probably the deglycosylated monomer and a band just below this thought to be a 
proteolytic fragment of the monomer (Fig 6.4, lane 1). The putative H4R monomer 
was reduced from Mr 36,000 to 34,000 by the action of PNGase F, the size of the 
supposed proteolytic fragment decreased to Mr 32,000 indicating that it had also been 
deglycosylated (Fig 6.4, lane 2). There was simultaneously a decrease in the lowest 
extent of the diffuse band arising from putative higher H4R oligomers. 
Enzymatic deglycosylation of native H4R was also undertaken in human PHA plasts. 
H4 receptors were only detected as higher molecular weight oligomers in untreated 
cells (Fig 6.5, lane 1). Upon enzymic N-deglycosylation of PHA blasts, the Mr 77,000 
species was greatly reduced in intensity, and a new Mr 34,000 species was detected, 
consistent with the monomeric hH4R (Fig 6.5, lane 2). It is possible that the high 
molecular weight band at Mr 77,000 is a heavily glycosylated H4R monomer rather 
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than a receptor dimer. However H4R expressed in HEK 293 cells are only moderately 
glycosylated (ca. 2 kDa). In addition oligomeric forms of both the H3R and H4R 
appear to predominate in native tissue preparations (Figs in Chapters 3 and 5 
respectively). Although data presented here suggest that glycosylation is not essential 
for receptor dimerisation, it may be that it helps to stabilize the H4R dimers. Thus 
deglycosylation of the receptors with PNGase F results in some of the dimers breaking 
down into their constituent monomers. A similar stabilizing effect of glycosylation on 
receptor dimers has recently been shown for the human bradykinin B2 receptors 
(Michineau et al, 2006). In this study a range of processes including sialylation of 0- 
linked polysaccharide, N-glycosylation, disulphide bonding and processes as yet 
unknown, were found to be involved in B2 receptor dimerisation. This matter clearly 
warrants further investigation. Interestingly in immunoblots of human spleen lysate 
(Fig 5.9 A) bands were detected at Mr 31,000, compatible with the monomer; and Mr 
59,000 and 66,000; potentially glycosylated receptors and/or receptor dimers. 
Comparing these sizes with those obtained for nonglycosylated receptors it appears 
that the H4R in spleen cells may be predominantly the nonglycosylated versions. This 
could also account for the presence of the H4R monomer in spleen lysate, because if 
glycosylation does indeed stabilize the dimers one might expect to find more of the 
monomer in tissues where the receptor is not glycosylated. It is known that the 
glycosylation state of transmembrane receptors can vary significantly in different 
tissue types (Heidenreich & Brandenburg, 1986; Muller et al, 2002). In addition the 
glycosylation state of the ß1AR in particular is known to be regulated via polymorphic 
variation between individuals (Rathz et al, 2002). Thus it appears that glycosylation 
can be regulated differentially between tissues and between individuals. 
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To assess whether N-glycosylation is absolutely required for ligand binding to the hH3 
445 receptor, cells expressing H3R and grown in the presence of tunicamycin were 
subjected in parallel to [3H]-clobenpropit binding analysis. Near complete prevention 
of N-glycosylation using 0.1 gg/ml tunicamycin resulted in no significant reduction in 
[3H]-clobenpropit binding, while complete prevention, yielded only a modest 33% 
reduction in specific binding (Fig 6.2 B). This was perhaps not surprising since the 
putative glycosylation site on Asn11 is not within the ligand binding pocket, in 
addition it appears to be only moderately glycosylated and therefore unlikely to have a 
large steric effect on TM domains which are involved in agonist binding. N- 
glycosylation of the canine H2R was not required for cell surface localization, ligand 
binding or functional coupling to G-proteins (Fukushima et al, 1995). Conversely for 
the histamine H1R, the glycosylation inhibitors tunicamycin and swainsonine inhibited 
the expression of high affinity pyrilamine binding sites during differentiation of 
cultured smooth muscle cells, BC3H1 (Mitsuhashi & Payan, 1989). The molecular 
weight of high affinity [3H]-pyrilamine binding sites on differentiated cells was 
approximately Mr 68,000, which after treatment with N-glycanase was shifted to Mr 
40,000, a molecular weight similar to that of low affinity [3H]-pyrilamine binding sites 
on undifferentiated cells. These data suggest that one element contributing to H1 
receptor heterogeneity is receptor N-glycosylation. 
The majority of secreted and cell surface proteins that transit to the cell surface 
through the endoplasmic reticulum (ER) are N-glycosylated (95% of GPCRs) (Lanctot 
et al, 2005). In order for a GPCR to elicit intracellular signalling appropriately the 
right quantity of properly folded functional receptors must be available in the plasma 
membrane. It is equally essential that the signalling can be terminated at the proper 
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time and the receptors either recycled or permanently degraded. The regulatory 
mechanisms controlling export trafficking of GPCRs, including glycosylation, have 
recently been reviewed (Duvernay et al, 2005). 
The role of post-translational changes to receptors is complex and an area where there 
is a great deal of interest. The functions of N-linked glycosylation are manifold and 
vary not only between different GPCRs but may also depend on the stage of 
differentiation of the cell (Mitsuhashi & Payan, 1989). Several studies have shown 
that glycosylation is involved in GPCR transport from the ER through the Golgi to the 
cell surface (reviewed in Duvernay et al, 2005). In this chapter it has been clearly 
demonstrated that both the H3 and H4 receptors are indeed N-glycosylated, although 
the immunoblot evidence suggests that they are not heavily glycosylated. Receptor 
dimerisation does NOT appear to be dependent on glycosylation. However, in the 
case of endogenous H4R expressed in human PHA blasts, deglycosylation appears to 
destabilise the preformed dimeric species to individual monomers. It has been shown 
that human bradykinin B2 receptor dimers result from heterologous association of 
differently glycosylated mature receptors (Michineau et al, 2006). Importantly, 
receptor sialylation and N-glycosylation participate with disulphide bonding in the 
stabilisation of the cell surface B2R dimers. For growth factor receptors, such as the 
epidermal growth factor receptor, N-glycosylation strongly regulates receptor 
dimerisation and autophosphorylation (Fernandes et al, 2001). By contrast the 
involvement of N-glycosylation in GPCR dimerisation has not been widely reported 
though it has been described for 0 1-adrenergic homo-dimerisation (He et al, 2002) and 
for a2A- and ßl-adrenergic receptor hetero-dimerisation (Xu et al, 2003), where it has 
been a positive and negative regulator respectively. Furthermore for the H3R lack of 
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N-glycosylation did not appear to affect binding of the selective H3R agonist [3H]- 
clobenpropit. Clearly the location of glycosylated sites will determine their likely 
affect on receptor pharmacology. On the H3R the Asnll glycosylation site is not close 
to the regions thought to participate in agonist binding, in addition the site appears to 
be only moderately glycosylated. A study using artificial N-glycosylation sequons 
engineered into the human angiotensin II receptor subtype 1 (hAT1) (Lanctot et al, 
2005) was used to explore the importance of N-glycosylation positioning for cell- 
surface expression, targeting, affinity and quality control of the hATI receptor. 
Glycosylation within el had a major influence on the pharmacological properties, 
while glycosylation within e2 did not affect the level of cell surface expression but the 
receptor was misfolded and therefore non-functional; glycosylation within e3 caused a 
significant decrease in membrane expression. Site-directed mutagenesis of the putative 
sites would confirm the location of the N-glycosylation sites, and functional studies 
would be useful to address the role of this post-translational modification on cell 
surface H3 and H4 histamine receptors. 
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CHAPTER 7 
GENERAL DISCUSSION 
During the course of this PhD project, new antibodies specific to the two most recent 
histamine receptors H3R and H4R have been generated and validated (Chapters 3 and 
5). These novel immunological tools have been used to characterise the structural and 
molecular pharmacological properties of the rodent and human H3R and H4R receptors. 
A number of key hypotheses have been addressed: 
1) Histamine H3 and H4 receptors are able to homo-oligomerise 
Cross-linking experiments have confirmed the presence of homo-dimers for human 
and rodent H3R and human H4R. Furthermore these higher molecular weight species 
are evident both in recombinant expression systems and native tissue. There is an 
indication that some splice variants may have a greater potential to oligomerise than 
others. Results suggested that the hH3 (329) formed homo-oligomers more readily than 
the hH3 (445). In the case of rat H3 receptors, rH3 (C) dimers were not observed while H3 
(A) dimers were clearly evident. There was also evidence for interspecies differnces in 
receptor oligomerisation. In human putamen putative dimeric H3R species were 
detected, similarly for endogenous hH4R, oligomeric species were predominant. In 
contrast to this in rodent brain monomeric species were detected rather than receptor 
oligomers using the anti-rH3 (268 - 277)/anti-hH3 (445) antibody. The cross-linking 
evidence was corroborated by a range of biophysical and biochemical techniques for 
both the H3 and H4 receptors (Chapters 4 and 5). 
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2) Human H3 and H4 receptors are able to hetero-oligomerise with their 
respective splice variants 
Both H3 and H4 receptors undergo alternative splicing, and many of these splice 
variants have overlapping expression profiles in vivo. This offers up the possibility that 
splicing may be a way of regulating the structure and function of these receptors. Tr- 
FRET experiments provided the first in vitro evidence for the existence of hH3R 
hetero-oligomers, consisting of the full length receptor together with a shorter isoform. 
For the hH4R immunoprecipitation was used to confirm the existence of hetero- 
oligomers in vitro. 
Histamine H3 and H4 receptors are therefore able to form both homo- and hetero- 
oligomers. These appear to be robust, stable oligomers and histamine is not necessary 
for their formation. 
3) Splice variants can act as dominant negative regulatory subunits 
The human H3 isoforms show differential tissue distribution, however in some brain 
regions several variants are expressed together. The 445 and 329 isoforms are co- 
expressed in key locations including the basal ganglia, a focus of this thesis (See 
Chapter 3). Ebenshade et al, 2006 reported that the 445 and 329 isoforms displayed a 
similar binding affinity for [3H]-NAMH, however the total binding to the 329 was 
approximately five-fold less than to the 445. In the same study the 329 isoform was 
also incapable of activating calcium signalling responses to RAMH. We have limited 
preliminary data (not presented in this thesis) to suggest that while the 329 isoform 
does not itself bind the selective H3 antagonist [3H]-clobenpropit, it is able to 
dramatically reduce binding of this ligand to the 445 receptor. If confirmed these data 
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concur with the dominant negative nature of rat H3 isoforms (Bakker et al., 2006). 
This paper also provided the first evidence that isoform expression can be controlled 
by neuronal activity in vivo, which may have significant implications in situations of 
excessive excitatory transmission (eg. epilepsy). 
mRNA encoding all three of the H4R isoforms known to date is found in a number of 
different types of white blood cells (van Rijn et al., manuscript submitted). Neither of 
the truncated H4 isoforms can bind or transduce a signal. On co-expression with the 
full length H4 (390) receptor the number of histamine binding sites is reduced by 55% 
(390 + 302) and 30% (390 + 67), which concurred with surface expression studies 
performed in this thesis (Chapter 5). 
Therefore, splice variants may act as dominant negative regulatory subunits in many, if 
not all, GPCRs. This is analogous to the situation which is also apparent in the ligand- 
gated channel superfamily, e. g. the NR3 subunits of the NMDA receptor act as a 
dominant negative subunit to reduce calcium permeability (function) of this key 
excitatory receptor. It would be interesting to assess whether histamine H4R isoform 
expression is also controlled in an activity dependent manner. 
4) N-glycosylation is a prerequisite for receptor dimerisation 
Most, if not all GPCRs, are assumed to be N-linked glycoproteins, although this has 
not been formally proved. Histamine H3 and H4 receptors were expressed in HEK 293 
cells in the presence of the N-glycosylation, inhibitor tunicamycin. Immunoblot 
analysis of cell homogenates confirmed that both receptors were indeed N- 
glycosylated. Interestingly, inhibition of N-glycosylation did not prevent the 
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formation of H3 or H4 homo-dimers. H4R chemical deglycosylation of mature 
receptors using PNGase F enzyme was also undertaken. Deglycosylation reduced, but 
not completely, receptor dimers in both a recombinant expression system and in 
native tissue. Therefore, there was some indication that N-glycosylation may help to 
stabilise receptor dimers once they are formed as deglycosylation of H4R in human 
PHA blasts reduced the amount of putative dimer with a concomitant appearance of 
the putative monomer. Interestingly, differential glycosylation was observed between 
different native preparations, as well as different in vitro expression systems 
(Chapters 3-6). The significance of this heterogeneity is still to be determined. For the 
H3 receptor, near complete prevention of glycosylation had no significant effect on 
[3H]-clobenpropit binding and complete inhibition saw only a modest reduction in 
binding. In conclusion, N-glycosylation is NOT a prerequisite for receptor 
dimerisation for either the H3 or H4 receptor, and plays a limited role in ligand binding 
for the H3 receptor. 
5) H3 and H4 histamine receptors are both expressed in brain and subserve 
distinct functions 
The H3 receptor is found almost exclusively within the brain. However there have 
been few reports of the latest H4 receptor being detected in the CNS, and these 
describe mRNA distribution rather than H4R protein itself. Using our novel anti- 
human H4R, we have provided the first evidence for the presence of H4R protein in 
human putamen and rat forebrain. In addition we have immunohistochemical data 
showing strong anti-H4R immunoreactivity in human and rat brain slices. Interestingly 
the distribution pattern is different from that observed using our anti-H3 antibodies, 
suggesting these two histamine receptors are likely to serve distinct functions within 
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the CNS. In addition the H4R has been located in the rat gastrointestinal (GI) tract 
both in endocrine cells of the fundic mucosa and also in the myenteric plexus of all 
regions of the GI tract examined. This is the first report of the H4R in the mammalian 
parasympathetic nervous system. 
Understanding the biology of histamine and respective receptors is crucial to 
developing novel therapies targeting histamine receptors. Receptor heterogeneity has 
been a recurrent theme throughout this thesis because it is central to a complete 
understanding. Drugs which act at H1 and H2 receptors have been available for many 
years chiefly as treatments for allergies and gastric inflammation respectively. 
Expectations for similar successes with H3 and H4 specific compounds are high. 
Cloning of the H3 and H4 receptors, and subsequent awareness of the potential for 
different receptor isoforms derived from splice variants, has opened up a number of 
possibilities for explaining the observed diversity. We have generated H3 (Chapter 3) 
and H4 (Chapter 5) specific antibodies with which to investigate this variety using a 
number of different techniques. 
First and most importantly we, and our collaborators, have shown that different 
receptor isoforms are expressed in both rodent and human native tissue and are 
therefore not merely a laboratory artefact. The anti-H3R described here was specific 
for the full length human H3 (445) isoform and two of the rat isoforms namely the rat 
H3A and H3C isoforms. The distribution of the H3R detected by this antibody in mouse 
brain slices was comparable to that found previously using a pan-H3R antibody in 
rodent brain (Chazot et al, 2001; Victoria Hann, thesis, 2004). 
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Similarly mRNA encoding for all three of the human H4R isoforms known to date is 
found at different levels in a number of white blood cell types. This requires 
confirmation with isoform-selective antibodies. 
The purpose of the different isoforms is a topic of great interest. Previous studies have 
shown pharmacological differences between the different isoforms. We have 
preliminary evidence for the shorter human H3R isoform affecting the pharmacology 
of the full length version of the receptor (consistent with the rat). These studies were 
performed in a recombinant system with the receptors artificially expressed in HEK 
293 cells. However the hH3 (445) and hH3 (329) isoforms are known to be co-expressed in 
some important brain regions, thus providing the potential for such an interaction. In 
order to assess their functional significance, compounds capable of distinguishing 
between these isoforms alone or as hetero-oligomers are needed. 
Receptor dimerisation and post-translational changes such as glycosylation, may also 
contribute to heterogeneity; both of which we were able to investigate using our 
specific antibodies. Homo-dimers and hetero-dimers were confirmed in recombinant 
systems using a variety of techniques. Our results suggest that some isoforms may 
dimerise more readily than others. For example, putative hH3 (329) homo-dimers 
appeared stronger in immunoblots than bands compatible with hH3 (445) homo-dimers. 
In agreement with this the FRET signal from homo-dimers was greater in hH3 (329) R 
transfected cells compared with cells expressing hH3 (445), although this did not reach 
statistical significance. Similarly using a cross-linking technique, homo-dimers were 
observed for the rH3A isoform but not for the rH3C isoform. Interestingly in native 
tissue both H3 and H4 were detected predominantly as higher molecular weight species 
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(with the exception of rodent brain using the anti-rH3 (268 - 277)/anti-hH3 (445) 
antibody) compatible with the existence of oligomeric versions of the receptors. 
Glycosylation was demonstrated for both the human hH3 (445)R and the hH4R. Neither 
are heavily glycosylated having only one (H3R) or two (H4R) potential glycosylation 
sites. Glycosylation did not appear to be necessary for ligand binding to the H3R, 
however it may contribute to dimer stability in the case of the H4R. 
What is the purpose of this heterogeneity? In common with the other aminergic 
systems, histamine and the histaminergic system appears to have a modulatory role. It 
is important in homeostasis and helping the animal to respond appropriately to its' 
environment. It may be particularly important in stressful situations. Complex 
information has to be continually processed and integrated, flexibility in the system is 
crucial to its function. Heterogeneity may be the mechanism underlying this flexibility. 
Dimerisation has been discussed in chapters 4 (H3R) and 5 (H4R), glycosylation was 
covered in chapter 6. Both are likely to be involved in regulating receptor function. As 
described in the relevant chapters there are many points at which receptor function 
can be modulated: from synthesis and trafficking to the cell surface, ligand binding, 
signalling and eventual desensitisation, internalisation and recycling. 
A number of areas for future research are clear from the results accrued in this thesis: 
Antibodies to the other H3 and H4 receptor isoforms should be generated and used 
to map their distribution in detail. It would be interesting to find out whether 
expression levels and/or distribution patterns are influenced by environmental 
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factors such as day length, behavioural states or disease. In addition double 
labelling experiments to analyse their distribution in relation to other receptors 
may improve current understanding of the observed functional heterogeneity. We 
have preliminary data which suggests that the H3 receptor is expressed on subsets 
of histaminergic and GABA-ergic neurons in the substantia nigra and 
tubomammilary nucleus, respectively which consequently control distinct output 
neurons (see Appendix), and therefore subserve distinct functions in the 
mammalian brain. 
This thesis provides the first evidence that the H4 receptor is expressed in the 
rodent and human CNS. We have preliminary evidence that the H3 and H4 
receptors are expressed on distinct subsets of endocrine cells and most recently, 
that the H4 receptor is expressed on ganglia in the myenteric complex within the 
GI tract. Therefore, both H3 and H4 receptors may have complimentary roles in the 
PNS and CNS. For effective therapeutic targeting of these two receptors this is a 
critical issue to follow up. 
The putative regulatory role of splice variants and the mechanisms which underlie 
it require further investigation. Studies to investigate the role of post- and/or co- 
translational changes such as glycosylation and palmitoylation in relation to 
function should be undertaken. In addition the question as to whether receptors are 
differentially glycosylated (or otherwise changed) in different tissues should be 
addressed. 
219 
Research investigating receptor interactions with other cell components is in its 
infancy. Studies should include not only protein-protein interactions but 
relationship with lipids and other components of cell architecture. It has been 
proposed that neurotransmitter signalling might occur through a clustering of 
receptors and mediators of receptor-activated signalling in lipid rafts (Allen et al, 
2007). 
We have new evidence (not reported in this thesis) that the H4 receptor can 
directly interact with a chemokine receptor. This has profound implications in 
both the brain and the periphery. Studies to probe the relationship between the 
H4R and chemokine receptors may improve our current understanding of the 
relationship between CNS and immune system responses. This may be important 
for a number of neurodegenerative diseases where an inflammatory response is 
thought to contribute to the pathology. 
While the histamine receptors clearly have potential as therapeutic targets, predicting 
the likely effect of any particular ligand is difficult in the face of the complexity found 
both within and across species. The work described in this thesis has furthered 
understanding of the two most recently described histamine receptors - where they are 
found and how they may be regulated. These are preliminary studies which will need 
to be extended to investigate the full range of receptor isoforms, their molecular 
characteristics and how they interact with other cell components. Advances in 
molecular biology are enabling scientists to unravel complex systems in minute detail, 
and the detail itself is intriguing. However, it is essential not to lose sight of the 
relevance of all this to the workings of the whole animal. In addition advances which 
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can transfer to the clinic will be the result of a combined effort from the fields of 
molecular biology, chemistry, pharmacology, animal behaviour and medicine. 
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APPENDIX 
HETEROGENIETY OF H3 RECEPTORS IN THE RODENT BRAIN: THE 
TUBEROMAMMILARY NUCLEUS (TMN) 
FIGURE 1: The H3 receptor is expressed on subpopulations of GABA-ergic neurons in the rat TMN 
Double labeling immunoflurorescence experiments were performed using pan anti-H3 (green) and anti- 
GAD67 (red) antibodies in the tuberomammilary nucleus (TMN). Images were captured using a confocal 
microscope. A. Low magnification merged image; B. Region of high GAD-positive staining and low H3- 
postive staining; C. Region of low GAD-staining and high H3-positive staining; D. Region of GAD/H3 
double labeling; E and F. examples of H3 +ve/GAD -ve and a H3 +ve/GAD +ve cells. (S Trelfel', S 
Cragge', FC Shenton and PL Chazot, unpublished) ' /)epariment (? f Pharmacology, Oxford ('nivcrsitty 
A. B. 
('. 
E. i. 
FIGURE 2: The H3 receptor is expressed on subpopulations of histaminergic neurons in the rat TMN 
Double labeling immunoflurorescence experiments were performed using pan anti-H3 (red) and anti-HDC 
(green) antibodies in the tuberomammilary nucleus (TMN). Images were captured using a confocal 
microscope (B Passani', P Blandina', FC Shenton and PL Chazot, unpublished)' Department of Preclinical 
and Clinical Pharmacology, University of Florence, Italy 
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H4 RECEPTOR EXPRESSION IN THE RODENT AND HUMAN CENTRAL AND PERIPHERAL 
NERVOUS SYSTEM 
FIGURE 3: The expression of histamine H, R in the mouse brain (A) and rat gastrointestinal tract 
(B), respectively, using our anti-hH4R (374-390). 
A). High levels of H4-IR were evident in the thalamus, layer IV of the cerebral cortex, entorhinal cortex and 
CA3 of the hippocampus (FC Shenton and PL Chazot, unpublished). B). H4-IR was present in the 
myenteric plexus of all regions of the gastrointestinal tract examined (Colon shown as an example). 
Staining for H4R was particularly strong in ganglion soma and present, although to a lesser degree, on 
neuronal fibres. By contrast, the submucosal plexus was immunonegative for H4R (PL Chazot, FC Shenton, 
D Grandy' and G Morini', 2007) 'Department of Human Anatomy, Pharmacology and Forensic Medicine, 
University of Parma, 43100 Parma, Italy 
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FIGURE 4: Expression of the H., receptor in the human brain. 
A). Strong H4R-IR punctuate decoration of putative neurons was observed in cortical and caudate regions 
of human brain slices by IHC (H Waldvogel', FC Shenton and PL Chazot, unpublished, ' Medical and 
Health Sciences, University of Auckland, NZ. B). We have identified the first human H4 receptor isoforms 
which act as dominant negative subunits in vitro. Both isoforms reduce the numbers of full length dimeric 
hH4 receptors determined pharmacologically (Chapter 5, van Rijn ei a!., 2007). 
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Introduction 
Molecular cloning has confirmed that the H3 receptor is a 
G-protein coupled receptor (GPCR), subject to alternative 
splicing [1], which yields multiple potential receptor iso- 
forms in rat, guinea pig and man [2]. The full-length gene 
product H3 445 appears to be consistently expressed in all 
species studied to date and has been the most intensively 
studied isoform. R-a-Methylhistamine (RaMH) is consid- 
ered the prototypical H3 receptor full agonist and has been 
used widely as a selective pharmacological tool [3]. Many 
GPCR studies have identified guanine nucleotide-insensitive 
agonist binding, a feature which has been commonly attrib- 
uted to a `tight coupling mode constitutively active' state of 
the particular GPCR. There is growing compelling evidence 
that the H3 receptor is endowed with a high level of constitu- 
tive activity, being most evident in the rodent striatum [4]. 
Here, we report that both native rodent and cloned human H3 
receptors display GTP-insensitive agonist binding, and the 
degree of insensitivity was comparable in both preparations, 
indicating a similar level of constitutive activity. 
Materials and methods 
IIEK 293 cells were cultured and transfected with pCI-neo hH, 445 
(20 µg) or pCISNMDARI (10µg) (mock) using the calcium phosphate 
precipitation method [5]. Transfected cells were harvested 48 h post- 
transfection, cell homogenates were prepared and subjected to immuno- 
blotting [6] and ['H]-clobenpropit binding assays [7]. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was carried out using 7.5% polyacrylamide slab gels 
under reducing conditions. Immunoblots were probed with our previ- 
ously described polyclonal anti-h1i3445 (349-358) antibody [6], used 
at a final protein concentration of 2 µg/ml. 
['H] clobenpropit binding was performed essentially as described in 
(7]. Briefly, HEK 293 cell homogenates were incubated for 3h at room 
temperature in 20 mM HEPES-NaOH buffer, in the presence of 3 mM 
metyrapone. Specific binding was defined using 10-'M thioperamide. 
High affinity ['H] R-a-Methylhistamine (RaMH) (2 nM) binding 
assays were performed on well-washed rat striatal P2 membranes, essen- 
tially as described by Harper et al. [8]. Adult rat (Wistar strain) striatal 
membranes (400 µg protein) were incubated, in triplicate for 3h at 
Correspondence to: P. L. Chazot 
22°C, with ['H] RaMH (2 nM) in 20 mM HEPES buffer pH 7.4. Non- 
specific binding was defined using unlabelled RaMH or thioperamide 
(both at 10-5M). The assays were terminated by rapid filtration through 
Whatman GFB filters pre-soaked in 0.1 % polyethyleneimine, which 
were washed (3 x3 ml) with ice-cold 10 mM sodium phosphate buffer 
(pII 7.4), using a 12-place Brandell cell harvester. Bound radioactivity 
was determined by liquid scintillation counting. The data were analysed 
using GraphPad Prism and all values cited are mean ± SD for at least 
3 independent determinations. 
Results and discussion 
HEK 293 rNRI (control) and HEK 293 hH3 445 receptor cell 
homogenates were probed in parallel by immunoblotting, 
with our anti-H3 445 (349-358) antibody. Selective expres- 
sion was observed of a major polypeptide species of approx. 
Mr 45,000, corresponding to the predicted size of the 
monomeric H3 445 receptor [1]. 
In pharmacological competition studies with HEK 293 
hH3445 receptor cell homogenates, using [3H] clobenpropit 
(Bm, 
x < 500 
fmol specific [3H]-clobenpropit binding sites/mg 
protein), RaMH behaved as a classical agonist, displaying a 
complex binding curve, best fit to a two-site binding model, 
with a high affinity (apparent IC50 = 1.10 ± 0.06nM) and a 
low affinity (apparent IC50 = 89.13 t 3.29 nM) binding com- 
ponent in the ratio 40: 60 (high: low %, SD = 3), respectively. 
The presence of the non-hydrolysable GTP analogue, 
5-guanylylimidodiphosphate (GppNHp) (0.1 mM) elicited a 
rightward shift in the RaMH competition curve. Interesting- 
ly, in the presence of GppNHp, RaMH can still discriminate 
between two binding sites, (apparent ICsa = 1.62 ± 0.09 nM 
and 60.26 t 0.92 nM, respectively), but in the ratio 22: 78 
(high: low SD = 9). Notably the apparent IC50 values are 
very similar in the presence or absence of GppNHp. 
In a parallel study, we investigated the GppNHp-sensitiv- 
ity of [3H] RaMH binding to native H3 receptors expressed in 
the rat striatum. Both GppNHp (100 µM) and NaCL (1 M) 
promoted dissociation of the G-protein, eliciting a 68 ± 8% 
and 94 ± 18% reduction in specific [3H] RaMH binding, 
respectively. 
The molecular nature of this high-affinity guanine 
nucleotide-insensitive agonist binding to the H3 receptor 
remains to be fully established. Some insight may be provid- 
S68 
cd by the allosteric ternary complex model, which was devel- 
oped to account for the phenomenon of constitutive activity. 
The H3 receptor has recently been shown to be constitutively 
active in vivo, and the striatum reported to display the high- 
est constitutive activity due to the high density of receptors in 
this region [4]. The GppNHp-insensitive RaMH component 
of [3H] clobenpropit binding to the cloned hH3 445 receptor 
(22 ± 9%) compares well with the GppNHp-insensitive com- 
ponent of [3H] RaMH binding to native rat striatal H3 recep- 
tors (32 ±8 %). This is consistent with a recent proposal that 
constitutive activity is observed at physiological densities of 
both human and rat H3 receptors (with expression levels 
< 500 fmol/mg protein) [4]. This study provides evidence 
that we have a useful model system to study the pharmacol- 
ogy of a major human H3 receptor isoform. 
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Introduction 
The neurotransmitter histamine is synthesized in 
the cell bodies of histaminergic neurons exclusively 
localized in the tuberomammillary nuclei of the 
hypothalamus. These neurons project widely in 
the CNS, lending credence to the idea that the 
histaminergic system may act as a major regulatory 
centre for the mammalian brain. Histamine elicits 
its major actions by binding to four distinct 
Histamine receptors, termed H1-H. 4, based on 
amino add sequence identity. Schwartz and col- 
leagues first demonstrated the presence of a novel 
pre-synaptic Histamine autoreceptor, termed H3, in 
1983.1 Pharmacological confirmation of this recep- 
tor followed swiftly in 1985,2 but it has taken 14 
further years to finally identify the receptor itself, 
with the seminal work of Lovenberg and colleagues 
in the US. 3 
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Summary The Histamine H3 receptor was identified over 20 years ago, but it was 
only recently cloned in 1999. This achievement has led to major strides in our 
understanding of the receptor, and a growing appreciation of the H3 receptor as a 
novel therapeutic candidate particularly in the CNS. A number of recent gene- 
deletion 'knockout' studies have been reported which strengthen this optimism, 
particularly in areas of obesity, movement disorders, pain, dementlas and anxiety. 
0 2004 Elsevier Ltd. All rights reserved. 
Structural features 
Consistent with previous predictions, the H3 re- 
ceptor deduced protein sequence possesses all the 
primary structural characteristics of a G-protein 
coupled receptor (GPCR). Since the initial cloning 
of the human H3 receptor, both the guinea pig and 
rat H3 receptor orthologues have been successfully 
cloned 4-7 Subsequently, the number has grown 
with the identification of multiple H3 receptor 
splice isoforms In guinea pig, rat and, importantly, 
man. 4"6.8 This expansion now offers the possibility 
of new therapeutic targets and more selective drug 
design. 
The human H3 receptor splice isoforms display 
either a deletion in the second transmembrane 
(TM) domain (14 amino acids), a variable deletion 
in the third intracellular (IL) loop (30,80,116 
amino adds) or a deletion in the fifth TM and the 
third IL (119 amino acids). 9 A consistent splice site 
identified for all three mammalian species occurs in 
the third IL, which implies that the different 
isoforms could couple to different G-proteins or 
to the same G-protein with different efficiencies, 
with resultant differential signalling consequences 
0953.71121S-see front matter o 2004 Elsevier Ltd. All rights reserved. 
doi: 10.1016/ j. cacc. 2004.01.006 
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Figur. 1 Schematic diagram of the H3 histamine 
receptor. 
(Fig. 1). It still remains unclear whether the H3 
receptor isoforms exist in vivo. 10 
Anatomical framework 
The H3 receptor polypeptide(s) has a widespread 
and abundant neuronal expression throughout the 
mammalian brain. High levels of H3 receptor 
protein expression were detected in the deep 
layers of the cerebral cortex, the CA3 field and 
the dentate gyrus of the hippocampal formation, 
cerebellar purkinje cells, thalamus and striatum. 
Modest levels of H3 receptor expression were also 
observed in many other areas of the brain. " In situ 
hybridization studies of human3 and guinea pig, 4 
the full length (445 amino acids) H3A receptor 
isoform revealed no significant gross species differ- 
ences in distribution patterns. However, interest- 
ingly two studies have shown that the rat and 
human H3 receptor splice isoforms display differ- 
ential expression patterns in the brain. °" 9 In the 
rat, the H3C mRNA is the most strongly expressed 
isoform in many therapeutically relevant tissues, 
Including the striatum, deep cortical layers, pyr- 
amidal layers of hippocampal fields CA1 and CA2 
and locus ceruleus. HMA expression is the most 
prominent isoform in the dorsal part of the dentate 
gyms and CA1 field in the ventral hippocampus. The 
H» Isoform displays the weakest expression gen- 
erally and appears not to be expressed In the 
dentate gyrus. In man, interestingly, two of the 
short H3 isoforms, with deletions in the third IL [H3 
(D113,329 a. a. ); H] (A13,365 a. a. )), are preferen- 
tially expressed in the hippocampus and the 
amygdala (implications for learning and memory). 
An important issue, yet to be addressed is whether 
P. L. Chazot, F. C. Shenton 
the isoforms show any differential protein expres- 
sion at the synaptic level. This awaits appropriate 
immunological tools. " 
The knockout story so far 
The histamine H3 receptor subtype was originally 
discovered on histamine-containing neurons as a 
pre-synaptic receptor regulating the release and 
synthesis of histamine. ' However, modulation of a 
number of other neurotransmitter systems through- 
out the brain via pre- and post-synaptic H3 
heteroreceptors has been clearly demon- 
strated. ' 20 The widespread distribution of H3 
receptors in the mammalian (rodent and human) 
CNS indicates strongly the multifaceted physiologi- 
cal role of this receptor family and hence the 
therapeutic potential as novel drug targets. 
An important advance made possible by the 
cloning of the H3 receptor has been the generation 
of H3R knockout mice (H3 / ). The first description 
of an H3 receptor-deficient mouse was by Toyota 
and colleagues. 21 Knockout mice were created from 
mouse embryonic stem cells in which the H3 
receptor gene had been disrupted. Histamine 
receptors play a complex role in the regulation of 
several important neurotransmitters in the brain. 
Therefore, the brain levels of a number of 
neurotransmitters and their metabolites were 
measured. The only change was a clear decrease 
in histamine levels in the cortex of H3 ( /-) mice. 
This decrease was attributed to removal of the 
stimulatory effect of the H3 receptor on the 
synthesis of histamine. There was no change in 
the levels of the other neurotransmitters, including 
dopamine, homovanillic acid, 3,4-dihydroxypheny" 
lacetic acid, noradrenaline, serotonin and S-hydro- 
xyidolacetic acid. 
Arousal and locomotion 
The pre-synaptic autoregutatory H3 receptor In- 
hibits the release of neuronal histamine, which in 
turn leads to decrease of post-synaptic H, receptor 
function. 22 The rote of the central H, receptor in 
arousal is well known and is the reason for the 
sedative effects of many H, receptor antagonists. 
The absence of the H3 receptor might be expected 
to increase arousal via an increase in histaminergic 
transmission, but interestingly, this was not the 
case. H3 (/) mice showed a decreased level of 
motor activity at night (normally their active 
period) and decreased wheel-running behaviour. 
H3 Histamine receptors: the gene knockout data so far 
Several possible explanations were put forward to 
explain this anomaly: 
(1) H, receptors may be downregulated to com- 
pensate for increased levels of histamine at the 
synapse. But H1R binding experiments dis- 
proved this possibility. 
(2) Removal of H3 receptors may have lead to 
perturbations in the homeostasis of neurotrans- 
mitter levels borne out perhaps by lower levels 
of histamine in the H3 (-/-) mice. The hypoth- 
esis being that although the braking effect of 
the H3 receptor is removed, there is a 
compensatory decrease in the availability of 
histamine in the nerve terminals leading to an 
overall decrease in histaminergic neurotrans- 
mission. 
(3) Histaminergic neurons may have diminished 
histamine content, due to the lack of inhibition 
by the H3R throughout development. 
(4) The influence of the histaminergic system on 
Locomotor activity is complex e. g. the unex- 
pected effects of H, receptor (-/-) on Locomo- 
tion in light/dark, H1 -/- mice actually 
displayed an increase in locomotor activity 
during the light phase. 
(5) Finally the continuous absence of H3 receptor 
throughout development could be compen- 
sated by changes in expression of other genes. 
Although H3 (-/-) mice showed decreased overall 
locomotion, wheel running behaviour, and body 
temperature during the dark phase, they main- 
tained normal circadian rhythms. H3 (-/-) mice 
were insensitive to the wake-promoting effects of 
the H3 antagonist thioperamide, confirming the role 
of the H3 receptor as a mediator of wakefulness. 
The pre-synaptic H3 receptor regulates the 
release of histamine and other neurotransmitters 
such as dopamine and acetylcholine. 1 17 There- 
fore, the effects of disruption of the H3 receptor on 
these transmitter systems were investigated. Do- 
paminergic transmission is affected by metham- 
phetamine which increases locomotor activity and 
stereotypic behaviour, by increasing dopamine 
release. Methamphetamine had less effect on H3 
(-/-) mice than controls, the increase in locomotor 
activity was less, and H3 (-/-) mice scored lower on 
a stereotypy scale in response to methampheta- 
mine. These data suggest that H3 (-/-) mice may 
have decreased dopaminergic activity. This could 
play a part in the decrease in total activity and 
wheel running behaviour seen in these mice. 
However, it should also be noted that methamphe- 
tamine has effects on other pathways including 
serotonergic transmission. 
25 
Cognition and anxiety 
The H3 receptor appears to play a role in memory in 
some experimental models. It was found, using the 
passive avoidance model, that H3 (-/-) mice 
learned as normal, but were Insensitive to the 
amnesia-inducing effects of the muscarinic antago- 
nist scopolamine. This is in agreement with studies 
where H3 receptor antagonists have been shown to 
have the same effect on scopolamine-induced 
memory deficits 24 Interestingly the H3 (-/-) mice 
were not insensitive to scopolamine in the open 
field habituation test, which measures memory as 
the habituation of exploratory activity in a new 
environment. The fact that H3 (-/-) mice were only 
insensitive to the effects of scopolamine in an 
aversion model may point to a specific rote for the 
H3 receptor in memory formation associated with 
painful stimuli. 
In another study, H3 (-/-) mice were used to 
probe the role of the H3 receptor in anxiety and 
cognition. H3 (-/-) mice displayed an age-depen- 
dent enhanced acquisition of spatially encoded 
information, using the water-maze model. Further- 
more, the H3 (-/-) mice displayed age-independent 
reduced measures of anxiety in the elevated plus 
maze and elevated zero maze models25 These 
findings point to the H3 receptor as a potential new 
target for treating dementias and anxiety, respec- 
tively. 
Obesity 
Takahashi and colleagues generated a further H3 
(-/-) mouse26 and probed the issue of obesity. They 
found that changes in the brain histamine tone lead 
to an obese phenotype. H3 (-/-) mice manifest a 
mild obese phenotypes characterized by increased 
body weight, increased food intake and adiposity 
and decreased energy expenditure. As with the 
Toyota H3 (-/-) mouse, body temperature and 
locomotor activity were found to be reduced (in 
this case both total and dark-phase locomotor 
activity were affected), while circadian rhythmi- 
city was unaffected. Consistent with this obese 
phenotype, H3 -/- mice have insulin and leptin 
resistance; increased levels of plasma insulin and 
leptin, and increased expression of UCP1 and UCP3 
in brown adipose tissue, white expression in white 
adipose tissue and skeletal muscle is decreased. 
Increase in adipose weight is known to increase 
leptin and insulin secretion in rodents. UCP1 and 
UCP3 are amongst a number of genes associated 
with food consumption and energy expenditure. 
26 
Changes in UCP expression may be caused by 
impaired leptin signalling in the hypothalamus of 
H3 (-/-) mice, since leptin not only regulates 
appetite but also UCP expression in some periph- 
eral tissues. Furthermore, injection of fluoro- 
methylhistidine, which inhibits histamine 
synthesis, before leptin administration, blocked 
the anorexigenic effect of leptin, 27 and leptin 
receptor-deficient mice and Zucker fatty rats have 
decreased levels of hypothalamic histamine. " It is 
suggested that a possible underlying mechanism to 
these observations is impaired regulation of hista- 
minergic neurons. The increased levels of the 
histamine metabolite, tele-methylhistamine, found 
in all brain areas of the H3 (-/-) mice would support 
this. The lack of inhibitory H3 autoreceptors could 
result in continuous release of histamine from pre- 
synaptic neurons. This could in turn lead to over- 
load of the histamine synthesis machinery and a 
chronic shortage of histamine in the nerve term- 
inals. Total histamine levels were lower in the 
hypothalamic/ thalamic region of H3 (-/-) mouse 
brains, although total brain histamine was not 
significantly altered. Since several H3 antagonists 
have been shown to increase histamine release 
within the CNS and decrease food intake, increases 
in the concentration of tele-methylhistamine in the 
hypothalamic region together with increased food 
intake was unexpected. One explanation offered 
here is the desensitization of H, receptors. H1 
receptors could be downregulated to compensate 
for constitutive histamine exposure. In support of 
this, H, receptors were slightly reduced in the 
hypothalamic region of H3 (-/-) mice compared 
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with controls. More studies are needed to investi- 
gate the role of H1 receptors in regulation of 
appetite. The anorexigenic effect of thioperamide 
following the administration of the hyperphagia- 
inducing peptide neuropeptide Y (NPY), was not 
observed in H3 (-/-) mice, confirming the role of H3 
receptors in this system. 
Pain 
Earlier studies have indicated a possible pain- 
modulatory role for H3 histamine receptors, but 
the loci and nature of this modulation has been 
poorly understood. The H3 receptor agonist, Im- 
mepip produced robust antinociception in the rat 
mechanical (tail pinch) test, but not the thermal 
(tail flick) test, indicating a differential role of H3 
receptors. Intrathecat administration of thiopera- 
mide reversed the antinociceptive responses in- 
duced by systemically administered Immepip, 
indicating a spinal site of action. Significantly, 
intrathecally administered immepip produced a 
maximal antinoceptive response on the tail pinch 
test in wild type, but not in H3 (-/-) mice. " 
Recently, we have demonstrated immunologically, 
that the H3 receptor is specifically located on deep 
dermal vascular innervation. Although more studies 
are underway, the present work reveals a group of 
H3 receptor-containing fibres that may mediate 
some forms of mechanical nociception and could be 
a target for analgesic drugs that activate H3 
receptors. 30 
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H3 Histamine receptors: the gene knockout data so far 
Cardiac arrythmias 
H3 receptors are present in cardiac sympathetic 
nerve in man, where they attenuate norepinephr- 
ine release under normal physiological conditions, 
and in hyperadrenerigc states, e. g. myocardial 
ischaemia. Using H3 (-/-) mice, It' has been 
recently demonstrated that in the absence of H3 
receptors, norepinephrine release from an ischae- 
mic heart is greatly increased, which may underlie 
the major cause of arrhythmic cardiac dysfunction. 
Indeed, follow-up work has shown that H3 (-/-) 
mice display a markedly increased severity of 
reperfusion cardiac arrhythmias. These data reveal 
a significant cardioprotective role for H receptors 
on cardiac sympathetic nerve endings. 3?. 32 
Concluding remarks 
The H3 receptor is a highly topical and growing area 
of research, notably in the pharmaceutical indus- 
try, and it is easy to predict that our knowledge and 
understanding will grow rapidly in the next couple 
of years. These gene knockout publications have 
provided further compelling evidence that the H3 
receptor is a strong candidate for therapeutic 
targetting in many important clinical arenas 
(Table 1). 
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Evidence for native and cloned H. Histamine receptor higher 
oligomers 
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Introduction 
The H3 histamine receptor subtype is a classic G-protein cou- 
pled receptor (GPCR) expressed almost exclusively in the 
CNS. Pharmacological heterogeneity in H3 receptors within 
and across species has long been recognised, which may be 
explained by the presence of different isoforms and/or recep- 
tor oligomerisation reviewed in [1,2]. There is evidence for 
the existence of higher molecular weight (MW) oligomers of 
many GPCRs, including the H, [3] and H, [4] histamine 
receptors. We have developed the first panel of specific anti- 
H3 receptor antibodies, which have identified two specific 
immunoreactive species in adult rat and mouse brain 
homogenates analysed under reducing conditions, compati- 
ble with the presence of robust dimeric H3 receptor isoforms 
(M, 68,000 and 93,000) [5]. Here, we provide evidence using 
cross-linking strategies for the existence of native and recom- 
binant H3 receptor higher oligomers. 
Materials and methods 
Chemical cross-linking experiments were carried out on homogenates 
of rat forebrain membranes or HEK 293 cells expressing the hH, 445 
isoform, using both the reversible cross-linker dithiobis (succinimidyl 
propionate) (DSP) and the irreversible cross-linker his (sulfosuccin- 
imidyl) suberate (BS3). Cross-linking using DSP was carried out essen- 
tially as described by Brose et al. [6]. 
HEK 293 cells were transfected with cDNA encoding the FLAG- 
tagged hH, 445 receptor isoform, essentially using the Lipofectamine- 
Plus method described by Tucker et al. [7]. Cells were harvested 48 h 
post-transfection. 
Chemical cross-linking using BS, was performed as described by 
Haugeto et al. [8]. Briefly, adult rat (Wistar strain) forebrain membranes 
or HEK 293 (hH, 445) cell homogenates were incubated at a final 
concentration of 0.5 mg protein/ml buffer (150 mM sodium chloride, 
100 mM HEPES, pH 7.5, containing 5 mM EDTA and 5 mM DTT), 
with BS, (0.01-3 mM) freshly prepared in 20 mM hydrochloric acid, for 
12 min at room temperature, and the reaction terminated in 200 mM 
Tris-HCI pH 9.0. 
Proteins were extracted using the chloroform/methanol precipita- 
tion method, and the precipitate subjected to SDS-PAGE under reduc- 
ing conditions, using 6-7.5% (v/v) acrylamide slab gels. Proteins were 
transferred onto nitrocellulose and probed with the anti-hH, 349-358 
antibody [5] for the native experiments or the mouse anti-FLAG (Sigma 
Correspondence to: P. L. Chazot 
Aldrich, UK) antibody for recombinant experiments, antibodies used at 
a final concentration of I µg/ml and dilution of 1/5,000, respectively. 
Immunological detection was achieved as described in [5]. 
Results and discussion 
A series of chemical cross-linking experiments were per- 
formed on adult forebrain membranes and HEK 293 cell 
homogenates expressing the hH3 445 isoform. In the absence 
of either cross-linker, the anti-H3 349-358 antibody labelled 
two prominent immunoreactive species, M, 68,000 and M, 
93000 in adult rat forebrain membranes, as previously 
reported [5] (Fig. 1). These protein sizes are consistent with 
the presence of dimeric rH3 receptor isoforms. Low levels of 
putative monomers were also evident. By contrast, the 
recombinant hH3 receptor expressed in HEK 293 cells 
migrated as both prominent monomers (Mr 47,000) and 
K 93,000 -31 
6t. 000 
. 4-', 
0 
4wo "- M, 47.000 
0 
234 1 
Fig. I. Cross-linking of rat forebrain and recombinant FLAG-tagged 
hH, 445 receptors. Adult rat forebrain membranes and FLAG-tagged 
hH, 445 receptors expressed in IIEK 293 cells were subjected to cross- 
linking with the irreversible crosslinker BS, (I mM). The resultant 
preparations were then assessed by immunoblotting using anti-I1, (349- 
358) and anti-FLAG antibodies for native (Lanes I and 2) and recombi- 
nant samples (Lanes 3 and 4), respectively. Lane 1, rat forebrain with- 
out cross-linker. Lane 2, rat forebrain in the presence of 1 mM BS,. 
Lane 3, FLAG-tagged hH, 445 expressed in HEK 293 cells without 
cross-linker. Lane 4, FLAG-tagged hH, 445 expressed in IIEK 293 cells 
in the presence of 1 mM BS,. 
Inflamm. res., Supplement 1(2005) 
dimers (M, 93,000) (Fig. 1). The variation in dimer: 
monomer protein ratios between the native and recombinant 
preparations are likely to be due to the higher levels of over- 
all H3 receptor protein expression in the clonal cell line. 
Results with both the reversible and irreversible cross-link- 
ing agents (DSP and BS3, respectively) were essentially iden- 
tical. For the native tissue, in the presence of 0.1-3 mM DSP, 
little immunoreactivity was detected in the resolving gel. 
Notably, a concentration-dependent increase in hH3 445 
receptor dimers was observed up to 1 mM BS3 (results not 
shown). Again, anti-H3 receptor immunoreactivity was large- 
ly absent from the resolving gel in both preparations using 
concentrations of BS3 in excess of 1 mM (Fig. 1). 
The disappearance of detectable immunoreactivity in the 
resolving gel in the presence of the cross-linkers is most 
likely explained by the stabilisation of higher MW species 
(> M, 200,000), too large to enter the resolving gel. The 
higher molecular weight oligomers contain disulphide 
bridges as they are disrupted by reduction with 20 mM DTT 
(Fig. 1, lane 1), to yield putative H3 receptor dimers. The 
putative dimers in the untreated native tissue are robust 
non-disulphide linked oligomers since they are not disrupt- 
ed by strong reducing (up to 200 mM DTT)/denaturing 
gel conditions adopted (results not shown). These findings 
suggest, for the first time, that native H3 receptors exist 
as dimers and/or higher oligomers, which has important 
implications for understanding of the structure and function 
of H3 receptors. 
S49 
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Introduction 
The H3 histamine receptor subtype is a classic G-protein 
coupled receptor (GPCR) expressed almost exclusively in 
the CNS. Pharmacological heterogeneity in H3 receptors 
within and across species has long been recognised, which 
may be explained by the presence of different isoforms, 
receptor oligomerisation and/or glycosylation variance 
reviewed in [1] and [2]. The H3 receptor possesses one puta- 
tive N-glycosylation site, although the utility of this site has 
not been formally confirmed. Glycosylation has been previ- 
ously shown to be important for appropriate processing and 
trafficking of many GPCRs to the membrane. Interestingly, 
glycosylation appears to have a differential role in H, and H2 
histamine receptor pharmacology [3,4]. Tunicamycin is an 
N-glycosylation inhibitor, which has been previously used in 
our laboratory to probe the importance of post-translational 
N-glycosylation of the ionotropic NMDA receptor [5]. In 
this paper, we provide the first evidence that the human his- 
tamine hH3 445 receptor is indeed N-glycosylated and this 
post-translational modification is not absolutely required for 
antagonist binding to the H3 histamine receptor subtype. 
Materials and methods 
HEK 293 cells were transfected with cDNA encoding the FLAG 
epitope-tagged hH3 445 receptor isoform, essentially using the Lipo- 
fectaminePlus method described previously [6]. Cells were incubated 
with increasing concentrations of tunicamycin (0-2pg/ml) in the media 
and harvested 48 h post-transfection. 
Proteins were precipitated and subjected to SDS-PAGE under re- 
ducing conditions, using 6-7.5 % (v/v) acrylamide slab gels. Proteins 
were transferred onto nitrocellulose and probed with mouse anti-FLAG 
(Sigma Aldrich, UK), antibodies used at a final dilution of 1/5,000. Im- 
munological detection was achieved as described in [7]. 
Correspondence to: P. L. Chazot 
['H] clobenpropit binding was performed as described in [6]. We 
have evidence that clobenpropit acts as a neutral antagonist in this sys- 
tem (not shown). Specific binding was defined using thioperamide or 
R-alpha-Methylhistamine (10pM). 
Results and discussion 
The effect of increasing concentrations of tunicamycin was 
investigated using immunoblotting and radioligand binding 
assays with [311] clobenpropit. Cells transfected with the 
hH3 445 receptor and grown in the absence of tunicamycin, 
yielded, upon immunoblotting, a closely spaced doublet im- 
munoreactive species (M, 47,000 and M, 45,000), consistent 
with the presence of a glycosylated and non-glycosylated 
hH3 receptor monomer, respectively. As previously reported, 
a range of higher molecular putative oligomers were also de- 
tected (not shown) [8]. Incubation of HEK cells transfected 
with the hH3 445 with increasing concentrations of the 
N-glycosylation inhibitor, tunicamycin, dose-dependently 
reduced the molecular weight of the M, 47,000 immunoreac- 
tive species to the M, 45,000 immunoreactive species (Fig. 
1). This suggests that the h113 445 receptor is indeed mod- 
estly N-glycosylated, consistent with the predicted single 
putative glycosylation site. 
In parallel, cell samples were subjected to [3H] cloben- 
propit binding analysis, to assess whether N-glycosylation 
is absolutely required for ligand binding to the h13 445 
receptor. Partial inhibition of N-glycosylation using 0.1 pg/ 
ml tunicamycin resulted in no significant reduction in [311] 
clobenpropit binding, while near complete inhibition yielded 
only a modest 33% reduction in specific binding (Fig. 1). 
In conclusion, these findings demonstrate, for the first 
time, that human H3 receptors are N-glycosylated and pre- 
vention of N-glycosylation does not appear to have a major 
effect upon [3H] clobenpropit binding to the hH3 445 recep- 
tor. This suggests that N-glycosylation is not absolutely re- 
quired for antagonist binding to H3 receptors. 
Influmm. res. Supplement 1 (2006) 
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Fig. 1. N-glycosylation inhibition of the human H, 445 receptor. 
FLAG-tagged hH, 445 receptors expressed in HEK 293 cells were in- 
cubated with increasing concentrations of tunicamycin. harvested 48 h 
post-transfection and subjected, in parallel, to (A) [3H1 clobenpropit 
binding assays (B) immunoblotting. A: FLAG-tagged hH, 445 ex- 
pressed in HEK 293 cells grown in the absence and presence of 0.1 and 
2pg/mI tunicamycin (mean +/- SD for triplicate determinations from 
two independent transfections). B: Lane I FLAG-tagged hH3 445 ex- 
pressed in HEK 293 cells without tunicamycin; Lane 2-6 FLAG-tagged 
hH, 445 expressed in HEK 293 cells grown in the presence of 0.1,0.2, 
0.5, I and 2µg/ml tunicamycin. Representative immunoblot, replicated 
with similar results. 
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ABSTRACT 
We described previously the cDNA cloning of three functional 
rat histamine H3 receptor (rH3R) isoforms as well as the differ- 
ential brain expression patterns of their corresponding mRNAs 
and signaling properties of the resulting rH3A, rH3E, and rH3c 
receptor isoforms (Mol Pharmacol 59: 1-8). In the current re- 
port, we describe the cDNA cloning, mRNA localization in the 
rat central nervous system, and pharmacological characteriza- 
tion of three additional rH3R splice variants (rH3D, rH3E, and 
rH3F) that differ from the previously published isoforms in that 
they result from an additional alternative-splicing event. These 
new H3R isoforms lack the seventh transmembrane (TM) helix 
and contain an alternative, putatively extracellular, C terminus 
(6TM-rH3 isoforms). After heterologous expression in COS-7 
cells, radioligand binding or functional responses upon the 
application of various H3R ligands could not be detected for the 
6TM-rH3 isoforms. In contrast to the rH3A receptor (rH3AR), 
detection of the rH3D isoform using hemagglutinin antibodies 
revealed that the rH3D isoform remains mainly intracellular. The 
expression of the rH3D_F splice variants, however, modulates 
the cell surface expression-levels and subsequent functional 
responses of the 7TM H3R isoforms. Coexpression of the rH3AR 
and the rH3D isoforms resulted In the intracellular retention of 
the rH3AR and reduced rH3AR functionality. Finally, we show 
that in rat brain, the H3R mRNA expression levels are modu- 
lated upon treatment with the convulsant pentylenetetrazole, 
suggesting that the rH3R isoforms described herein thus rep- 
resent a novel physiological mechanism for controlling the ac- 
tivity of the histaminergic system. 
Histamine receptors are members of the superfamily of 
seven transmembrane domain (7TM) G-protein-coupled re- 
ceptors (GPCRs). The histamine H3 receptor (H3R) was phar- 
macologically identified in 1983 and holds great promise as a 
target for the development of therapeutics for numerous dis- 
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orders, including obesity, epilepsy, and such cognitive dis- 
eases as attention deficit hyperactivity disorder and Alzhei- 
mer's disease (see Bakker, 2004; Leurs et al., 2005 for 
reviews). The cloning of the HgR cDNA allowed for the sub- 
sequent cloning of related sequences, including a variety of 
H3R isoforms from different species (for review, see Bakker, 
2004; Leurs et al., 2005). 
Alternative splicing of pre-mRNA represents a widespread 
mechanism for increasing the variability of eukaryotic gene 
expression by generating structurally distinct isoforms from 
a single gene. Alterations in the expression of GPCR isoforms 
could be associated with disease (Schmauss et al., 1993). 
Although al-AR adrenoceptors and dopamine receptors are 
prime examples of alternatively spliced GPCRs (Coge et al., 
ABBREVIATIONS: 7TM, seven transmembrane domain; GPCR, G-protein-coupled receptor; H3R, histamine H3 receptor, PTZ, pentylenetetrazole; 
HA, hemagglutinin; HEK, human embryonic kidney; GTPyS, guanosine 5'-0-(3-thio)triphosphate; APT, aminopotentidine; 125IPP, [1251]iodophen- 
propit; ELISA, enzyme-linked immunosorbent assay; FRET, fluorescence resonance energy transfer; BS3, bis(sulfosuccinimidyl)suberate; PCR, 
polymerase chain reaction; CREB, cAMP-responsive element-binding protein; tr-FRET, time-resolved fluorescence resonance energy transfer; ER, 
endoplasmic reticulum; 7TM-rH3R Isoforms, the rH3,,,, rH3R, and rH3C receptors; 6TM-rH3R Isoforms, the rH3D, rH3E, and rH3F isoforms. 
1194 
Discovery of Dominant-Negative Rat Histamine H3 Isoforms 1195 
1999; Kilpatrick et al., 1999; Hawrylyshyn et al., 2004), more 
and more GPCR splice variants are identified for other mem- 
bers of the GPCR superfamily. A variety of H3R isoforms 
from several species has been reported (for review, see Bak- 
ker, 2004; Leurs et al., 2005). In addition to the 445 amino 
acids containing rH3AR, two presumably nonfunctional trun- 
cated isoforms (reported as rH3T or rH3(nr1) and rH3(, )) (Drutel et al., 2001; Morisset et al., 2001) and three func- 
tional rH3R isoforms have been detected: rH3B, rH3C, and the 
rH3(41o) receptor, generated by deletions in the third intra- 
cellular loop of the rH3R of 32,48, and 35 amino acids, 
respectively. Because several H3R isoforms have been shown 
to possess specific pharmacological characteristics in terms 
of ligand-binding and initiation of signal-transductions 
events (Drutel et al., 2001), the H3R mRNA splicing can 
significantly affect cellular responses to histamine. A de- 
tailed understanding of the spectrum of H3R splice variants 
in different species is of importance not only for the under- 
standing of histaminergic system, but also for future drug 
development efforts. 
In the present study, we describe the identification of three 
additional 6TM-rH3 isoforms after an RT-PCR approach us- 
ing rat brain cDNA. Although the mRNA for these 6TM-rH3 
isoforms is detected in the rat brain, in attempting their 
characterization, we failed to detect radioligand binding us- 
ing Hall specific radioligands as well as functional effects 
upon heterologous expression in COS-7 cells. Coexpression of 
7TM-rH3Rs with the 6TM-rH3 isoforms, however, revealed 
that the 6TM-rH3 isoforms inhibit the cell surface trafficking 
and subsequent functional activity of the 7TM-rH3Rs. The 
regulation of the expression of the 6TM-rH3 isoforms may 
therefore represent a novel mechanism for the regulation of 
H3R functionality. To study possible in vivo functional rela- 
tionships between 7TM-rH3R and 6TM-rH3 isoforms, rela- 
tive expression levels were analyzed in a model of general- 
ized tonic-clonic seizures induced by pentylenetetrazole 
(PTZ). Data from a study on kainic acid-induced status epi- 
lepticus indicates that systemic kainic acid induces a direct 
or indirect selective increase in H3R isoforms with a full third 
intracellular loop in areas that suffer rapid neuronal damage 
(Lintunen et al., 2005). No data are currently available re- 
garding whether 7TM-rH3R and 6TM-rH3 isoforms are sim- 
ilarly regulated under pathophysiological conditions in the 
rat brain. The PTZ seizure model used in this study allows us 
to determine whether an H3R isoform-specific response oc- 
curs in a pathological setting. Our findings therefore uncover 
a new mechanism that may control the regulation of H3R 
activity in the brain. 
Materials and Methods 
Materials. Immepip, clobenpropit, and thioperamide were 
synthesized at the department of Medicinal Chemistry at the 
Vrije Univeristeit Amsterdam. Gifts of pcDEF3 (Dr. J. Langer, Rob- 
ert Wood Johnson Medical School, Piscataway, NJ), pTLN21CRE- 
Luc (Dr. W. Born, National Jewish Medical and Research Center, 
Denver, CO), and of the cDNAs encoding the PTX-insensitive mutant 
rat Gail, proteins Gai1C"1I, Gai2C352I, Ga sC351I, and Ga, C951I (Dr. G. Milligan, University of Glasgow, Glasgow, UK), the cDNA encod- 
ing the FLAG-tagged rHBAR (Dr. F. Coge, Institut de Recherches 
Servier, Croissy sur Seine, France), the cDNA encoding the human 
histamine H1 receptor (Dr. H. Fukui, University of Tokushima, To- 
kushima, Japan), the cDNA encoding the KSHV-GPCR ORF74 (Dr. 
T. Schwartz, University of Copenhagen, Copenhagen, Denmark), 
mianserin hydrochloride (Organon NV, The Netherlands), and the 
HA antibody and rhodamine-labeled secondary antibody (Dr. J. van 
Minnen, Vrije Universiteit, Amsterdam, The Netherlands), are 
greatly acknowledged. All other materials were from commercial 
suppliers. 
Constructs. The reverse transcription and PCR amplification for 
cloning of the rH3D-F (6TM-rH3) isoform cDNAs were performed as 
described previously (Drutel et al., 2001). The full-length cDNAs 
were isolated with primers overlapping the rat H3R cDNA sequence. 
The forward sequence included a Kozak sequence (underlined) (5'- 
CCGCCCA CCA TGG AGC GCG CGC CGC CCG ACG GGC TG-3'). 
The reverse sequence was based on cDNA for rat orphan GPCR 
(Genbank accession number AB015646) (5'-CTC TAC CCC ATA 
ACC ACC CAC C-3'). The use of these primers resulted in the 
amplification of at least three different products. After cloning in 
pCRII-TOPO, the cDNAs were sequenced on both DNA strands and 
subcloned in pcDNA3. The sequence of the identified rH3F isoform is 
identical to one of the sequences found in the GenBank database 
(accession number AB015646; GI: 6681587), the sequences of the 
rH3D and rH3a isoforms have been deposited in the GenBank data- 
base (accession numbers DQ112342 and DQ112343, respectively). 
The hydropathic profile of the IisD-F isoforms was analyzed using the 
TMHMM Server at the Center for Biological Sequence Analysis, 
Technical University of Denmark, DTU, Lyngby, Denmark (httpJ/ 
www. cbs. dtu. dk/services/TMHMM/). 
Construction of rH3R-Ga Protein Fusion Constructs. Fusion 
proteins between the rat H3R and PTX-insensitive mutant rat Ga- 
proteins of the G11, class were created by PCR using Turbo Pfu to 
remove the translation initiation codon from the Ga-protein cDNA 
sequence and the stop codon from the rH3AR cDNA sequence. 
HA-Tagging of the rH3R Isoforms. N-Terminal hemagglutinin 
(HA)-tagged expression constructs of the rH3AR and rH3D isoform 
were generated by PCR (5'-GCC ACC ATG GGC TAC CCA TAC GAC 
GTC CCA GAC TAC GCC GCG GAG CGC GCG CCG C-3') and 
cloned into pcDNA 3.1 (Invitrogen, Leek, The Netherlands). Con. 
struct integrity was verified by sequence analysis. 
Animals. The study was conducted in accordance with the Euro- 
pean Convention (1986) guidelines and approved by the local com- 
mittee for Animal Experiments and the Provincial State Office of 
Western Finland and the Animal Ethics Committee of Abo Akademi 
University. Male Sprague-Dawley rats (260-280 g) were given PTZ 
(50 mg/kg, i. p. ). Animals were stunned with CO2 and killed by 
decapitation 6h (PTZ, ne 3), 24 h (PTZ, n= 3), and 48 h (PTZ, n= 
3; saline control, n= 3) after injection. 
In Situ Hybridization Histochemistry. Probes were labeled 
with deoxy-(a-89PIATP (PerkinElmer Life and Analytical Sciences, 
Boston, MA) at their 3' ends using terminal deoxynucleotide trans. 
ferase (Promega, Madison, WI), and subsequent in situ hybridization 
histochemistry was performed essentially as described previously 
(Drutel et al., 2001). The following oligo-probe sequence was used for 
detecting HSDEF isoform mRNAs: 5'-AAG TTT CCC GAG GCG CTC 
GAC ACA GTA ATC GGG GAT GCA GCG GCC-3'. 
Image Analysis and Data Interpretation. Autoradiographic 
films were quantified by digitizing the film images using the MCID 
5+ image analysis system (Imaging Research, St. Catherines, ON, 
Canada) and by measuring gray scale pixel values. The relative optic 
density was converted to integrated optic density based on a curve 
derived from 14C standards exposed to films. Gray scale values were 
determined by using a total of four sections for each animal. 
Cell Culture and Transfection. African green monkey kidney 
COS-7 cells were maintained and transfected as described previously 
(Drutel et al., 2001; Bakker et al., 2004a). HEK 293 cells were 
cultures under similar conditions and transfected with cDNA encod. 
ing the rH3AR using the LipofectaminePlus method according to the 
manufacturer's protocols. 
Reporter-Gene Assay. H3R isoform-mediated modulation of 
CAMP mediated gene transcription activity was measured using the 
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luciferase reporter-gene plasmid pTLNC121-3 (2.5 µg/106 cells) con- 
taining 21 cAMP-responsive elements. Luminescence was assayed 
48 h after incubation of transfected cells with ligands as described 
previously (Bakker et al., 2004b). 
[US]GTPyS Binding Assays. Transfected COS-7 cells were re- 
suspended in 4°C binding buffer (20 mM HEPES, 3µM GDP, 10 mM 
MgCl, and 150 mM NaOH, pH 7.4). For measurement of agonist- 
stimulated GTPyS binding, 6 µg of the crude cell extract was incu- 
bated in binding buffer with ligands for 15 min at 30°C after which 
0.1 to 0.2 nM [36S]GTPyS (1250 Ci/mmol; PerkinElmer Life and 
Analytical Sciences) was added to make a final total volume of 100 
µl. Bound radioactivity was separated by filtration after 15 min 
through Whatman GF/C filters on a Brandel cell harvester using 4°C 
wash buffer (20 mM HEPES and 5 mM MgCl2, pH 7.4). Radioactivity 
retained on the filters was measured by liquid scintillation counting. 
Receptor Binding Studies. Radioligand binding studies for the 
H1R, H2R, and H3R using [3Hlmepyramine, [1251]aminopotentidine, 
and [N°-methyl. SH]histamine, respectively, were performed as de- 
scribed previously (Bakker et al., 2004b). The HsR radioligand 
binding studies using [12'I]iodophenpropit (125IPP) were carried out 
under the same experimental conditions as for [N°-methyl-sH]hista- 
mine. CXCL8 was labeled with 1251 using the Iodogen method 
(Pierce, Rockford, IL) and subsequently used in ORF74 radioligand 
binding studies as described previously (Smit et al., 2002). 
Detection of Tagged rH3Rs. In the enzyme-linked immu- 
nosorbent assays (ELISA), a mouse anti-HA monoclonal primary 
antibody was used as primary antibody, and a goat anti-mouse- 
horseradish peroxidase conjugate as secondary antibody for the 
detection of tagged rHeRs in transfected cells. The 3,3'-, 5,5'- 
tetramethylbenzidine liquid substrate system for ELISA was used 
as substrate and the optical density was measured at 450 nm 
using a Victor2 Wallac multilabel counter (PerkinElmer Life and 
Analytical Sciences). The same primary antibody was used for 
immunocytochemistry in conjunction with a secondary rhodamine 
labeled goat-anti-mouse antibody. Permeabilization of cells was 
achieved by an optional incubation of the cells for 5 min with 0.5% 
Nonidet P-40 in TBS before antibody application. For imaging, 
coverslips were mounted in 90% glycerol containing 0.02 M Tris- 
IHCI, pH 8.0,0.002% NaNs, and 2% 1,4-diazabicyclo-(2,2,2)-octane 
(Merck, Darmstadt, Germany). 
Time-Resolved FRET. The time-resolved fluorescence reso- 
nance energy transfer (FRET) experiments were conducted essen- 
tially as described previously (Bakker et al., 2004a). Energy transfer 
was measured by exciting the Eus+ at 320 nm and monitoring the 
allophycocyanin emission for 1 ms at 665 nm using a Novostar (BMG 
LABTECH GmbH, Offenburg, Germany) configured for time-re- 
solved fluorescence after a 50-µs delay. 
Cross-Linking and Immunoblotting of rHgA Receptors. Cells 
were harvested by centrifugation, and the resulting pellet was re- 
suspended in 150 µl of cross-linking buffer (150 mM NaCl, 100 mM 
Na-HEPES, 5 mM EDTA, p11 7.5, and 5 mM DTT) to give a final 
protein concentration of approximately 0.5 mg/ml. The samples were 
incubated at room temperature with continual mixing for 12 min 
with either a 0.12 mM or a 0.25 mM concentration of the cell per- 
meable cross-linker bis(sulfosuccinimidyl)suberate (BS3), after 
which the cross-linking mixture was removed by centrifugation and 
the resultant pellet was used for immunoblotting as described pre- 
viously (Chazot et al., 2001). Immunoblots were probed either with 
anti-Hac 188-197Cys antibody (Shenton et al., 2005) at a 0.2 µg/ml, 
or with an anti-H3 329-358 antibody used at a final protein concen- 
tration of 1.6 µg/ml (Chazot et al., 2001). 
Analytical Methods. All data shown are expressed as mean 
S. E. M. Data from radioligand binding assays and functional assays 
data were evaluated by a nonlinear, least-squares curve-fitting pro- 
cedure using Prism (GraphPad Software, Inc., San Diego, CA). 
Results 
Cloning of cDNAs Encoding Additional Rat H3R Isoforms 
The existence of additional H3R isoforms was investigated 
by RT-PCR analysis of rat whole-brain total RNA using spe- 
cific primers 1 and 2 (see Materials and Methods), and re- 
vealed the existence of three previously uncharacterized full- 
length cDNAs with putative corresponding proteins of 497 
(rH3D), 465 (rH3E), and 449 (rH3F) amino acids. The amino 
acid sequence of the rH3F isoform corresponds to one of the 
sequences found in the GenBank database (accession number 
AB015646; GI: 6681587). These three new rH3 isoforms cor- 
respond in a large part to the sequences of rat histamine H3R 
isoforms A, B, and C (rH3AR, rH3BR, and rH3CR, respec- 
tively) and exhibit exactly the same differences in length for 
the third intracellular loop (Fig. W. This insertion in the 
third intracellular loop in the rH3D, rH3E, and rH3F isoforms 
seems to be created by a retention/deletion system already 
described for the third intracellular loop (Coge et al., 2001; 
Drutel et al., 2001; Morisset et al., 2001). However, the rH3D, 
rH3Ei and rH3F. isoforms differ from the rHSAR, rH$8R, and 
rH3CR in their C-terminal region, in which the last C-termi- 
nal 53 amino acids, which correspond to the seventh trans- 
membrane-domain and carboxyl terminus of the rH3AR, 
rH3BR, and rH3CR proteins, are replaced by a sequence of 
105 amino acids that do not share any homology with the last 
53 C-terminal amino acids of the rH3AR, rH3BR, and rH3CR. 
Sequence analysis of the rH3R gene indicates that the alter- 
native C-terminal domain that is found in the rH3D_F 'So' 
forms is due to a change in the open reading frame upon 
alternative splicing using previously unidentified exon/in- 
tron junctions present within the rH3R gene (see Fig. 1B). 
Analysis of the hydropathic profile of the rH3D, rH3E, and 
rH3F isoforms does not reveal a clear putative seven trans- 
membrane domain (Fig. 2, A and B). Therefore, the rH3D, 
rH3E, and rH3F isoforms are predicted to possess only six 
transmembrane domains 6TM-rH3 isoforms) and an extra- 
cellular C-teriminal domain (Fig. 2, C and D). 
Heterologous Expression of Epitope-Tagged rH3R Iso- 
forms. We have successfully characterized the rH3AR, rH3BR, 
and rH3CR using COS-7 cells heterologously expressing these 
receptors (Drutel et al., 2001). We therefore used the same 
approach in this study to characterize the three additional 
6TM-rH3 isoforms described herein. To evaluate the cell surface 
expression of the 6TM-rH3 isoforms, we generated the cDNAs 
coding for the N-terminally HA-tagged rH3AR (HA-rH3AR) and 
the N-terminally HA-tagged rH3D (HA-rH3D) isoform by PCR. 
Although we detected clear immunological evidence for the cell 
surface expression of the HA-rH3AR with the use of an ELISA 
assay using anti HA-antibodies on intact cells, we can hardly 
detect the HA-rH3D isoforms on the cell surface on intact cells 
(Fig. 2E). We observe, however, a clear immunofluorescent sig- 
nal upon permeabilization of cells expressing the HA-rH3D iso- 
form (Fig. 2E), indicating successful synthesis of the HA-tagged 
rH3D isoform protein and retention of the HA-tagged rH3D 
isoform inside the cell. There is an apparent difference in de- 
tection of the HA-rH3D isoform versus the HA-rH3AR, which 
might indicate differences in, for example, the rate of synthesis, 
the inherent stability, or the rate of degradation of the H3 
isoforms, but we have not pursued this issue further. To eval- 
uate the plasma membrane localization of the HA-rH3AR and 
the HA-rH3D isoform, we subsequently performed immunocy- 
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Fig. 1. Sequence alignment of r113R isoforms and genomic organization of the rH3R gene. A, amino acid sequence alignment of various rH3R, 
isoforms. 
The r1138R and rH3CR isoforms exhibit amino acid deletions in the third intracellular loop of the rIl3R protein compared with the 
full-length rH3AR. 
The rH3D, rII3E, and r113y isoforms differ from the r1I3AR, rH3BR, and rH3CR isoforms, respectively, in an alternative C-terminal 
domain as a result 
of an additional splicing event. Indicated above the amino acids are the seven transmembrane domains as they are found for the rH3AR, rH3BR, and 
rIi, cR isoforms (TM1 through TM7), li, diagram of the exon/intron structure of the rat 
H3R gene on chromosome 3 (Genbank accession number 
NM_053506.1; GI: 16758263) and the resulting amino acid (aa) sequences found in rH3R-C receptors and rlI3D. E isoforms generated 
by retention/ 
deletion of the pseudointrons. The exon/intron junctions within the rH3R gene are indicated in bold (GT and AG), whereas the codon that corresponds 
to the cysteine (C) found in the rH3D. r isoforms (formed by IG and T) is underlined. For simplicity, only part of 
the exon/ntron structure of the rat 
113a gene and of the rH3R gene sequence is shown (indicated by //). See Morisset et al. (2001) for an overview of the exon/intron structure of the rH3R 
gene corresponding to the two presumably nonfunctional H3R isoforms, H&anº and and the four previously described functional shorter 
isoforms, rH313 (rH&, 13)), rH&a,, ), and rH3C (rH&3, n, ). 
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tochemistry studies using rhodamine labeled anti-HA antibod- 
ies. Plasma membrane localization of the rhodamine-derived 
fluorescence was easily detected using cells expressing HA- 
rH3ARs in intact cells (Fig. 2F, top left) and only a limited 
intracellular fluorescence was observed in Nonidet P40-perme- 
abilized cells (Fig. 2F, top right). In contrast, corroborating the 
findings obtained by the ELISA studies, using cells transfected 
with cDNA encoding the HA-rH3D isoform, appreciable rho- 
damine-derived fluorescence is detected only in permeabilized 
cells (Fig. 2F, bottom right) and not on intact cells (Fig. 2F, 
bottom left). Moreover, no plasma membrane localization of the 
rhodamine-derived fluorescence was detected using permeabil- 
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Fig. 2. Topology of the rH3R isoforms. Prediction of the topology of the 
rH3AR (A) versus the rH, t, R (B), as predicted 
by the TMHMM Server at 
the Center for Biological Sequence Analysis, Technical University of 
Denmark, DTU (http: //www. cbs. dtu. dk/servicesiTMHMM/). Indicated by 
the solid line are the probabilities for localization on the extracellular side 
(outside); the probabilities of localization on the intracellular side (inside) 
are indicated by the dotted lines. The probability for transmembrane 
(TM) domains are indicated by the filled areas. From these two plots, it 
can be deduced that seven TM domains are predicted for the rH3AR, 
whereas for the rH3DR, only six TM domains are predicted, as indicated 
above the graphs. C, graphical representation of the topology of the rH3R, 
rH3E, and rH3c receptors, versus the rH3D, rH3E, and rH3F isoforms (D). 
In contrast to the rH3A, rH3E, and rH3c receptors, the rH3D, rH3E, and 
rH3F isoforms are predicted to possess an extracellular C-terminal do- 
main. Also indicated in C and D are the variations in the third intracel- 
lular loop between the isoforms. E and F, immunological detection of 
N-terminally HA-tagged rH3ARs (HA-rH3A) and the N-terminally HA- 
tagged rH3D isoform (HA-rH3D) on transfected COS-7 cells. E, Detection 
of HA-rH3ARs and the HA-rH3D isoform in intact cells versus cells that 
have been permeabilized using 0.5% Nonidet P-40 in an ELISA assay. F, 
immunocytochemical detection of HA-tagged rH3R isoforms using a rho- 
damine conjugated antibody directed against the HA-tag. Detection of 
HA-rH3ARs on intact COS-7 cells (top left) and in permeabilized cells (top 
right). Detection of the HA-rH3D isoform on intact cells (bottom left) and 
in permeabilized cells (bottom right). 
*K, . ... .. 
, Hn ...... 
iNif . .. 
ized HA-rH3D isoform-expressing cells. These data indicate an 
intracellular localization for the HA-rH3D isoform. 
Are the 6TM-rH3 Isoforms Functional H3Rs? 
Radioligand Binding Studies. To evaluate whether the 
identified mRNA species for the 6TM-rH3 isoforms code for 
functional H3Rs, we transfected COS-7 cells with the cDNA 
encoding either the rH3AR or one of the 6TM-rH3 isoforms 
and evaluated corresponding membrane preparations for 
their ability to bind either the inverse H3R agonist radioli- 
gand 125IPP or the H3R agonist radioligand [NT'-methyl- 
3H]histamine. Cell homogenates derived from cells express- 
ing the rH3AR bind 125IPP with high affinity (K, - 2.1 nM, 
B,,,, 
_ = 
2.5 pmol/mg of protein) and exhibits the expected 
affinities for IPP, immepip, and thioperamide (pKb for 
'25IPP, 8.2 ± 0.1; pK, values for immepip and thioperamide, 
6.5 ± 0.2 and 7.7 ± 0.1, respectively). In contrast, we failed 
to detect specific 1251PP-binding to cells transfected with 
cDNAs coding for any of the 6TM-rH3 isoforms (Fig. W. 
Likewise, we did not detect [IT'-methyl-'H] histamine bind- 
ing to membranes of cells transfected with cDNAs encoding 
the 6TM-rH3 isoforms (data not shown). 
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Fig. 3. Functional analysis of the rH3AR and the rH3C isoform upon 
transient transfection of their corresponding cDNAs in COS-7 cells. A, 
transfection of cells with rH3AR coding cDNA (pcDEF,, rH., AR; 
5 mg/108 
cells) resulted in the expression of 126IPP binding sites, whereas no 
specific "RIPP binding was detected to membrane fractions of cells trans- 
fected with an equal amount of cDNA coding for either the rH3D, rH1E, or 
rH3F isoform, B, dose-dependent modulation of 10 mM forskolin induced 
responses by histamine, immepip, and R(a)-methylhistamine using 
COS-7 cells cotransfected with 5 mg/106 cells of both pcDEF3rH3AR and a 
CREB-responsive firefly-luciferase reporter gene (pTLNC121CRE). C, 
modulation of forskolin (10 mM) induced responses by 10 mM histamine, 
R(a)-methylhistamine (RaMH), and thioperamide using cells transfected 
with both pcDEF3rH3AR and pTLNC121CRE. The forskolin-induced re- 
sponses are set to 100% as indicated by "control". D, effects of 10 mM 
R(a)-methylhistamine on forskolin (10 mM) induced responses using cells 
cotransfected with either pcDEF3rH3AR, pcDEF;, rH3D, pcDEF3rH3E, or 
pcDEF3rH3F, and pTLN121CRE. The forskolin induced responses are set 
to 100% as indicated by the dashed line. 
Ii 
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Functional Assays. The H3R couples to members of the 
G,, 
a 
family of G-proteins to inhibit adenylyl cyclase activity 
and subsequently inhibits the formation of intracellular 
cAMP (Leurs et al., 2005). Cotransfection of COS-7 cells with 
the rH3AR encoding cDNA together with pTLN121CRE, a 
cAMP-responsive element-binding protein (CREB)-respon- 
sive firefly-luciferase reporter gene, allowed us to monitor 
H3R-induced modulation of forskolin-induced reporter-gene 
expression. In concert with the G;,,. -coupled nature of the 
H3R (see Leurs et al., 2005), treatment of cotransfected cells 
with varying concentrations of the H3R agonists immepip, 
R(a)-methylhistamine, and histamine results in the dose- 
dependent inhibition of 10 mM forskolin-induced firefly-lu- 
ciferase expression by approximately 60% with EC50 values 
of approximately 2,7, and 43 nM, respectively (Fig. 3B), in 
rH3AR-expressing cells. Under these assay conditions, we do 
not observe constitutive activity for the rH3AR because the 
inverse H3R agonist thioperamide (Leurs et al., 2005) is 
without effect on the forskolin-induced luciferase expression 
(Fig. 3C). Although 1 mM R(a)-methylhistamine potently 
induces signaling via the rH3AR, under the same assay con- 
ditions, R(a)-methylhistamine is without effect on the fors- 
kolin-induced firefly-luciferase expression in cells cotrans- 
fected with cDNAs encoding the reporter gene and either of 
the 6TM-rH3 isoforms (Fig. 3D). 
Is There a Role for the 6TM-rH3 Isoforms? 
Detection of Epitope-Tagged rH3R Isoforms in Coex- 
pression Studies. The immunological and immunocyto- 
chemistry data obtained with the N-terminally HA-tagged 
HA-rH3D isoform indicates poor plasma membrane expres- 
sion of the rH3D isoform (Fig. 2, E and F). In addition, in cells 
transfected with cDNA encoding either of the 6TM-rH3 iso- 
forms we have been unable to detect 1) specific 125IPP or 
[N"-methyl-3H]histamine binding (Fig. 3A) and 2) modula- 
tion of forskolin-induced transcriptional events that are oth- 
erwise modulated by rH3AR activation under the same con- 
ditions. In recent years, accumulating evidence suggests that 
some GPCRs (e. g., the GABAB receptors (White et al., 1998) 
and odorant receptors (Hague et al., 2004a)] require partic- 
ular protein-protein interactions to allow proper plasma 
membrane expression. It seems that the 6TM-rH3 isoforms 
are retained intracellularly; we postulated, therefore, that 
the additional expression of GPCRs might aid the cell surface 
expression of the 6TM-rH3 isoforms. Conversely, the 6TM- 
rH3 isoforms may possibly retain the coexpressed GPCRs 
intracellularly by acting as dominant-negative isoforms. 
Do the 6TM-rH3 Isoforms Interfere with Cell Surface 
Expression of 7TM-rH3Rs? We cotransfected COS-7 cells 
with the cDNAs coding for the HA-rH3AR and the rH3D 
isoform. Similar to the effects of coexpression of alternative 
splice variants of human «lA-adrenoceptors (Coge et al., 
1999), we found that the coexpression of the rH3D isoform 
reduced the expression of the HA-rH3AR at the plasma mem- 
brane. This phenomenon is observed using either an ELISA 
assay on intact cells or by applying immunocytochemistry 
techniques using a rhodamine labeled anti-HA antibody (Fig. 
4, A and B, respectively). 
Evaluation of Ligand-Binding Sites upon Coexpres. 
sion of 7TM-H3R and 6TM-rH3 Isoforms. To evaluate 
whether the loss of HA-rH3AR-derived immunofluorescence 
at the cell surface upon coexpression of the rH3D isoform also 
results in a loss of ligand binding sites for H. 1R ligands we 
performed radioligand binding assays. As shown in Fig. 3A, 
125IPP binding sites are detected upon the expression of 
7TM-rH3Rs (Drutel et al., 2001), such as the rH3AR, whereas 
expression of the 6TM-rH3 isoforms does not result in the 
formation of 125IPP binding sites. 
The transfection of 0.25 mg/106 cells of cDNA coding for the 
rH3AR resulted in the expression of 2.5 pmol/mg of protein 
125IPP binding sites. Coexpression of the rH3AR together 
with the rH3D isoform, however, resulted in an rH3D-isoform 
gene-dosage-dependent reduction of rH3AR-derived 125ipp 
binding sites (Fig. 5A); the remaining 125IPP binding sites 
exhibit a pharmacological indistinguishable from that of the 
rH3AR (pKb for 125IPP, 8.1 ' 0.1; pK; values for immepip and 
thioperamide, 6.9 ± 0.2 and 7.6 ± 0.1, respectively). The 
coexpression of the rH3E or rH3F isoform together with the 
rH3AR resulted in a similar reduction of 125IPP binding sites 
(Fig. 5, B and C, respectively), indicating that the 6TM-rH3 
isoforms interfere with the expression of the rH3AR. The 
maximal inhibition of 125IPP binding sites (as evaluated by a 
transfection of cells with an rH3AR16TM-rH3 isoform cDNA 
ratio of 1: 10) is -50 to 75% (Fig. 5, A-C). To evaluate 
whether the observed inhibition of 125IPP binding-site ex- 
pression is specific for the 6TM-rH3 isoforms, we performed 
additional experiments in which we cotransfected cells with 
the same amount of rH3AR cDNA in combination with vari- 
ous amounts of cDNA encoding the human histamine H, 
receptor (hH1R) (Fig. 5D). Although the transfection of 
COS-7 cells with the hH1R cDNA resulted in the formation of 
binding-sites for the H1R radioligand [3H]mepyramine with 
pharmacological characteristics of the hH1R (data not 
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Fig. 4. Immunological dial ction of N-terminally I IA-tnggcd rII, Rs (IiA- 
rH3A) on COS-7 cells cotransfected with cDNA coding for IIA-rli, A recep- 
tors and the N-terminally HA-tagged rH3D isoform (HA-rH3D). A, effects 
of the cotransfection of pcDEF, rH3D on the detection of HA-rH3ARs on 
intact cells using an ELISA assay. B, immunocytochemical detection of 
HA-rH. 
ARs using a rhodamine conjugated antibody 
directed against the 
HA-tag. Detection of HA-rH, ARs on 
intact COS-7 cells (top left) and in 
permeabilized cells (top right), and effects of cotransfection cells with 
both pcDEF3-HA-rH3A and pcDEF3rH3D on the detection of the HA- 
rH3ARs on intact cells (bottom left) and in permeabilized cells (bottom 
right). Control slides of cells transfected with N-terminally HA-epitope 
tagged H3 isoforms that did not receive the primary antibody or of 
untransfected cells showed no appreciable staining. 
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shown), no specific 12. IPP binding was detected in hH1R- 
expressing cells (Fig. 5D). Cotransfection of cells with cDNAs 
encoding both the rH3AR and the hH1R, however, did not 
influence the formation of 1281PP binding sites. 
Similar to the findings with the hH1R, expression of the rat 
H2R (rH2R) or the viral chemokine receptor from Karposi's 
sarcoma herpes virus KSHV-GPCR (also known as 0RF74) 
in COS-7 cells resulted in the formation of binding sites for 
the H2R radioligand 125IAPT and 1251-CXCL8, a radioligand 
for 0RF74, respectively, but not in the formation of 125IPP 
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binding sites. Coexpression of the rH3AR with either the 
rH2R or ORF74, however, did not affect the formation of 
rH3AR-derived 126IPP binding sites (Fig. 5E). 
We also evaluated the effects of the coexpression of the 
rH3BR and rH3cR with the rHE and rHF, isoforms, respec- 
tively, on the formation of 1251PP binding sites. Similar to the 
expression of the rH3AR, expression of the rH3BR or rHscR in 
COS-7 cells results in the formation of 1251PP binding sites 
(Drutel et al., 2001). Coexpression of the rH3IIR or rH3CR 
together with either the rH3E or rH3F isoform resulted in an 
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Fig. 5. Effects of cotransfection of cDNA coding for rH3R 
isoforms on the expression of 37'IPP binding sites. Evalu- 
ation of the effects of cotransfection of either 0.25 mg/10s 
cells of pcDEF3rH3AR (A, B, C, D, and E), pcDEF3rH88R 
(F), or pcDEF3rH3CR (G) together with varying amounts 
(0-2.5 mg/106 cells) of either pcDEF3rH3D (A), pcDEF3rH3E 
(B and F), pcDEF3rH3F (C and G), pcDEF3hH1 (D), 
pcDEF3rH2R (E), or pcDEF3ORF74 (E) on the relative 
number of expressed'21IPP binding sites. H, evaluation of 
the effects of cotransfection of pcDEF3rH3AR (0.25 mg/10° 
cells) together with 2.5 mg/101 cells of either pcDEF3rH3D 
(0) or pcDEF3hH1 (") on the ability of IPP to displace 
16IPP bound to expressed 125IPP binding sites (homolo- 
gous displacement). Also shown in E are the effects of the 
transfection of 2.5 mg/106 cells of either pcDEF3rH3AR, 
pcDEF3rH2R, pcDEF3ORF74, or pcDEF3rH3D alone on the 
expression of IPP binding sites. The proper expression in 
COS-7 cells of the hH1R, the rHR, and ORF74 was con- 
firmed using [3H]mepyramine, ['I]iodoaminopotentidine, 
and 12I-CXCL8 binding assays, respectively (data not 
shown). In each condition, the total amount of cDNA has 
been kept constant using pcDEF3. 
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rH35 isoform and rH3N. isoform gene-dosage dependent re- 
duction of rH3BR-derived (Fig. 5F) and rH3CR-derived (Fig. 
5G) 125IPP binding sites, respectively. The maximal inhibi- 
tion of 125IPP binding sites, as evaluated by a transfection of 
cells with an rH3BR or rH3CR-to-6TM-rHg isoform cDNA 
ratio of 1: 10 is -50 to 75% (Fig. 5, F and G), similar to our 
findings on the coexpression of the rH3AR with the 6TM-rH3 
isoforms (Fig, 5, A-C). 
Although the coexpression of the rH3AR with the rH3D 
isoform inhibits the formation of 125IPP binding sites, the 
remaining 125IPP binding sites exhibit unchanged pharma- 
cological characteristics of the rH3AR, as evidenced by its 
unchanged affinity for IPP (Fig. 5H). Taken together, these 
radioligand-binding data clearly demonstrate that the ex- 
pression of the 6TM-rH3 isoforms selectively interferes with 
the expression of the 7TM-rH3Rs. 
Evaluation of H3R Ligand-Induced [35S]GTPyS Binding 
upon Coexpression of 7TM-H3R and 6TM-rH3 Isoforms 
Creation of rH3AR Ga Fusion Proteins. Because we 
failed to detect H3R-agonist mediated [98S]GTPyS binding to 
activated Ga proteins in cell membranes derived from 6TM- 
rH3 isoform expressing cells (data not shown), we chose to 
evaluate H3R-agonist induced [3bS]GTPyS binding to assess 
the effects of the coexpression of 6TM-rH3 isoforms on the 
functionality of 7TM-rH3Rs. To assess the effects of the co- 
expression of 6TM-rH3 isoforms on the functionality of 
7TM-rH3Rs, we chose to evaluate H3R-agonist induced 
[3bS]GTPyS binding to activated Ga proteins. To increase the 
sensitivity of this assay (Milligan, 2000), we created fusion 
proteins consisting of the rH3AR fused to one of the PTX- 
insensitive mutant rat Ga; /,, proteins: Gai1C351I, Gai2C352I, 
Ga; 3C351I, or Ga0C3S1I (creating rHgAR-Gao1C3b1I, rH3AR- 
Ga11C3b1I, rH3AR-Gai2C112I, and rHgAR-Gai3CS51I, respec- 
tively) by PCR according to Materials and Methods. 
Characterization of rH3AR. Ga fusion proteins-the 
four different rHgAR fusion proteins rHgAR-Gao1C351I, 
rH3AR-Gai1C351I, rH3AR-Gai2C352I, and rHgAR-Gai3C351I- 
were subsequently characterized by 125IPP binding assays 
upon their heterologous expression in COS-7 cells. Based on 
these studies (data not shown), we decided to continue our 
experiments using the rHgAR-Gao1C351I fusion protein as 
this fusion protein exhibited a pKb value for 125IPP of 8.4 t 
0.2 that corresponds to the obtained pKb value of 125IPP for 
the wild-type rH3AR of 8.2 t 0.1. In addition, the affinities of 
the wild-type rH3AR and the rH3AR-Gao1C351I fusion protein 
for the H3R agonist immepip and the inverse H3R agonist 
thioperamide are similar (6.5 t 0.2 and 7.7 ± 0.1 versus 
6.9 t 0.1 and 7.9 t 0.1, respectively). 
Subsequently, we compared the capability of the rH3AR- 
Gao1C$b1I fusion protein to mediate the inhibition of 10 mM 
forskolin-induced activation of cAMP response element-me- 
diated gene transcription in COS-7 cells. We found the 
rH3AR-Gao1C351I fusion protein to potently inhibit the fors- 
kolin-induced response upon activation with H3R agonists. In 
concert with our findings on the wild-type rH3AR, treatment 
of cells cotransfected with cDNAs encoding the rH3AR- 
Gao1C351I fusion protein and the cAMP response element- 
reporter gene with varying concentrations of the H3R ago- 
nists immepip, R(a)-methylhistamine, and histamine results 
in the dose-dependent inhibition of 10 mM forskolin-induced 
firefly luciferase expression by approximately 40% with EC50 
values of approximately 4,30, and 76 nM, respectively (Fig. 
6A). These data indicate that the rH3AR-Gao1C351I fusion 
protein is fully functional and shows an rH9AR pharma- 
cology. 
Coexpression of rIISAR-Gao1C381I Fusion Proteins 
and the r113D Isoform. Consistent with our findings on the 
coexpression of 7TM-rH3ARs with the 6TM-rH3 isoforms (see 
Fig. 5), coexpression of the rH9AR-Gao1C361I fusion protein 
together with the rHBD isoform, results in an rH3D-isoform 
gene-dosage dependent reduction of rH3AR-Gao1C361I fusion 
protein-derived 126IPP binding sites (Fig. 6B), and the re- 
maining 12. IPP binding sites exhibit an rH3AR-Gao1C351I- 
like pharmacological profile (pKb for 126IPP, 8.5 *_' 0.1; pKK 
values for immepip and thioperamide, 7.0 ± 0.2 and 7.6 ± 
0.1, respectively). The maximal inhibition of rH3AR- 
Gao1C361I-derived 126IPP binding sites, as evaluated by a 
transfection of cells with an rH3AR-Gaol/rH3D isoform cDNA 
ratio of 1: 10 is -65% (Fig. 6B). 
We subsequently assessed the influence of coexpression of 
the rH3D isoform on the (35S]GTPyS binding induced by 
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Fig. 6. Effects of cotransfection of the rli, D isoform on the function of the 
rH, AR. A, dose-dependent modulation of 
10 mM forskolin induced re- 
sponses by histamine, immepip, and R(a)-methylhistamine using PTX- 
treated (100 ng/ml) COS-7 cells cotransfected with 5 mg/10e cells of both 
pcDEF, rH, AR-GaoiC361I and a CREB-responsive 
firefly-luciferase re- 
porter gene (pTLNC121CRE). B. evaluation of the effects of cotransfec- 
tion of 0.25 mg/106 cells of pcDEF3rH3AR-Ga0IC351I together with varying 
amounts of pcDEF, rH, D (0-2.5 mg/106 cells) on the relative number of 
expressed 146IPP binding sites. C, effects of the cotransfection of 0.25 
mg/106 cells pcDEF, rHIR and 2.5 mg/10° cells pcDEF rH3D on 
[36S]GTPyS binding to the PTX-insensitive mutant Gao1C361I protein 
fused to the C-terminal domain of the rH3AR (rH3AR-GaOIC351I fusion 
protein). Shown are the effects of cotransfection of pcDEF, r113D on the 
113R agonist immepip (1 mM)-induced [36S]GTPyS binding to the rH, AR. 
Ga. IC 81I fusion protein in PTX. treated cells 
(100 ng/ml), and the effects 
of the inverse H, R agonist thioperamide (1 mM) on the 1 mM immepip- 
induced [36S]GTPyS binding. Shown are the averages of three indepen- 
dent experiments. 
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agonist-mediated activation of coexpressed rH3AR-GaO1C35'I 
fusion proteins. The H3R agonist immepip (1 mM) resulted in 
a robust stimulation of [35S]GTPyS binding in rH3AR- 
Ga 1C351I expressing cells that was inhibited by coincuba- 
tion with a1 mM concentration of the inverse H3R agonist 
thioperamide (Fig. 6C). Under the assay conditions used, we 
could not detect significant thioperamide-mediated inhibi- 
tion of basal rH3AR-Gai1C351I mediated [`35S]GTPyS binding, 
indicating that we could not detect constitutive rH3AR- 
Gar1C381I activity. The 1 mM immepip-induced [35S]GTPyS 
binding was inhibited by 70% by coexpression of the rH. 1AR- 
Gao1C351I fusion protein with the rH3D isoform (Fig. 6C). The 
6TM-rH3 isoforms themselves did not mediate changes in 
[35S]GTPyS binding upon incubation with H3R ligands (data 
not shown). 
Can rH3Rs Form Homo-Oligomers? In view of the 
emerging concept of GPCR dimerization that is now well 
documented in literature (for review, see, for example, 
Pfleger and Eidne, 2005), we speculated that the 6TM-rH3 
isoforms might interfere with the cell surface expression of 
7TM-rH3 receptors through dimerization. 
We have described the generation of anti-rH3,268-277Cys 
antibodies (Shenton et al., 2005), which, based on immuno- 
blotting, selectively recognize both the rH3AR and rH3CR 
isoform, but not the rH3BR isoform expressed in HEK 293 
cells. Wild-type rH3AR-expressing cells were collected and 
subjected to cross-linking with varying amounts of the cell 
permeable cross-linker bis(sulfosuccinimidyl)suberate (BS3) 
before resolving the samples using SDS-PAGE. Immunoblot- 
ting with anti-H3C 268-277Cys antibody yielded three major 
protein species (Mr 90,000,135,000, and -200,000, respec- 
tively), corresponding well to putative dimeric, trimeric and 
tetrameric rH3AR oligomers, respectively (Fig. 7, lanes 1-3). 
Performing similar experiments using native rat brain tis- 
sue, the major species observed is a coincident Mr 90,000 
species (Fig. 7, lane 4). It is noteworthy that a recombinant 
putative monomeric Mr 47,000 species was clearly observed, 
which was barely detectable in the native forebrain prepara- 
tion. Higher cross-linker concentrations yielded >200,000 
species for both recombinant and native H3R preparations 
(Shenton et al., 2005). 
We have successfully used the time-resolved FRET (tr- 
FRET) fluorescence (665-nm emission after excitation at 320 
nm) for the detection of hH1R dimerization using epitope- 
tagged hH1Rs and fluorescently labeled antibodies recogniz- 
ing the N-terminally epitope-tagged receptors (Bakker et al., 
2004a). We have used this approach to confirm the formation 
of oligomerization of rH3Rs. 
tr-FRET fluorescence results obtained with the different 
samples are shown in Fig. 7B. A clear specific tr-FRET signal 
is observed using live cells expressing the HA-rH3ARs. The 
data are presented as the tr-FRET that is observed using 
HA-rH3AR-expressing cells that have been incubated with 
both anti-HA-E u3+ and anti-HA-allophycocyanin antibodies 
versus the tr-FRET that is observed using a mix of two 
populations of HA-rH3AR-expressing cells that before mixing 
were independently incubated with either of the two antibod- 
ies. The increased tr-FRET signal can only be explained by 
the resonance energy transfer from anti-HA-Eu 3+ antibodies 
bound to HA-rH3ARs to anti-HA-allophycocyanin antibodies 
bound to HA-rH3ARs, indicative of the formation of rH3AR 
multimers in living cells. 
Modulation of rHsnu and rH,,,,,; Isoform-Specific 
mRNAs in Rat Brain after Delivery of a Systemic Con- 
vulsant. We have successfully used specific oligonucleotide 
probes to characterize the 7TM-rH, R mRNA expression in 
the rat brain (Drutel et al., 2001). To evaluate the CNS 
expression of the 6TM-rH3 isoforms, we have designed do- 
main specific probes. We have used one probe specific for the 
C terminus present in the 6TM-rH3 isoforms, and, for com- 
parison, we have also performed studies using a oligonucle- 
otide probe specific for the (full-length) third intracellular 
loop of the rH3AR, which is also present in the rH3n isoform 
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Fig. 7. Detection of oligomerization of heterologous and native rH3ARs, A, 
biochemical evidence for rH3AR oligomers. Membranes derived from ei- 
ther cells heterologously expressing rH3ARs or from native rat forebrain 
membranes were analyzed by immunoblotting (lanes 1-3 and 4, respec- 
tively) as described under Materials and Methods. In addition, samples of 
membranes expressing rH;, ARs were subjected 
to chemical cross-linking 
with either 0.12 mM or 0.25 mM BS3 (lanes 2 and 3, respectively) 
before 
immunoblotting. Lanes 1 to 3 were subsequently probed with rabbit 
anti-H3,. 268-277Cys antibody (0.2 ug/ml), and 
lane 4 was probed with 
rabbit anti-H3 349-358 antibody (1.5 µg/ml). 
The immunoblot is repre- 
sentative of at least three separate experiments. 
The molecular mass 
standards are displayed on the left and are indicated 
in kilodaltons. B, 
detection of dimeric rH., ARs 
by Ir-FRET. Upon measuring fluorescence 
emission at 665 nm, after excitation at 337 nm, it-FRET signals are seen 
using live cells expressing HA-rH3ARs, because of the resonance energy 
transfer of specific HA-rH3ARs bound to anti-HA-Eu' antibody to the 
specific HA-rH3ARs bound to anti -HA-allophycocyanin antibody. tr-FRET 
signals were seen only using membranes of 
HA-rH3AR expressing cells 
that were coincubated with both the anti-HA-Eu3` 
(Eu3') antibody and 
the anti-HA-allophycocyanin (XL665) antibody (Eu3' + 
XL665). Mixing 
of two populations of cells expressing HA-rH3AR8 
independently incu- 
bated with either anti-HA-Eu: " or anti-HA-allophycocyanin antibodies 
resulted in a reduced tr-FRET signal. Data are plotted as the tr-FRET 
that is observed using HA-rH3AR expressing cells that 
have been incu- 
bated with both anti-HA-Eu3' and anti-HA-allophycocyanin antibodies 
versus the Ir-FRET that is observed using a mix of two populations of 
HA-rH3AR expressing cells that before mixing were 
independently incu- 
bated with either of the two antibodies. 
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(but not any of the other rH3 isoforms identified to date; 
Fig. 8A). 
Significant increases in mRNA expression levels of H3R 
isoforms with full-length third intracellular loop (detected 
using probe H3AD) were observed in layers II-Vlb of cortex 
(48 h after injection), caudate putamen (48 h after injection), 
piriform cortex (48 h after injection), and CAI region of the 
hippocampus (24 h after injection) (Fig. 8B) after PTZ. Figure 
8C illustrates mRNA expression levels and differences for 
H3A and H3D isoforms in representative sections from control 
and 48 h after injection animals. 
In contrast, decreases in mRNA expression pattern of 
6TM-rH3 isoforms (detected using probe H. DFF) were ob- 
served in layers II-VIb of cortex (6 h after injection), piriform 
cortex (6,24, and 48 after injection), CA1 region of the hip- 
pocampus (24 h after injection), and CA3 region of the hip- 
pocampus (24 h after injection) (Fig. 8D). Figure 8E shows 
mRNA expression patterns and differences for 6TM-rH., iso- 
forms in representative sections from control animals and 
animals 24 h after injection. 
Discussion 
Our search for additional alternative splice variants of the 
rH., R resulted in the identification of three mRNAs coding for 
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heretofore uncharacterized rH;, isoforms. In contrast to the 
known functional H3Rs, sequence analysis of these newly 
identified isoforms reveals that an additional splicing event 
occurs within a region corresponding to TM6, resulting in 
isoforms with an alternative C-terminal domain and isoforms 
that are predicted to possess only 6 TMs. The mRNAs encod- 
ing these 6TM-rH3 isoforms are expressed in the rat brain 
with a distribution pattern that is similar to the previously 
identified functional 7TM-rH;, Rs (Drutel et al., 2001). Al- 
though there may be differences in the rate of synthesis, the 
inherent stability, and the rate of degradation of the various 
H3 isoforms, resulting in differences in their expression lev- 
els, extensive analysis of the 6TM-rH3 isoforms through het- 
erologous expression studies, however, failed to identify any 
ligand-binding and functional signaling events modulated by 
these 6TM-rH3 isoforms. The 6TM-rH3 isoforms seem to be 
localized intracellularly, and succeeding studies revealed the 
ability of the 6TM-rH., isoforms to interfere with the cell 
surface expression and subsequent signaling of the previ- 
ously identified 7TM-rH3 isoforms, thus acting as dominant- 
negative isoforms. 
An increasing number of GPCRs have been shown to exist 
as oligomeric complexes (for review, see, for example, Pfleger 
and Eidne, 2005), which are thought to be formed early 
TM-7 
H3DEF 
PTZ 24h 
Excess Probe 
Fig. S. Detection of rll,, isoform mRNA in rat 
brain. A, diagrammatic representation of mRNA 
sequences recognized by probes H. mD and 
H;, i, Ei,.. 
B, mRNA levels of isoforms detected with probe 
H, 
AL,. C, images of representative sections 
from 
control animals and animals 48 h after PTZ injec- 
tion. D, expression mRNA levels of isoforms de- 
tected with probe H;,,,,,,, -. E, images of representa- 
tive sections from control animals and animals 
24 h after injection. Data are presented as inte- 
grated optic density ± S. E. M.; levels of significance 
are as follows: *, p<0.05;  *, p <' 0.01; ***, p< 
0.001. ctx II"VIb, cortex layers II to VIb; CPu, 
caudate putamen; Pir, piriform cortex; CA1, CA1 
region of the hippocampus; CA3, CA3 region of the 
hippocampus. 
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during biosynthesis (Terrillon et al., 2003). In this study, we 
show also that the rH3AR is present as dimeris or higher order 
oligomeric complexes in both transfected cells and rat brain. 
The oligomerization of GPCRs during biosynthesis and mat- 
uration seems crucial for proper exportation of receptors to 
the plasma membrane (for review, see Bulenger et al., 2005). 
The coexpression and formation of heterodimeric 92-ARs 
(Hague et al., 2004a) aids, for instance, the cell surface traf- 
ficking of olfactory GPCRs that are otherwise retained and 
degraded in the ER (Lu et al., 2003,2004), as well as of the 
alt)-AR that normally is trafficked poorly to the cell surface 
(Uberti et al., 2005). The coexpression of differentially spliced 
GPCR variants may also aid the cell-surface expression, as 
shown for instance by the coexpression of the amD-AR with 
aia-ARs (Hague et al., 2004b). In contrast, certain alterna- 
tively spliced variants of, for instance, the alA-AR (Cogd et 
al., 1999), the calcitonin receptor (Seck et al., 2003), and the 
dopamine D3 receptor (Karpa et al., 2000) seem to dimerize 
with their cognate full-length receptors and impede their cell 
surface expression because of mislocalization to an intracel- 
lular compartment. The coexpression of the 6TM-rH3 iso- 
forms described herein not only reduced cell surface expres- 
sion of the 7TM-rHsRs but also consequently resulted in a 
reduced 7TM-rH3R-mediated signaling. Our data are there- 
fore consistent with the reported findings on the coexpression 
of N-terminal truncated, dominant-negative mutants and 
wild-type V2 receptors, which results in the formation of 
heterodimers and reduced agonist binding, signal transduc- 
tion, and cell-surface trafficking of the full-length V2 receptor 
(Zhu and Wess, 1998). Similar to our findings on the 6TM- 
rH3 isoforms, mutants of the a2-AR (Zhou et al., 2006), va- 
sopressin V2 (Zhu and Wess, 1998), dopamine D2 (Lee et al., 
2000), chemokine receptor CCR5 (Benkirane et al., 1997; 
Blanpain et al., 2000; Chelli and Alizon, 2001), gonadotropin- 
releasing hormone receptor (Brothers et al., 2004), and the 
platelet-activating factor (Le Gouill et al., 1999) receptors 
also impede the cell surface expression of their coexpressed 
wild-type counterparts, thus exhibiting trans-dominant-neg- 
ative effects on wild-type receptor expression (Benkirane et 
al., 1997; Chelli and Alizon, 2001; Brothers et al., 2004), most 
likely through dimerization. It seems most likely that the 
6TM-rH3 isoforms interfere with the functional expression of 
the 7TM-rHsRs through heterodimerization. Although direct 
heterodimerization of the 6TM-rH3 isoforms with the 7TM- 
rH3Rs remains to be established, we have shown the rH3AR 
to be constitutively expressed as a dimeric receptor in the 
brain as well as upon heterologous expression. 
GPCRs have been found to interact with accessory pro- 
teins, which can be critical for their biogenesis (for review, 
see Bermak and Zhou, 2001; Metherell et al., 2005). A con- 
served F(X)6LL motif, which is suggested to be important for 
the proper GPCR folding and subsequent export from the ER 
(Duvernay et al., 2004), is also present in the C-terminal 
domain of the 7TM-rH3Rs but is lacking in the 6TM-rH3 
isoforms. Mutations in regions overlapping the F(X)6LL motif 
in the dopamine D1 receptor resulted in ER retention of the 
mutant receptor and loss of cell surface expression, and sub- 
sequent studies revealed that this region is important for a 
interactions with a specific ER-membrane-associated protein 
that regulates transport of GPCRs (Bermak et al., 2001). It is 
noteworthy that, instead of the F(X)6LL motif, the 6TM-rH3 
isoforms possess an RXR ER retention signal. Taken to- 
gether, these data suggest that the 6TM-rH3 isoforms lack 
protein-protein interactions with specific accessory proteins 
in the ER that are required for cell-surface expression. Al- 
though the localization of the 6TM-rH3 isoforms within the 
ER seems likely, this needs to be verified by future experi- 
ments. Nonetheless, the findings on GPR30 as an intracellu- 
lar GPCR (Revankar et al., 2005) points out that the 6TM- 
rH3 isoforms may well have yet undiscovered intracellular 
functions in addition to their capability to retain the 7TM- 
rH3Rs intracellularly. 
On the one hand, the 6TM-rH3 splice variants may act as 
"antichaperones" inhibiting specific chaperones' activities or 
preventing their access to the 7TM-rH3Rs. On the other 
hand, the association of the 6TM-rH3 isoforms with the 7TM- 
rH3R isoforms in the ER may actively unfold or result in the 
misfolding of the protein complex. Because we find that the 
rH3D isoform does not interfere with the cell surface expres- 
sion of unrelated GPCRs, it seems unlikely the 6TM-rH3 
isoforms act through blocking either the ER or Golgi, or to 
promote ER-associated protein degradation. The precise 
mechanism underlying the action of the newly identified 
isoforms, however, remains unknown. Our data suggest that 
the regulation of the alternative rH3R mRNA splicing is a 
new and effective means for the regulation of H3R signaling. 
Functional (including constitutive) H3R activity may be reg- 
ulated through the regulation of the splicing events under- 
lying the occurrence of the various H3R isoforms. It is note- 
worthy that several cell signaling pathways, including the 
MAPK pathway, regulate mRNA splicing (reviewed in Shin 
and Manley, 2004). It is intriguing that the H3R activates the 
MAPK pathway (Drutel et al., 2001; Giovannini et al., 2003), 
arguing for the possibility of activation of splicing factors and 
hence, an autoregulation of the H3R activity. 
Our studies also show that the expression pattern of the 
7TM-rH3Rs and the 6TM-rH3 isoforms overlaps substan- 
tially in rat brain. Moreover, PTZ-induced seizures result in 
suppression of 6TM-rH3 (probe H3DEF) isoform mRNAs in 
particular brain regions, whereas mRNA levels of the iso- 
forms with the full third intracellular loop (probe H3,,, D) are 
increased. A characteristic transient and short-living in- 
crease in the mRNA for the full-length third intracellular 
loop (probe H3AD), hippocampal CA3Q area, followed by piri- 
form cortex, amygdala, and hippocampal CA, area is ob- 
served after systemic injection of kainic acid, a model of 
temporal lobe epilepsy (Lintunen et al., 2005), indicating a 
spatiotemporal correlation to progressing neuronal damage 
in this model of temporal epilepsy. Previous studies on PTZ 
have indicated damaged neurons in the rostral limbic cortex 
(both the orbital, agranular insular, and prelimbic), the lat- 
eral hypothalamus (in the vicinity of the rostral medial fore- 
brain bundle), the bed nucleus of the stria terminalis, the 
claustrum, the hippocampal formation (CA3 and entorhinal 
cortex), and lateral thalamic nuclei 50 min after injection 
(Ben-Ari et al., 1981). The increases in H3R mRNA with full 
third intracellular loop as observed in this study after PTZ 
were observed significantly later than the reported damage 
begins (Ben-Ari et al., 1981), in agreement with the concept 
that the mechanisms of neuronal damage after kainic acid 
and PTZ are different. Although the piriform cortex has not 
been reported to suffer significant damage after PTZ (Ben- 
Ari et al., 1981), it seems not to be only a primary sensory 
area but because of its neuronal organization and associative 
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fiber system may also be involved in the pathological mech- 
anisms leading to seizures (Löscher and Ebert, 1996). Of the 
areas studied here, the piriform cortex showed a sustained 
decline in 6TM-rH3 mRNA expression. We observed a signif- 
icant transient increase in H3R radioligand binding in piri- 
form cortex at 6h after PTZ concomitantly with the decline of 
H3DEF isoform mRNAs (data not shown). However, a similar 
strong correlation was not found in all areas where smaller 
changes were seen, suggesting that other factors in addition 
to mRNA ratios may affect receptor binding. The high sus- 
ceptibility for induction of seizures by chemical or electrical 
stimulation and various studies addressing its role in seizure 
generation suggest that the piriform cortex can also function 
as an amplifier region to increase and propagate seizure 
activity induced in other limbic regions (Löscher and Ebert, 
1996). Increased H3R activity (e. g., expression and transla- 
tion) in this region could result in decreased glutamate re- 
lease (Brown and Haas, 1999; Molina-Hernandez et al., 
2001), because glutamatergic neurons exist in the piriform 
cortex (Riba-Bosch and Perez-Clausell, 2004), for control of 
overall neuronal activity in the region. 
The abundance of mRNA coding for the 6TM-rH3 isoforms 
suggest that its production may have important biological 
implications. For example, in addition to its ability to inter- 
fere with cell surface expression of functional rH3Rs, which 
may arise from modification of the stability of the mRNA 
encoding functional 7TM-rH3Rs, the 6TM-rH3 isoform 
mRNAs might encode proteins with yet unidentified func- 
tions. Further analysis of the alternatively spliced pro- 
ducts of the H3R gene is required to elucidate their biolog- 
ical significance. 
In conclusion, we have identified three additional splice 
variants of the rH3R. The mRNAs of these isoforms are 
abundantly expressed in the brain and the expression pat- 
tern largely overlaps with that of the known rH3A_CR iso- 
forms. Analysis of the sequence of these rH3D, rH3E, and rH3F 
isoforms reveals these isoforms to consist of 6TM domains. 
The 6TM-rH3 isoforms are retained intracellularly upon het- 
erologous expression, and in subsequent pharmacological 
analysis studies we could detect no ligand binding or func- 
tional activity for these 6TM-rH3 isoforms. The 6TM-rH3 
isoforms, however, selectively impede cell surface expression 
of the functional 7TM-rH3Rs. Moreover, the mRNA levels of 
the rH3 isoforms in rat brain are modulated by treatment 
with the convulsant PTZ. Although the functional sig- 
nificance and possible roles of these 6TM-rH3 isoforms in 
(patho)physiology remain to be established, these findings 
provide novel insight in the regulation of the histaminergic 
system in the brain. 
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Abstract 
Activation of histamine H3 receptors (H3Rs) reduces inflammation and nociception, but the existence of H3Rs on peripheral 
innervation has never been demonstrated. Here we use antibodies to locate H3Rs in whisker pads, hairy and glabrous hind paw skin, 
dorsal root ganglia (DRGs), and spinal cords of rats, wild type mice, and H3R knockout (H3KO) mice. Although H3Rs have been 
hypothesized to be on C and sympathetic fibers, H3R-like immunoreactivity (H3R-LI) was only detected on presumptive periarterial 
AS fibers and on Aß fibers that terminated in Meissner's corpuscles and as lanceolate endings around hair follicles. The H3R-posi- 
tive periarterial fibers were thin-caliber and coexpressed immunoreactivity for calcitonin gene-related peptide (CGRP), substance P, 
acid sensing ion channel 3, and 200 kDa neurofilament protein (NF). H3R-LI was also detected on epidermal keratinocytes and 
Merkel cells, but not on Merkel endings, C fibers, any other AS fibers, or sympathetic fibers. In DRGs, H3R-LI was preponderantly 
on medium to large neurons coexpressing NF-LI and mostly CORP-LI. In dorsal horn, CGRP-positive fibers with and without 
H3R-LI ramified extensively in lamina II; many of the former formed a plexus in lamina V. Low levels of H3R-LI were also present 
on Aß fibers penetrating superficial and into deeper laminae. The distribution of H3R-LI was similar in rats and wild type mice, but 
was eliminated or strongly reduced in AS fibers and Aß fibers, respectively, in H3KO mice. Taken with recently published behavioral 
results, the present findings suggest that periarterial, peptidergic, H3R-containing AS fibers may be sources of high threshold 
mechanical nociception. 
0 2006 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved. 
Keywords: Histamine; H3 receptors; Arterial innervation; AS fibers; Aß fibers; Calcitonin gene-related peptide; Substance P; Sensory innervation 
1. Introduction to exist in the CNS as presynaptic inhibitory autorecep- 
tors (Arrang et al., 1983; Arrang et al., 1987), lesion 
Histamine is a chemical messenger that is released by studies have revealed that a large fraction of brain 
neuronal and non-neuronal sources (Hough and Leurs, H3Rs exist as postsynaptic inhibitory heteroreceptors 
2006). Histamine can act at four known types of hista- (Pollard et al., 1993). Subsequently, pre- and postsynap- 
mine receptors, including H3 receptors (Hough, 2001). tic expression of H3Rs has been detected throughout the 
Although H3 receptors (H3Rs) were originally reported CNS. Detailed H3R radioligand binding in rat brains 
revealed high densities of binding sites in the cerebral 
Corresponding author. Tel.: +1 518 262 5384; fax: +1 518 262 cortex, striatum, and olfactory 
tubercles (Pollard et al., 
5799.1993). In agreement with this distribution, in situ hybrid- 
E-mail address: ricef@mail. amc. edu (F. L. Rice). ization studies showed strong H3R mRNA signals 
in the 
0304-39591$32.00 ® 2006 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved. 
doi: 10.1016/j. pain. 2006.09.039 
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cerebral cortex, thalamus, and striatum of the rat 
(Lovenberg et at., 1999; Drutel et at., 2001). Although 
the majority of H3Rs are located in the brain, H3R 
mRNA is also found in various non-brain tissues, 
including skin, dorsal root ganglia, stomach, intestines, 
and brown adipose tissue (Heron et al., 2001; Karlstedt 
et al., 2003). 
Administration of H3R agonists has been shown to 
inhibit neuropeptide release from sensory fibers in the 
heart, lung, and skin, leading to the hypothesis that 
H3Rs are located on peptidergic C fibers (Dimitriadou 
et at., 1994; Delaunois et at., 1995; Ohkubo et at., 
1995; Imamura et at., 1996; Dimitriadou et al., 1997; 
Nemmar et at., 1999). Consistent with this hypothesis, 
recent studies revealed that H3R agonists have anti- 
inflammatory as well as some antinociceptive properties 
(Rouleau et at., 1997; Rouleau et at., 2000; Cannon 
et at., 2003; Cannon and Hough, 2005). Other studies 
suggest that H3Rs are located on sympathetic eflerents 
(Ishikawa and Sperelakis, 1987; Molderings et al., 
1992; Koss, 1994; Godlewski et al., 1997a, b). However, 
no immunohistochemical studies have been performed 
to determine the precise localization H3Rs on either sen- 
sory or sympathetic fibers. Thus, the present study has 
performed the first investigation of the distribution of 
H3R immunofluorescence on nerve cells and fibers in 
skin, dorsal root ganglia, and spinal cords of rats and 
mice. 
2. Materials and methods 
2.1. Specimens 
The subjects were 6 rats, 6 wild type mice, and 6 H3KO 
mice. Animal housing and procedures were approved by the 
Institutional Animal Care and Use Committee of Albany 
Medical College. Male Sprague-Dawley rats (300-350 g, 
Taconic Farms, Germantown, NY), housed in groups of 
two or three per cage, and female wild type or H3KO mice 
(10-14 weeks old, 20-30 g), housed up to seven per cage, 
were maintained on a 12 h light/dark cycle (lights on 
from 7: 00 to 19: 00 h). Food and water were provided 
ad libitum. 
Table I 
List of antibodies used for immunofluorescence studies 
Antigen 
Protein gene product 9.5 (PGP) 
Calcitonin gene-related peptide (CGRP) 
Neurofilament 200 kDa (NF) 
Substance P (SP) 
Neuropeptide Y (NPY) 
Acid-sensing ion channel 3 (ASIC3) 
Histamine 113 receptor (113R) 
(1) Intracellular loop 3' (rat and human) 
(2) C-terminusb (rat) 
H3KO mice, kindly provided by Millennium Pharmaceuti- 
cals, Inc. (Cambridge, MA), were generated by targeted dele- 
tion of exon 3 of the mouse 113R gene (Cannon et at., 2003). 
H3KO mice showed no detectable histamine 113R mRNA in 
the brain or the spinal cord by in situ hybridization (Cannon 
et at., 2003). Brains from these subjects also had no detectable 
histamine 113R binding (Mobarakeh et at., 2003). Following an 
overdose of sodium pentobarbital, the animals were transcar- 
dially perfused with 0.9% saline, followed by 4% paraformal- 
dehyde in 0.1 M phosphate-buffered saline (PBS, pH 7.4, 
4 °C). Immediately after perfusion, the tissues were dissected 
and post-fixed at 4 °C in perfusion fixative for 4 h. Following 
post-fixation, the tissues were rinsed several times in PBS 
and stored in 0.1% sodium azide PBS. The following tissues 
were taken from each animal: (1) lumbar spinal cord, (2) 
lumbar dorsal root ganglia (DRG), (3) superior cervical gan- 
glia (SCG), (4) glabrous and hairy skin from hind paws, and 
(5) whisker pads. The forebrains were removed from some 
rats, wild type mice and H3KO mice for control purposes. 
For cryostat sectioning, tissues were cryoprotected by over- 
night immersion in PBS containing 30% sucrose at 4 °C. Serial 
sections (14 µm-thick) were cut on a cryostat and thawed in 
sequential order onto and rotating across 5-15 gelatinized 
slides. The slides were air dried overnight and processed for 
single or double immunolabeling. 
2.2. Production and characterization of lfjR antibodies 
Our study used two different rabbit polyclonal antibodies 
for H3R: one produced by Chazot et al. (2001) and the other 
obtained commercially (AB5660P, Chemicon, see Table 1). 
The Chazot antibody was directed against residues 349-358 
of the human and rat H3R, which is identical in the mouse 
sequence (Chen et at, 2003). Western blots on P2 membranes 
taken from wild type and H3KO forebrains were performed 
with this antibody as previously described (Chazot et al., 
2001). Proteins (30 µg) were extracted using the chloroform/ 
methanol precipitation method, and the precipitate subjected 
to SDS-PAGE under reducing conditions, using 7.5% (v/v) 
acrylamide slab gels. Proteins were transferred onto nitrocellu- 
lose, probed with the H3R antibody (2 pg/ml), and detected 
using an ECL PLUS system (Amersham, UK). The Chemicon 
antibody was targeted against an 18 amino acid sequence in 
the C-terminus region of rat H3R. This sequence is 100% iden- 
tical in mouse, 88% conserved in guinea pig, and 82% in 
human H3R. 
Antibody (dilution) 
Rabbit polyclonal (1: 800) 
Guinea pig polyclonal (1: 400) 
Rabbit polyclonal (1: 800) 
Guinea pig polyclonal (1: 400) 
Sheep polyclonal (1: 800) 
Guinea Pig (1: 500) 
Source 
UltraClone Ltd. (Wellow, Isle of Wight, UK) 
Peninsula Laboratories Inc. (San Carlos, CA) 
Chemicon International Inc. (Temecula, CA) 
Research Diagnostics Inc. (Flanders NJ) 
Chemicon International Inc. 
Neuromics Antibodies (Northfield, MN) 
Rabbit polyclonal (1: 50-500) 
Rabbit polyclonal (1: 50-500) 
Chazot et al.. 2001 
Chemicon International Inc. 
" This antibody was raised against a 10 amino acid peptide sequence found in intracellular loop 3 of the rat and human 113R protein. 
b This commercial antibody was raised against the C-terminus of rat H3R. 
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2.3. Immunofluorescence preparation and observation 
As previously described (Rice et al., 1997; Pare et al., 2002), 
serial 14 pm sections were prepared for single or double label- 
ing with the antibodies listed in Table 1. Antibodies were dilut- 
ed in a PBS solution containing 1% bovine serum albumin 
(BSA) and 0.3% Triton X-100. Appropriate species of second- 
ary antibodies were raised in donkey or goat and conjugated 
with either Cy3 (1: 250; Jackson ImmunoResearch Laborato- 
ries, Inc. ), Cy2 (1: 500; Jackson ImmunoResearch Laborato- 
ries, Inc. ), or Alexa 488 (1: 500; Molecular Probes, Inc. ). 
Slides were first preincubated in PBS containing 1% BSA 
and 0.3% Triton X-100 for 30 min, then incubated overnight 
at 4 °C in primary antibody under high humidity. Following 
a 30 min rinse in PBS, slides were incubated under the appro- 
priate secondary antibody for 2h at room temperature then 
rinsed for 30 min in PBS. For double labeling, the sequence 
was repeated with the desired additional primary antibody 
and its appropriate secondary antibody. After the final rinse, 
slides were coverslipped with 90% glycerin/10% PBS solution. 
If the two primary antibodies were raised in different species, 
then the double labeling revealed by Cy3 and Cy2 (or Alexa 
488) was clearly separate. In some cases, double labeling com- 
binations were desired where only two rabbit primary antibod- 
ies (A and B) were available or optimal. After verifying that 
separate single labeled preparations with each antibody labeled 
similar innervation in a specific anatomical location, some 
slides were incubated first with antibody A followed by anti- 
rabbit Cy3, then incubated with antibody B followed by 
anti-rabbit Cy2 or Alexa 488. Other slides with alternating tis- 
sue sections were processed with the sequence of primary anti- 
bodies reversed (i. e., first B, then A). The validity and 
limitations of this double labeling method have been discussed 
in detail (Rice et al., 1997). For example, if fibers and endings 
labeled with A are a subset of those labeled with B, then the 
first sequence will have some fibers and endings that will be 
double labeled both with Cy3 and Cy2, whereas additional 
fibers and endings will only be labeled with Cy2. In the reverse 
sequence, all fibers and endings will be double labeled, and 
none will be only labeled with Cy2. 
2.4. Immunochemical specificity and fiber classification 
As shown in previous studies, protein gene product 9.5 
(PGP) is a pan-neuronal cytoplasmic enzyme (Rice et al., 
1997). As such, anti-PGP labels all types of normal cutaneous 
innervation in rats and mice including sympathetic fibers and 
various types of sensory fibers (i. e. Aß, AS, and C fibers), as 
well as their terminations (Rice et al., 1997; Fundin et al., 
1997a, b; Rice et al., 1998; Fünfschilling et al., 2004; Zylka 
et al., 2005). Other antibodies directed against 200 kDa neuro- 
filament (NF), CGRP, substance P (SP), and neuropeptide Y 
(NPY) discriminate between specific types of innervation. 
The previous studies on rat skin cited above demonstrated that 
NF-LI was present on all thick-caliber and many thin-caliber 
sensory fibers. The anti-NF labeling in the rat was consistently 
coexpressed with myelin basic protein (MBP) LI indicating 
that these thick and thin fibers are Aß and AS fibers, respec- 
tively. NF-positive fibers with thick and thin calibers that have 
similar distributions and types of endings are also present in 
mouse skin. Based upon their morphologically distinct end- 
ings, the thick caliber fibers are the clear equivalent of the 
Aß fibers in the rat. The thin NF-positive caliber fibers in 
the mouse are presumably the equivalent AS fibers, although 
in attempting to directly confirm this presumption we have 
not found an antibody that effectively reveals myelin basic pro- 
tein in sections of mouse skin. CGRP-LI and SP-LI are vaso- 
dilatory neuropeptides commonly coexpressed in subsets of AS 
and C "peptidergic" fibers in mouse and rat skin. Likewise, in 
mouse and rat skin, NPY is a neuropeptide normally expressed 
mostly in adrenergic sympathetic fibers that also are immuno- 
reactive for tyrosine hydroxylase and are implicated in 
vasoconstriction. 
Three experiments were performed to control for nonspecif- 
ic labeling. First, incubations were conducted without the pri- 
mary antibody to observe immunofluorescence provided by 
the secondary antibody alone. Second, slides were incubated 
under primary antibodies that had been preincubated with 
their specific blocking peptide to observe any nonspecific inter- 
actions of the primary antibody. Blocking peptide was added 
to the H3R antibody at 1000-fold molar excess and was 
allowed to sit at room temperature for one hour prior to appli- 
cation to tissue sections. Third, immunolabeling was assessed 
in H3KO mice. To recognize the possibility that an antibody 
made against a particular antigen might label a different, albeit 
antigenically similar molecule, all detectable immunofluores- 
cence will be referred to as a particular antigen-like immunore- 
activity (LI), for example H3R-LI. For simplicity, structures 
having LI for a particular antigen will also be referred to as 
positive for that antigen, for example H3R-positive. 
Sections were analyzed with an Olympus Provis AX70 
microscope equipped with conventional fluorescence: (1) Cy3 
filters (528-553 nm excitation, 590-650 nm emission), and (2) 
Cy2 filters (460-500 nm excitation, 510-560 nm emission). 
Fluorescence images were captured with a high resolution 
(1280 x 1024 pixels) three chip color CCD camera (Sony, 
DKC-ST5) interfaced with Northern Eclipse software (Empix 
Imaging, Inc., Mississauga, ON). 
Since the intensity of immunolabeling for the numerous 
antibodies used in the present study is attributed to many vari- 
ables that cannot be individually quantified, this study does 
not attempt to quantify the relative amounts of labeled anti- 
gens. These variables include: (1) true differences in the pres- 
ence and quantity of the antigen, (2) whether the antibody is 
monoclonal or polyclonal, (3), background labeling, (4) anti- 
body concentration, (5) efficacy of the antibody, and (6) loca- 
tion of the antigen (i. e. membrane or cytosol). Because the 
labeling intensities differed between the various types of anti- 
bodies, the photomicrographs compiled for illustrative purpos- 
es were adjusted using Northern Eclipse, Adobe Photoshop 
(San Jose, CA), and Microsoft Powerpoint (Redmond, WA) 
software so that the maximum labeling contrast and intensity 
were similar for each antibody. 
2.5. Dorsal root ganglia quantifications 
Analyses of the double labeling combinations in DRGs and 
SCGs were performed with Neurolucida software (Micro- 
BrightField, Inc., Willston, VT). Analyses were conducted 
for sections spaced at least 100 gm apart from three L4 or 
L5 DRGs double-labeled with antibodies for (1) H3R and 
calcitonin gene-related peptide (CGRP), (2) H3R and 
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substance P (SP), and (3) for H1R and 200 kDa neurofilament 
protein (NF). The H3R and CGRP antibodies were raised in 
rabbit and guinea pig (respectively), allowing for distinct detec- 
tion of single or double labeling. The H1R and NF antibodies 
were both made in rabbit. Single labeling with anti-H3R or 
anti-NF revealed that many neurons expressed H3R-LI and/ 
or NF-LI. Sequential incubations first with anti-H, R followed 
by anti-rabbit Cy3, then in anti-NF followed by anti-rabbit 
Cy2 revealed that many neurons had NF-LI without H, R- 
LI. Sequential incubations first with anti-NF followed by 
anti-rabbit Cy3, then anti-H, R followed by anti-rabbit Cy2 
revealed that virtually all the anti-H3R labeled neurons coex- 
press NF-LI. Interestingly, since anti-H3R labeling was much 
less robust than anti-NF labeling, when H, R antibodies were 
used first in the double labeling sequence the subsequent bind- 
ing of the first anti-rabbit secondary antibody effectively 
blocked any erroneous cross labeling by the anti-rabbit sec- 
ondary antibody used in the second round of incubations. 
In order to standardize assessment of labeling, digital imag- 
es of double labeled ganglion sections were captured separately 
for the red (Cy3) and green (Cy2 or Alexa 488) fluorescent 
channels, using camera settings that produced a comparable 
range of low fluorescence intensities in each channel. The low- 
est fluorescence intensities captured for each antibody were set 
to levels comparable to the fluorescence captured from sections 
processed only with the secondary antibodies. Next, the range 
of fluorescence intensities in each channel was adjusted linearly 
so that many cells remained barely evident, and the most 
brightly fluorescing cells had a comparable intensity in both 
channels. The resultant images in the red and green channels 
were merged by Boolean addition and the double labeled 
images were stored. A copy of each double labeled image 
was purposefully extremely enhanced so that contours of even 
the most faint cell profiles in the background could be delineat- 
ed. Using these extremely enhanced images, the contours of all 
visible cells were circumscribed to calculate the area of each 
cell for as many cells as possible. The contour outlines 
obtained in the enhance images were then superimposed onto 
separate copies of the unenhanced red and green images. In 
each channel, the labeling of the cell underlying each contour 
was subjectively rated as: (1) blank, (2) very weak, (3) weak, 
(4) moderate, or (5) strong. The independent results from each 
channel were then combined to conclude which cells had label- 
ing for either or both antibodies. Only those cells regarded as 
weak, moderate, or strong in each channel were regarded as 
"labeled" for the antibody corresponding to the particular 
channel. The Abercrombie (1946) correction was used to com- 
pensate for the progressive under representation or cells that 
occurs in proportion to decreasing diameter. 
H, R mRNA in rats (Pollard et al., 1993; Heron et al., 
2001; Pillot et al., 2002). For example, in both species 
we found robust H1R-LI in the striatum (Fig. IA), con- 
sistent with the previous detection in rats of H3R 
mRNA in the striatum and H, R-LI on striatal, medium 
spiny neurons of rats. H, R-Ll was also observed in the 
cingulate cortex, substantia nigra pars reticulata, and 
cerebral cortex of rats and wild type mice (data not 
shown). In contrast, the medial septal regions and hip- 
pocampal pyramidal layers of rats and wild type mice 
contained little to no H, R-LI (data not shown), consis- 
tent with the published paucity of H, R mRNAs in these 
locations (Pollard et al., 1993; Heron et al., 2001; Pillot 
et al., 2002). Analysis of brain sections taken from 
H 3KO mice revealed a virtually complete absence of 
H3R-LI in most brain regions examined, including the 
striatum (Fig. 1C). However, a weak residual H; R-LI 
remained in the cerebral cortex and cingulate cortex of 
H, KO mice (data not shown). 
In Western blots performed on membrane extracts 
from the forebrains of wild type mice (Fig. ID), two 
major H3R-related species were detected (M, 93,000 
and M, 68,000), as previously seen in the rat (Chazot 
et al., 2001). These immunoreactive species were 
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3. Results 
3.1. Characterization u/tln, 11rR untiholi, 
In order to more fully characterize the H, R antibody 
first developed by Chazot et al. (2001), this antibody was 
used to detect H; R-LI in coronal brain sections of rats, 
wild type mice and H3KO mice. In rats and wild type 
mice, pronounced H1R-LI was observed in several brain 
regions known to contain moderate to high levels of 
.. "... 9 
..... . --lo 
WT H, KO 
I ,-1l , inii 11, 
R l. il,, Iing. (A-C) Digital images of 
punctatc anti-I I, R labeling among the neurons in the striatum as seen 
in coronal sections from wild type (A and B) and 11, KO mice (C). 
Scale bar, 25 µm. Comparable labeling was obtained with anti-1-1,11 
antibodies produced independently by Chazot et al. (2001) (A) and 
C'hemicon (B). Virtually all labeling is absent in the striatum of IIIKO 
mice prepared with the Chazot antibody (C'). (D) A Western blot with 
the Chazot antibody reveals two dense bands (solid arrowheads) in the 
wild type mice that are eliminated in t{, KO mice, and a faint band 
(open arrowheads) that is reduced but still persists in the Ei, KO mice. 
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eliminated in H3KO forebrain extracts (Fig. 1D). The 
two species are likely to represent dimeric mouse H3R 
isoforms as has been suggested using cross-linking 
strategies (Shenton et al., 2005). A third, previously 
unknown species (M, 95,000) was faintly labeled in wild 
type extracts and persisted at lower levels in H3KO 
extracts (Fig. 1D), which might account for weak resid- 
ual immunolabeling in H3KO tissues. The residual label- 
ing may be due to an H3R-like protein or protein 
fragment, or to a protein completely unrelated to 
H3Rs. However, a GenBank BLASTp search of the 
H3R antibody peptide sequence revealed no similarities 
to any other known vertebrate protein. Although several 
H3R isoforms have been proposed to exist (Tardivel- 
Lacombe et al., 2000; Coge et al., 2001; Drutel et al., 
2001; Wellendorph et al., 2002; Rouleau et al., 2004), 
the H3KO gene construct eliminated the sequences 
encoding the epitopes used to make both of the H3R 
antibodies. 
In other control experiments, brain sections as well as 
hind paw and whisker pad skin sections from rats, wild 
type mice, and H3KO mice were examined after incuba- 
tion with H3R antibody serum that had undergone pre- 
absorption with the specific blocking peptide. The 
preabsorbed serum failed to label any components in 
all three types of animals (e. g. Fig. 2J-L). Finally, 
immunofluorescence studies of brain, skin, and spinal 
cord were repeated in rats, wild type mice, and H3KO 
mice using a commercially available H3R antibody (see 
Table 1) that targeted a different portion (C-terminus) 
of the H3R protein sequence. In all cases, results with 
the commercially available H3R antibody yielded com- 
parable H3R-LI patterns in rat, wild type mouse and 
H3KO mouse tissues similar to the labeling patterns 
observed with the Chazot anti-H3R (e. g. Figs. 1B and 
4A-C). However, the Chazot antibody produced consis- 
tently more robust labeling and was used for most of the 
double labeling analyses (e. g. compare Figs. 3A-C and 
4A-C). 
3.2. Anti-II3R labeling in skin 
In order to determine specifically which types of cuta- 
neous innervation express H3Rs, sections of glabrous 
and hairy hind paw skin and of whisker pad skin from 
rats, wild type mice and H3KO mice were processed 
for immunofluorescence with the two H3R antibodies 
in combinations with antibodies for several other neuro- 
nal antigens (Table 1). As expected, anti-PGP labeled all 
types of previously known sensory and sympathetic 
innervation in our skin specimens, including all the types 
labeled with the other antibodies. The anti-PGP-labeled 
innervation consisted of numerous thin-caliber fibers 
that ramify and terminate as free nerve endings (FNEs) 
in the epidermis and superficial dermis (Fig. 2). Virtually 
all of the thin-caliber epidermal and superficial dermal 
innervation lacked H3R-LI in rats and wild type mice 
(Fig. 2A-F). This included all combinations of CGRP, 
SP, and NF-positive and negative fibers indicative of 
peptidergic and nonpeptidergic AS and C fibers. Surpris- 
ingly, H3R-LI was detected on thick-caliber Aß fibers 
that terminated as lanceolate endings around hair and 
whisker follicles and as endings in Meissner corpuscles 
located in the dermal papillae of glabrous skin 
(Fig. 2A-F; D-F inset). Likewise, the H3R antibodies 
labeled the more proximal portions of these Aß fibers 
passing through large nerves in the deep dermis (Figs. 
3 and 4). As has been published previously, all of the 
Aß fibers labeled with anti-NF (not shown). H3R-LI 
was also detected on Merkel cells located in lamina 
basalis of the glabrous epidermis and in the outer root 
sheath of whisker follicles (Fig. 2D-F), but I13R-LI 
was not definitively evident on the Aß fibers that inner- 
vate the Merkel cells. Finally, H3R-LI was detected on 
keratinocytes of the epidermis, with the strongest 
expression in the stratum granulosum and stratum 
spinosum (Fig. 2A-F). Anti-H3R labeling in H3KO mice 
was severely reduced but faint labeling persisted on the 
Aß fibers, Merkel cells and keratinocytes (Fig. 2G-I). 
Although the H3R antibodies failed to label thin-cal- 
iber fibers of the epidermis and upper dermis, H3R-LI 
was detectable on a subset of thin-caliber fibers affiliated 
with arteries and arterioles deep in the dermis of rats 
(Fig. 3A-C) and mice (Fig. 3D-F). However, unlike 
the faint residual labeling on Aß fibers, H3R-LI was 
completely absent on these deep dermal, periarterial 
fibers of H3KO mice (Fig. 3G-I). 
Next we sought to determine the identity of these 
fibers. Previous studies in rats and mice demonstrated 
that the cutaneous periarterial innervation consists of 
thin-caliber sensory and sympathetic fibers (Fundin 
et al., 1997b; Fünfschilling et al., 2004). In the rat, all 
of the sensory innervation labels with anti-CGRP and 
anti-SP. Some of it also labels with anti-NF, and anti- 
MBF, and is presumptively classified as AS. The sensory 
innervation is relatively sparse and is located primarily 
in the tunica adventitia (Fundin et al., 1997b; Fünfschill- 
ing et al., 2004). Other peptidergic periarterial sensory 
fibers in mouse and rat lacked NF-IR and MBP-IR, 
indicating that they are C fibers. In contrast to the sen- 
sory innervation, virtually all of the normal periarterial 
sympathetic innervation coexpresses tyrosine hydroxy- 
lase and NPY, and distributes as a dense plexus at the 
border between the tunica adventitia and tunica media. 
Thus, both the anatomical localization of the innerva- 
tion, and the immunochemical characteristics of the per- 
iarterial innervation permit a clear classification of these 
fibers as either AS, C, or sympathetic. 
As seen in our anti-PGP double labeled preparations, 
virtually all of the anti-H3R labeled periarterial fibers 
were located in the tunica adventitia on a subset of fibers 
within the small vascular nerves and on some of the 
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Fig. 2.114R-LI is absent on thin ý: alibcr innervation to the cpidermis and upper dcrnlls, but is plesCnt 1n, Umc : \It lihcr innd . Ell m. \1CILCl ýrll, and 
keratinocytes. Digital images of glabrous hind paw sections from rats (A-C), wild type mice (D-F and J-L), and 113KO (G-1) mice double labeled 
with anti-PGP (left panels) and anti-H3R (middle panels). Merged double labeled images are shown in the right panels. Insets in (D-I) show labeling 
in whisker follicles from mystacial pads. Scale bars = 25 µm (50 . sm for insets). In this and subsequent figures, green (Cy2 or Alexa 488) and red (Cy3) 
symbols indicate single labeled structures; yellow symbols indicate double labeled structures. (A-F) As seen in rat and wild type mouse skin, thin 
caliber innervation labeled with anti-PGP (green arrowheads) in the epidermis or upper dermis is not labeled with anti-H3R. This includes all C-fiber 
and AS-fiber innervation. Anti-PGP and anti-H3R double labeling was present on some large caliber Aß fibers (yellow curved arrows), and on Aß- 
fiber endings in Meissner corpuscles (yellow chevrons with asterisks) and Aß-fiber endings on whisker follicles (yellow chevrons) and hair follicles 
(not shown). H3R-LI is also present on keratinocytes in the epidermis (red stars) as well as on anti-PGP labeled Merkel cells (yellow straight arrows) 
in lamina basalis of the epidermis and the outer root sheath of whisker follicles. H3R-LI was not evident on the Aß fibers that innervate the Merkel 
cells. (G-I) In H, KO mice, H3R-LI is drastically reduced but faint residual Cy3 labeling was detected on keratinocytes in the epidermis (red stars), 
some Aß fibers (yellow curved arrows), Meissner corpuscles (yellow chevrons with arrowheads), lanceolate endings (yellow chevrons), and Merkel 
cells (yellow straight arrows). All thin caliber innervation was Cy3 negative (green arrowheads). (J-L) Images of wild type glabrous mouse skin 
double labeled with anti-PGP and peptide preabsorbed anti-H1R. None of the innervation (green arrowheads and curved arrows) nor cells in the 
epidermis were labeled with the preabsorbed anti-I-I3R. 
individual fibers (Fig. 3A-F). Moreover, the anti-H3R The remaining CGRP/SP-positive fibers, which lack 
labeled fibers consistently colabeled with anti-CGRP NF-LI, were virtually all H3R-negative indicating that 
(Fig. 4D-F), anti-SP (Fig. 4G 1), and anti-NF most if not all of the C fibers were H3R-negative. 
(Fig. 4J -L) indicating that the H3R-LI was primarily if Although some C fibers could potentially be H3R- 
not exclusively on the presumptive AS fiber innervation. positive, H3R-LI was never detectable unless some 
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Fig. 3. llR-Ll on periartcii. i. i-- ,, 'i, p Uertnu. I _.:, .. . IL........ 1; u, n;; i, u, i\(), wild type QliLC ( 
1) l 1, 
and HKO mice (G-I) double labeled with anti-PGP (A, 
D, and G) and anti H3R revealed with Cy3 (B, E, and H). Scale bars, 25 gm. L= arterial 
lumens, TM = tunica media. (A-F) Double labeling is present among individual axons and bundles of axons (yellow straight arrows) which are 
located in the tunica adventitia (which surrounds the tunica media) and have previously been shown to be mostly CGRP-positive presumptive C 
fibers and AS fibers (see also Fig. 4). Thin-caliber fibers that ramify at the interface between the tunica adventitia and tunica media have previously 
been shown to be NPY and TH-positive and are presumptive sympathetic innervation. They were entirely labeled only with anti-PGP (green 
arrowheads) in the rat, but some double labeled with anti-H3R in the mouse (yellow arrowheads). Many Aß fibers in large deep dermal nerves were 
double labeled (yellow curved arrows). (G-I) No H3R-LI was present among sensory (green arrows) and sympathetic (green arrowheads) periarterial 
fibers in H3KO mice, but faint residual labeling was detected on Aß fibers (yellow curved arrows). 
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Fig. 4. Co-localization of fl, receptors N+ith ( (iRP. SP. NI , and 
ASR hut not Ni'\ "micrh &rinal, pep dcrýi:.. ut: i Digital 
images of glabrous hind paw sections from rats double labeled with antibodies against H, R (middle panels) and against several other neuronal 
antigens (left panels). Merged images are in the right panels. The Chemicon anti-H, R used in B (yellow arrows) did not label innervation as intensely 
as the Chazot antibody used in all the other middle panels (red and yellow arrows). Scale bar, 25 µm. L= lumen of arteries. (A-C) H, R-LI was 
expressed almost entirely among the anti-PGP individual fibers and bundles of fibers (yellow arrows) located in the tunica adventitia which surrounds 
the tunics media. Anti-PGP labeled fibers that ramify at the interface between the tunica adventitia and tunica media lack II, R-LI (green 
arrowheads). (D-F) CGRP-LI was expressed in the periarterial innervation that is presumably sensory (yellow and green arrows). A subset of this 
innervation co-expresses H3R-LI (yellow arrows). (G-I) SP-LI was also expressed in periarterial fibers that are presumably sensory (yellow and green 
arrows). H, R-LI was expressed on a subset of this innervation (yellow arrows). (J-L) H, R-LI was expressed on periarterial fibers that co-labeled with 
anti-NF. Previous studies showed that the NF-positive fibers are a subset of those that label with anti-CGRP. (M -O) 1, R-LI was only expressed on 
fibers (red arrows) that were distinct from those that label with anti-NPY (green arrowheads). (P--R) 11, R-positive fibers also labeled with anti-ASIC3 
(yellow arrows). 
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NF-LI was also present. Unfortunately, the H3R-LI was 
not sufficiently intense for capture by confocal microsco- 
py at a resolution that was any better than that achieved 
by epifluorescence, especially since the sections were 
only 14 µM thick. In a study of vascular innervation 
in muscle (Molliver et at., 2005), the AS vascular fibers 
were also found to label with antibodies against the acid 
sensing ion channel 3 (ASIC3). Likewise, we found that 
the H3R-positive periarterial fibers also colabeled with 
anti-ASIC3 in the skin (Fig. 4P-R). 
Our double label assessments with anti-PGP revealed 
very little H3R-LI among the dense plexus of fibers that 
ramify at the tunica media and adventitia border. H3R- 
LI was especially absent in this location in the rat 
(Fig. 3A-C), but barely detectable H3R-LI was present 
on some fibers in this location in wild type mice 
(Fig. 3D-F). Double labeling assessments with anti- 
NPY revealed no co-labeling with H3R-LI (Fig. 4M- 
0), thereby supporting the observations indicating that 
the detectable anti-H3R labeling was restricted to the 
AS sensory innervation. H3R-LI was also absent among 
the sweat glands of the glabrous skin that are the site of 
dense cholinergic sympathetic terminations (data not 
shown). 
3.3. Anti-H3R labeling in DRG cell bodies 
Our immunochemical localization of H3Rs on some 
cutaneous innervation was consistent with previously 
detected moderate levels of H3R mRNA in DRGs (Her- 
on et al., 2001). However, as noted above, our assess- 
ments of cutaneous innervation indicated that H3R-LI 
was definitively detectable only on Aß fibers that termi- 
nated as lanceolate endings and Meissner's corpuscles, 
and on CGRP/SP-positive AS fibers that innervate 
arteries and arterioles. Therefore, our next objective 
was to assess the size and immunochemical characteris- 
tics of neurons in rat lumbar DRGs. Consistent with a 
general relationship between DRG neuronal diameter 
and fiber caliber (McCarthy and Lawson, 1990), virtual- 
ly all neurons less than 25 gm in diameter were NF-neg- 
ative, about 20-30% of neurons from 25 to 35 µm were 
NF-positive, and virtually all larger neurons were NF- 
positive (Fig. 6A). Although there are known to be 
exceptions to this correlation, smaller neurons are typi- 
cally the source of C fibers and larger neurons the source 
of Aß fibers (McCarthy and Lawson, 1990). AS fibers 
presumably arise mostly from medium sized neurons. 
Depending upon whether anti-H3R treated DRG 
sections were double labeled with anti-NF or anti- 
CGRP, a considerable discrepancy was evident 
between the percentage of total neurons that were ini- 
tially judged as H3R-positive: i. e. 33% in section double 
labeled with anti-NF vs. 55% with anti-CGRP. Pre- 
sumably the percentage of H3R-LI neurons should be 
the same in both types of preparations. An assessment 
of the overall distribution of all labeled and unlabeled 
cells revealed that the discrepancy was among the cells 
less than 25 µm in diameter, where a much greater total 
number of cells regarded as unlabeled were detected in 
anti-H3R/anti-NF treated sections than in anti-113R/ 
CGRP treated sections. Thus, unlabeled cells were 
over-represented in the former and/or under represent- 
ed in the latter. This may have been due to the poten- 
tial additive effect of background levels of cross 
labeling among the primary and secondary antibodies 
raised in the same species. Based on prior assessments 
of the proportion of CGRP-positive and negative small 
cells and of NF-positive and negative small cells in 
DRGs (e. g. Zylka et al., 2005), it was evident that 
the discrepancy in small cell counts was primarily due 
to a lack of overall unlabeled small cell detection in 
our anti-CGRP labeled specimens. Therefore the 
graphs in Fig. 6B were normalized to the small cell 
counts in Fig. 6A. Independent of the small cell dis-, 
crepancy, it must be emphasized that H3R-LI in the 
DRG was detected primarily on medium to large cells 
equal to or greater than 25 µm in diameter. Among 
cells of this size, 33-55% are H3R positive. 
In DRG sections taken from H3KO mice, H3R-LI 
was virtually eliminated on the small and medium size 
neurons, but some weak residual labeling persisted on 
large neurons (Fig. 5B). Consistent with our peripheral 
innervation double labeling results, about two-thirds 
of the neurons with H3R-LI also coexpressed anti- 
CGRP labeling (Figs. SC, D and 6B, C), and nearly 
all H3R-LI cells (97%) co-labeled with anti-NF 
(Fig. 5G, H and 6D, E). In comparison to CGRP/ 
H3R co-localization, about half as many small, medium 
and large H3R-positivc neurons also coexpressed SP-LI 
(Fig. SE and F). This is consistent with previous obser- 
vations that SP is present in about half of the neurons 
that contain CGRP (Ju et al., 1987; Lawson, 1995), 
although SP has previously been shown to have nearly 
complete co-localization with CGRP in cutaneous fibers 
(Fundin et al., 1997a, b; Rice et al., 1997). At least some 
of the medium-sized neurons that are positive for 
CGRP, SP, NF, and H3R (approximately 25-35 µm) 
may be the source of the vascular AS fibers that express 
the same immunolabeling characteristics. Likewise, the 
larger-sized neurons (greater than 35 µm) with H3R-LI 
may be the source of the H3R-positive Aß fibers seen 
in the skin that supply lanceolate or Meissner endings 
(Fig. 2D-F). Interestingly, many if not most of the large 
neurons with H3R-LI also expressed CGRP and SP-LI. 
This is consistent with previous observations of low lev- 
els of CGRP and SP-LI in lanceolate and Meissner end- 
ings, even though the peptide immunoreactivity was 
usually below detectable levels in their Aß source axons 
(Fundin et al., 1997a; Rice et al., 1997; Pare et al., 2001). 
A bimodal distribution was observed among H3R- 
negative/NF-positive, medium- and large-sized neurons 
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Fig. 5. Immunochemical characterization of IIR expressing neurons in lumbar dorsal rout ganglia (UR( i) and supcnor : cnical ganglia (S(( j (. 
Sections of ganglia were all labeled with anti-H, R (red) and some sections were double labeled with other antibodies (green). Small size neurons are 
indicated by arrowheads, medium size neurons by straight arrows and large size neurons by curved arrows. Red indicators show neurons only labeled 
with anti-H, R, green indicators only neurons labeled with other antibodies, and yellow indicators neurons that are double labeled. Empty indicators 
show neurons that were regarded as having only background fluorescence. Scale bar = 25 µm. (A and B) Images from mouse DRG sections. Anti-I I, R 
labeled many of the small (red arrowhead), medium (red arrow), and large (red curved arrow) DRG neurons from a wild type mouse (A). Anti-I I, R is 
virtually eliminated in DRG neurons from a H1KO mouse (B) except for very low residual leveling on some relatively large neurons (red curved arrow). 
(C-H) Images from rat lumbar DRG sections. (C and D) Small neurons double labeled with anti-CGRP and anti-H, R (yellow arrowheads), only 
labeled with anti-CGRP (green arrowhead), or only labeled with anti-H, R (red arrowhead). Some small neurons were not labeled with either antibody 
(unfilled arrowheads). Most medium size neurons expressed both CGRP-IR and H, R-IR (yellow straight arrows). Large neurons were typically 
immunolabeled for both CGRP and H, R (yellow curved arrows) or were negative for both (unfilled curved arrows). (E and F) Overall, fewer neurons 
label with anti-SP than with anti-CGRP. Some small neurons were double labeled with anti-SP and anti-I IR (yellow arrowheads), only labeled with 
anti-SP (green arrowhead), or only labeled with anti-HAR (red arrowhead). Some small neurons were not labeled with either antibody (unfilled 
arrowheads). Most medium size neurons were immunolabeled for both SP and H, R (yellow arrows) or negative for both (unfilled arrow). The green 
straight arrow indicates a relatively rare medium size neuron that only expressed SP-IR. Some large neurons were double labeled with anti-SP and anti- 
H, R (yellow curved arrows), some were labeled only with anti-H, R (red curved arrow), and others were not labeled with either antibody (unfilled 
curved arrows). (G and H) Virtually all small neurons were NF-negative, whereas virtually all medium and large neurons were NF-positive. Small 
neurons were H, R-positive (red arrowheads) or negative (unfilled arrowheads). Medium and large neurons were 143R-positive (yellow straight arrows 
and curved arrows) or H, R -negative (green straight arrows and curved arrows). (I and J) Double labeling of rat superior cervical ganglia revealed 
neurons that coexpressed anti-NPY-IR and anti-H, -IR (yellow arrows) or that are positive only for NPY (green arrow) or HR (red arrow). 
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Fig. 6. Quantification of anti-H, R labeling in rat dorsal root ganglia. Distribution of cell sizes and labeling characteristics in rat lumbar DRG 
neurons as assessed in sections double labeled with anti-H3R and anti-NF (A) or with anti-H, R and anti-CGRP (B). Data were normalized from 
measurements of 758 cells in three L4 and L5 rat DRGs and the proportions were corrected for cell size. (A) After double labeling with anti-H, R and 
anti-NF, 33% of all presumptive neurons had H, R-LI. Most of these H, R-LI neurons were NF-positive (30% vs. 3%) and had medium to large 
diameters. I7% of all detected neurons were NF-positive and H R-negative and had a bimodal distribution among medium and large cells. 50% of 
presumptive neurons were negative for both H3R-Ll and NF-LI, and most had relatively small diameters. (B) After double labeling with anti-H, R 
and anti-CGRP, the actual detected proportions of H3R-positive and negative neurons are shown in the solid line enclosed bars and pie chart sectors. 
The actual percentages of double-labeled, single-labeled, and unlabeled neurons are shown by the numbers without brackets in the pie chart sectors. 
The proportion of anti-H, R labeled neurons in (B) was much higher (55%) than in (A) (33%), but presumably should be the same. This was most 
likely due to a failure to detect many unlabeled cells in the anti-H3R and anti-CGRP labeled sections (see Sections 2 and 3). To correct for this likely 
lack of detection, the total % of H3R-LI neurons observed in the anti-H3R and anti-CGRP (B) was normalized to 33% by adjusting the proportion of 
H3R-negative/CGRP-negative cells to reflect the level of H3R-negative neurons observed in the anti-HR and anti-NF labeled sections (A). The 
adjusted increase is indicated by broken line bars and pie sectors, and the adjusted percentages are the numbers shown in brackets in (B). With or 
without this adjustment, neurons with H3R-LI had predominantly medium to large diameters, with a 3: 1 ratio of CGRP-positive to CGRP-negative 
neurons (24% vs 9% in adjusted percentages). Based on adjusted percentages, 12% of the neurons were H, R-negative and CGRP-positive and had a 
bimodal distribution among small and medium diameters. Even without an adjustment, the neurons that lacked both H3R-Ll and CGRP-LI were 
skewed towards smaller diameters (white bars and white pie sector within solid lines). 
(Fig. 6A). The larger of these neurons may give rise to 
Aß fibers that innervate Merkel endings. As noted 
above, the Merkel cells in the epidermis of the glabrous 
skin and outer root sheath of whisker follicles expressed 
H3R-LI, but this labeling was not definitively evident on 
the Aß fibers that form endings on the Merkel cells. The 
more medium-sized H3R-negative/NF-positive neurons 
may be the source of A6 fibers that have been shown 
to innervate the epidermis, upper dermis and hair folli- 
Iles where no anti-H; R labeling was detected among 
thin-caliber fibers (Fundin et al., 1997a; Rice et al., 
1997; Fünfschilling et at., 2004). Likewise, about one- 
third of the small- to medium-sized anti-CGRP labeled 
neurons lacked H, R-LI (Fig. 6B). These cells may be 
sources of peptidergic C fibers (some of which terminate 
on arteries) and non-arterial peptidergic AS fibers that 
also lacked immunodetectable H3R in the skin (Fundin 
et al., 1997a, b; Rice et al., 1997). Regardless of some 
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discrepancy in the detection of unlabeled small neurons H3R. This is consistent with the lack of anti-H, R label- 
in anti-CGRP as compared to anti-NF double labeled ing on any C fibers in the skin of which most are non- 
section, most small neurons in both types of prepara- peptidergic (Fundin et al., 1997a, b; Rice et al., 1997; 
tions lacked immunodetectable CGRP, SP, NF, or Zylka et al., 2005). 
Fig. 7. Anti-H, R labeling in the dorsal horn of rats, wild tNl, c 1111. C. , tn. i I1, hU mice, I)i it, l cross sectional un, ; r, o iun, har shard cords (rant rat,, 
(A-I), wild type mice (J-L), and H3KO (M 0) mice. The sections are double labeled with anti-CGRP revealed by Cy2 or Alexa 488 conjugated 
secondary antibodies (left panels) and with the Chazot anti-H, R revealed by Cy3 conjugated antibodies (middle panels). Merged images are shown in 
the right panels. Fibers definitively labeled with only anti-CGRP are denoted by green indicators; with only anti-HIR by red indicators, and with 
both antibodies by yellow indicators. Scale bars, 25 µm. Anti-CGRP and anti-H, R labeling is shown at low magnification in the rat dorsal horn (A- 
C). Areas in (A-C) that include lamina V (white broken line boxes) and laminae I-III (white solid line boxes) are shown at higher magnification in 
(D-F) and (G-I), respectively. Comparable high magnification images of the superficial dorsal horn are shown for WT (J-L) and H, KO (M--O) mice. 
High magnification images from lamina V of mice are shown in insets in (J-O). As shown in (D-F) and in the insets in (J-L), most of the CGRP- 
positive fibers that ramify in lamina V coexpress H, LI (yellow arrows), whereas few fibers only express CGRP-LI (green arrowheads). As shown in 
the inset in E, some dorsal horn neurons deep to lamina II have faint levels of H, R-LI detectable primarily over the cell body. As shown in (G-L), 
anti-CGRP labeled fibers ramify extensively in superficial lamina and include fibers that express HR-LI (yellow arrows) and those that lack H, R-LI 
(green arrows). Some individual CGRP-positive fibers express H, R-LI (yellow arrowheads) and others lack H, R-Li (green arrowheads). Some thick- 
caliber Aß fibers passing through the superficial laminae have low levels of H, R-LI (red curved arrows). As seen in (M-O), HR-LI is absent on the 
CGRP-positive innervation in H3KO mice (green arrows and arrowheads), but very faint residual labeling persists on some Aß fibers (red curved 
arrows). 
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3.4. Anti-H3R labeling in superior cervical ganglia 
Although many previous functional studies suggested 
that the H3R may be located on sympathetic innervation 
(Ishikawa and Sperelakis, 1987; Molderings et al., 1992; 
Koss, 1994; Godlewski et al., 1997a, b), we rarely detect- 
ed H3R-LI on any NPY-positive fibers or on fibers in 
sites where sympathetic fibers are known to terminate 
on arteries. Therefore, we assessed anti-H3R labeling 
in superior cervical ganglia of rats in double label com- 
bination with an antibody against NPY which is widely 
expressed among adrenergic sympathetic neurons. These 
results revealed a heterogeneous mix with some neurons 
coexpressing NPY-LI and H3R-LI and others express- 
ing only NPY-LI or H3R-LI (Fig. 51 and J). 
3.5. Anti-H3R labeling in dorsal horn 
Consistent with the characteristics of H3R-positive 
cutaneous fibers, our immunofluorescence assessments 
of rat and wild type mouse spinal cords revealed H3R- 
LI on several thick and thin-caliber axons entering the 
superficial dorsal horn via dorsal roots (Fig. 7A-L). 
The thick-caliber, H3R-LI axons passed through lami- 
nae I and II and penetrated at least as far as lamina 
III in both species (Fig. 7G-I and J-L). Although a 
few cases were found in which thick-caliber, H3R-LI 
axons were also faintly labeled with anti-CGRP, most 
of the thick-caliber, H3R-LI axons were CGRP-negative 
(Fig. 2G-L). In contrast, thin-caliber, H3R-LI axons 
consistently co-expressed anti-CGRP labeling 
(Fig. 7D-L). Many of these thin-caliber fibers ramified 
extensively in lamina II, and some extended to and ram- 
ified in lamina V (Fig. 7D-F and J-L). These observa- 
tions suggest that the thin-caliber, H3R-LI fibers 
synapse on neurons in both locations. Interestingly, 
CGRP and H3R-LI was coexpressed on most of the 
fibers ramifying in lamina V, whereas lamina II also 
had many CGRP fiber ramifications that lacked H3R- 
LI. In general, CGRP-positive fibers that lacked H3R- 
LI were thinner than those that expressed H3R-LI. 
Superficial (i. e. laminae I-III) dorsal horn neurons 
appeared to lack H3R-LI. Sparsely scattered neurons 
in the deep dorsal horn and ventral horn were faintly 
labeled with anti H3R (inset, Fig. 7E) and lacked 
CGRP-IR making it unlikely that they were the source 
of any H3R/CGRP-positive fibers in the dorsal horn. 
Moreover, the sparsely scattered locations of these neu- 
rons did not correlate with the concentrated sites of 
H3R-LI fibers in the dorsal horn. In spinal sections from 
H3KO mice, H3R-LI was completely absent on thin-cal- 
iber axons in the superficial and deep dorsal horn 
(Fig. 7M-O). Although the labeling intensity was drasti- 
cally reduced, faint detectable H3R-LI was observed in 
H3KO mice on thick-caliber atTerents found in the lum- 
bar dorsal roots as well as thick-caliber fibers that 
passed through laminae I-II and entered into laminae 
III-V (Fig. 7M-O). 
4. Discussion 
Functional studies have suggested that H3Rs exist on 
sensory peptidergic C-fibers and on sympathetic effer- 
ents, but no previous immunochemical experiments 
have been reported. The present work has not confirmed 
these suggestions. Results with various combinations of 
double labeling found that H3R-LI was detectable only 
on (1) peptidergic presumptive AS fibers that innervate 
cutaneous arteries and on (2) Aß fibers that terminate 
in Meissner corpuscles in glabrous skin and as lanceo- 
late endings in hairy skin. H3R-LI was also present on 
epidermal keratinocytes, which contain H3R mRNA 
(Heron et al., 2001), as well as on Merkel cells in lamina 
basalis of the epidermis and the outer root sheath of 
whisker follicles. All of these H3R-positive structures 
contain CGRP-LI. Low levels of this labeling in kerati- 
nocytes were seen previously but disregarded as nonspe- 
cific (Rice et al., 1997; Rice and Rasmusson, 2000; Pare 
et al., 2001; Khodorova et al., 2003; Fünfschilling et al., 
2004). H3R-LI was not definitively evident on (1) pepti- 
dergic C fibers, non-peptidergic C fibers, or AS fibers 
that innervate the epidermis or hair follicles; (2) pepti- 
dergic C fibers or any sympathetic fibers that innervate 
vasculature; or (3) Aß-fibers that innervate Merkel cells. 
Our use of two antibodies from the same species, and 
the absence of confocal microscopy for double-labeling 
leave open the possibility that false positive colocaliza- 
tions were observed. However, the use of two different 
H3R antibodies, and the extensive control procedures 
employed minimize this possibility. 
The present findings strongly support the hypothesis 
that the H3R-LI labels the H3R. All present results were 
verified with two different antibodies targeted against 
different domains of the H3R. Both antibodies labeled 
CNS regions known to express this receptor (e. g. stria- 
turn, cerebral cortex, Pollard et al., 1993). All of the 
H3R-LI was eliminated or severely attenuated in H3R 
knockout skin, DRGs and CNS. We previously showed 
that the H3KO mice used presently lack H3R radioli- 
gand binding, and lack responses to H3R agonists 
(Cannon et al., 2003). Although H3R isoforms may exist 
(Tardivel-Lacombe et al., 2000; Coge et al., 2001; Drutel 
et al., 2001; Wellendorph et al., 2002; Rouleau et al., 
2004), the H3KO gene construct eliminated the coding 
for both antigenic epitopes used presently. 
In situ hybridization studies found moderate levels of 
H3R mRNA in rat DRGs (Heron et al., 2001), but the 
characteristics of the positive neurons were not elucidat- 
ed. Although our methods cannot determine which 
DRG neurons are the source of particular sensory fibers 
and endings, the size and immunochemical characteris- 
tics of the H3R-positive neurons are consistent with 
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the caliber and immunochemical characteristics of the 
H3R-positive cutaneous innervation. These neurons 
were primarily medium to large DRG cells that coex- 
pressed NF and CGRP-LI, consistent with our observa- 
tion that H3R-LI was expressed on particular types of 
peptidergic AS and Aß fibers. In contrast, the large neu- 
rons that lacked H3R-LI as well as CGRP-LI are consis- 
tent with the characteristics of Aß fibers that are the 
source of Merkel endings. Many of the medium size neu- 
rons with and without CGRP-LI were also NF-positive, 
but lacked H3R-LI. This is consistent with the presence 
of peptidergic and nonpeptidergic AS fibers in the upper 
dermis that innervate hair follicles and the epidermis 
(Fundin et al., 1997a; Rice et al., 1997; Fünfschilling 
et al., 2004). Importantly, most of the small DRG neu- 
rons lacked H3R-LI. These include CGRP-positive and 
negative neurons that are the source of peptidergic and 
nonpeptidergic C fibers. Cumulatively, our data indicate 
that, at least for cutaneous innervation, H3R functions 
previously attributed to sensory peptidergic C fibers 
are most likely to be mediated through peptidergic per- 
iarterial AS-fiber endings and perhaps Aß-fiber lanceo- 
late and Meissner endings. 
Although functional studies suggest that H3Rs exist 
on sympathetic innervation, H3R-LI was not detected 
on cutaneous sympathetic NPY-expressing fibers in the 
rat, and only a few double labeled fibers were seen in 
the mouse. Some NPY-positive/H3R-negative neurons 
were observed in the SCG which could be a source for 
the sympathetic cutaneous arterial innervation. Howev- 
er, most of the SCG neurons co-expressed H3R-LI and 
NPY-LI, implying an H3R localization on sympathetic 
neurons. Apparent mismatches between ganglion cell 
and axon immunochemistry have been noted previously 
(Fundin et al., 1997a; Rice et al., 1997). The lack of 
detectable H3R-LI on the arterial sympathetic fibers 
may be due to a diffuse distribution among their exten- 
sive terminal arborizations. Alternatively, the SCG may 
contain H3R-positive sympathetic neurons that inner- 
vate structures other than the skin. 
4.1. Functional roles for the H3R 
H3R agonists are known to inhibit neuropeptide 
release from presumed sensory fibers in the heart, lung, 
and skin. Consistent with this, H3R agonists have some 
anti-inflammatory and antinociceptive properties (Rou- 
leau et al., 1997,2000; Cannon et al., 2003, Cannon and 
Hough, 2005). The present results show that periarterial 
AS fibers possess the H3R and are likely to be a site of 
H3 agonist action. However, some Aß fibers, as well as 
keratinocytes, also have both H3R-LI and CORP immu- 
noreactivity, and therefore may also have functional 
significance. 
H3R antagonists have been reported to produce pru- 
ritus-like effects in mice, possibly mediated by C fibers 
(Schmelz et al., 1997; Hossen et al., 2003; Sugimoto 
et al., 2004). Because H3R-LI is present on keratinocytcs 
but not on epidermal endings, the former may partici- 
pate in these effects of H3R antagonists (also see Fitzsi- 
mons et al., 2001). Recently, keratinocytes have been 
shown to be critical mediators following the activation 
of endothelin B (Khodorova et al., 2003) and cannabi- 
noid CB2 receptors (Ibrahim et al., 2005). 
Although the lanceolate and Meissner endings that are 
supplied by H3R positive Aß-fibers are thought to be rap- 
idly adapting low threshold mechanoreceptors, the Mei- 
ssner endings express a wide range of immunochemical 
properties associated with nociception (Pare et al., 
2001). Both types of endings are also intimately affiliated 
with several types of C fibers (Fundin et al., 1997a; Pare 
et al., 2001). The functional importance of these chemical 
characteristics and potential interactions with the affiliat- 
ed C fibers in the skin has not been investigated. Howev- 
er, modulation of Aß fiber activity is known to affect pain 
sensations that have typically been attributed to C fiber 
and/or AS fiber activity. Peripheral, as well as central, 
mechanisms could account for these observations. 
We recently reported that pharmacological activation 
of spinal H3Rs inhibits mechanical nociceptive respons- 
es to tail pinch in wild type, but not, H3KO mice (Can- 
non et al., 2003). This effect is both modality- and 
intensity-specific (Cannon et al., 2003; Cannon and 
Hough, 2005). For example, noxious thermal responses 
are unaffected. The intensity of the mechanical stimulus 
needed to elicit these responses suggests that the relevant 
fibers are high threshold mechanoreceptors (HTM) 
(Burgess and Perl, 1967; Beck et al., 1974; Szolcsanyi 
et al., 1988; Yeomans and Proudfit, 1996; Ringkamp 
et al., 2001). Consistent with the spinal H3R inhibition 
of mechanical nociception, we detected H3R-LI on 
small-caliber CGRP-positive fibers ramifying in the 
superficial laminae of the dorsal horn, as well as in lam- 
ina V, which are known sites of HTM termination 
(Light and Perl, 1979). We hypothesize that these HTMs 
are the periarterial AS fibers. Consistent with this, AS 
HTMs in the deep dermis of guinea pigs were shown 
to be CGRP-immunoreactive (Lawson et al., 2002). 
We also found that these periarterial AS fibers coexpres- 
sed immunoreactivity for ASIC3, a channel which has 
been implicated in mechanical nociceptive transmission 
(Price et al., 2001). Conceivably, the high intensity 
mechanical stimulus needed to activate HTMs and the 
lack of thermal responsiveness may not be an inherent 
property of the fiber, but may be due to their relatively 
deep disposition in the skin. The close proximity of these 
fibers to blood vessels and their probable mechanosensi- 
tivity suggest the possibility that vasodilation could pro- 
vide local mechanical forces to activate these fibers. 
The H3R-mediated inhibition of neuropeptide release 
in skin may be an important mechanism to control the 
extent of inflammation that occurs during or following 
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injury. CGRP and SP, released during tissue damage, 
produce vasodilation and plasma extravasation (Lem- 
beck and Holzer, 1979; Brain and Williams, 1989; Saria, 
1984; Brain et al., 1992), which, in turn, allow the infil- 
tration of additional inflammatory mediators (Bar-Sha- 
vit et al., 1980; Payan et al., 1984; Helme and Andrews, 
1985; Hartung et al., 1986; Saito et al., 1986). Peptide 
release also activates mast cells to release histamine 
(Johnson and Erdos, 1973; Owen et al., 1980; Owen 
and Woodward, 1980). Subsequent activation of H1 
receptors on nociceptive fibers results in sensitization 
and increased pain (Owen and Woodward, 1980; Owen 
et al., 1980; Mobarakeh et al., 2000), but activation of 
H3Rs can inhibit further peptide release from such end- 
ings as the periarterial AS fibers, thereby limiting subse- 
quent inflammatory events (Dimitriadou et al., 1994; 
Ohkubo et al., 1995; Delaunois et al., 1995; Imamura 
et al., 1996; Dimitriadou et al., 1997; Nemmar et al., 
1999). Consistent with this, several studies have demon- 
strated that systemic administration of the H3R agonist 
immepip significantly attenuates formalin-induced paw 
swelling (Imamura et al., 1996; Cannon et al., unpub- 
lished). Thus, the injury-induced release of histamine 
may play a pro-nociceptive, pro-inflammatory role 
through H1 receptors, and/or an anti-inflammatory, 
antinociceptive role via H3Rs (Imamura et al., 1996). 
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ABSTRACT 
In this study, we report the homo- and hetero-oligomerization 
of the human histamine H4R by both biochemical (Western blot 
and immobilized metal affinity chromatography) and biophysi- 
cal [bioluminescence resonance energy transfer and time-re- 
solved fluorescence resonance energy transfer (tr-FRET)] tech- 
niques. The H4R receptor is the most recently discovered 
member of the histamine family of G-protein-coupled recep- 
tors. Using specific polyclonal antibodies raised against the 
C-terminal tail of the H4R, we demonstrate the presence of H4R 
oligomers in human embryonic kidney 293 and COS-7 cells 
heterologously overexpressing H4Rs and putative native H4R 
oligomers in human phytohaemagglutinin blasts endogenously 
expressing H4Rs. Moreover, we show that H4R homo-oll- 
gomers are formed constitutively, are formed at low receptor 
densities (300 fmol/mg of protein), and are present at the cell 
surface, as detected by tr-FRET. The formation of these oli- 
gomers is independent of N-glycosylation and is not modulated 
by H4R ligands, covering the full spectrum of agonists, neutral 
antagonists, and inverse agonists. Although we show H4R 
homo-oligomer formation at physiological expression levels, 
the detection of H, R-H4R hetero-oligomers was achieved only 
at higher H, R expression levels and are most likely not physi- 
ologically relevant. 
The human histamine H. receptor (hH4R), a prototypical 
member of the superfamily of G-protein-coupled receptors 
(GPCRs), has been identified recently through the use of 
bioinformatics by several groups simultaneously (Oda et al., 
2000; Liu et al., 2001; Morse et al., 2001; Nguyen et al., 2001; 
Zhu et al., 2001). The H4R couples to members of the G; /0 
family of heterotrimeric G-proteins to mediate the inhibition 
of adenylyl cyclase. In addition, the receptor may activate 
phospholipase C and induce calcium mobilization We Esch et 
al., 2005). The H4R expression is almost exclusively re- 
stricted to hematopoietic cells and is suggested to mediate 
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doi: 10.1124/mol. 105.020818. 
functions of the immune system. As such, the H4R is a target 
for the development of anti-inflammatory drugs (Hofstra et 
al., 2003; Thurmond et al., 2004; de Esch et al., 2005). 
The use of various biochemical and biophysical approaches 
has revealed recently that members of the GPCR family may 
exist as homo- and hetero-oligomers at the cell surface. When 
considering the heterotrimeric G protein, which is approxi- 
mately twice the size of the GPCR (Lambright et al., 1996), it 
seems reasonable that GPCRs need to oligomerize to interact 
with the G protein, as suggested for the leukotriene B4 re- 
ceptor (Baneres and Parello, 2003). Hetero-oligomerization 
has been shown to be pivotal for the GABABR1, which needs 
to associate with GABAnR2 receptors to be transported to the 
cell membrane (Jones et al., 1998), and for the T1R taste 
receptors, which require hetero-oligomerization to form re- 
ceptors that can recognize sweets (Nelson et al., 2001) or 
amino acids (Nelson et al., 2002). In other cases, hetero- 
oligomerization may change the ligand binding characteris- 
tics, potentially giving rise to a new dimension in GPCR drug 
ABBREVIATIONS: hH4R, human histamine H4 receptor GPCR, G-protein-coupled receptor, BRET, bioluminescence resonance energy transfer, 
tr-FRET, time-resolved fluorescence resonance energy transfer; HA, hemagglutinin; HEK, human embryonic kidney, eYFP, enhanced yellow 
fluorescent protein; Rluc, Renilla reniformis luciferase; PCR, polymerase chain reaction; APC, allophycocyanin; PHA, phytohemagglutinin; PBMC, 
peripheral blood mononuclear cell; PBS, phosphate-buffered saline; Nit*-NTA, nickel-nitrilotriacetic acid; JNJ 7777120,1-((5-chloro-1H-indol- 
2-ygcarbonyl]-4-m ethylpiperazine. 
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discovery (Devi, 2001; Terrillon and Bouvier, 2004; Waldhoer 
et al., 2005). 
We have reported previously the detection of homo-oli. 
gomers of the human histamine H1 receptor (H1R) by apply- 
ing biochemical and tr-FRET experiments and by the forma- 
tion of H1R radioligand binding sites upon the coexpression 
of two ligand binding-deficient mutant H1Rs (Bakker et al., 
2004). The H1R is a well-known target for the treatment of 
seasonal allergies but has also been shown to mediate inflam- 
matory responses in keratinocytes (Giustizieri et al., 2004; 
Matsubara et al., 2005). The H1R is ubiquitously expressed 
and is coexpressed together with the H, 4R in leukocytes, including monocytes and T lymphocytes (Cameron et al., 
1986; Morse et al., 2001), suggesting that on these cells, 
histamine may modulate inflammatory actions through the 
action on both H1Rs and H4Rs. We therefore investigated the 
potential homo-oligomerization of the H4R and the hetero. 
oligomerization of the H1R with the H4R using heterologous 
expression systems. 
Herein, we report on the generation of specific antibodies 
raised against the H4R, the detection of homo-oligomers of 
the H4R, and the potential formation of H1R-H4R hetero- 
oligomers by using biochemical and BRET and tr-FRET ap- 
proaches. Using these methodologies, we show the human 
H4R to constitutively form homo-oligomers at the cell surface 
and that the oligomerization is independent of ligand stimu- 
lation of the receptors. Furthermore, N-glycosylation of the 
H4R receptor is not a prerequisite for oligomer formation. 
Although we can detect H4R homo-oligomers at physiologi- 
cally relevant H4R expression levels and in endogenously 
H4R expressing PHA blast cells, the detection of H1R-H4R 
hetero-oligomers requires higher receptor expression levels. 
Materials and Methods 
Materials. Reagents for tr-FRET were from Cis Bio International 
(Bagnols-sur-CPze Cedex, France). Coelenterazine was purchased 
from Chemicon International (Temecula, CA). Sheep anti-mouse IgG 
horseradish peroxidase was from GE Healthcare (Little Chalfont, 
Buckinghamshire, UK). Bovine serum albumin, chloroquine diphos- 
phate, DEAE-dextran (chloride form), histamine (2-14-imidazolyl. 
jethylamine hydrochloride), mepyramine (pyrilamine maleate), 
monoclonal mouse anti-FLAG (DYKDDDDK), and polyethylenei- 
mine were purchased from Sigma (St. Louis, MO). Calf serum (Inte- 
gro BV, Dieren, The Netherlands). Cell culture media, penicillin, and 
streptomycin were obtained from Invitrogen (Merelbeke, Belgium). 
Cell culture plastics were from Greiner Bio-one (Wemmel, Belgium). 
Tris was from AppliChem (Darmstadt, Germany). [9H]Histamine 
(12.40 and 18.10 Ci/mmol) and ['Hlmepyramine (23.00 Ci/mmol) 
were purchased from PerkinElmer Life Science (Boston, MA). Oligo- 
nucleotides were purchased from Isogen Biocience (Maarsen, The 
Netherlands). Pfu Turbo DNA polymerase was purchased from 
Stratagene (La Jolla, CA). Restriction enzymes were from MBI Fer- 
mentas (St. Leon-Rot, Germany). Thioperamide, iodophenpropit, clo- 
benpropit, and JNJ 7777120 were synthesized at the Department of 
Medicinal Chemistry, Vrije Universiteit Amsterdam (Amsterdam, 
The Netherlands). Gifts of mouse anti-hemagglutinin (anti-ILA) an- 
tibody (Dr. J. van Minnen), pcDNA3.1-eYFP vector (Dr. T. Schmidt), 
pRL-CMV vector (Dr. G. Milligan), pCR3.1-HA-H1R and pcDEFs-c- 
myc-H1R (Dr. S Hill), expression vector pcDEF3 (Dr. J. Langer) 
(Goldman et al., 1996), and mianserin (Organon NV, Oss, The Neth. 
erlands) are greatly acknowledged. 
Wild-type human H4R in pcDNA3.1 was purchased from Guthrie 
cDNA resource center (Sayre, PA). The vector was subcloned into the 
pcDEFs using BamHI/XbaI sites. 
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Construction of Epitope-Tagged Proteins for er-FRET. An 
N-terminally FLAG (DYKDDDDK) epitope-tagged 114R was created 
by PCR. The coding sequence of the h114 gene was amplified using 
the sense oligonucleotide primer 5'. GGGAAGC GCCACCATGGA- 
CTACAAGGACGACGATGACAAGGATCQAGATACTAATAGCA- 
C-3' and the antisense primer 6'-GGAAGG CACGGGGGAGGGC-3'. 
The amplified gene was first cloned into the pCRII-Topo vector by 
TOPO TA cloning (Invitrogen BV, Breda, The Netherlands) and 
subsequently subcloned into the pcDEFs expression vector using 
EcoRV/XbaI sites. 
An N-terminally HIA (YPYDVPDYA) epitope-tagged H4R was cre- 
ated by PCR in two steps. The H4R gene was amplified by PCR with 
a 6' SacII site and without start codon using the sense primer 
5'-ACCGCGGCCCCAGATACTA_ ATAGCACAATC-3'and the anti- 
sense primer 5'-GGAAGGCACGGGGAGGGC-3'. The fragment was 
directly cloned to the pCRII-Topo vector. The gene was subsequently 
subcloned using SaclI/Xba1 sites into the pcDNA3.1-ILA-rHSAR vec- 
tor (Bakker et al., 2006). The HA-H4 gene was finally subcloned 
using BamHUXbaI sites to pcDEFs. The HIA-1L1R gene was subcloned 
from the pCR3.1. HA-H1R into the pcDEF3 using Bspl4071/Spel re- 
striction sites. 
Construction of Fusion Proteins for BRET. For the BRET 
assay, H4Rs were C-terminally fused to either a Renilla reniformia 
luciferase (114R-Rluc) or a yellow fluorescent protein (H4R-eYFP) in 
two steps. The coding sequence of the h114R gene was amplified 
without its stop codon using the sense primer 5'-TCGaGATCCAC- 
CATGCCAGATACTAATAGC-3' and the antisense primer 5'- 
CCGCGGC CGCACTAGTAGAAGATACTGACCGAC-3', harboring 
unique BamHI and Notl restriction sites, respectively. The gene was 
cloned directly into the pCRII-Topo vector and subsequently sub- 
cloned to a pcDEFs vector using Bam11UNotI sites [pcDEFs-H4R (Del 
stop)]. 
The coding sequence for the Rluc gene was amplified from the 
pRtrCMV vector lacking a start codon and harboring a NotI restric- 
tion site using the sense primer 5'-AGCGGCCGCGACTTC- 
GAAAGTTTATGATCC-3' and the antisense primer 5'-TCTAGAAT- 
TATTGTTCATTTTTGAG-3'. The gene was directly cloned to the 
pCRII-Topo vector and subsequently subcloned in frame using NotI/ 
Xbal sites into the pcDEFs-H4R (Del stop) vector. 
The coding sequence for the eYFP gene was amplified from the 
pcDNA3.1-eYFP vector lacking a start codon and harboring a Notl 
restriction site using the sense primer 5'-CGCGGCCGCGGTGAG- 
CAAGGGCGAGGAG-3' and the antisense primer 5'-GTCTAGAT- 
TACTTGTACAGCTCGTCCATG-3'. The gene was directly cloned to 
the pCRII-Topo vector and subsequently subcloned in frame using 
NotI/XbaI sites into the pcDEFs-114R (Del stop) vector. 
An h1L1R-eYFP fusion was generated by PCR using the sense 
primer5'-AAGAGAATTCTGCATATTCGCTCCATGGTGAGCAAG- 
GGCG-3' and the antisense primer 5'-TTCTCTAGATTACTTGTAC- 
AGCTCGTCC-3', harboring unique EcoRI and XbaI restriction sites, 
using pcDNA3. leYFP as template. The PCR fragment was digested 
using EcoRl and XbaI, and the purified fragment was subsequently 
ligated together with the fragment that was obtained by digestion of 
the pcDEFs-hHIR plasmid using EcoRI/Xbal sites. 
An h1L1R-Rluc fusion was generated by PCR using the sense 
primer 6'-AAGA VTGCATATTCGCTCCATGACTTCGAAAG- 
TTTATGATCC-3' and the antisense primer 5'-CGCTCTAGAATTA- 
TTGTTCATTTTTGAGAACTCGC-3', harboring unique EcoRI and 
XbaI restriction sites. The PCR fragment was digested using EcoRI 
and XbaI and the purified fragment was subsequently ligated toge. 
ther with the fragment that was obtained by digestion of the pcDE- 
Fs-hHIR plasmid using EcoRI/XbaI sites. Each construct was fully 
sequenced before its expression and analysis. 
Construction of Ilis10-Tagged Proteins for Immobilization. 
An N-terminally c-myc (EQKLISEEDL) and C-terminally Hislo- 
epitope-tagged H4R was created as follows. First, a c-myc epitope- 
tagged 114R was created by PCR in two steps. The c-myc tag was 
amplified by PCR using a pcDEFs-c-myc-H1R vector as template 
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with a 3'-NheI site using the sense primer 5'-GGGTGGAGAC 
TGAAGTTAGGCC-S'and the antisense primer 5'. GTGCTAGCAG- 
GTCCTCCTCGGAG-3'. The fragment was directly cloned to the 
pCRII-Topo vector (pCRII-topo-myc). The H4R gene was amplified 
without start codon and contained a 5'-NheI restriction site using 
the following sense 5'-CCGCTAGCCAGATACTAATAGCAC-3' and 
the antisense primer 5'- TCTTTAAGAAGATACTGACC-3', The gene 
was directly cloned to the pcDNA3.1N5-His-Topo vector. The H4R 
gene was subsequently subcloned in frame using Nhel/NotI into the 
pCRII-topo-c-myc vector (pCRII-topo-c-myc-H4R). The c-myc. H4R 
gene was subsequently subcloned into the pcDEF3 expression vector 
using the BamHI/Xbal sites. 
Second, the gene of the wild-type H4R was amplified by PCR 
without a start and stop codon with a 5'-BamHI site and a 3'-SpeI 
site using the sense primer 5'-CCGG ATCCCCAGATACTAATAG. 
CACAATCAA-3' and the antisense primer 5'-CCGCGGCCG CAC- 
TAGTAGAAGATACTGACCGAC-3' and directly cloned into the pC. 
RII-Topo vector. The H4R gene was then subcloned in frame from the 
pCRII-topo-vector using BamHI/SpeI sites in the pSFV2genB vector. 
An N-terminally tagged FLAG and C-terminally tagged H4R-Hisao 
gene was subcloned from the pSFV2genB-FLAG-H4R-Hisao behind 
the p10 promoter of the pFastbac_DUAL vector using Ncol/NheI 
restriction sites. 
The H4R-Hisao gene was amplified by PCR from the pFastbac_ 
DUAL-FLAG-H4R-Hisao vector without start codon and a 3'-XbaI 
site using the sense primer 5'-CATCTAGATTAATTACCCACT. 
GGGCCC-3'and the antisense primer 5'-GAGGATCCGCCAGATAC- 
TAATAGCACAATC-3' and directly cloned into the pcDNA3.1N5- 
His-Topo vector by TOPO TA cloning and subsequently subcloned 
into the pcDEFs-c-myc-H4R vector using BoxI/XbaI restriction sites. 
Each construct was fully sequenced before its expression and anal- 
ysis. 
Cell Culture and Transfection of COS-7 Cells. COS-7 African 
green monkey kidney cells were maintained at 37°C humidified in 
6% C02195% air atmosphere in Dulbecco's modified Eagle's medium 
supplemented with 5% (v/v) fetal calf serum, 50 IU/ml penicillin and 
50 µg/ml streptomycin and grown in 100-mm dishes. Cells were 
transiently transfected using the DEAE-dextran method as de- 
scribed previously (Bakker et al., 2001). The total amount of DNA 
transfected was maintained constant by the addition of pcDEF3, 
Cell Culture and Transfection of HEK 293 Cells. HEK 293 
cells were maintained at 37°C humidified in 5% C02/95% air atmo- 
sphere in Dulbecco's modified Eagle's medium/F. 12 (Cambrex, Not- 
tingham, UK) supplemented with 10% (v/v) fetal calf serum, 50 
IU/ml penicillin, and 50 µg/ml streptomycin and grown in 100-mm 
dishes. HEK 293 cells were transfected with pcDEFs-H4R receptor 
essentially using the Lipofectamine Plus method described by Shen- 
ton et al. (2005). In brief, for each cDNA, two microtubes were 
prepared: tube 1 contained 2µg of cDNA, 6 pl of Lipofectamine Plus 
reagent (Invitrogen), and 150 pl of Opti-MEM I media (Invitrogen); 
tube 2 contained 5 pl of Lipofectamine reagent (Invitrogen) and 150 
pl of Opti-MEM I media. The mixtures were incubated at room 
temperature for 15 min, after which the contents of tube 2 were 
added to tube 1, followed by a further 15-min incubation. In the 
meantime, the HEK 293 cells at 50 to 80% confluence in 2-ml Petri 
dishes were washed three times with Opti-MEM I media. At the end 
of the second incubation period, the contents of tube 1 were increased 
to 1.5 ml with Optimem-I media and added to the washed HEK 293 
cells. The cells were incubated at 37°C for 6 h. The transfection 
mixture was then removed and replaced with growth media. The 
cells were harvested 48 h after transfection, and cell homogenates 
were prepared for immunoblotting. 
[3H]Histamine Binding Studies. Cells used for radioligand 
binding studies were harvested 48 h after transfection and homoge. 
nized in ice-cold H4R binding buffer (50 mM Tris, pH 7.4). For 
saturation isotherms, cell membrane homogenates were incubated 
at 37°C for 60 min with 0 to 125 nM [3H]histamine in a total assay 
volume of 200 µl. Nonspecific binding was determined by incubation 
in the presence of 10 µM JNJ 7777120. For competition binding 
assays, the cell homogenates were incubated at 37°C for 60 min with 
0.1 to 10,000 nM ligand in the presence of -16 nM [31I]histamine in 
a total volume of 200 µl. The incubations were stopped by rapid 
dilution with ice-cold 114R binding buffer. The bound radioactivity 
was separated by filtration through GF/C filter plates (Whatman, 
Maidstone, UK) that had been treated with 0.3% polyethyleneimine. 
Filters were washed four times with 114R binding buffer, and radio. 
activity retained on the filters was measured by liquid scintillation 
counting. 
[3H]Mepyramine Binding Studies. Cells used for radioligand 
binding studies were harvested 48 h after transfection and homoge- 
nized in ice-cold H1R binding buffer (50 mM Na"/potassium phos. 
phate buffer, p11 7.4). For saturation isotherms, cell membrane ho- 
mogenates were incubated at room temperature for 30 min with 0 to 
25 nM [3H] mepyramine in a total assay volume of 200 µl. Nonspecific 
binding was determined by incubation in the presence of 1 µM 
mianserin. For competition binding assays, the cell homogenates 
were incubated at room temperature for 30 min with 0.1 to 10,000 
nM in the presence of -1.5 nM 1311lmepyramine in a total volume of 
200 Al. The incubations were stopped by rapid dilution with ice-cold 
H1R binding buffer. The bound radioactivity was separated by filtra- 
tion through Whatman GF/C filter plates that had been treated with 
0.3% polyethyleneimine. Filters were washed four times with H1R 
binding buffer, and radioactivity retained on the filters was mea- 
sured by liquid scintillation counting. 
Anti-H4R Antibody Generation. The unique peptide corre- 
sponding to the amino acids CIKKQPLPSQHSRSVSS of the human 
H4R subtype was conjugated to thyroglobulin by the cysteine-cou- 
pling method (Chazot et al., 1998). The resultant conjugate was used 
to generate polyclonal antibodies in rabbits. Antibody production 
and affinity purification was performed as described previously 
(Chazot et al., 2001). 
Production of Human PHA Blasts. Human peripheral blood 
mononuclear cells (PBMCs) stimulated with phytohemagglutinin 
(PHA blasts) were generated essentially as described previously 
(Bradford et al., 2005). In brief, heparinized human whole blood was 
obtained from healthy volunteers (with local ethical approval), and 
PBMCs were separated using Lymphoprep (Axis-Shield Poc AS, 
Oslo, Norway) and centrifuged at 400g for 25 min. The PBMCs were 
isolated from the interfacial layer, washed twice in RPMI 1640 
medium without L-glutamine (Invitrogen), and resuspended in RPMI 
1640 medium complemented with 10% (v/v) fetal calf serum, 1% (v/v) 
penicillin and streptomycin, and 1% (v/v) 1-glutamine. Cell density 
was adjusted accordingly to 1X 106 cells/ml with RPMI 1640 me- 
dium. Next, 100 µl of PHA (Lectin; Sigma, Poole, Dorset, UK) was 
added to the cells to make PHA blasts. These were grown in culture 
for 24 h, harvested, and a cell homogenate was prepared in the 
presence of protease inhibitors (Protease Inhibitor Cocktail III; Cal- 
biochem, Beeston, Nottingham, UK). 
Immunoblotting. SDS-polyacrylamide gel electrophoresis was 
carried out using 6 or 7.5% polyacrylamide slab gels under reducing 
conditions. Samples of HEK 293 cells, COS-7 cells, and PHA blasts 
(20-50 µg of protein) were prepared using a chloroform/methanol 
method of protein precipitation, and immunoblotting was performed 
as described previously (Chazot et al., 2001; Bakker et al., 2006). 
Immunoblots were probed with anti-Ii4 374-390 antibody at a con- 
centration of 0.5 µg/ml. 
Blots containing FLAG or c-myc-tagged receptors were probed 
with primary antibodies, mouse anti-FLAG (1.5 µg/ml), or mouse 
anti-c-myc (1 µg/ml), respectively. Horseradish peroxidase-conju- 
gated goat anti-mouse antibodies (1: 2000-5000) were used as sec- 
ondary antibodies. 
Immunoprecipitation. IIEK 293 cells were transfected with 
HA-H4 receptor and solubilized with 1% Triton X-100/0.15 M NaCl 
for 30 min at 4°C. Immunoprecipitation was performed essentially as 
described previously (Chazot et al., 1994). Solubilized HEK 293 cell 
extracts were incubated with 5 µg of rat anti-1IA antibody (Roche 
Diagnostics, Mannheim, Germany) or rat nonimmune Ig (ADI, San 
Antonio, TX) at 4°C for 1 h. Prechilled, washed Protein G agarose 
slurry (50 Al; Sigma) was added and incubated for 1h at 4°C on a 
rocking platform. Precipitation pellets were collected by centrifuga. 
tion at 10,000g for 30 s at 4°C, washed with 3X PBS, resuspended in 
sample buffer, vortex-mixed, and heated to 90 to 100°C for 3 min. 
The sample was then recentrifuged, and the supernatant was sub- 
jected to immunoblotting. Control experiments were performed us- 
ing untransfected HEX 293 cells. 
Cross-Linking Experiments. The cross-linking method used 
was essentially as described by Shenton et al. (2005; Bakker et al., 
2006). In brief, aliquots of COS-7 cells expressing c-myc-H4Rs were 
pelleted, and the suspension buffer was removed and replaced with 
150 µl of cross-linking buffer (150 mM NaCl, 100 mM sodium 
HEPES, 5 mM EDTA, pH 7.5, and 5 mM dithiothreitol) to give a final 
protein concentration of approximately 0.5 mg/ml. The cross-linker 
[bis(sulfosuccinimidyl) suberate sodium salt] was dissolved in 20 mM 
HCl to give a 100 mM stock solution. The tubes were incubated at 
room temperature with continual mixing for 12 min with 0.25,0.5, 
1.0, and 2 mM cross-linker, centrifuged at 10,000 rpm for 5 min, the 
cross-linking mixture was removed, and the resultant pellet was 
prepared for immunoblotting. 
Tunicamycin Experiments. HEK 293 cells expressing H, Rs 
were incubated with 2,4,6, and 8 µg/ml tunicamycin (stock dissolved 
in dimethyl sulfoxide at 2 mg/ml) immediately after transfection and 
were harvested 48 h after transfection, homogenized, and subjected 
to immunoblotting (Chazot et al., 1995). Cells grown in the absence 
of tunicamycin were incubated with the respective volume of di- 
methyl sulfoxide. 
Deglycosylation of Native H4 Receptor. Human PHA blast 
cell suspensions were resuspended in deglycosylation buffer (50 µM 
sodium phosphate, pH 6.0, containing 0.1% SDS, 0.1% ß-mercapto- 
ethanol, and 20 mM EDTA) and incubated with either water (con- 
trol) or PNGase F enzyme (Sigma) at a final enzyme concentration of 
400 IU/ml (test) for 16 hat 37°C. The samples were then subjected to 
immunoblotting and probed with anti-H4 374-390 antibody at a 
concentration of 2 gg/ml. The NMDAR1 transfected into HEK 293 
cells was used as a positive control essentially as described by Chazot 
et al. (1992). 
Receptor Immobilization. Membranes of COS-7 cells tran- 
siently expressing c-myc-H4R-His and FLAG-H4R or HA-H1R-His 
and FLAG-H4R receptors were homogenized, solubilized, and subse- 
quently immobilized on Niz+-NTA columns (Invitrogen) as described 
previously (Bakker et al., 2006). Immobilized receptors were eluted 
using 250 mM imidazole. Samples were prepared for immunoblot. 
ting and were subjected to chloroform/methanol extraction loaded on 
a 7.5% SDS page gel and subsequently blotted on nitrocellulose 
paper (GE Healthcare). 
BRET Assay. Forty-eight hours after transfection, cells were 
detached with trypsin and washed twice with PBS. Approximately 
50,000 cells per well were distributed in white-bottomed 96-well 
microplates (Corning By, Schiphol-Rijk, The Netherlands). Coelen- 
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terazine was added to a final concentration of 6µM, and readings 
were collected immediately after this addition using a Victors allow- 
ing signal detection at 460 and 630 nm. 
tr"FRET Assay. tr-FRET assays were performed using Europium 
(Eus`)-labeled and allophyocyanin anti-FLAG and anti-HA antibod- 
ies as described by Bakker et al. (2006). In brief, tr-FRET was 
assessed in 1X 106 whole COS-7 cells transiently expressing the 
appropriate HA- and FLAG-tagged receptors. Cells were incubated 
in PBS containing 60% fetal calf serum (v/v), 0.8 nM Eus'-labeled 
antibody, and 8 nM allophycocyanin-labeled antibody for 2h at room 
temperature on a rotating wheel, after which the membranes were 
washed twice with PBS. The final pellet was resuspended in 50 µl of 
PBS and transferred to a 384-microtiter plate. Energy transfer was 
measured by exciting the Eus+ at 320 nm and monitoring the XL-665 
allophycocyanin emission for 500 µs at 665 nm using a Novostar 
(BMG LabTechnologies, Offenburg, Germany) configured for time- 
resolved fluorescence after a 100-µs delay. 
Analytical Methods. Binding data were evaluated by a nonlin- 
ear least-squares curve-fitting program using Prism software 
(GraphPad Software Inc., San Diego, CA). Protein concentrations 
were determined according to Bradford's method (1976) using bovine 
serum albumin as standard. All data are represented as mean ± 
S. E. M. from at least three independent experiments performed in 
triplicate. Statistical significance was determined by a Student's 
unpaired t test (p < 0.05 was considered statistically significant). 
Results 
Pharmacological Characterization of the hII4R and 
hH1R Expressed in COS-7 Cells. We have used COS-7 
cells previously successfully for the heterologous expression 
of the hH1R and for the identification of H1R oligomers (Bak- 
ker et al., 2004). To investigate the potential oligomerization 
of the hH4R, we therefore expressed the hH4R heterologously 
in COS-7 cells. Transfection of these cells with cDNA coding 
for the hH4R resulted in the expression of a high-affinity 
[3Hjhistamine binding site (Table 1). Subsequent displace- 
ment studies using [3H]histamine as a radioligand revealed 
these binding sites to display a characteristic H4R pharma- 
cological profile (Table 1). The H1R and H4R constructs used 
in the tr-FRET, BRET, and immobilization assays were also 
characterized by radioligand binding (saturation and dis- 
placement) assays. COS-7 cells were transiently transfected 
with cDNA encoding the HA-H4R, FLAG-H4R, HR-Rluc, 
H4R-eYFP, c-myc-H4R-His, HA-H1R, H1R-Rluc, or the H1R- 
eYFP. [3H]Histamine bound to the H4Rs according to a one- 
site saturable model with Hill slopes of approximately 1 and 
dissociation constants (Kd) similar to those of the wild-type 
hH4R, although the B.. value is affected by fusion of the R. 
reniformis luciferase enzyme (Table 1). Bound [3Hjhistamine 
TABLE 1 
Characterization of epitope-tagged and H4R fusion constructs 
The pKK values of histamine and thioperamide for the H4R constructs used in the experiments were determined by [sii]histamine saturation and displacement binding assays. 
The pECso values of histamine and thioperamide were determined using a CRE-luciferase reporter gene assay. The values are expressed as mean s S. E. 
M. of at least three 
separate experiments performed in triplicate. 
Receptor 
[3H]Histamine 
Kd Bmaa 
pKi pECyO 
nM pmollmgprotein 
Wild-type H4R 19.9 ± 1.4 1.0 ± 1.4 
HA-H4R 23.2 ± 0.6 2.0 ± 0.5 
FLAG-H, R 26.3 ± 5.5 1.3 ± 0.3 
H, R-Rluc 30.8 ± 2.3 0.1 ± 0.02 
H4R-eYFP 57.4 2: 3.6 1.1 = 0.3 
c-myc-H4R-His, o 33.3 ± 2.0 2.6 ± 0.5 
Histamine Thioperamide Histamine Thioperamide 
7.620.1 7.3±0.1 8.8 0.2 6.420.3 
7.4 ± 0.1 7.0±0.1 8.90.2 6.420.2 
7.620.1 7.420.1 9.0±0.1 6.5 ± 0.4 
7.6=0.1 7.4.0.1 9.0 ± 0.1 6.0 ± 0.3 
7.2±0.1 7.320.2 8.6±0.3 5.7±0.1 
7.320.1 7.6±0.1 9.0 ± 0.1 6.3±0.3 
608 van Rijn et al. 
could be displaced from all of the N- and/or C-terminally 
tagged H4Rs by the agonist histamine and the inverse ago- 
nist thioperamide with affinity values (pK, ) comparable with 
the wild-type (Table 1). Likewise, the H1R radioligand 
[3H]mepyramine bound the various hH1R constructs accord- 
ing to a one-site saturable binding model with Kd values 
similar to those of the wild-type hH1R (data not shown). The 
agonist histamine and H1R inverse agonist mepyramine 
were able to displace the radioligand with affinities equal to 
those of the wild-type H1R (data not shown). The aforemen- 
tioned H4R constructs were functionally characterized using 
a cAMP response element-luciferase-luciferase reporter gene 
assay. In these assays, histamine behaved as a full H4R 
agonist and thioperamide as a full inverse H4R agonist for 
each H4R construct, with pEC50 values comparable with 
those obtained for the wild-type H4R (Table 1). 
Generation of hH4R-Specific Antibodies. To enable 
our biochemical approaches and to study H4R function in 
native tissue, we raised a rabbit polyclonal anti-hH4 (374- 
390) receptor antibody, which represents the first published 
selective immunological probe for the hH4R. The antibody 
was generated against the last 17 amino acids of the C- 
terminal tail of the H4R (Fig. W. The selectivity of the 
anti-hH4R antibody was confirmed by blockade with the C- 
terminal peptide of the H4R (Fig. 1B, lane 3) and a lack of 
A 
72- 
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9. 
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hH3(u5)R -+ pep -+ pep 
hH4R PHA blasts 
Fig. 1. Characterization of specific polyclonal H4R antibodies. A, snake 
plot of the hH4R; the region of the C-terminal tail (374-390) against 
which the antibody was raised is marked in gray. HEK 293 cells express- 
ing hH3144b, Rs or hH4Rs (B), and human PHA blasts (C) were probed by 
immunoblotting using the anti-H4 (374-390) antibody (0.5 µg/ml) either 
alone or preincubated for 16 h at 4°C with 500 µg/ml (374-390) peptide. 
The major immunoreactive species labeled in the HEK 293 hH4R and 
the human PHA blasts were greatly suppressed by preincubation with 
the antigen peptide (B, lane 3; and C, lane 2, respectively), demonstrating 
the sequence selectivity of the antibody. Furthermore, no significant 
labeling of the hH31441)R (B, lane 1) or in untransfected HEK 293 cells 
(data not shown) was detected. 
cross reactivity with the human H. R, the most related GPCR 
(de Esch et al., 2005) (Fig. 1B, lane 1). In transfected HEK 
293 cells, the antibody detects two major reactive species at 
34 to 36 and 65 to 72 kDa (Fig. 1B, lane 2). The lower bands 
most likely represent monomeric H4Rs. An additional band 
(approximately 45 kDa) was occasionally detected; such 
bands are likely to represent a proteolytic fragment. We 
suspect the 34-kDa species to be the unglycosylated product 
of the species at 36 kDa. The higher molecular mass species 
could either represent a heavily glycosylated form of the H4R 
or dimeric H4Rs. 
Evidence that Native H4R Are Robust Dimers. The 
H4R clearly plays a role as an immune modulator, with 
mRNA expression shown in human mast cells, neutrophils, 
eosinophils, and T lymphocytes (Nakamura et al., 2000; Oda 
et al., 2000; Morse et al., 2001; Zhu et al., 2001; Gantner et 
al., 2002; Hofstra et al., 2003). A single major diffuse immu- 
noreactive species (approximately 77 kDa) coincident with 
the putative recombinant dimeric hH4R species expressed in 
COS-7 cells was detected in human PHA blasts (Fig. 1C, lane 
1). This species was abolished by preincubation with the 
374-390 peptide, again demonstrating the peptide selectivity 
of the antibody. Little or no protein monomers were detected 
in the native preparation, consistent with our previous data 
with the H3R (Chazot et al., 2001; Bakker et al., 2006). It is 
noteworthy that these experiments were performed under 
reducing conditions, indicating the robust nature of the 
dimeric species in native tissue. An identical labeling pattern 
was detected with the anti-hH4 374-390 antibody probing 
human spleen lysates (data not shown). The putative dimeric 
recombinant hH4R species expressed in HEK 293 cells was 
consistently smaller (approximately 72 kDa), which may re- 
flect differential glycosylation in the two cell lines (Fig. 3). 
Coincident protein species were detected by the anti-hH4 
374-390 and the anti-epitope-tagged antibodies in the re- 
spective cell lines, further confirming that the hH4 receptor is 
being labeled by the anti-hH4 374-390 antibody (data not 
shown). No signal was detected in either COS-7 or HEK 293 
cell lines, further supporting the selectivity of the anti-hH4 
374-390 antibody. These data identify for the first time the 
H4R protein in human T lymphocytes. 
Immunoprecipitation of Recombinantly Expressed 
HA-H4Rs from HEK 293 Cells. To further characterize the 
selectivity of the H4R antibody, an immunoprecipitation as- 
say was performed. HA-H4Rs expressed transiently in HEK 
293 cells (Fig. 2, lanes 3-5) were immunoprecipitated using 
anti-HA antibodies (Fig. 2, lane 4) or a nonimmune Ig (Fig. 2, 
lane 3). As negative controls, nontransfected HEK 293 cells 
(Fig. 2, lane 1) and nontransfected HEK 293 cells immuno- 
precipitated with anti-HA antibodies (Fig. 2, lane 2) were 
used. As positive control, solubilized HEK 293 cells express- 
ing HA-H4Rs (Fig. 2, lane 5) was used. All samples were 
subjected to immunoblotting using the anti-H4R antibodies. 
Immunoreactive species were only detected for the HEK 293 
cells expressing the HA-H4R, which had been anti-HA-im- 
munoprecipitated (Fig. 2, lane 4). The immunoreactive spe- 
cies represent the putative monomeric and dimeric H4R and 
are identical with the reactive species in the positive control 
(Fig. 2, lane 5). 
Cross-Linking of H4Rs. To further investigate the homo- 
oligomeric structure of the H4R, a cross-linking study was 
performed using N-terminally c-myc-tagged H4R expressed 
in COS-7 cells. Upon application of increasing concentrations 
of the cell-impermeable cross-linker BS3, a progressive re- 
duction in the monomeric doublet species (34 and 36 kDa) 
kDa 1 2345 
72-º º. ý fa 
36- 
IP 
abdo ý 
HA 19 HA 
WS H4 H4 H4 H4 H4 
Fig. 2. The anti-H4R antibodies recognize anti-HA immunoprecipitated 
(IP) HA-H4Rs. HEK 293 cells alone (lanes 1 and 2) or transfected with 
cDNA encoding the HA-H4R (lanes 3-5) were subjected to immunopre- 
cipitation with an anti-HA antibody (lanes 2 and 4) or a nonimmune Ig 
(lane 3). The precipitates (lanes 2-4) or solubilized cells (lanes 1 and 5) 
were immunoblotted using the anti-H4R antibody. 
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was observed (Fig. W. Concomitant the appearance of, ini- 
tially, a diffuse species of 77 kDa (putative glycosylated and 
unglycosylated dimers) and then higher molecular mass spe- 
cies (> 175 kDa) at 0.25 mM and 2 mM BS3, respectively, was 
noticed (Fig. W. These data are highly consistent with 
hH4Rs expressed in HEK 293 cells (data not shown). 
Biochemical Evidence that the hH4Rs Is an N-Glyco- 
sylated Homodimer. In the N terminus of the hH4R, Asn5 
and Asn9 are potential sites for N-glycosylation (Fig. 3B). To 
study whether the higher molecular mass species are the 
N-glycosylated forms of the hH4R, we expressed H4Rs in the 
presence of the N-glycosylation inhibitor tunicamycin. In the 
absence of tunicamycin, two major putative monomeric spe- 
cies, 34 and 36 kDa, and a diffuse 65- to 72-kDa species were 
detected as in Fig. 1 (also see Fig. 3C, lane 1). In the presence 
of 2 µg/ml tunicamycin, a complete loss of the 36-kDa species 
and concomitant increase in intensity of the 34-kDa species 
and an additional species at 32 kDa were observed (Fig. 3C, 
lane 2). Furthermore, the diffuse 65- to 72-kDa species, de- 
tected in the absence of tunicamycin, was reduced to a single 
65-kDa species. It is noteworthy that an increase in tunica- 
mycin concentration had no further effect on either the 34- or 
65-kDa species (Fig. 3C, lanes 3-5). The 32-kDa species ob- 
served upon tunicamycin treatment is probably a breakdown 
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Fig. 3. Evidence for hH4R dimers and 
higher oligomers and glycosylation of 
the hH4R dimers. A, COS-7 cells 
r r: rnsfected with cDNA encoding the 
hll4R were subjected to cross-linking 
using increasing concentrations of 
BS. 4 (0.12-2 mM). 
The resultant pel- 
lets were subjected to immunoblotting 
and probed with the anti-hH4 (374- 
. 390) antibody (0.5 µg/ml). Lane 1, 
(1)S-7 cells expressing hH4Rs as con- 
trol; lanes 2 to 5, COS-7 cells express- 
ing hH4Rs treated with 0.12,0.5,1, 
and 2 mM BS3, respectively. ", a spe- 
cies that is likely to be a proteolytic 
fragment of the hH4R (observed in 
both host cells). B, snake plot of the 
N-terminal tail and beginning of 
transmembrane 1 of the H4R; arrows 
indicate possible N-glycosylation 
nuns. C, HEK 293 cells transfected 
%%, th the hH4R were grown in the ab- 
rice and presence of 2,4,6, and 8 
gig'/ml tunicamycin for 48 h. The cells 
w "re harvested, and homogenates 
wore prepared and subjected to im- 
niunoblotting. Immunoblots were 
probed with the anti-hH4 (374-390) 
receptor antibody. Lane 1, hH4Rs in 
absence of tunicamycin; lanes 2 to 5, 
hH4Rs in presence of 2,4,6, and 8 
µg/ml tunicamycin, respectively. D, 
PHA blasts were subjected to N-de- 
glycosylation with PNGase F enzyme 
at a final enzyme concentration of 400 
IU/ml for 16 h at 37°C. Control PHA 
blasts were incubated in parallel with 
deglycosylation buffer alone. Samples 
were then subjected to immunoblot- 
ting, and immunoblots were probed 
with the anti-hH4 (374-390) receptor 
antibody. Lane 1, control; lane 2, in 
the presence of PNGase F. Enzymatic 
deglycosylation resulted in the reduc- 
tion in intensity of the 77-kDa species 
and appearance of the 34-kDa puta- 
tive monomer. 
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product of the glycosylated 36-kDa species in untreated cells. 
These data strongly suggest that the recombinant hH4R is 
N-glycosylated and forms dimers. This last process is inde- 
kDa 
53- 
335- 
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% 16 f- HA-F4R 
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Fig. 4. Biochemical detection of homodimeric H4Rs. Cells coexpressing 
H4Rs with an N-terminal c-myc- and C-terminal Hisl, -tag (c-myc-H4R- 
Hislo) and an N-terminally HA-tagged H4Rs (HA-H4R) receptors were 
solubilized and loaded onto an Nit+-NTA column. Samples were taken of 
the solubilized receptors before loading onto the column (lane 1), of the 
unbound fraction (lane 2), and of the bound fraction that was eluted using 
250 mM imidazole (lane 3). Samples were resolved by SDS-polyacryl- 
amide gel electrophoresis and then immunoblotted using anti-HA anti- 
bodies. 
A 
pendent of post-translational N-glycosylation. It is notewor- 
thy that upon enzymic N-deglycosylation of PHA blasts, the 
77-kDa species was greatly reduced in intensity, and a new 
34-kDa species was detected, consistent with the monomeric 
hH, R (Fig. 3D, lane 2). 
HA-H4Rs Associate with c-myc-H4R-His, o. To further 
investigate whether the H4Rs can associate with each other 
to form homo-oligomers, membranes of COS-7 cells coex- 
pressing N-terminally c-myc and C-terminally His, tagged 
hH,, Rs (c-myc-H4R-His,, ) and N-terminally HA-tagged 
hH4Rs (HA-H4R) were solubilized and loaded on an Ni2'- 
resin column. The HA-H4Rs, when coexpressed with the 
c-myc-H4R-His, o, were retained on the Nit' -column and 
could be eluted with 250 mM imidazole, as detected with 
anti-HA antibodies (Fig. 4, lane 3). When cells individually 
expressing c-myc-H4R-His, o and HA-H4Rs were mixed 
before 
solubilization and subsequently loaded on the column, no 
HA-H4Rs were found to interact with the Ni2 ` resin (data not 
shown). 
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Fig. 5. Evaluation of homo-oligomerization of the H, R and homo-oligomerization of the H, R by BRET using the cocxpression of Rluc and eYFP 
C-terminal receptor-fusion proteins. A, schematic representation of BRET. After addition, coelenterazine is converted by the Rluc enzyme fused to the 
C terminus of a receptor into light of a wavelength of 470 nm, which when in close proximity (<100 A) can excite the eYFP protein fused to the C 
terminus of another receptor, leading to the emission of light at a wavelength of 530 nm. B, BRET ratios for the hH, R homo-oligomers compared with 
the hH, R homo-oligomers. Cells expressing the indicated receptor-fusion proteins were exposed to 5µM coelenterazine, after which energy transfer 
was measured. Cells individually expressing either H, R-Rluc or H, R-Rluc were mixed before exposure to coelenterazine with cells individually 
expressing H, R-eYFP or H, R-eYFP, respectively (Q). C, effects of a 15-min stimulation of 10 µM histamine (Hist), iodophenpropit (IPP), or 
thioperamide (TP) on the BRET ratios for the hH, R homo-oligomers. D, effects of a 15-min stimulation of 10 µM histamine on H4Rs homo-oligomers. 
Cells were expressed with a constant amount of H, R-Rluc (-0.2 pmol/mg of protein) and a decreasing amount of H4R-eYFP. Total H4R expression was 
1.0,0.6, and 0.3 (pmol/mg of protein). Ratios are expressed as the mean ± S. E. M. from at least three experiments performed in triplicate. 
BRET Shows Constitutive Ligand-Independent 
Homo-Oligomerization of hH4Rs. The use of biophysical 
techniques has been of great value to the study of GPCR 
oligomerization. We have used BRET to study in further 
detail the homo-oligomerization of the H4R. BRET was per- 
formed on COS-7 cells expressing either the H4R-Rluc or 
coexpressing the H4R-Rluc with the H4R-eYFP. After the 
addition of coelenterazine, a robust BRET signal could be 
observed in the cells coexpressing the two H4Rs (Fig. 5B). As 
a negative control, cells individually expressing either of the 
H4R constructs were mixed before adding coelenterazine 
(Fig. 5B). Previous studies have reported the ability of H1Rs 
to oligomerize (Carrillo et al., 2003; Bakker et al., 2004) 
Therefore, cells in which the H1R-Rluc and the H1R-eYFP 
were coexpressed were taken as a positive control. In these 
cells, a BRET signal was detected that was approximately 
2-fold lower than that observed for the H4Rs (Fig. 5B). 
To investigate the effect of ligands on H4R oligomerization, 
cells coexpressing the H4R-Rluc with the H4R-eYFP were 
incubated with a 10 gM concentration of the agonist hista- 
mine, the neutral antagonist iodophenpropit (Lim et al., 
2005) or the inverse agonist thioperamide for 15 min before 
the actual BRET measurement. No significant change was 
observed in BRET signal between stimulated and nonstimu- 
lated cells (Fig. 5C). 
Agonist-induced increase in oligomerization of somatosta- 
tin receptors occurs at physiological expression levels (160 
fmol/mg of protein) but not after overexpression (Patel et al., 
2002). We therefore also tested the effect of histamine stim- 
ulation on H4R oligomerization at different expression levels. 
While maintaining H4R-Rluc expression level constant (ap- 
proximately 0.2 pmol/mg of protein), we reduced the amount 
of expressed H4-eYFP. The concomitant reduction of the do- 
nor/acceptor ratio resulted in an expected decrease in BRET 
signal. At total H4R expression levels of 1.0,0.6, or 0.3 
pmol/mg, a significant BRET signal was observed. However, 
histamine also did not effect the H4R oligomerization at 
lower H4R expression levels (Fig. 5D). 
tr-FRET Shows the Presence of hH4R Oligomers at 
Cell Surface. To study whether the H4Rs oligomers are 
actually present at the cell surface, we performed tr-FRET 
assays on COS-7 cells coexpressing N-terminally FLAG- 
tagged H4Rs (FLAG-H4R) and HA-H4Rs. These cells were 
incubated with Eu3'-labeled anti-FLAG antibodies or a com- 
bination of the Eu3+-labeled anti-FLAG and allophycocyanin 
(APC)-labeled anti-HA antibodies. As control, cells individu- 
ally expressing the FLAG-H4Rs and the HA-H4Rs were 
mixed and exposed to the two antibodies. Only from the cells 
coexpressing the FLAG-H4Rs and HA-H4Rs was a pro- 
nounced signal observed (Fig. 6B). This FRET signal can only 
be explained as a result of the resonance energy transfer 
from Eu3+ anti-FLAG antibodies bound to FLAG-H4Rs to 
APC anti-HA antibodies bound to HA-H4Rs. Because this 
resonance energy transfer can only take place within 100 A, 
the data indicate the formation of H4R oligomers at the cell 
surface of living cells. Stimulation of the COS-7 cells with 10 
gM histamine or 10 gM thioperamide preceding tr-FRET 
measurement did not result in a significant change in signal 
(Fig. 6B). The used antibodies did not have an influence on 
the ligand binding to the H4Rs because no significant differ- 
ence was found in [3H]histamine binding in the absence or 
presence of the antibodies (data not shown). 
Oligomerization of the Human Histamine H4 Receptor 611 
Lack of Hetero-Oligomerization between H4R and 
H, Rs. We have subsequently used tr-FRET to investigate 
whether hetero-oligomerization occurs between H4Rs and 
H1Rs. tr-FRET was performed on COS-7 cells coexpressing 
the FLAG-H4Rs and N-terminally HA-tagged histamine 
H1Rs (HA-H1Rs). As a control, cells individually expressing 
the FLAG-H4Rs and the HA-H, Rs were mixed and exposed to 
the two antibodies. No significantly increased tr-FRET signal 
could be observed compared with the signal obtained from 
cells individually expressing the two receptors that were 
mixed before incubation with the antibodies (Fig, 6C). The 
ratio and total amount of antibodies was maintained equal 
between experiments with H1R-H4Rs and H4R-H4Rs to en- 
sure proper comparison. 
Comparable results were obtained using Eu3' anti-HA 
antibodies and APC anti-FLAG antibodies (data not shown). 
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Fig. 6. Evaluation of homo-oligomerization of the H4R and hetero-oli- 
gomerization of the H,, R with the H, R by tr-FRET using coexpression of 
differentially epitope-tagged receptors. A, schematic representation of 
tr-FRET. Excitation at 337 nm of anti-FLAG Eu3' antibody bound to the 
FLAG-epitope-tagged receptor leads to the emission of light at a wave- 
length of 620 nm, which, when in close proximity (- 100 
A), can excite the 
anti-FLAG APC antibody bound to another FLAG-epitope-tagged recep- 
tor, leading to the emission of light at a wavelength of 665 nm. B, tr-FRET 
using cells coexpressing FLAG- and HA-tagged H4Rs. Cells were incu- 
bated for 2h with the Eu3'-labeled anti-FLAG antibodies (Q, Eu3') or 
with both Eu3' -labeled anti-FLAG and APC-labeled anti-HA antibodies 
( , APC) in the presence or absence of 10 µM histamine (Hist) or 10 µM 
thioperamide (Thiop). C, tr-FRET using cells coexpressing FLAG-tagged 
H4Rs (FLAG-H4R) and either HA-tagged H4Rs (HA-H,, R) or HA-tagged 
H1Rs (HA-H, R). Cells were incubated for 2h with the Eu3'-labeled 
anti-FLAG antibodies U 1, Eu3' ). or with both Eu3'-labeled anti-FLAG 
and APC-labeled anti-HA antibodies ( , APC). Data are normalized for 
the it-FRET signal obtained from a mixture of cells that was obtained by 
mixing of cells that have been incubated with Eu3' -labeled anti-FLAG 
antibodies with cells that have been incubated with APC-labeled anti- 
FLAG antibodies. Data shown are from a representative experiment. 
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Stimulation of cotransfected cells with 10 µM histamine did 
not lead to a change in FRET signal (data not shown). 
Ilomo-Oligomerization of H4Rs versus Hetero-Oli- 
gomerization between H, Rs and H1Rs. To further inves. 
tigate hetero-oligomerization between H4Rs and H1Rs, 
BRET saturation curves were produced for both the H4R 
homo-oligomer and the H1R-H4R hetero-oligomer. Experi- 
ments were performed in which COS-7 cells were transfected 
with a fixed amount of H4-Rluc and increasing amounts of 
either H4R-eYFP or H1R-eYFP cDNA. Expression levels were 
determined by radioligand binding. Expression of the H4R- 
Rluc was maintained at approximately 0.2 pmol/mg of pro- 
tein. Expression levels of H4R-Rluc were correlated with 
luminescence and expression levels for the eYFP fused H1R 
and H4R were correlated with fluorescence. A linear correla- 
tion was obtained for all three constructs. Expression for the 
H4R-eYFP ranged from 0.3 to 2.5 pmoUmg of protein, 
whereas expression levels of the H1R-eYFP ranged from 0.5 
to 16 pmoUmg of protein. For the H4R homo-oligomers, a 
steep increase in BRET signal is observed, showing detect. 
able BRET when total H4R expression is 0.3 pmoUmg of 
protein. For the H1R-H4R hetero-oligomers, a more gradual 
increase in BRET signal is observed upon increased expres. 
sion of the H1R-eYFP. A BRET signal is observed for the first 
time at expression levels of 1 pmol/mg of protein of the 
H1R-eYFP. The H4R-H4R homo-oligomer showed a 2-fold 
lower BRET50 value (0.77 versus 1.6) and a 2.5-fold higher 
B.. (0.1 versus 0.04) than the H1R-H4R hetero-oligomer as 
determined from the BRET saturation curve (Fig. 7). 
Discussion 
GPCR oligomerization has become a generally accepted 
phenomenon and has been reported to occur in all GPCR 
classes (George et al., 2002). Data obtained from atomic force 
microscopy (Fotiadis et al., 2003), electron microscopy, and 
Western blot analysis (Suda et al., 2004) have provided com- 
pelling evidence that the light-sensitive rhodopsin is predom- 
inantly present as a dimer in the retinal disc membrane. For 
histamine receptors, oligomerization has been shown con- 
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Fluorescence (normalized) 
Fig. 7. Evaluation of receptor-expression dependence of the detection of 
114R homo-oligomers and H, R-H4R hetero-oligomers using BRET. BRET 
saturation curves for the hH4R homo-oligomers (H4R-Rluc + H4R-eYFP, 
solid line) compared with H1R-H4R hetero-oligomers (H4R-Rluc + H1R. 
eYFP, broken line) at increasing expression levels of the eYFP-tagged 
receptor. COS-7 cells were transfected with a fixed amount DNA encod. 
ing for the H4R-Rluc and increasing amounts of DNA encoding for the 
H4R-eYFP or the H1R-eYFP. Plotted on the x-axis is the fluorescence 
obtained from the eYFP, which has been correlated to the expression of 
114R-eYFP (0) and H1R-eYFP (0). Expression level of the H4R-Rluc was 
maintained at approximately 200 fmol/mg of protein, as determined from 
the luminescence, which has been correlated to the expression of the 
11, R-Rluc. 
vincingly for the hH1Rs (Carrillo et al., 2003; Bakker et al., 
2004), the hH2Rs (Fukushima et al., 1997), and H3Rs (Shen- 
ton et al., 2005; Bakker et al., 2006). In view of the emerging 
role of GPCR oligomerization in GPCR function and our 
interest in the H4R as a new target for inflammatory condi- 
tions (de Esch et al., 2005), we investigated oligomerization 
of the human H4R by various means. Combining biophysical 
measurements like tr-FRET and BRET (Angers et al., 2002; 
Boute et al., 2002) with biochemical approaches, like Western 
blot analysis and histidine-tag-based affinity chromatogra- 
phy, we provide compelling evidence for homo- and hetero- 
oligomer formation of hH4Rs. 
To enable our biochemical approaches and to study H4R 
function in native tissues, we report in this study on the first 
polyclonal H4R antibody that can successfully be used for 
Western blot analysis. This new molecular tool is directed 
against the C-terminal tail of the H4R and detected mono- 
meric and potential dimeric H4R species after Western blot 
analysis of membranes from HEK 293 and COS-7-trans- 
fected cells. The selectivity of the new H4R antibody was 
confirmed by blockade with the C-terminal peptide used to 
raise the antibody and the lack of cross-reactivity toward the 
highly related human hH3R. Furthermore, through an im- 
munoprecipitation study, the H4R antibody was shown to 
detect the same HA-H4Rs as detected by a commercially 
available anti-HA antibody. 
Western blot analysis of the H4R expressed in tunicamy- 
cin-treated cells indicates that the H4R normally is N-glyco- 
sylated, most likely at Asn° and/or Asn9 of the extracellular 
N terminus of the H4R (Nguyen et al., 2001). However, inhi- 
bition of N-glycosolyation did not affect the presence of pu- 
tative dimeric H4R species on the Western blot. To show that 
H4R proteins are in close proximity of each other, a require- 
ment for oligomerization, a cross-linking experiment, using 
BS3 was performed. With increasing concentrations of the 
cross-linker BS3, the bands representing the monomeric H4R 
disappeared. At the same time, bands representing oligo- 
meric H4Rs became more apparent. These data indicate that 
the H4Rs are in close enough proximity for cross-linking by 
BS3 and suggests that the 65- to 72-kDa species might rep- 
resent dimerized H4R proteins. Finally, the polyclonal H4R 
antibody allowed us to study the presence of H4R proteins in 
human PHA blasts. High-level H4R mRNA expression has 
been shown in various white blood cells, including T-lympho- 
cytes (Nakamura et al., 2000; Oda et al., 2000; Morse et al., 
2001; Zhu et al., 2001; Hofstra et al., 2003), but H4R protein 
expression so far has not been shown. Western blot analysis 
of membranes of PHA blasts with our polyclonal anti-H4R 
antibody indeed revealed the presence of H4R protein in PHA 
blasts. It is interesting to note that the endogenously ex- 
pressed H4R was only detected as a high molecular mass 
species. Enzymatic deglycosylation of the native H4R protein 
resulted in a partial reduction of the high molecular mass 
species (77 kDa) to monomeric H4Rs (34 kDa). These data in 
themselves do not directly exclude a heavily glycosylated 
(approximately 33 kDa) H4R protein. However, the hH4Rs in 
human HEK 293 cells is only moderately glycosylated (ap- 
proximately 2 kDa), and the high molecular mass species 
coincide with the putative dimeric H4Rs when recombinantly 
expressed in COS-7 (77 kDa) and HEK 293 cells (72 kDa). 
These data can be explained by assuming that in human 
PHA blasts, the hH4R functions predominantly as a dimer. 
We hypothesize that N-glycosylation is not a prerequisite for 
dimerization, but it helps to stabilize the H4R dimers. A 
similar stabilizing effect of glycosylation on receptor dimers 
has recently been shown for the human bradykinin B2 recep- 
tors (Michineau et al., 2006). The putative H4R dimerization 
in native tissue clearly warrants further investigation. 
As an alternative biochemical method, we used an im- 
mobilized metal (Ni2+) affinity chromatography approach 
with a histidine-tagged H4R protein. To this end, we coex- 
pressed c-myc-H4R-Hisao and HA-H4Rs receptors to study 
oligomer formation via affinity column chromatography. In 
contrast to c-myc-H4R-Hisao receptors, HA. H4Rs are not 
robustly retained onto an Ni2+-NTA resin when expressed 
alone. Yet c-myc-H4R-Hisao receptors immobilized onto 
Ni2'-NTA resin were shown also to retain coexpressed 
HA-H4Rs on the Ni2 4 -NTA column, as determined by HA- 
immunoreactivity detected after elution of histidine- 
tagged proteins with high imidazole concentrations. These 
findings indicate that c-myc-H4R-Hisao receptors physi- 
cally interact with the coexpressed HA-H4Rs to form oli- 
gomers that can be retained on the Ni2+-NTA resin 
through the C-terminal Hisao tag. 
We continued our investigation of the oligomerization of 
the H4Rs in living cells using BRET and tr-FRET assays. 
Using the BRET assay, a clear signal could be detected when 
coexpressing H4R-Rluc with H4R-eYFP in nonstimulated 
cells, suggesting constitutive homo-oligomerization of H4Rs. 
Because the oligomers detected in the immobilization and 
BRET assays do not necessarily have to be present at the cell 
surface, we also studied H4R oligomerization on the cell 
membrane of living cells by tr-FRET. The tr-FRET approach 
uses antibodies that do not permeate the cell membrane and 
detects cell surface H4R oligomers present at the cell surface. 
Similar to the BRET assay, we detected a robust signal, 
indicating the constitutive presence of H4R homo-oligomers 
at the cell surface. 
A number of studies have investigated the effect of ago- 
nists on receptor oligomerization. However, at present, the 
effects of ligand stimulation on GPCR oligomerization are not 
consistent. It has been found that agonists can promote or 
reduce GPCR oligomerization or are without effect on GPCR 
oligomerization (Angers et al., 2002; George et al., 2002; 
Pfleger and Eidne, 2005). In the case of the H4R, we did not 
detect any significant difference in BRET signal if cells were 
treated with either the H4R agonist histamine, the neutral 
H4R antagonist iodophenpropit (Lim et al., 2005), or the 
inverse H4R agonist thioperamide (Morse et al., 2001; Lim et 
al., 2005), suggesting that H4R ligands do not modulate H4R 
homo-oligomerization. Likewise, no agonist- or inverse ago- 
nist-induced modulation of H4R oligomerization was detected 
in the tr-FRET assay. Patel et al. (2002) reported that ago- 
nist-induced oligomerization of somatostatin receptors was 
only detected at physiological expression levels but not after 
overexpression. We therefore performed BRET experiments 
at various H4R expression levels. First, it is noteworthy that 
already at an H4R expression level of approximately 300 
fmol/mg of protein, significant BRET signals can be observed. 
These data indicate that at physiological expression levels, 
the H4R can indeed homo-oligomerize and corroborate our 
findings of H4R dimers, detected on PHA blasts with our 
anti-H4R antibody. Second, from the BRET experiments, we 
also conclude that also at low expression levels of the H4Rs, 
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homo-oligomerization is not affected by agonist stimulation. 
Nevertheless, one should be aware that results concerning 
ligand effects on dimerization obtained with these biophysi- 
cal assays can be difficult to interpret, because agonist-in- 
duced changes in H4R conformation could potentially influ- 
ence the energy transfer between the energy acceptor and 
donor (Angers et al., 2000). 
The H4R has been linked to play a role in inflammation 
based on its expression pattern and recent findings, show- 
ing that the H4R induces chemotaxis of eosinophils 
(O'Reilly et al., 2002; Buckland et al., 2003) and mast cells 
(Hofstra et al., 2003) and stimulates the release of inter- 
leukin-16 from CD8* T cells (Gantner et al., 2002) and the 
release of leukotriene B4 in zymosan-challenged mice 
(Takeshita et al., 2003). The H1R is colocalized with the 
H4R in several white blood cells (Cameron et al., 1986; 
Morse et al., 2001) and plays a prominent role in inflam- 
matory conditions (Giustizieri et al., 2004; Matsubara et 
al., 2005). Because both the Hills (Carrillo et al., 2003; 
Bakker et al., 2004) and the HR (this study) are able to 
form homo-oligomers, we were prompted to study whether 
the H4Rs can form hetero-oligomers with the H1Rs. In fact, 
previous work with hetero-oligomeric opioid receptors has 
revealed that GPCR hetero-oligomerization brings an ad- 
ditional layer of complexity to the class of GPCR proteins 
(Bouvier, 2001; Devi, 2001; Franco et al., 2003; Waldhoer 
et al., 2005) but also offers opportunities to develop hetero- 
oligomeric-selective ligands (Waldhoer et al., 2005). Yet 
using tr-FRET assays, we were unable to detect H1R-H4R 
hetero-oligomers, suggesting that such GPCR hetero-oli- 
gomers are not present at the cell surface. In contrast to 
the tr-FRET experiments, we were able to detect an ex- 
pression level-dependent formation of H1R-H4R hetero- 
oligomers using BRET. Distinct from the detection of H4R 
homo-oligomers, H1R-H4R hetero-oligomers were only de- 
tected at high-expression levels, and we failed to detect 
hetero-oligomers at physiologically relevant conditions. 
Results from BRET saturation studies demonstrate a 
higher propensity for the formation of H4R-H4R homo- 
oligomers over H1R-H4R hetero-oligomers. We presume 
that the signal observed with BRET at high expression 
levels possibly originates from intracellular 111R-H4R het- 
ero-oligomers. Whereas some receptors, such as the 5-hy- 
droxytryptamine-1A receptor seem to readily form hetero- 
meric receptors (Salim et al., 2002), our present H4R data 
corroborate the idea that GPCR hetero-oligomerization is 
highly selective, as reported for the adrenergic receptors 
(Stanasila et al., 2003; Uberti et al., 2005) and the thyro- 
tropin-releasing hormone receptors (Kroeger et al., 2001). 
Although hetero-oligomerization has been shown to occur 
even between receptors from different classes (Ferre et al., 
2002), the relatively low homology (23%) between H1R and 
H4R (Oda et al., 2000) is apparently too low to readily form 
hetero-oligomers. 
In conclusion, we have developed specific antibodies 
against the C terminus of the 114R which allowed the 
detection of endogenously expressed H4R proteins. This 
anti-hH4R antibody is an important new molecular tool for 
studying the localization and function of the H4R. More- 
over, we determined by various methods that the H4R 
constitutively forms cell surface homo-oligomers. Homo- 
dimeric H4Rs are not only found using heterologous ex- 
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pression systems but are also present in PHA blasts and 
spleen lysates endogenously expressing H4Rs. The forma- 
tion of H4R oligomers is not dependent on N-glycosylation 
or affected by ligand stimulation but is possibly destabi- 
lized by deglycosylation. Although H1R-H4R hetero- 
oligomers could be detected using BRET upon receptor 
overexpression, these hetero-oligomers are probably not 
present at the cell surface. Moreover, H1R-H4R hetero- 
oligomers were not found at physiologically relevant ex- 
pression levels. Future studies will have to reveal whether 
the H4R can form hetero-oligomers with other GPCR fam- 
ily members or if it preferentially exists as homo-oligomer. 
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Histamine downregulates monocyte CCL2 
production through the histamine H4 receptor 
Dorothea Dijkstra, MSc' Rob Leurs, PhD, b Paul Chazot, PhD' Fiona C. Shenton, MSc' 
Holger Stark, PhD, d Thomas Warfel, MD, ' and Ralf Gutzmer, MD' Ilannoverand Frankfurt/ 
Main, Germany, Amsterdam, The Netherlands, and Durham, United Kingdom 
Background: The expression of the recently cloned histamine 
114 receptor (H4R) by leukocytes suggests a role In 
immunomodulation. 
Objective: The expression and function of the H4R on human 
monocytes obtained from peripheral blood was Investigated. 
Methods: H4R expression was studied by using flow cytometry. 
Effects of H4R stimulation on Ca 2+ mobilization was 
determined fluorometrically, CCL2 production was determined 
by means of ELISA, Intracellular CCL2 staining was measured 
with How cytometry, and CCL2 mRNA was measured by using 
real-time quantitative LightCycler PCR. The relevance of 
CCL2 production was determined in chemotaxis 
transmigration assays. 
Results: H4R protein was expressed by monocytes and 
upregulated by IFN-'y. H4R agonists (clobenpropit and 4- 
methylhistamine) Induce a Ca2+ mobilization In monocytes, 
which could be blocked with the selective H4R antagonist 
JN, J7777120. Furthermore, H4R agonists downregulated CCL2 
protein production. This effect could also be blocked by 
JNJ7777120. Supernatants Of H411 agonist-stimulated 
monocytes attracted less monocytes in transmigration assays. 
The downregulation of CCL2 production was regulated at 
different levels. First, the synthesis of CCL2 mRNA was 
significantly decreased. Second, Intracellular staining suggested 
an Inhibition of CCL2 secretion after stimulation with II4R 
agonists. 
Conclusion: Human monocytes express the H4R, and Its 
stimulation leads to a Ca2+ Influx and an Inhibition of 
CCL2 production, resulting in a reduction of monocyte 
recruitment. 
Clinical Implications: The H4R could represent an Important 
anti-Inflammatory receptor on monocytes and could be an 
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Interesting target for drug development. (j Allergy Clin 
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Histamine is an important mediator of allergic reac- 
tions. In the periphery it is released mainly by mast cells' 
and basophils 2 The effects of histamine are diverse and 
mediated through 4 known G-protein-coupled receptors. 
the histamine Hr, H2,113, and H4 receptors (1-I4Rs). The 
recently discovered and cloned histamine 114R3-ß is ex- 
pressed by leukocytes and is thought to have an immuno- 
modulatory function. Several functions of the histamine 
H4R expressed by different cell types have been found. 
In particular directly on chemotaxis of mast cells9 and 
eosinophilsto. 1 t and indirectly, through leukotriene B4 
produced by mast cells, on neutrophil mobilization from 
the bone marrow. 12 Recently, we showed that monocyte- 
derived dendritic cells (DCs) are chemoattracted through 
the histamine H4R, and stimulation of the 114R led to sup- 
pression of IL-12p70 production. 13 Furthermore, effects 
on T lymphocytes have also been observed. Agonist stim- 
ulation of the H4R upregulates IL-16 release by CD8+ T 
lymphocytes. 14 The importance of the 1148 in modulation 
of CD4+ T-lymphocyte activation and TH2 responses in a 
murine model of asthma has been shown. 13 These results 
indicate that the H4R is an important modulator during 
DC-T-lymphocyte interactions. Because the monocyte 
(CD14+) fraction of PBMCs contain the direct precursors 
of DC- and skin-associated macrophages, we investigated 
the expression and function of the 14R on monocytes. We 
demonstrate that the 114R is expressed and uprcgulated by 
IFN-y. In microarray experiments the mRNA expression 
of several cytokines and chemokines after incubation 
with the most specific 114R agonist, 4-methylhistamine. 16 
was investigated (results not shown). The results indicated 
an inhibition of CCL2 mRNA and prompted us to investi. 
gate the effect of histamine on the expression of this ehe- 
mokine in more detail because it plays an important role in 
allergic inflammation. In mice lacking CCL2, macrophage 
attraction to sites of inflammation was disturbed, and anti- 
gen-specific TH1 cells were producing less IFN-, y. '7 In 
mice lacking CCR2 (the receptor for CCL2). an enhanced 
airway TH2 response was found (eg, eosinophilia, IS sub- 
class switching, and IL-5 production). " In human subjects 
CCL2 production of keratinocytes was enhanced by the 
1 
2 Dijkstra et al 
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DC: Dendritic cell 
GAPDH: Reduced glyceraldehyde-phosphate 
dehydrogenase 
H4R: Histamine H4 receptor 
MMP: Matrix metalloproteinase 
TH2 cytokine IL-13, which is found, for example, in le- 
sions of atopic dermatitis. 19 Furthermore, a polymorphism 
(-2518G) in the gene regulatory region of CCL2, which 
resulted in a higher expression of CCL2, was found asso- 
ciated to a more severe asthma phenotype in children. 0 
Thus CCL2 is induced by and contributes to a TH2 environ- 
ment in allergic inflammation and leads to migration of 
cells found in allergic inflammation, such as monocytes, 
activated T lymphocytes, and natural killer cells, which 
express CCR2.21 Here we show that histamine H4R stimu- 
lation results in the downregulation of spontaneous CCL2 
production in monocytes. This could represent a negative 
feedback mechanism to avoid an overwhelming TH2 envi- 
ronment in case of a persistent histamine release at sites 
of allergic inflammation and could contribute to the shift 
from TH2 to TH1 observed in the transition from acute to 
chronic allergic inflammation (eg, in atopic dermatitis). 22 
METHODS 
Monocyte enrichment and isolation 
Buffy coats from anonymous healthy blood donors obtained from 
the local blood bank were used. The buffy coats were disposed of by 
the blood bank after thrombocyte preparation. Total IgE levels, as 
well as levels IgE against common aeroallergens (sx-1 screening 
test), were measured (CAP System; Pharmacia, Freiburg, Germany) 
and were less than the normal limits of 100 kU/L and 0.35 kU/L, 
respectively. In case of increased IgE levels, the patient was excluded 
from the study. Human PBMCs were separated from the buffy coats 
by means of density gradient centrifugation on Lymphoprep 
(Fresenius Kabi Norge AS, Oslo, Norway). 
PBMCs were then cultured in supplemented Iscove medium on 
flat-bottom plates (6-well plate: IX 107 cells per well for chemotaxis- 
supernatants; 24-well plate: 1X 106 cells per well for ELISA or 
intracellular CCL2 measurements) for 1 hour (37°C, 5% CO2. humid- 
ified atmosphere). Then the nonadherent cells were removed by 
washing with PBS. The adherent cells (enriched monocytes, purity 
>_85%) were further cultured (and stimulated with H4R agonists or 
other substances used in the H4R regulation studies) in supplemented 
RPMI 1640 medium (6-well plate: 2 mL; 24-well plate: 400 AL; 96. 
well plate: 250 µL). Adherent cells were counted after detaching 
them with trypsin-EDTA (Pan Biotech GmbH, Aidenbach, Ger- 
many). The number of adherent cells was generally around 2.5 X 
10' cells per well in a 24-well plate. The purity of the adherent 
monocytes was 85% minimum. This was controlled by using flow 
cytometry to determine CD 14' cells in each experiment Contaminat- 
ing cells were evaluated in selected experiments by means of flow 
cytometry and included minimal numbers of T lymphocytes (CD3' 
cells. <0.5%). B lymphocytes (CD 19. <0.5%), and natural killer cells 
(CD56, <3.0%), whereas granulocytes (CD 16) were absent. Macro- 
phages (CD206) and DCs (CDIa) represented around 10% of the 
nonmonocyte fraction. The viability of trypsinated cells (used for 
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the intracellular CCL2 staining and staining controls only) was tested 
in each experiment by staining with trypan blue and was greater than 
95%. In experiments for quantitative PCR. we Isolated monocytes by 
means of magnetic cell sorting (MACS; Monocyte isolation kit 11; 
Miltenyi Biotec Inc. Bergisch Gladbach, Germany; monocyte purity 
>_95%), adhered the cells (2 X 103 cells per well on a 96-well flat- 
bottom plate) for I hour (37°C, 5% CO2, humidified atmosphere) in 
supplemented Iscove medium, and cultured them in supplemented 
RPMI medium. 
Media 
For the adherence of monocytes. Iscove medium supplemented 
with AB serum (5% vol/vol), nonessential salts (1% wt/vol), t. -gluta- 
mine (1% wt/vol), penicillin/streptomycin (1% wt/vol), and gentami- 
cin (0.5% wt/vol) was used. For culturing monocytes after adherence, 
we used RPMI 1640 medium supplemented with FCS (5% vol/vol), 
12 mmol/L Hepes, t. -glutamine (1% wt/vol), and penicillin/strepto- 
mycin (1% wt/vol; all media and supplements were from Biochrom 
AG, Berlin, Germany). 
Chemicals 
Clobenpropit was obtained from Sigma-Aldrich (Deisenhofen, 
Germany). 4-Methylhistamine was kindly provided by R. Leurs and 
synthesized in the Department of Pharmacochemistry of the Vrije 
Universiteit Amsterdam in The Netherlands, as described previ- 
ously. ts JNJ7777120 was synthesized by H. Stark from the Johann 
Wolfgang Goethe University in Frankfurt/Main, Germany. as de- 
scribed previously. GM600124 was obtained from Chemikon 
(Hampshire, United Kingdom). 
The polyclonal rabbit anti-human H4R antibody and its antigenic 
peptide were prepared by F. C. Shenton and P. Chazot from Durham 
University, United Kingdom. and was described previously. '' The 
antibody recognizes the amino acid sequence (374-390) that is posi- 
tioned in the C-terminal tail of the H. R. Neutralizing anti-CCL2 was 
obtained from R&D Systems (Wiesbaden, Germany). CCL2 was 
obtained from TebuBio (Offenbach. Germany). 
H4R (amino acid 374-390) staining 
Cells were stained according to the protocol and with the reagents 
provided by BD Biosciences (Heidelberg, Germany) for intracellular 
epitope-directed antibodies. In brief, cells were fixed and perrneabi- 
lized. Subsequently, the cells were labeled with (1) H4R antibody. (2) 
polyclonal rabbit isotype antibody, or (3) H4R antibody preincubated 
with a 10-fold higher concentration of antigenic oligopeptide used to 
generate the antibody. This was followed by labeling with goat anti- 
rabbit antibody conjugated with biotin (Jackson ImmunoResearch 
Laboratories, Suffolk, England). Subsequently, staining was per- 
formed with fluorescein isothiocyanate-coupled streptavidin. and 
the H4R positivity of the cells was quantified by means of flow cytom- 
etry (FACS Calibur, Becton Dickinson. Heidelberg. Germany). 
Calcium mobilization assay 
Monocytes were plated after isolation by means of magnetic cell 
sorting (Miltcnyi Biotec, Inc) and adhered on flat-bottom 96-well plates 
(2.5 X 103 cells per well). Then they were labeled with FLUO. 4 accord. 
ing to the manufacturer's description (lnvitrogen OmbH, Karlsruhe, 
Germany). Calcium mobilization was measured in a FiuoStar plate 
reader (BMG Lab Technologies OmbH. Jena, Germany). Fluorescence 
(excitation, 485 nm: emission, 520 run) was measured per second for 
50 seconds, and at a time of 5 seconds, the HA ligands histamine, clo- 
benpropit, and 4-methylhistamine (10-3 mol/L) were addcd to the cells. 
A calcium ionophore (20 nmol/L A23187. Sigma) was used as a posi- 
tive control. JNJ7777120 (10-3 mol/L) was added to respective wells 
30 minutes before the measurements. 
_`. ý,.,.., 
'_''ýý 
J ALLERGY CLIN IMMUNOL 
VOLUME ., NUMBER w 
A 
6ý; 
B 
20, 
is. 
c ý 
d 
ý 
10-ý 
ý14-, 
c 
12 -I 
ý lo 
8 
H4R 
Oljkstra et al 3 
SI 
ý 
nll ICI n 
ti 
t ýý 
a ý I 
I 
'ý 
p 
ý 
FIG I. The H4R is expressed by monocytes and upregulated by IFN-y. A, Staining of monocytes with H4R (solid, 
thick line), isotype (dotted line), and blocked H4R antibody (solid, thin line). B, H4R protein expression after 
48 hours' Incubation with different ligands. Averages and SDs of 3 experiments are shown (statistical test: 
ANOVA). NS, Nonstimulated cells. 
CCL2 ELISA 
CCL2 levels were investigated by using a CCL2 sandwich ELISA 
with a lower detection limit of 8 pg/mL and a highest detection limit 
of 3000 pg/mL. For the CCL2 ELISA (TebuBio), PBMCs were 
plated in supplemented Iscove medium on a 24-well plate (1 x 106 
cells per wellf250 pi). Monocytes were allowed to adhere for 
1 hour, as previously described, and subsequently washed vigorously 
with PBS. Adherent cells were incubated in RPMI with ligands at the 
indicated concentrations for 4,24, and 48 hours; supernatants were 
taken; and CCL2 was determined according to the manufacturer's 
instructions. The plate was read at a wavelength of 405 nm on a 
FluoStar plate reader (BMG Lab Technologies, GmbH). 
CCL2 intracellular staining 
Adherent cells (from 1X 106 PBMCs per well) were stimulated 
with 10-5 M IHR ligands for 4 or 48 hours to measure amounts of 
intracellular CCL2. Cells were detached with trypsin-EDTA at 
37°C, and the reactions were stopped with an equal volume of heat- 
inactivated FCS after 10 minutes. Then the cells were washed twice 
with PBS, and intracellular CCL2 was stained according to the pro- 
tocol provided by BD Biosciences for intracellular staining. In 
brief, cells were fixed and permeabilized and then stained with the al- 
lophycocyanin-labeled anti-CCL2 antibody (50 ng/mL, IgG2B, 
clone 23002) or an allophycocyanin-labeled isotype control antibody 
(IgG2B) for 30 minutes at 4°C. The cells were washed, and CCL2 
positivity was quantified by means of flow cytometry. 
CCL2 quantitative PCR 
Monocytes were isolated by means of magnetic cell sorting 
(Miltenyi Biotec, Inc) and then adhered on flat-bottom 96-well plates 
(2 X lO' cells/200 p. L), as previously described. After transfer to 
supplemented RPMI, monocytes were stimulated with ligands for 
4 hours. Total RNA was isolated, according to the manufacturer's in- 
structions, with the High Pure mRNA Isolation kit (Roche Molecular 
Biochemicals, Mannheim, Germany). The cDNA was synthesized by 
means of reverse transcription (Quantitect reverse transcription kit; 
Qiagen, Hilden, Germany). Real-time quantitative PCR was performed 
with Quantitect primer assays for CCL2 (QT00212730) and reduced 
glyceraldehyde-phosphate dchydrogenase (GAPDH; QT00079247) 
by using SYBR Green, according to the manufacturer's instructions 
(Qiagen). A genomic DNA digestion was included in this kit. 
The following settings in the LightCycler PCR were used. An 
initial activation step of 15 minutes at 95°C and a ramp of 20°C/s was 
followed by 3-step cycling (42 cycles): denaturation; 15 seconds at 
94°C, annealing; 20 seconds at 55°C. extension; and 20 seconds at 
72°C (all 3 with a ramp of 2°C/s). A melting curve was recorded by 
cooling the samples down to 60°C and then increasing the tempcr- 
ature to 95°C (ramp, 2°C/s). The amounts of CCL2 relative to the 
amount of the reference GAPDH in the same sample was calculated 
by using the relative quantification approach with the software pro- 
vided by the manufacturer (Roche). Mathematically, the result for 
each sample is expressed as the ratio of CCL2 and GAPDH derived 
from the crossing points, which are obtained in the Ughtcyclcr soft- 
ware (version 1.0, Roche). In addition, because the basal levels of 
CCL2 were different per patient, the data were normalized to the 
CCL2 level in the nonstimulated sample (100%). The values obtained 
for H4R agonist-stimulated monocytes were then expressed as the 
percentage of the nonstimulated monocytes. 
Chemotaxis assay 
Chemotaxis of monocytes was measured over polycarbonate 
membranes with a 5-Am pore diameter (Coming, Inc/Costar, NY). 
A 600-µL supernatant from cultured adhered monocytes (with 10-3 
mol/L stimuli and neutralizing anti-CCL2 antibody. as Indicated in 
the text) was used as a chemoattractant in the lower chamber. The up- 
per chamber with the membrane was filled with 250 µL of medium 
with 106 isolated monocytes. Chemotaxis was allowed for 1.5 hours, 
and the number of transmigrated cells was counted after staining with 
trypan blue (Sigma-Aldrich) in a Durker-TUrk counting chamber. 
Controls were conducted as described in the text and figures. 
Statistics 
Paired t tests and ANOVA (the Bonferonni multiple comparisons test) 
were used, and aP value of less than . 05 was regarded as significant (P < 
. 05 was labeled with an asterisk. and P <. 005 was labeled with a 
double 
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FIG 2. Histamine, 10-5 mol/L, Induces calcium mobilization In mon- 
ocytes through the H4R. JNJ7777120 at 10"6 mol/L blocks this 
effect. Injection of the ligands was at a time of 5 seconds (arrows), 
and FLUO-4 fluorescence was measured for 40 seconds. A repre- 
sentative of 3 experiments is shown. 
asterisk). For the statistical analyses, the program GraphPad Prism, 
version 3.02 (GraphPad Software, Inc, San Diego, Calif), was used. 
RESULTS 
Expression of the H4R in monocytes 
Monocytes have been shown to express the H4R at the 
mRNA level, as described by us13 and others 6 Here we 
showed H4R protein expression on monocytes by means 
of flow cytometry after staining with a selective H4R anti- 
body directed against the C-terminal tail 25 The specificity 
of the immunoreactivity was controlled by blocking the 
staining of the H4R antibody with the respective peptide 
used to generate the antibody (Fig 1, A). 
Upregulation of H4R expression by IFN-y 
The regulation of H4R protein expression was investi- 
gated after incubation with various ligands, such as IFN-y 
(20 ng/mL), IL-4 (20 ng/mL), TNF-a (0.5 ng/mL), and the 
Toll-like receptor 3 ligand poly I: C (2 pg/mL), as well as 
combinations of these. The H4R expression was measured 
by means of antibody staining, followed by flow cytome- 
try. We found that IFN-y upregulated the H4R signifi- 
cantly at the protein level (Fig 1, B). In contrast, IL-4. 
TNF-a, and poly I: C or combinations of these did not 
regulate H4R protein expression. 
Calcium influx 
The H4R agonists histamine, clobenpropit, and 4-methyl- 
histamine16 were all able to stimulate calcium mobilization 
in monocytes. The effects caused by 10-5 mol/L clobenpro- 
pit and 4-methylhistamine were blocked by 10-5 mol/L 
JNJ7777120 26 the specific H4R blocker (Fig 2). 
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H4R agonists inhibit monocyte CCL2 
production dose dependently 
Monocytes synthesize CCL2 spontaneously. " Ilista- 
mine, 4-methylhistamine, and clobcnpropit as 114R ago- 
nists dose-dependently and effectively inhibited CCL2 
production with different inhibitory concentration of 
50% values (4-methylhistamine > histamine > clobenpro- 
pit; Fig 3, A). The inhibition of CCL2 production by 
histamine and the N4R agonists clobenpropit and 4-meth- 
ylhistamine was already seen after 4 hours of incubation 
and was consistent after 24 and 48 hours of incubation 
(Fig 3, B). This effect was inhibited by the specific 114R 
antagonist JNJ7777120 at 10`5 mol/L. The amount of 
CCL2 produced by nonstimulated monocytes was increas- 
ing with time (Fig 3, C). In some experiments, also TNF-ac 
was measured (results not shown). The cells did not 
spontaneously produce this inflammatory cytokine, dem- 
onstrating that the adherent cells were not activated during 
this isolation method. 
Histamine Inhibits CCL2 synthesis 
and secretion 
We investigated the mechanism of CCL2 downregula- 
tion by the H4R agonists. First, it was found that the 
mRNA synthesis for CCL2 was downregulated in mono- 
cytes incubated with 14R agonists for4 hours at 10`3 mot/ 
L (Fig 4). Furthermore, when monocytes were incubated 
with the most selective 114R ligand, 4-methylhistamine, 
for 4 hours at 10`3 mol/L, the intracellular level of 
CCL2, as determined by means of intracellular staining 
and flow cytomctry, was higher than in nonstimulated cells 
(Fig 5). Second, after 48 hours of incubation, 10-5 mol/L 
of 4-methylhistamine inhibited intracellular CCL2 content 
compared with that seen in nonstimulated cells. The melt- 
ing point of the amplified CCL2 was 74.7°C (see Fig EI in 
the Online Repository at www. jacionlinc. org). 
Matrix metalloproteinases (MMPs) 1,3, 
or 8 are not responsible for the decrease 
of CCL2 levels 
MMP1, MMP3, and MMP8 are known to degrade 
CCL2.211 To test whether MMPs were responsible for the 
histamine-induced CCL2 decrease, we applied an appro- 
priate inhibitor, GM6001 24 This potent broad-spectrum 
MMP inhibitor was coincubated with the 114R agonists. 
No change in the effect induced by 114R agonists was 
seen (see Fig E2 in the Online Repository at www. jacion- 
line. org) at GM6001 concentrations of I or 10 p. M. This 
indicates that the lower CCL2 level was not caused by a 
higher MMP secretion by the monocytes. 
Monocyte chemotaxis is lower toward 
supernatants of 1-1413-stimulated monocytes 
The medium from 114R-stimulated monocytes (48 
hours) attracted less monocytes than medium from nonsti- 
mulated monocytes (Fig 6). This effect was caused by 
CCL2 in the supernatants because chernotaxis toward 
nonstimulated monocyte medium was inhibited by a 
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neutralizing CCL2 antibody. Furthermore, addition of hu- 
man recombinant CCL2 to the H4R agonist-stimulated 
monocyte media could reinduce chemotaxis. As a control, 
fresh medium with histamine, clobenpropit, or 4-methyl- 
histamine did not induce chemotaxis of monocytes. 
DISCUSSION 
Previously, it has been shown that the H4R has important 
immunomodulatory effects on human T lymphocytes 14.29 
and human DCs'3 in vitro. In a recent investigation using 
a murine model of allergic airway inflammation, an immu- 
nomodulatory role for the H4R was also shown in vivo. H4R 
knockout mice and mice treated with the H. R inhibitor 
JNJ7777120 had decreased T-lymphocyte function, which 
was attributed to a decreased cytokine and chemokine pro- 
duction by DCs. 15 The monocyte cell fraction that contains 
the precursor cells for DCs and skin-associated macro- 
phages has not been investigated thus far and was addressed 
in this study. 
Here we show for the first time that human monocytes 
express the H4R at the protein level, taking advantage of 
I ý 
E 
ý 
U 
C) 
ISO- 
100. 
so 
ý 
g 
ý 
FIG 3. A, Dose dependency of CCL2 downregulation by histamine (HA), clobenpropit (Clob), and 4-methylhist- 
amine (4-MH). B, Inhibition of CCL2 production is blocked by JNJ7777120. C. Absolute CCL2 production at dif- 
ferent incubation times. Data are normalized to nonstimulated (NS) values In Fig 3, A and B. Averages and 
SEMs (Fig 3, A), SDs (Fig 3, B), and SEMs (Fig 3, C) of at least 3 experiments are shown (statistical test: 
ANOVA). 
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the newly developed anti-human H4R antibody. 
2' The ex- 
pression of H4R mRNA by monocytes has already been 
shown by our group'3 and another group, 6 but thus far, 
no function for the H4R expressed by monocytes has 
been reported. Here we show that monocytes express 
H4R protein and that IFN-y upregulates the receptor. It 
has been shown previously that stimulation of the H4R 
leads to a calcium mobilization in cells. 46.8.9 Also, in 
human monocytes H4R agonists induced calcium mobili- 
zation, which was inhibited when the cells were coincu- 
bated with the H4R-specific antagonist JNJ7777120.23 
Furthermore, we show that monocytes, on stimulation 
with the H4R-specific agonists clobenpropit and 4-methyl- 
histamine and the H4R-nonspecific agonist histamine, 
downregulate CCL2 production dose dependently. 
JNJ7777120 was able to fully block this downregulation. 
We found 2 possible mechanisms to explain the H4R- 
mediated decrease in CCL2 levels produced by mono- 
cytes. First, an inhibition of synthesis was demonstrated 
by decreased CCL2 mRNA levels (4 hours of incubation), 
leading to decreased intracellular CCL2 levels (48 hours 
of incubation) when cells were incubated with H4R 
agonist compared with levels seen in nonstimulated cells. 
Second, intracellular CCL2 protein levels were increased 
after 4 hours of incubation with 4-methylhistamine com- 
pared with levels in the nonstimulated control cells, 
demonstrating an inhibition of CCL2 secretion after H4R 
agonist binding. In contrast, no evidence was found for 
CCL2 degradation by MMPs, which were previously 
shown to potently degrade CCL. 2.21 
Histamine has not been shown previously to modulate 
the secretion of soluble mediators, although it is able to 
inhibit the production of IL-12p70 by monocytes and 
monocyte-derived DCs through the H. R and H4R, 13'30 as 
well as of TNF-et by macrophages and mast cells through 
the H2R and H-IR. 31 32 The possible downregulation of se- 
cretion of these mediators, however, has not been investi- 
gated, and the decreased cytokine levels were explained 
by a downregulation of synthesis. In this study we provide 
evidence that CCL2 synthesis and secretion is indeed 
downregulated. 
The supernatants of monocytes stimulated with H4R 
agonists were used as chcmoattractants in Boyden cham- 
ber assays. We observed significantly lower monocyte 
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tistical test: ANOVA). 
migration levels into supernatants from cells incubated 
with the H4R agonists clobenpropit and 4-methylhist- 
amine compared with that of nonstimulated monocytes. 
The migration of monocytes to supernatants from nonsti- 
mulated monocytes could be blocked close to media con- 
trol levels by a CCL2-neutralizing antibody, which 
demonstrated the importance of CCL2 as a monocyte che- 
moattractant. The ligands themselves did not stimulate 
chemotaxis of freshly isolated monocytes, as was previ- 
ously shown for monocyte-derived DCs, 13 eosino- 
phils, 10'11 and mast cells .9 
In summary, we showed, for the first time, that the H4R 
protein is expressed by monocytes and that the H4R is 
functional. This is demonstrated by the induction of a 
Ca2+ influx and the downregulation of CCL2. This ex- 
tends our understanding of the immunologic role of the 
H4R and the therapeutic potential of H4R antagonists in 
inflammatory disorders. 
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Introduction All experiments were approved by the Italian Animal Care and Use 
Committee. 
The histamine H3 receptor (H3R) is a presynaptic receptor, 
reported to be abundantly expressed in the central nervous 
system of different animal species [1]. Recent studies have Results and discussion 
also suggested that the H, R plays various roles in the periph- 
cry [2,3]. Ligands for histamine H3 receptors are reported to Anti-H3 receptor (anti-H, R) immunoreactivity was difleren- 
regulate gastric acid secretion, maintenance of gastric mu- tially distributed in the various regions of the rat gastrointes- 
cosal integrity as well as gastric and intestinal epithelial cell 
proliferation [4,5]. In the present study, we have determined 
the anatomical distribution of the H3R in the gastrointestinal 
tract, and probed the influence of activation by the selective 
histamine H3-receptor agonist (R)-a-methylhistamine [(R)a- 
McHA] upon the levels of H, Rs in fed and fasted rats. 
Materials and methods 
Adult male Wistar rats (180-200g, Harlan, Italy), were treated with 
(R)a-MCHA, l00mg/kg, or saline, intragastrically in a 5ml/kg volume, 
I and 48h before sacrifice. Half the rats in each group were fed ad li- 
bitum or fasted with free access to water for 24h before the sacrifice. 
Four to five rats were employed for each treatment subgroup. Tissue 
samples were taken from stomach, distal ileum and distal colon, fixed 
in 10% (v/v) formalin, prepared for immunohistochemistry and probed 
with our anti-H, 349-358 antibody previously generated in rabbits j61 
and validated using H, R knockout mice (Cannon et al., submitted). The 
positive cells were visualized by diaminobenzidine and counterstained 
with hematoxylin. The number of positive cells was counted in at least 3 
different sections for a total of 40 glands or crypts per rat and the results 
were expressed as number of positive cells per unit. (R)a-MeHA was 
synthesized by W. S. 
Results are expressed as mean ±SEM. Comparisons between the 
mean values of control and treated groups were performed with one-way 
ANOVA followed by Newman-Keuls test. AP value <0.05 was consid- 
ered statistically significant. 
Correspondence to: G. Morini 
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Fig. 1. Effect of (R)-a-methylhistamine on density of anti-li, receptor 
positive cells in the fundic mucosa of the rat stomach. Positive cells 
are decreased by 24 h fasting in control group. At Ih and 48 h after the 
administration of a single dose. (R)-a-methylhistamine, 100mg/kg 
intragastrically, reduces the number of positive cells in freely fed rats 
only, while it is ineffective in fasted rats. Mean ±SEM: n= 4-5. MP < 
0.01 between freely fed and fasted control rats; "P < 0.05 and **P< 0.01 
between corresponding control and (R)-a-methylhistamine-treated rats. 
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Fig. 2. Representative sections of the tundic nwcosa of the stomach in 
freely fed rats. (A) Control rat and (B) rat sacrificed 48 h after the single 
administration of (R)-a-methylhistamine, 100mg/kg intragastrically. 
Prior treatment with (R)-a-methylhistamine decreases the density of 
anti-H, receptor positive cells with no change in their position along the 
gland. Scale bar = 28 pm. 
final tract. The immunoreactive cells were most frequently 
detected in the gastric fundus, where they occurred in the 
basal half of the mucosa. Their density sharply decreased 
in the antrum, with a further gradual decrease towards the 
distal ileum and distal colon. In the fundic mucosa 24 h fast- 
ing significantly lowered anti-H, R immunoreactivity, the 
number of positive cells per gland being 5.31 ± 0.53 and 
3.44 ± 1.59 in freely fed and fasted rats respectively (Fig. 1). 
In freely fed rats administration of (R)a-MeHA 100 mg/kg 
promptly decreased the density of anti-H, R immunoreactive 
cells. The number of immunoreactive cells/gland was 4.24 
± 0.33 and 3.83 ±0.31 at Ih and 48h respectively after dos- 
ing. Compared with controls, the decrease was 20% (P < 
0.05) and 28 % (P < 0.01) in I h- and 48 h-treated groups 
respectively (Figs. 1.2). By contrast in fasted rats the density 
of immunoreactive cells was unaffected by prior treatment 
with (R)a-McHA. Interestingly the number of immunoreac- 
tive cells was similar in fasted and (R)a-McHA treated rats. 
Food deprivation or (R)a-McHA did not influence positive 
cell density in the regions of the gastrointestinal tract other 
than gastric fundus. 
These data are of interest to compare to recent studies 
which showed agonist-dependent down-regulation of HR, 
resulting in a significant loss of function in the rat striatum 
17]. These results suggest homologous desensitisation may- 
be a common regul; itorv mcch; iniýni for hoth the cntr; il and 
I)ri iI hrr, il III: 
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LAY SUMMARY 
"..... the Hitch Hiker's Guide has already supplanted the great 
Encyclopaedia Galactica as the standard repository of all 
knowledge and wisdom...... it scores over the older, more 
pedestrian work in two important respects. 
First, it is slightly cheaper; and secondly it has the words 
DON'T PANIC inscribed in large friendly letters on its cover. " 
The Hitch Hikers Guide to the Galaxy, Douglas Adams 
Background 
Many people have heard of histamine and may know that it is important in allergies, 
inflammation and excess gastric acid secretion. Although it is involved in conditions that 
can be harmful, it is also an important chemical messenger in the body. Histamine is 
found almost everywhere, but is present in highest concentrations in the lungs, skin and 
particularly the gut. It is also found in the brain. Outside the brain it is found mainly in 
special white blood cells: mast cells and basophils; inside the brain it is also found in 
nerve cells (neurons). Most of the early studies describing the biological action of 
histamine were carried out by Sir Henry Dale and colleagues in the 1930s. Following 
these studies, anti-histamines were developed as successful therapies for many allergic 
and inflammatory conditions. It was recognized that anti-histamines had a sedative action 
and were therefore affecting the brain. Further studies demonstrated that histamine is one 
of the many different chemical messengers found in the brain. These are called 
neurotransmitters and they are released from neurons when they are electrically 
stimulated by a nerve impulse (Fig 1). The neurotransmitter is released into the tiny gap 
between the neuron and its target. In the brain this is usually another neuron. The 
histamine then binds to special receptors on the next neuron which either stimulates or 
inhibits the activity of the receiving neuron. 
I 
Fig 1 Release of neurotransmitter from a neuron. 
Pfizer. com 
I 
Neurons which carry histamine as their neurotransmitter are called histaminergic neurons 
and almost all of them originate from a tiny part of the brain called the tuberomammillary 
nucleus (Fig 2), located in a very important brain structure called the hypothalamus. 
Fig 2 Histaminergic system in the brain 
Histaminergic neurons branch to many different areas of the brain and down into the 
spinal cord. They occur in many key regions, including those important in learning and 
memory, voluntary movement and responses to stress. This is perhaps not surprising 
since the hypothalamus is an important control centre essential for the survival of an 
organism and reproduction. The hypothalamus sends out messages along pathways that 
use both nerve impulses and hormones, and it also responds to messages which come 
back from the systems that it regulates. In this way the hypothalamus can orchestrate the 
complex and diverse behaviours that underlie the way in which the body's internal 
environment is maintained, reproduction and motivated action. 
So far four different histamine receptors have been identified. These bind histamine to 
cells, tissues and organs and mediate the effects of histamine on various targets. The H, 
and H2 receptors mostly excite neurons or potentiate excitatory inputs whereas H3 is an 
inhibitory receptor. The H4 receptor is the most recently described, and not much is 
known about it yet. The H, histamine receptor is found on smooth muscle and it is also 
important in the brain. It causes dilation of blood vessels, bronchoconstriction and 
smooth muscle activation. It is involved in hayfever, pain and itching due to insect stings, 
3 
and travel sickness. The H2 histamine receptor is located on special cells in the gut which 
primarily regulate gastric acid secretion. Again it is also important in the brain. H3 
histamine receptors are found almost exclusively in the brain, although it has also been 
reported at low levels in the spinal cord, gut, skin and some blood vessels. It usually 
inhibits neurotransmitter release. It can inhibit the release of histamine itself and a 
number of other important neurotransmitters including acetylcholine, noradrenaline and 
serotonin. H4 histamine receptors have been located primarily on white blood cells in the 
thymus, small intestine, spleen, and colon. They are likely to have a role in immune 
function. There are however a number of laboratories, including our own, reporting H4 
histamine receptors in rodent and human brain. 
All four histamine receptors come from a family of receptors called G-protein coupled 
receptors (GPCRs). GPCRs are also known as seven transmembrane receptors (7TM 
receptors) because they loop back and forth across the outer membrane of the cell seven 
times (Fig 3). 
G protein 
Fig 3 GPCR Cartoon 
They convert or transduce signals from outside the cell into an intracellular signal via 
activation of a G-protein. The GPCRs are the largest protein family known with over 
1000 identified to date. They are involved in all types of stimulus-response pathways and 
regulate all known physiological pathways in higher vertebrates. As GPCRs are involved 
at some stage in all normal biological processes it is not surprising that they are the target 
for 40 to 50% of modern medicinal drugs. The diversity of functions is matched by the 
wide range of ligands (a ligand is anything that can bind and activate a receptor) 
recognized by members of the family, from photons, as is the case for rhodopsin 
receptors in the eye, to small molecules, like histamine, and proteins, for example, 
hormones. The role of GPCRs is often regulatory and the manner in which they function 
is ideally suited to this. They work relatively slowly compared with other receptors taking 
4 
seconds rather than milliseconds. In addition the signalling pathways involve many steps 
so there are multiple points at which the signal can be manipulated and fine tuned. This is 
extremely important so that the organism is able to continually adapt to a changing 
environment. GPCR signalling is enormously complex and new layers of complexity are 
uncovered almost daily. However the broad principle remains the same. When a ligand 
binds a GPCR it alters the shape of the receptor in such a way that it is able to couple to a 
G-protein on the inside of the cell. This has the effect of activating the G-protein which in 
turn activates other intracellular events or signalling cascades. These intracellular signals 
eventually trigger an effector within the cell to bring about some change or action (Fig 4). 
Ligand (e. g. Histamine) binds GPCR 
ý 
GPCR couples to intracellular G-protein and activates it 
I 
Activated G-protein switches on an amplifier (usually an enzyme) 
I 
Amplifier initiates a signalling cascade within the cell 
i 
Signalling brings about an effect (e. g. release of a neurotransmitter) 
Fig 4 GPCR signalling 
In the case of histamine acting as a neurotransmitter in the brain, if it binds to either an II, 
or H2 histamine receptor the end result is likely to be the release of more histamine from a 
histaminergic neuron. However if it binds to a histamine H3 receptor it usually inhibits 
neurotransmitter release. The H4 receptor is also likely to be inhibitory. 
We are trying to establish the function of H3 and H4 receptors in the brain. The 113 
receptor is widespread in many important brain areas. In contrast, the H4 appears to be at 
rather low levels in the brains of rodents and humans. In some species we do not know 
yet whether the H4 receptor is in the brain at all. Histamine in the brain helps to co- 
ordinate bodily functions and behaviours in response to changing needs. In particular it 
5 
plays a part in circadian rhythms (responding appropriately to the normal 24 hour daily 
cycle), eating and drinking, maintaining body temperature, paying attention and learning. 
Knowing more about all the histamine receptors in the brain and how they work will help 
our understanding of how the brain functions. Histamine receptors may provide the key 
to future therapies. Drugs which can activate the receptors in a similar way to histamine 
could be used to intervene where the equilibrium has been lost through disease or 
physical damage. Histamine receptors H1 and H2 are already the targets of some very 
effective modern drugs outside the brain and there are high hopes that the most recently 
discovered receptors, H3 and H4, may prove just as useful. With its widespread 
distribution in the brain and its effects on other important neurotransmitters besides 
histamine there are a number of neurological disorders and diseases where manipulation 
of the H3 receptor could have potential. These include Attention Deficit Hyperactivity 
Disorder (ADHD), Alzheimers Disease, Parkinsons Disease and Schizophrenia. Also, due 
to the role of histamine in eating and drinking, drugs which affect the H3 histamine 
receptor might have a use in combating obesity. The H4 receptor is found on many types 
of immune cells and has been shown to influence the production of some of the chemical 
messengers which these cells manufacture. Drugs which target the H4 receptor may be 
useful in controlling inflammatory diseases such as rheumatoid arthritis. In addition it has 
some effects on cell growth and development so anti-cancer therapies are also a 
possibility. 
The purpose of my research was to delve deeper into the details of the structure of the H3 
and H4 receptors and the way in which they work. So far no drugs targeting the H3 
receptor have made it into the clinic, although it was first described over 20 years ago. 
This is mainly because there is a great deal of variation in the pharmacology (ie how the 
receptors respond to H3 directed drugs) which has not yet been explained. This variation 
or heterogeneity is seen both when comparing H3 pharmacology between different animal 
species, and even within the same animal species when comparing H3 receptors from 
different brain regions or tissues. In my research I have sought to find explanations for 
this variation. Even less is known about the H4 histamine receptor. However, since the 
gene which codes for it is very similar to the H3 receptor gene, it is likely that both 
receptors have many characteristics in common. Before I can explain the work I carried 
out for my PhD it is necessary to explain more about GPCRs in general and histamine 
receptors H3 and H4 in particular. 
1) The H3 and H4 receptors can exist as different isoforms (slightly different types) 
Due to the way the message from the genes coding these two receptors is translated into 
protein slightly different types (isoforms) can be generated. It seems likely that these 
isoforms are part of the explanation for the observed variations in pharmacology. For the 
H3 receptor the isoforms are often the result of deletions within the third intracellular loop 
of the full length receptor (Fig 5). 
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Full length H3(445) isoform 
Fig 5 H3R isoforms 
H3 
(329) 
isoform 
For the H3 receptor over twenty different isoforms may exist. There is evidence that the 
pharmacology of some of the different isoforms differs from that of the full length 
receptor. In addition the distribution of the various isoforms throughout the brain differs. 
I concentrated on the full length receptor which is 445 amino acids long H3 (445) and a 
shorter isoform which is 329 amino acids long H3 (329), because they are both found in a 
region of the brain which is crucial to the control of voluntary movement 
At present only two isoforms of the H4 receptor have been identified by our collaborators 
at the Vrije University in Amsterdam, however there are likely to be more. These are 
drastically truncated versions of the full length receptor, lacking two or more of the 
transmembrane domains (Fig 6). 
7 
H4(302) 
Fig 6 H4R isoforms 
Full length H4(390) 
H4(67) 
Many of the H3 isoforms and both the H4 isoforms appear to be non-functional because 
they neither bind histamine nor signal. However it is very unlikely that they have no 
purpose at all. My work has shed light on a possible role for these apparently non- 
functional isoforms. 
2) Two or more GPCRs are likely to join together in order to signal 
Although in Fig 4 one GPCR is shown interacting with one G-protein the current thinking 
is that GPCRs operate as dimers (two together) or higher oligomers (two or more 
together), a process called oligomerisation. I wanted to investigate whether this is true of 
H3 and H4 receptors; not only for the full length receptors: homo-oligomers (like with like) 
but can hetero-oligomers exist (full length with a different isoform). In addition if hetero- 
oligomers can exist does the shorter isoform affect the functioning of the full length 
receptor in any way? 
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3) GPCRs undergo various small changes during and after translation of the genetic 
message into receptor 
In common with most cell surface proteins GPCRs undergo various changes during and 
after the translation of genetic message into protein receptor. Often this is the addition of 
certain sugar groups, a modification known as glycosylation (Fig 7). 
Sugar groups 
G protein 
Fig 7 Glycosylation of GPCRs 
The reason for this glycosylation is not fully understood, current research suggests a 
number of possible functions which may not be the same for all receptor types. For 
example, for some GPCRs these additional sugar groups appear to be necessary for the 
trafficking of the receptor to the cell membrane, in others they may help with drug 
binding. Glycosylation might also be involved in the formation of GPCR oligomers. I 
carried out experiments to find out whether H3 and H4 receptors are glycosylated since 
differences in glycosylation might affect the way in which receptors work and could 
underlie some of the variation seen in receptor pharmacology. 
There were five main hypotheses I set out to address - 
1) Human H3 and H4 receptors are able to homo-oligomerise 
2) Human H3 and H4 receptors are able to hetero-oligomerise with their respective 
isoforms 
9 
3) Shorter isoforms can influence how the full length human H; and 114 receptors 
work 
4) N-glycosylation is a prerequisite for receptor oligomerisation 
5) Both H3 and H4 receptors are present in human brain where they serve distinct 
functions 
My work concentrated on human receptors because of the longer term goal of providing 
information which may be useful in designing therapies for use in people. I will next 
describe briefly the techniques I used to test these hypotheses and then provide a summary 
of my findings. 
Methods 
Generation of antibodies specific for histamine H3 and H4 receptors 
The first task was to generate antibodies which would specifically bind to human H3 and 
H4 receptors. These receptors are proteins, constructed from chains of amino acids which 
are the building blocks of all proteins. Our strategy was to choose a short sequence of 
around 10 amino acids which was unique to the receptor we wanted to make antibodies 
against. This peptide (or short protein) was then used to immunise rabbits. The rabbits 
body recognises the peptide as foreign and makes antibodies against it. Blood is taken 
from the rabbit and the antibody is purified from the liquid part of the blood. These 
purified antibodies bind specifically to proteins which contain the unique 10 amino acid 
sequence of the peptide injected into the rabbits. Therefore they can be used to identify the 
human H3 and H4 receptors from which the sequence was derived. 
After purification the antibody has to be tested to make sure that it will only pick up the 
receptor it is intended to recognise. The antibody can be tested in a number of ways. 
Immunobiotting 
This technique was used to visualise histamine receptors from two different sources: 
1) The gene coding for a receptor can be temporarily introduced (transfected) into 
cultured mammalian cells for experimental purposes. These are called recombinant 
receptors because the receptor DNA is combined (although not fully) with the 
normal DNA of the cell. It is therefore translated along with the other cell proteins 
and expressed at the cell surface. Cells expressing the histamine receptors were 
homogenised in a special glass pestle and mortar, and the protein mixture from this 
homogenate was used for immunoblotting. 
2) Histamine receptors from native tissue were also used. Native tissue just means 
tiny pieces of normal brain, skin, bone or whatever body part you are investigating. 
In this case brain tissue was used, it is homogenised in a similar way to the 
recombinant receptors. 
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To carry out immunoblotting the homogenised proteins were prepared and applied to a 
very thin slab of polyacrylamide gel (Fig 8). Under the influence of an electric current 
passed through the gel the proteins migrate from the top to the bottom. The smaller the 
protein the faster it will migrate so that eventually the proteins spread out down the gel 
according to their size. The smallest ones are at the bottom, the biggest ones still near the 
top. The proteins were then blotted onto a piece of special nitrocellulose paper. It is called 
immunoblotting because an immune antibody is used to identify the protein of interest. 
We used our purified anti-histamine receptor antibody. The antibody binds to the part of 
the receptor which contains the unique peptide sequence which was used to immunise the 
rabbit in the first place. The location of the receptor with the antibody bound to it is 
visualised using a special enzyme linked probe which attaches to the rabbit antibody. The 
enzyme on the probe is used to bring about either a colour change or a luminescent 
reaction which can be picked up on a photographic film. The end result is bands which 
correspond to the position of the histamine receptors (Fig 9). 
ý Histamine receptor 
Anti-histamine receptor antibody (purified from immune rabbit serum) 
.H 
RP.,,, Anti-rabbit antibody linked to HRP enzyme 
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1 Proteins spread down gel according to size 
2 Proteins transferred to nitrocellulose sheet 
3 Antibodies select histamine receptor protein 
4 HRP enzyme catalyses a colour change so that the position 
of the histamine receptor protein is visualised as a band on 
the nitrocellulose sheet 
Fig 8 Steps involved in immunoblotting 
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Fig 9 Immunoblot result 
Big proteins move more slowly so they stay near the top, the smaller the protein is the 
nearer the bottom it will be. The darker the band itself the more there is of that particular 
protein. 
Immunohistochemistry 
This involves mapping the distribution of receptors in very thin tissue slices. Immuno 
refers to the fact that (as with the immunoblotting) the receptor is identified using an 
immune antibody. Histo refers to histology which is the study of tissue sectioned as a thin 
slice. In my work I used very thin slices of mouse brain. Fortunately the full length human 
and mouse H3 receptors are enough alike to be picked up by the anti- human H3 antibody. 
The principle is similar to immunoblotting in that rabbit antibody binds to the receptor 
which is then visualised with an enzyme linked anti-rabbit probe. In this case the enzyme 
causes a colour reaction so that areas with histamine receptors are stained brown (Fig 10). 
To be certain that the antibody was picking up the H3 receptor we carried out 
immunohistochemistry on mouse brain slices from a normal mouse and compared them 
with the staining pattern on slices from mice where the H3 gene had been artificially 
knocked out, so the mouse did not have any H3 receptors. Apart from being a little 
overweight and showing slightly unusual circadian rhythms H3 knock out mice appear to 
be perfectly healthy. 
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Fig 10 Immunohistochemistry on mouse brain slice. Anti-1-13Receptor antibody in Wild 
Type (WT) and H3 Knockout (KO) Mouse Brain. 
The antibodies generated against the H3 and H4 receptors were both able to reliably detect 
their respective receptors in immunoblots of recombinant and native tissue, and they 
worked well for immunohistochemistry. The anti-H4 antibody was also tested using a 
technique called immunoprecipitation, described below. 
Immunoprecipitation to confirm H4R selectivity of the antibody 
Mammalian cells are transfected with a histamine receptor labelled with a special tag 
called haemagglutinin (HA). The cells are homogenised and the proteins solubilised. The 
solubilised proteins are then mixed with anti-HA antibodies which bind to the HA-H4 
receptor. The protein mixture was then passed over special beads which only pulled out 
of solution antibody together with the proteins bound to that antibody. Proteins which do 
not have antibody bound to them will not be isolated in this way. The HA-H4R was then 
eluted from the beads and subjected to immunoblotting where the protein is run out on a 
polyacrylamide gel and transferred to a nitrocellulose sheet as described above. Our new 
anti-H4R antibody was used to test whether it could identify the HA- H4R on the 
nitrocellulose paper. 
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Having demonstrated the presence of specific anti-H3R and anti-H4R antibodies, I used 
them to investigate the hypotheses listed above. 
Methods to demonstrate the presence of receptor oligomers: 
Chemical cross-linking 
Mammalian cells were transfected with the histamine receptors. The cells expressing the 
receptors were harvested and incubated with a chemical cross-linker which can 
irreversibly link receptors if they are present as oligomers in the cell membrane. After 
incubation the cells were homogenised and subjected to immunoblotting. If oligomers 
have been irreversibly linked they appear as high molecular weight proteins on the 
immunoblot. 
Biophysical techniques: 
Fluorescence Resonance Energy Transfer (FRET) 
Bioluminescence Resonance Energy Transfer (BRET) 
Both techniques rely on the transfer of resonance energy from a donor to an acceptor this 
in turn excites an emission from the acceptor which can be measured. For the FRET assay 
it is a fluorescent emission whilst with BRET the reaction bioluminesces, otherwise the 
principle is identical. Importantly the donor and acceptor must be within I ooA range for 
resonance energy transfer to occur. Cells were transfected with different combinations of 
histamine receptors, either the full length receptors alone or the full length receptor 
together with one of the other isoforms. The receptors were differently labelled one with a 
donor and the other with an acceptor. Excitation of the donor generates resonance energy 
which can be transferred to the acceptor providing the two receptors are close enough 
together in the membrane (ie within IOOA range). Therefore a FRET or BRET signal will 
only be detected if the receptors are present as oligomers. 
Nickel Column Purification 
Cells were transfected with equal amounts of histamine receptors artificially tagged with 
either haemagglutinin (HA) or histidine (HIS). The cells were homogenised and passed 
over nickel beads in a column. The HIS tagged receptors were isolated on the nickel 
column because nickel binds strongly to histidine. If HA tagged receptors are found in the 
fraction immobilised on the nickel beads this will confirm the existence of HIS-H4R/HA- 
H4R oligomers. 
Methods to test whether shorter isoforms can influence the full length receptors: 
Saturation Binding 
Here cells transfected with histamine receptors were incubated with increasing 
concentrations of radiolabelled histamine which is the natural ligand that binds to the 
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receptor in the brain. Modern drugs which target GPCRs can be thought of as synthetic 
ligands which manipulate the receptor in a beneficial way. Drugs which bind and activate 
the receptor, are called agonists, whilst those that block the receptor are termed 
antagonists. Some compounds do more than just block the receptor. Many receptors, 
including the H3R, show some baseline (or constitutive) activity even in the absence of 
the natural ligand. Many compounds previously called antagonists are now known to 
actually decrease this constitutive activity and are known as inverse-agonists. The 
radiolabelled ligand I used was an antagonist called clobenpropit. It is best to use an 
antagonist for this type of experiment because antagonists bind to the receptor without 
affecting its activity. In the presence of increasing concentrations of clobenpropit 
increasing amounts will be bound which can be tracked by measuring the radioactivity in 
the samples. Eventually there is a point at which no more ligand can be bound because all 
the receptors are saturated (Fig 11). I used saturation binding to find out whether binding 
of ligand to the full length receptor could be affected by the presence of a shorter isoform. 
Therefore I carried out three assays in parallel: one with cells expressing the full length 
isoform alone, one with cells expressing the shorter isoform alone, and one with cells 
expressing both the full length and the shorter isoform together. 
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Fig 11 Saturation binding curve. 
I also carried out total binding experiments on cells expressing histamine receptors which 
had been cultured in the presence of an antibiotic called tunicamycin. Tunicamycin 
inhibits receptor glycosylation. I wanted to find out whether glycosylation was necessary 
for ligand binding. 
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Surface biotinylation 
This technique is used to compare how much receptor is present on the cell surface, and 
therefore available for ligand binding, and how much is inside the cell. Cells expressing 
histamine receptors were incubated in the presence of biotin (biotin is another name for 
the vitamin B7, here it is being used merely as a way of tagging cell surface proteins). 
Receptors inside the cell are not accessible to the biotin, therefore they will remain 
untagged. Next the cells are broken up and homogenised so that the surface receptors and 
the ones from inside the cell (the intracellular fraction) are all mixed up. The receptors 
from the surface can be separated from the intracellular fraction using beads coated with 
streptavidin. Streptavidin is a protein purified from Streptomyces avidinii that binds very 
tightly to the biotin. This is one of the strongest biological interactions known, and is 
widely taken advantage of in scientific laboratories for separating biotin labelled proteins 
from a mixture. In this way two different fractions are obtained one containing the 
surface receptors and one with the intracellular receptors. These are run out on a gel and 
visualised by immunoblotting in the usual way. I used this method to find out whether the 
amount of full length H4R expressed at the cell surface was altered in cells transfected 
with the full length receptor plus one of the other truncated isoforms. This would shed 
light on a possible role for the shorter isoforms in regulating the amount of full length 
receptor available for ligand binding. 
Methods to investigate whether receptors have to be glycosylated in order to form 
oligomers or bind ligand: 
Inhibiting glycosylation 
As described above receptor glycosylation can be inhibited by growing cells transfected 
with histamine receptors in the presence of an antibiotic called tunicamycin. 
Deglycosylating mature histamine receptors 
Mature receptors which are already glycosylated can be deglycosylated by treatment with 
an enzyme called PNGase F. 
Receptors which were not glycosylated (either by preventing glycosylation or by 
removing sugar groups from mature receptors) were analysed by immunoblotting to find 
out whether oligomers were still present. In addition ligand binding experiments were 
carried out on unglycosylated H3 receptors to see whether they were still able to bind 
ligand. 
Often a number of different techniques were used to ask the same question. This is 
because my experimental systems are artificial, therefore the results from these 
experiments may not reflect what happens in a whole animal. For example, we often 
make use of artificially tagged receptors, and these tags may interfere with the normal 
functioning of the receptor. One can be more confident of a hypotheses being correct if it 
is supported by data from a number of different approaches. 
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Findings 
1) Human H3 and H4 receptors are able to homo-oligomerise 
Cross-linking experiments have confirmed the presence of homo-oligomers for human 
and rodent H3R and human H4R. Importantly these receptor oligomers were evident in 
native tissue as well as in the artificial recombinant expression system. In fact the H3R 
was mainly found as oligomers in native tissue, similarly for endogenous H4R (that is for 
H4R in real tissue) oligomeric receptors were predominant. There is an indication that 
some isoforms may have a greater potential to oligomerise than others. Results suggested 
that the H3 (329) formed homo-oligomers more readily than the H3 (445). The cross- 
linking evidence was corroborated by FRET data for the H3R, and by both nickel column 
purification and BRET assay in the case of the H4R. 
2) Human H3 and H4 receptors are able to hetero-oligomerise with their respective 
isoforms 
FRET experiments also provided evidence for the existence of hetero-oligomers: 
oligimers consisting of the full length receptor with a shorter isoform. 
Histamine H3 and H4 receptors are therefore able to form both homo- and hetero- 
oligomers. These appear to be robust, stable oligomers and histamine is not necessary for 
their formation. 
3) Shorter isoforms can influence how the full length human H3 and H4 receptors 
work 
The shorter isoforms can regulate their full length counterparts. The H3 isoforms have 
different distribution patterns within the brain, however in some brain regions several 
variants are expressed together, therefore they could influence one another. The 445 and 
329 isoforms are co-expressed in key locations including the basal ganglia, which are very 
important in voluntary movement. Although the 329 isoform did not itself bind the 
radiolabelled ligand used for saturation binding, it did dramatically reduce binding of this 
ligand to the full length 445 receptor. (Some of the controls in these binding experiments 
showed an unacceptably high background so this particular set of experiments needs to be 
repeated and the results verified before we can be truly confident that we are seeing a real 
effect. ) 
Message coding for all three H4R isoforms is found in different types of white blood cell. 
Neither of the truncated H4 isoforms can bind or transduce a signal. On co-expression 
with the full length H4 (390) receptor the number of histamine binding sites is reduced by 
55% (390 + 302 isoform) and 30% (390 + 67 isoform). The effect of the two truncated 
isoforms on surface expression of the full length receptor was investigated using the 
surface biotinylation technique. Results confirmed that the (302) and (67) isoforms 
decreased the surface expression of the H4 (390) in line with the histamine binding data. 
Therefore although the shorter isoforms are non-functional in regard to ligand binding and 
signalling they appear to have a role in regulating the activity of the full length receptors. 
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4) N-glycosylation is a prerequisite for receptor oligomerisation 
Histamine H3 and H4 receptors were expressed in mammalian cells in the presence of the 
glycosylation inhibitor tunicamycin. Immunoblot analysis of cell homogenates confirmed 
that both receptors were indeed glycosylated. Furthermore inhibition of glycosylation did 
not remove receptor oligomers. For the H4R deglycosylation of mature receptors using 
PNGase F enzyme was also undertaken. Deglycosylation did not remove receptor 
oligomers in either a recombinant expression system or in native tissue. However there 
was some indication that glycosylation may help to stabilise receptor dimers. 
Interestingly the molecular weights of bands seen in spleen lysates suggested that in this 
particular tissue H4R receptors may not be glycosylated. For the H3 receptor near 
complete prevention of glycosylation had no significant effect on radioligand binding and 
complete inhibition saw only a modest reduction. 
In conclusion N-glycosylation is NOT a prerequisite for receptor dimerisation for either 
the H3 or H4 receptor. H4 receptors might be glycosylated to varying degrees in different 
tissues. In the case of the H3 receptor preventing glycosylation has only a very modest 
effect on ligand binding to the receptor. 
5) Both H3 and H4 receptors are present in human brain where they serve distinct 
functions 
As well as histamine H3 receptors, we have been amongst the first to report that histamine 
H4 receptors are also present in human brain material. The two receptors have different 
distribution patterns within the brain suggesting that they are doing different things. 
Importantly, in collaboration with a team in New Zealand, we have been the first to prove 
that the brain H4 receptors are definitely working because H4 specific drugs can affect 
nerve cell output from brain regions expressing the receptor. 
While the H3 and H4 histamine receptors clearly have potential as therapeutic targets, 
predicting the likely effect of any new drug is difficult in the face of the complexity 
found both within and across different animal species. The work described in this thesis 
has furthered understanding of the two most recently described histamine receptors - 
where they are found and how they work. These are preliminary studies which will need 
to be extended to investigate the full range of receptor isoforms, how they are distributed 
within different brain areas, their molecular characteristics and how they interact with 
other cell components. Advances in molecular biology are enabling scientists to unravel 
complex systems in minute detail, and the detail itself is intriguing. However, it is 
essential not to lose sight of the relevance of all this to the workings of the whole animal. 
Advances which can transfer to the clinic will be the result of a combined effort from the 
fields of molecular biology, chemistry, pharmacology, animal behaviour and medicine. 
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